azacitidine has been researched along with Dysmyelopoietic Syndromes in 1069 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.09) | 18.7374 |
| 1990's | 8 (0.75) | 18.2507 |
| 2000's | 160 (14.97) | 29.6817 |
| 2010's | 669 (62.58) | 24.3611 |
| 2020's | 231 (21.61) | 2.80 |
| Authors | Studies |
|---|---|
| Amdouni, H; Auberger, P; Benhida, R; Bougrin, K; Driowya, M; Dubois, A; Dufies, M; Furstoss, N; Lacas-Gervais, S; Martin, AR; Métier, C; Orange, F; Robert, G; Zerhouni, M | 1 |
| Lane, SW; Straube, J; Vu, T | 1 |
| Aoyama, S; Inoue, S; Kasahara, S; Makino, T; Mizui, T; Morita, M; Nagaya, K; Osawa, T; Tachi, T; Tanaka, K; Teramachi, H; Watanabe, H; Yasuda, M | 1 |
| Gao, R; Wang, J; Wu, DY; Yan, XJ; Zhang, R | 1 |
| Maeda, T | 1 |
| Goldfinger, M; Saunthararajah, Y; Shastri, A; Verma, AK; Zavras, PD | 1 |
| Hansen, E; Xu, K | 1 |
| Baron, F; Beguin, Y; Berneman, Z; De Becker, A; Deeren, D; Graux, C; Herman, J; Kerre, T; Lewalle, P; Ory, A; Poiré, X; Schoemans, H; Selleslag, D; Zachée, P | 1 |
| Campbell, K; Cashen, AF; DiPersio, JF; Gao, F; Huselton, E; Jacoby, MA; Marcus, S; Pusic, I; Rettig, MP; Romee, R; Schroeder, MA; Uy, GL; Westervelt, P | 1 |
| Alhan, FN; Ataş, Ü; Boduroğlu, A; Doğan, Ö; Iltar, U; Salim, O; Sözel, H; Ündar, L; Vural, E; Yücel, OK | 1 |
| Aouba, A; Bouscary, D; Comont, T; Dion, J; Fenaux, P; Georgin-Lavialle, S; Heiblig, M; Kosmider, O; Le Guenno, G; Mathian, A; Mekinian, A; Rieu, V; Rivière, E; Rossignol, J; Terrier, B; Terriou, L; Vinit, J | 1 |
| Crawford, B; Kim, H; Suzuki, T; Tsutsué, S | 1 |
| Botteman, M; Hassan, A; Hill, K; Jayade, S; Joshi, N; Ruiters, D; Schmier, J; Zeidan, AM | 1 |
| Bauer, K; Berger, D; Bettelheim, P; Gamperl, S; Greiner, G; Hoermann, G; Knöbl, P; Kornauth, C; Schiefer, AI; Schwarzinger, I; Sillaber, C; Smiljkovic, D; Sperr, WR; Staber, PB; Stefanzl, G; Thalhammer, R; Valent, P | 1 |
| Diamantopoulos, PT; Dimou, M; Dryllis, G; Galanopoulos, A; Giannakopoulou, N; Giannopoulos, A; Hatzidavid, S; Kontandreopoulou, CN; Kotsianidis, I; Loupis, T; Panayiotidis, P; Pappa, V; Solomou, E; Symeonidis, A; Viniou, NA; Zoi, K | 1 |
| Beach, CL; Döhner, H; Garcia-Manero, G; La Torre, I; Santini, V; Skikne, B; Wei, AH | 1 |
| Hisasue, M; Neo, S; Tanaka, M | 1 |
| Griffiths, EA | 1 |
| Abeck, D; Cordts, I; Deschauer, M; Gauck, D; Götze, KS; Günthner, R; Haack, TB; Hammitzsch, A; Härtl, J; Hecker, JS; Hemmer, B; Moog, P; Park, J; Schoser, B | 1 |
| Busija, L; Kenealy, M; McQuilten, ZK; Seymour, JF; Stanworth, S; Weinkove, R; Wood, EM | 1 |
| Aakashi, K; Aotsuka, N; Fujita, J; Goto, M; Iwasaki, H; Kizaki, M; Matsumura, I; Miyazaki, Y; Nakazato, T; Naoe, T; Sekiguchi, N; Sugimoto, S; Takahara-Matsubara, M; Ueda, Y; Usuki, K | 1 |
| Dail, M; Donnellan, W; Feng, Y; Gerds, AT; Green, C; Greenberg, P; Lin, TL; Ma, C; Medeiros, BC; Pollyea, DA; Scott, BL; Verma, A; Yan, M; Yousefi, K | 1 |
| Czabak, O; Hus, M; Juda, A; Kozioł, M; Majowicz, D; Sokołowska, B; Soroka-Wojtaszko, M; Wąsik-Szczepanek, E | 1 |
| Beach, CL; Boss, I; Cavenagh, J; Copeland, WB; Fox, BA; Garcia-Manero, G; Hasle, VE; Hellmann, A; O'Connor, T; Ogasawara, K; Previtali, A; Rose, S; Silverman, LR; Thompson, E; Tormo, M; Voso, MT; Zeidan, AM | 1 |
| Anjos, R; Fogaça da Mata, M; Gonçalves, JP; Madeira, M; Rato, J; Teixeira, A; Vieira Martins, M | 1 |
| Assis-Mendonça, GR; Bueno, MLP; da Silva, JAF; Duarte, ASS; Ferro, KP; Pericole, FV; Rego, EM; Roversi, FM; Saad, STO; Shiraishi, RN; Torello, CO | 1 |
| Brunner, AM; Fell, G; Steensma, DP | 1 |
| Chiba, M; Hata, T; Hirooka, S; Iida, H; Ikezoe, T; Imada, K; Ito, Y; Kawashima, I; Kiguchi, T; Kubo, K; Miyazaki, Y; Morimoto, K; Morita, Y; Naoe, T; Nawa, Y; Ohno, R; Uchida, T; Ueda, Y; Yokota, A | 1 |
| Breier, A; Janotka, Ľ; Kavcová, H; Messingerova, L; Šimoničová, K; Sulová, Z | 1 |
| Harada, S; Hidaka, D; Kanaya, M; Kondo, T; Mori, A; Ogasawara, R; Onozawa, M; Ota, S; Senjo, H; Takahashi, S; Teshima, T; Yokoyama, S | 1 |
| Asatiani, E; Berenson, JR; Bordoni, R; Cook, RJ; Edenfield, WJ; Mohan, S; Savona, MR; Srinivas, N; Zeidan, AM; Zhou, G | 1 |
| Matsuoka, A; Tanibuchi, M; Taoka, T; Yamazaki, I | 1 |
| Bernard, E; Cavelier, L; Dybedal, I; Ebeling, F; Ejerblad, E; Flogegård, M; Garelius, H; Göhring, G; Grønbaek, K; Hellström-Lindberg, E; Jädersten, M; Kittang, AO; Lorenz, F; Marcher, CW; Möllgård, L; Nilsson, L; Nørgaard, JM; Öster Fernström, A; Papaemmanuil, E; Rasmussen, B; Saft, L; Tobiasson, M | 1 |
| Marini, BL; Olivier, T; Prasad, V | 1 |
| Al-Kali, A; Alkhateeb, H; Arana Yi, CY; Badar, T; Begna, KH; Foran, JM; Gangat, N; Hogan, W; Johnson, I; Litzow, MR; Mangaonkar, A; McCullough, K; Palmer, JM; Pardanani, A; Patnaik, MM; Shah, M; Sproat, L; Tefferi, A | 1 |
| Bazinet, A; Bravo, GM | 1 |
| Aguilar, C; Arzuaga, J; Bernal, T; Borrás, J; Brunet, S; Calabuig, M; Calbacho, M; Cedena, MT; Chen, TH; Coll, R; Collado, R; Cortés, M; Díaz-Beyá, M; Fernández, M; García, O; Jiménez, MJ; López-Cadenas, F; Marchante, I; Marco, V; Medina, A; Pedreño, M; Pedró, C; Ramos, F; Ribera, JM; Sanz, G; Simiele, A; Stoica, C; Talarn, C; Triguero, A; Xicoy, B; Zamora, L | 1 |
| Chen, H; de Claro, RA; Earp, J; Ehrlich, LA; Gehrke, BJ; Kim, N; Kitabi, E; Manning, ML; Norsworthy, KJ; Okusanya, OO; Pazdur, R; Subramaniam, S; Vallejo, J | 1 |
| Brasacchio, D; DiCorleto, C; Gamgee, J; Gasiorowski, R; Gregory, GP; Gruber, E; Hawkes, EA; Hogg, SJ; Jia, W; Jong, I; Kailainathan, G; Kats, LM; Kumar, B; Levy, S; Lewis, A; Luong, Q; Maher, B; Opat, S; Polekhina, G; Reynolds, J; Sabouri-Thompson, Z; Shortt, J; Skinner, H; So, J; Uhe, M; Vervoort, S; Waltham, M; Wong, J | 1 |
| Breems, D; Chan, G; Ching, K; Gallo Stampino, C; Gyan, E; Joris, M; Kovacsovics, T; Krauter, J; Kudla, A; Ma, WW; Maertens, J; O'Brien, T; Schuster, M; Sekeres, MA; Verma, A; Vyas, P; Wang, ES; Zeidan, AM | 1 |
| Chiba, S; Dobashi, N; Handa, H; Harada, H; Hata, T; Honda, S; Horiike, S; Ichikawa, M; Ishiyama, K; Ito, Y; Iyama, S; Kiguchi, T; Kiyoi, H; Kurokawa, T; Maeda, T; Matsuda, M; Matsumura, I; Miyazaki, Y; Moriuchi, Y; Naoe, T; Ohtake, S; Sato, S; Suzuki, T; Suzushima, H; Taguchi, J; Tomita, A; Usuki, K; Yamauchi, T; Yokota, K | 1 |
| Azizi, A; Bergamaschi, A; Corces, MR; Cruz Hernandez, D; Dutta, R; Ediriwickrema, A; Ellison, CK; Fan, A; Guler, GD; Karigane, D; Kaur, S; Köhnke, T; Ku, CJ; Levy, S; Majeti, R; Martinez-Krams, D; McCarthy, E; Nakauchi, Y; Ning, Y; Phan, P; Phillips, T; Reinisch, A; Sharma, R; Stafford, M; Thomas, D | 1 |
| Seymour, JF; Wei, AH | 1 |
| Ding, K; Duan, L; Fu, R; Guo, Y; Liu, Z; Shen, H | 1 |
| Corman, S; Epstein, RS; Joshi, N; Kale, H; Salimi, T; Wang, WJ; Zeidan, AM | 1 |
| Gardner, J; Heenan, J; Hitchins, S; Mohamed, M; Shahidi, R; Sharma, A | 1 |
| Chu, HT; Fung, SH; Gill, H; Kwong, YL; Lee, E; Lee, P; Li, J; Liao, JJ; Miu, KK; Tse, E; Wang, Z; Yim, R; Yip, PK; Yung, Y | 1 |
| Dusilková, N; Jonášová, A; Kalousová, M; Kulvait, V; Minařík, L; Pešta, M; Špaček, M; Stopka, T; Zemanová, Z | 1 |
| Guo, R; Jin, J; Lan, J; Miao, M; Xu, Y; Zhang, G | 1 |
| Kantarjian, H; Short, NJ | 1 |
| Abaza, Y; Zeidan, AM | 1 |
| Boucher, R; Bowen, D; Cargo, C; Coulthard, HC; Culligan, D; Dennis, M; Jackson, A; Metzner, M; Moore, R; O'Sullivan, J; Raghavan, M; Sternberg, A; Vyas, P | 1 |
| Dekker, TJA | 1 |
| Chai, L; Tenen, DG; Voso, MT | 1 |
| Alvarado, Y; Borthakur, G; Carraway, H; Chien, K; Daver, N; Dezern, A; DiNardo, CD; Garcia-Manero, G; Hammond, D; Kadia, T; Kantarjian, HM; Lachowiez, C; Loghavi, S; Maiti, A; Masarova, L; Montalban-Bravo, G; Patel, B; Ravandi, F; Roboz, G; Sasaki, K; Sekeres, M; Short, NJ; Sukkur, A; Takahashi, K; Venugopal, S; Wang, X | 1 |
| Aubrey, BJ; Brunner, AM | 1 |
| Bartholdy, BA; Benard, L; Choudhary, G; Cole, S; DeFronzo, S; Heckman, CA; Javarappa, KK; Okoye-Okafor, UC; Pallaud, C; Ramos, PM; Ruiz, S; Saad, J; Shastri, A; Tatiparthy, M; Thiruthuvanathan, VJ; Tsallos, D; Verma, A; Will, B; Yang, D; Zhang, C | 1 |
| Chien, KS; Darbaniyan, F; Daver, N; Do, KA; Ganan-Gomez, I; Garcia-Manero, G; Kanagal-Shamanna, R; Li, Z; Lockyer, PP; Montalban-Bravo, G; Soltysiak, KA; Wei, Y; Yang, H; Zheng, H | 1 |
| Pleyer, L; Sekeres, MA | 1 |
| Alvarado, Y; Andreeff, M; Bazinet, A; Chien, K; Colla, S; Darbaniyan, F; Ganan-Gomez, I; Garcia-Manero, G; Huang, X; Jabbour, E; Kadia, T; Kanagal-Shamanna, R; Kantarjian, H; Masarova, L; McCue, D; Mirabella, B; Montalban-Bravo, G; Ohanian, M; Qiao, W; Ravandi, F; Short, N; Takahashi, K; Yilmaz, M | 1 |
| Sekeres, MA; Taylor, J | 1 |
| Ades, L; Banos, A; Bezanahary, H; Chermat, F; Chevret, S; Comont, T; D'Aveni Piney, M; De Renzis, B; Denis, G; Desseaux, K; Diaz, JMT; Dimicoli-Salazar, S; Durot, E; Fain, O; Fenaux, P; Frenzel, L; Gourin, MP; Grobost, V; Gyan, E; Himberlin, C; Hirsch, P; Jachiet, V; Kosmider, O; Lemaire, K; Maria, A; Mekinian, A; Natarajan-Amé, S; Pascal, L; Peterlin, P; Rauzy, OB; Terriou, L; Thépot, S; Vey, N; Voillat, L; Wickenhauser, S; Zhao, LP | 1 |
| Chien, KS; Class, C; Darbaniyan, F; Do, KA; Estecio, M; Ganan-Gomez, I; Garcia-Manero, G; Kanagal-Shamanna, R; Lockyer, P; Lu, Y; Montalban-Bravo, G; Sasaki, K; Soltysiak, KA; Wei, Y; Yang, H; Zheng, H | 1 |
| Ichikawa, M | 2 |
| Usuki, K | 3 |
| Choi, EJ; Hong, J; Kim, YJ; Lee, JH; Lee, KH; Park, S; Park, SY; Shin, DY; Yoon, SS | 1 |
| Garcia-Manero, G | 6 |
| Gao, Y; Huang, D; Lin, H; Liu, L; Wang, A; Wang, Y | 1 |
| Cai, Z; Chen, Y; Ding, B; Dovat, E; Dovat, S; Duan, L; Ge, Z; Han, Q; He, B; Huang, Y; Li, B; Li, J; Liu, Z; Lu, X; Min, F; Qiu, H; Shi, P; Song, C; Sun, N; Sun, Y; SzeKely, L; Tang, H; Wei, Y; Wu, Z; Xia, Y; Xiao, R; Xie, J; Xu, H; Xu, Y; Yang, X; Zhang, Y; Zhao, L; Zhu, W; Zhuang, W; Zi, J | 1 |
| Bajel, A; Borate, U; Brunner, AM; Cheng, WH; Filshie, R; Garcia, JS; Garcia-Manero, G; Harb, JG; Hoffman, D; Krishnadasan, R; Naqvi, K; Odenike, O; Pollyea, DA; Potluri, J; Roncolato, F; Watson, AM; Zeidan, AM; Zha, J; Zhou, Y | 1 |
| Antin, JH; Arihara, Y; Bashey, A; Brunner, AM; Cullen, N; Cutler, C; Davids, MS; DeAngelo, DJ; Flamand, Y; Galinsky, I; Garcia, JS; Ho, V; Jonas, BA; Keng, M; Koller, P; Leonard, R; Luskin, MR; Mendez, LM; Neuberg, D; Penter, L; Pfaff, K; Ritz, J; Robertson, T; Rodig, SJ; Savell, A; Soiffer, RJ; Stone, RM; Streicher, H; Tomlinson, BK; Wadleigh, M; Winer, ES; Wolff, JO; Wu, CJ | 1 |
| Feld, J; Navada, SC; Silverman, LR; Tremblay, D | 1 |
| Arnan, M; Baer, MR; Brevard, J; Cortes, JE; De Botton, S; Dinner, SN; Donnellan, W; Ferrell, PB; Forsyth, S; Guichard, SM; Henrick, P; Jonas, BA; Kelly, P; Lee, S; Marzac, C; Mohamed, H; Montesinos, P; Pigneux, A; Prebet, T; Récher, C; Schiller, GJ; Schwarer, AP; Seiter, KP; Sweeney, J; Wang, ES; Watts, JM; Wei, AH; Yang, J | 1 |
| Gangat, N; Komrokji, RS; Tefferi, A | 1 |
| Chan, RJ; Daver, NG; Garcia-Manero, G; Hasegawa, K; Hu, H; Iqbal, S; Rajakumaraswamy, N; Sallman, DA; Tse, P; Wei, AH; Xie, F; Yan, J; Zoratti, MJ | 1 |
| Bewersdorf, JP; Boss, I; de Menezes, DL; Fox, B; Haferlach, T; Halene, S; Hasle, V; Rose, S; Shallis, RM; Thompson, E; Zeidan, AM | 1 |
| Blum, S; Bresser, H; Lübbert, M; Tsilimidos, G | 1 |
| Baker, K; Banos, A; Bixby, D; Braun, T; Carulli, J; Cluzeau, T; Cook, RJ; de Botton, S; Eaton, M; Fenaux, P; Fiore, C; Hodgson, G; Jurcic, JG; Kang-Fortner, Q; Kelly, MJ; Liesveld, JL; Madigan, K; McKeown, M; Paul, S; Rizzieri, DA; Roboz, GJ; Roth, DA; Rousselot, P; Savona, MR; Sekeres, MA; Stein, EM; Stephens, K; Vigil, C; Volkert, A | 1 |
| Han, Y; Jiang, L; Jin, J; Lang, W; Li, K; Lin, P; Liu, X; Lu, C; Luo, Y; Ma, L; Mei, C; Ren, Y; Shen, C; Sun, J; Tong, H; Wang, L; Wang, Y; Xu, G; Yang, H; Yang, W; Ye, L; Ye, X; Zhang, H; Zhang, Q; Zhang, X; Zhou, X; Zhu, S | 1 |
| Borate, U; Koenig, KL | 1 |
| Jiang, L; Jin, J; Lang, W; Lu, C; Luo, Y; Ma, L; Mei, C; Ren, Y; Tong, H; Xu, G; Xu, W; Yang, H; Ye, L; Zhou, X; Zhu, H | 1 |
| Sekeres, MA | 4 |
| Asch, AS; Assouline, S; Cheema, F; Erba, HP; Fang, M; Hay, AE; Jacoby, MA; Kingsbury, LL; Law, LY; Little, RF; Liu, JJ; Maher, T; Michaelis, LC; Moseley, AB; Othus, M; Radich, J; Schroeder, MA; Sweet, KL; Uy, GL; Walter, RB | 1 |
| Arvanitis, M; Bonifant, C; Christodoulou, I; Dalton, WB; DeZern, AE; Esteb, C; Ghiaur, G; Gondek, LP; Jain, T; Jones, RJ; Karantanos, T; Levis, MJ; Paun, BC; Perkins, B; Rajkhowa, T; Teodorescu, P; Varadhan, R; Yegnasubramanian, S | 1 |
| Braulke, F; Ganster, C; Haase, D; Leha, A; Pollock-Kopp, B; Schanz, J; Schweighöfer, A; Shirneshan, K | 1 |
| Baumann, J; Bender, M; Lübbert, M; Spindler, M; Throm, Y | 1 |
| Ando, K; Hara, R; Kawada, H; Kikkawa, E; Kitahara, T; Numata, H; Ogawa, Y; Toyosaki, M; Watanabe, S | 1 |
| Ciernikova, S; Fridrichova, I; Kalinkova, L; Sevcikova, A; Stevurkova, V | 1 |
| Madanat, YF; Xie, Z; Zeidan, AM | 1 |
| Dalal, M; Farrelly, E; Kota, V; Kristo, F; Ogbonnaya, A; Raju, A; Schroader, BK | 1 |
| Holter-Chakrabarty, J; Keruakous, AR; Khawandanah, MO; Schmidt, SA; Selby, G; Yuen, C | 1 |
| Fujimoto, M; Iwasaki, M; Kanda, J; Kataoka, A; Mizumoto, C; Nannya, Y; Ogawa, S; Oka, T; Sakurada, M; Takaori-Kondo, A; Yamamoto, Y; Yamashita, K | 1 |
| Ades, L; Balabanian, K; Bisio, V; Boy, M; Caignard, A; Clappier, E; Dulphy, N; Espeli, M; Fain, O; Fenaux, P; Gagne, K; Guidez, F; Henry, G; Kim, R; Larcher, L; Lereclus, E; Mekinian, A; Retiere, C; Rodrigues-Lima, F; Schell, B; Sebert, M; Toubert, A; Villemonteix, J; Zhao, LP | 1 |
| Saygin, C | 1 |
| Demir, AM; Demirci, U; Iflazoglu, H; Kirkizlar, O; Kirkizlar, TA; Umit, EG; Umut, A | 1 |
| Astolfi, A; Boultwood, J; Casalin, I; Cavo, M; Cocco, L; De Stefano, A; Finelli, C; Follo, MY; Indio, V; Manzoli, L; McCubrey, JA; Mongiorgi, S; Paolini, S; Parisi, S; Pellagatti, A; Pession, A; Ratti, S; Suh, PG | 1 |
| Akhmetzhanova, S; Baidurin, S; Ilmalieva, A; Orazbekova, A; Sagyndykova, G | 1 |
| Altrock, E; Costina, V; Darwich, A; Fabarius, A; Flach, J; Hofmann, WK; Jäger, E; Jann, JC; Jawhar, A; Jawhar, M; Kuzina, M; Levkin, PA; Marx, A; Metzgeroth, G; Neumaier, M; Nolte, F; Nowak, D; Nowak, V; Obländer, J; Palme, I; Rapp, F; Riabov, V; Schmitt, N; Sens-Albert, C; Sperk, E; Steiner, L; Streuer, A; Weimer, N; Weis, CA; Wolf, J; Wuchter, P; Xu, Q | 1 |
| Dalton, SO; El-Galaly, TC; Grønbæk, K; Lauritsen, TB; Nørgaard, JM; Østgård, LSG | 1 |
| Kim, E; Oh, S | 1 |
| Bourke, C; Cummings, NJ; Curtis, DJ; Das, TP; Fleming, SA; Ivey, A; Kliman, DS; North, D; O'Brien, ME; Patil, SS; Spencer, A; Swain, MI; Tan, JLC; Widjaja, JML | 1 |
| Bernard, E; Chiba, S; Creignou, M; Handa, H; Hellström-Lindberg, E; Hiramoto, N; Imada, K; Ishikawa, T; Kakiuchi, N; Kasahara, S; Kiguchi, T; Kusakabe, M; Makishima, H; Miyano, S; Miyazaki, Y; Nakagawa, M; Nakamura, N; Nannya, Y; Naoe, T; Ogawa, S; Ohtake, S; Ohyashiki, K; Papaemanuil, E; Sato, S; Shibata, Y; Shiozawa, Y; Shiraishi, Y; Taguchi, M; Takaori-Kondo, A; Takeda, J; Tanaka, H; Tobiasson, M; Tsurumi, H; Usuki, K; Watanabe, M; Yoshida, K; Zhao, L | 1 |
| Al-Kali, A; Bogenberger, J; Dueck, AC; Hashmi, S; Hogan, W; Kosiorek, HE; Litzow, MR; Mesa, R; Palmer, J; Sproat, L; Tibes, R | 1 |
| Giagounidis, A; Hertle, S; Hoef, MV; Ma, F; Santini, V; Sanz, GF; Sekeres, MA; Xiao, Z; Zeidan, AM | 1 |
| Bassi, L; Bertelli, S; Ciambella, S; Cippitelli, EE; Crocicchia, A; De Angelis, G; De Gregoris, C; Di Veroli, A; Fuschino, M; Innocenti, V; Isidori, R; Latagliata, R; Lippi, A; Mastini, C; Montanaro, M; Morucci, M; Panichi, V; Pessina, G; Pezzuti, G; Poscente, M; Randi, R; Talucci, R; Tarnani, M; Topini, G; Trapè, G | 1 |
| Cadeddu, RP; Christopeit, M; Drusenheimer, N; Esseling, E; Germing, U; Haas, R; Holtick, U; Jäger, P; Klein, S; Kobbe, G; Kröger, N; Mikesch, JH; Rautenberg, C; Scheid, C; Schroeder, T; Stelljes, M; Trenschel, R | 1 |
| Alsaadi, D; Clesham, K; Low, L; Rowan, F; Zubairu, M | 1 |
| Haiyan, C; Jie, W; Jing, L; Jun, L; Junxia, L; Ling, L; Ming, G; Xiaoqing, D | 1 |
| Chinen, S; Fuchida, SI; Fujino, T; Hirakawa, K; Inoue, Y; Kaneko, H; Kawaji-Kanayama, Y; Kawata, E; Kuroda, J; Kuwahara-Ota, S; Miyashita, A; Mizutani, S; Nishiyama, D; Okamoto, H; Shimura, Y; Tsukamoto, T; Uchiyama, H; Uoshima, N | 1 |
| Chasset, F; Fain, O; Fenaux, P; Hadjadj, J; Jachiet, V; Mekinian, A; Zhao, LP | 1 |
| Bailey, R; Beach, CL; Gaudy, A; Laille, E; Skikne, B; Zhou, S | 1 |
| Fan, J; Wen, X; Yu, J; Zheng, H; Zhu, S | 1 |
| Alvarado, Y; Bhalla, KN; Borthakur, G; Burger, J; Daver, N; DiNardo, CD; Fiskus, WC; Garcia-Manero, G; Issa, GC; Jabbour, E; Jain, N; Kadia, T; Khoury, JD; Konopleva, M; Masarova, L; Miller, D; Pemmaraju, N; Pierce, S; Qiao, W; Ravandi, F; Sasaki, K; Senapati, J; Short, NJ; Wilson, NR | 1 |
| Fujii, E; Hagihara, M; Kako, S; Kanamori, H; Kanda, Y; Kato, J; Kimura, SI; Komiya, Y; Mori, T; Nakano, H; Nakaseko, C; Nakasone, H; Okamoto, S; Sakurai, M; Tachibana, T; Tanaka, M; Wada, H; Watanabe, R; Yamamoto, W; Yokota, A | 1 |
| Ciccolini, J; Correard, F; Donnette, M; Fanciullino, R; Farnault, L; Hamimed, M; Ouafik, L; Sicard, G; Venton, G | 1 |
| Dworzak, MN; Hasle, H; Hoogendijk, R; Huitema, ADR; Janssen, JM; Laille, EJ; Lopez-Yurda, M; Niemeyer, CM; Rubio-San-Simón, A; van den Heuvel-Eibrink, MM; van Eijkelenburg, NKA; van Tinteren, H; Zecca, M; Zwaan, CM | 1 |
| Bouchla, A; Galanopoulos, A; Hatzimichael, E; Kotsianidis, I; Papageorgiou, SG; Pappa, V; Sakellari, I; Symeonidis, A; Thomopoulos, TP; Vyniou, NA; Zikos, P | 1 |
| Petzer, V; Wolf, D | 1 |
| Amaral, FMR; Batta, K; Chou, WC; Gurashi, K; Hou, HA; Hsieh, HT; Lin, CC; Liu, MC; Tien, HF; Wang, YH; Wingelhofer, B; Wiseman, DH; Yao, CY | 1 |
| Hagihara, M; Hua, J; Ide, S; Inoue, M; Ohara, S; Uchida, T | 1 |
| Ernst, T; Gawlitza, AL; Hochhaus, A; Müller, EK; Rinke, J; Sajzew, R; Schäfer, V; Speith, J | 1 |
| Daher-Reyes, GS; Merchan, BM; Yee, KWL | 1 |
| Amat, P; Calabuig, M; García, F; Hernández-Boluda, JC; Martín, I; Navarro, B; Remigia, MJ; Solano, C; Tormo, M; Villamón, E | 1 |
| Dufva, IH; Gillberg, L; Grønbæk, K; Hajkova, P; Hansen, JW; Jones, PA; Liu, M; Lykkesfeldt, J; Madaj, Z; Mogensen, JB; Nasif, A; Ohtani, H; Rapin, N; Ørskov, AD | 1 |
| Kuang, P; Liu, T; Qin, Y; Wu, Y; Zeng, Q | 1 |
| Akemoto, Y; Chinda, D; Fukuda, S; Hasui, K; Hiraga, H; Ishiguro, Y; Kamata, K; Kikuchi, H; Kishida, D; Maeda, T; Mayama, K; Mikami, T; Murai, Y; Ota, S; Sakuraba, H; Sawaya, M; Tanaka, M; Tanaka, N; Tatsuta, T; Watanabe, R; Yamagata, K | 1 |
| Steensma, DP | 5 |
| Morton, A | 1 |
| Adès, L; Chermat, F; Fenaux, P; Giagounidis, A; Gloaguen, S; Götze, KS; Krönke, J; Kubasch, AS; Middeke, JM; Mies, A; Oelschlägel, U; Platzbecker, U; Puttrich, M; Schlenk, RF; Schulze, F; Sockel, K; Stasik, S; Thiede, C; Weigt, C; William, D | 1 |
| Criscuolo, M; Fabiani, E; Falconi, G; Fianchi, L; Gurnari, C; Lavorgna, S; Lo-Coco, F; Ottone, T; Palmieri, R; Picardi, A; Piciocchi, A; Postorino, M; Voso, MT | 1 |
| Sanz, GF | 1 |
| Chandhok, NS; Lewis, R; Prebet, T | 1 |
| Berry, WA; Kelly, R | 1 |
| Attig, J; Bernard, E; Kassiotis, G; Kazachenka, A; Kordella, C; Kotsianidis, I; Lamprianidou, E; Papaemmanuil, E; Papoutselis, M; Vrachiolias, G; Young, GR; Zoulia, E | 1 |
| Atogami, S; Fujioka, M; Fukuda, Y; Furumoto, T; Hashimoto, M; Hata, T; Itonaga, H; Iwasaki, K; Kasai, S; Miyazaki, Y; Moriuchi, Y; Nakata, K; Nannya, Y; Ogawa, S; Sato, S; Sawayama, Y; Soda, H; Taguchi, M; Taniguchi, H | 1 |
| Ishii, H | 1 |
| Bewersdorf, JP; Davidoff, AJ; Gore, SD; Hu, X; Huntington, SF; Ma, X; Podoltsev, NA; Wang, R; Zeidan, AM | 1 |
| Anagnostopoulos, A; Diamantopoulos, PT; Dimou, M; Galanopoulos, A; Hatzimichael, E; Kotsianidis, I; Kotsopoulou, M; Kourakli, A; Kyriakakis, G; Megalakaki, A; Panayiotidis, P; Papadaki, H; Papageorgiou, S; Papaioannou, M; Papoutselis, MK; Pappa, V; Pontikoglou, C; Repousis, P; Solomou, E; Symeonidis, A; Tsokanas, D; Vassilopoulos, G; Viniou, NA; Zikos, P | 1 |
| Aloe Spiriti, MA; Avvisati, G; Breccia, M; Buccisano, F; Campagna, A; Carmosino, I; Cesini, L; Criscuolo, M; De Benedittis, D; De Fabritiis, P; De Luca, ML; Fianchi, L; Foà, R; Girmenia, C; Latagliata, R; Mancini, M; Maurillo, L; Niscola, P; Piccioni, A; Sarlo, C; Tafuri, A; Voso, MT | 1 |
| Itani, K; Kai, Y; Kohno, K; Kondo, Y; Matsumoto, M; Miura, G; Nakayama, T; Saburi, M; Soga, Y | 1 |
| Choi, CW; Choi, H; Jeon, MJ; Kang, KW; Kim, BS; Kim, DS; Lee, BH; Lee, SR; Park, Y; Sung, HJ; Yu, ES | 1 |
| Nohgawa, M; Oka, S; Ono, K | 2 |
| Amat, P; Calabuig, M; Chaves, FJ; Fuentes, A; García, F; Hernández-Boluda, JC; Martín, I; Navarro, B; Orts, M; Seda, E; Serrano, A; Solano, C; Tormo, M; Villamón, E; Yagüe, N | 1 |
| Al Ali, N; Auberger, P; Calleja, A; Cluzeau, T; Dadone-Montaudie, B; Gastaud, L; Karsenti, JM; Komrokji, R; Mannone, L; Moreilhon, C; Raynaud, S; Robert, G; Sallman, DA; Yun, S | 1 |
| Arlet, JB; Darnige, L; De Luna, G; Peyrard, T; Pouchot, J; Roueff, S | 1 |
| Fang, T; Shu, HE | 1 |
| Buckstein, R; Cheung, MC; Earle, CC; Liu, N; Mittmann, N; Mozessohn, L | 2 |
| Mizukawa, Y; Ohyama, M; Shimoda-Komatsu, Y; Takayama, N | 1 |
| Kawahara, N; Ogata, K; Sei, K; Yamamoto, Y | 1 |
| Abbott, LS; Cada, M; Dror, Y; Johnston, DL; Klaassen, RJ; Leung, EW; Schechter, T; Shabanova, I | 1 |
| Belickova, M; Cermak, J; Hrdinova, T; Hruba, M; Hrustincova, A; Jonasova, A; Klema, J; Krejcik, Z; Krijt, M; Kundrat, D; Merkerova, MD; Pecherkova, P; Szikszai, K; Valka, J; Vesela, J | 1 |
| Criscuolo, M; Cupelli, E; D'Alò, F; De Stefano, V; Fabiani, E; Falconi, G; Fianchi, L; Hohaus, S; Pagano, L; Zangrilli, I | 1 |
| Al Ali, N; Duong, VH; Komrokji, RS; Lancet, JE; List, AF; Padron, E; Sallman, D; Zhang, L | 1 |
| Ding, HK; DU, L; Feng, XQ; Gao, Y; Huang, JX; Lan, FF; Li, TL; Liu, SS; Mao, CX; Meng, FJ; Nie, SM; Qin, DQ; Wang, JC; Yan, XS; Yang, Q; Yao, CZ; Yuan, TL | 1 |
| Bassermann, F; Germing, U; Götze, KS; Heider, M; Kirchner, T; Müller-Thomas, C; Piontek, G; Rudelius, M; Schlensog, M | 1 |
| Adès, L; Angeli, E; Bally, C; Calleja, A; Chevallier, P; Cluzeau, T; Fenaux, P; Garnier, A; Guillaume, T; Jullien, M; Le Bourgeois, A; Le Gouill, S; Ngo Nloga, AM; Peterlin, P | 1 |
| Greil, R; Leisch, M; Pleyer, L | 1 |
| Bewersdorf, JP; Zeidan, AM | 2 |
| Akiyama, H; Hagino, T; Hidai, H; Kurimoto, M; Motomura, S; Saga, R; Shibata, Y; Shinomiya, W; Tsutsumi, H; Umeda, M | 1 |
| Alvarado, Y; Demakos, EP; Fruchtman, SM; Garcia-Manero, G; John, RB; Maniar, M; Navada, SC; OdchimarReissig, R; Ohanian, MN; Pemmaraju, N; Silverman, LR; Woodman, RC; Zbyszewski, PS | 1 |
| Andermann, TM; Batzoglou, S; Bhatt, AS; Bishara, A; Culver, RN; Handy, C; Ji, HP; Kang, JB; Moss, EL; Tkachenko, E; Weng, Z; Wood, C; Zlitni, S | 1 |
| Sallman, DA | 1 |
| Aisa, Y; Akimoto, M; Ito, C; Kamiya, T; Mizuno, K; Nakazato, T; Nishiyama-Fujita, Y; Ogura, S; Sakurai, A; Tanigawa, T | 1 |
| Endo, S; Fukao, T; Hama, A; Kadowaki, T; Kojima, S; Muramatsu, H; Nozawa, A; Ohnishi, H; Ozeki, M; Takahashi, Y; Yasue, S | 1 |
| Blijlevens, N; Cruijsen, M; de Boer, F; de Haan, AFJ; de Valk, B; Hoogendoorn, M; Huls, G; Klein, SK; Pruijt, J; Tromp, Y; van de Loosdrecht, AA; van der Spek, E; van der Velden, WJFM; van Rees, B; Vellenga, E; Verdonck, LF | 1 |
| Azizi, A; Dutta, R; Ediriwickrema, A; Gotlib, J; Greenberg, P; Iberri, D; Majeti, R; Mannis, G; Medeiros, B; Patel, SA; Shomali, W; Zhang, T | 1 |
| Andrews, C; Maze, D; Murphy, T; Sibai, H | 1 |
| Nakazato, T; Sakurai, A | 1 |
| Bartek, J; Bokorova, R; Fuchs, O; Hodny, Z; Hubackova, S; Jonasova, A; Moudra, A; Polackova, H; Pribyl, M; Salovska, B; Stopka, T; Stritesky, J; Vancurova, M | 1 |
| Kishtagari, A; Sekeres, MA | 1 |
| Franklin, AK; Gore, L; Maloney, KW; Treece, AL; Winters, AC | 1 |
| Abdel-Wahab, O; Alvarez, K; Chung, SS; Gönen, M; Klimek, VM; Mi, X; Paffenholz, SV; Park, JH; Penson, AV; Rampal, RK; Sen, F; Sigler, A; Stein, EM; Tallman, MS; Taylor, J | 1 |
| Anagnostopoulos, A; Diamantopoulos, PT; Dimou, M; Dryllis, G; Galanopoulos, A; Hatzimichael, E; Kotsianidis, I; Kotsopoulou, M; Kourakli, A; Kyrtshonis, MC; Megalakaki, A; Panayiotidis, P; Papadaki, H; Papageorgiou, S; Papaioannou, M; Papoutselis, MK; Pappa, V; Pontikoglou, C; Repousis, P; Solomou, E; Symeonidis, A; Tsokanas, D; Vassilopoulos, G; Viniou, NA; Zikos, P | 1 |
| Arbelbide, J; Belli, CB; Crisp, R; Di Stefano, M; Enrico, A; Espinosa, D; González, J; Iastrebner, M; Lazzarino, C; Perusini, MA; Pimentel, M; Pintos, N; Rosenhain, M; Schuster, S; Serrano, JC; Tavares, R | 1 |
| Ando, K; Chiwata, M; Hashimoto, M; Hata, T; Horai, M; Imaizumi, Y; Itonaga, H; Jo, T; Kamijo, R; Kawaguchi, Y; Matsuo, E; Matsuo, M; Miyazaki, Y; Moriuchi, Y; Sato, S; Sawayama, Y; Taguchi, J; Taguchi, M; Takasaki, Y; Toriyama, E; Tsushima, H; Yokota, KI; Yoshida, S | 1 |
| Cazzola, M | 1 |
| Curcio, T; Desai, P; Edirisinghe, B; Lee, S; Pianello, S; Ritchie, EK; Roboz, GJ; Samuel, M | 1 |
| Deeg, JH; Guan, F; Li, H; Li, X; Pang, X; Wan, T; Wang, H; Wang, Y; Wu, J; Xie, C | 1 |
| Geng, Y; Li, D; Li, J; Liu, L; Yang, Y | 1 |
| Beer, AGE; Laille, E; Mayer, G; Neuwirt, H; Stauder, R | 1 |
| Amigo, M; Antón, AI; Beltrán, V; Calabria, I; Carrillo-Tornel, S; Chen-Liang, TH; Cifuentes, R; Hurtado López, AM; Jerez, A; Muiña, B; Muro, M; Navarro-Villamor, N; Panadero, J; Salido, EJ; Teruel, R; Vicente, V; Zurdo, M | 1 |
| Ades, L; Fain, O; Fenaux, P; Jachiet, V; Mekinian, A; Wesner, N | 1 |
| Morita, Y | 1 |
| Alousi, AM; Champlin, RE; de Lima, M; Garcia-Manero, G; Giralt, S; Hosing, C; Lin, R; Oran, B; Popat, U; Rondon, G; Thall, PF; Woodworth, G | 1 |
| Choi, H; Kim, HJ; Kim, K; Kim, M; Kim, TM; Kim, YJ; Kwon, YR; Park, S; Ryu, D | 1 |
| Ajib, S; Bornhäuser, M; Bug, G; Crysandt, M; Dressler, S; Haas, R; Hausmann, A; Heidenreich, D; Hirschbühl, K; Hoepting, M; Jost, E; Kaivers, J; Klein, S; Kobbe, G; Koldehoff, M; Kordelas, L; Kriege, O; Müller, LP; Rautenberg, C; Schaffrath, J; Schmid, C; Schroeder, T; Schuler, E; Wagner-Drouet, EM; Wolff, D | 1 |
| He, HS; Hua, JS; Li, F; Ma, IX; Wang, XH; Wang, XQ; Wu, M; Xie, YH; Yang, RY; Ye, XJ | 1 |
| Bazani, E; Bouchla, A; Diamantopoulos, PT; Foukas, P; Galanopoulos, A; Gkontopoulos, K; Glezou, I; Kontandreopoulou, CN; Kontsioti, F; Kotsianidis, I; Lamprianidou, E; Mpakou, V; Mpamias, A; Papageorgiou, S; Pappa, V; Spathis, A; Symeonidis, A; Thomopoulos, T; Tsakiraki, Z; Viniou, NA; Zafeiropoulou, K | 1 |
| Wang, Y; Zhu, P | 1 |
| Bhari, N; Dev, T; Dudani, P | 1 |
| Alhan, C; de Miguel, D; Golbano, N; Nilsson, L; Oelschlaegel, U; Porwit, A; Psarra, K; Subirá, D; van de Loosdrecht, AA; Westers, TM | 1 |
| Bonifacio, G; Cao, X; Guerin, A; Latremouille-Viau, D; Sadek, I; Shi, S; Stein, EM; Wu, EQ | 1 |
| Dasanu, CA; Kaur, J; Tuler, S | 1 |
| Arenillas, L; Bargay, J; Borras, J; Buschbeck, M; Cabezón, M; Coll, R; Escoda, L; Font, LL; Garcia, A; Garrido, A; Hoyos, M; Jiménez, MJ; Malinverni, R; Marcé, S; Rámila, E; Tormo, M; Valcárcel, D; Vall-Llovera, F; Xicoy, B; Zamora, L | 1 |
| Abboud, C; Cashen, AF; Christ, S; DiPersio, JF; Eades, WC; Fletcher, T; Gehrs, L; Ghobadi, A; Huselton, E; Kulkarni, S; McFarland, K; Rettig, MP; Ritchey, J; Romee, R; Schroeder, MA; Stockerl-Goldstein, K; Trinkaus, K; Uy, GL; Vij, R; Westervelt, P | 1 |
| Adès, L; Bell, J; Campelo, MD; Cerrano, M; Faller, DV; Fram, RJ; Friedlander, S; Graux, C; Liesveld, J; Lopez, PF; Radinoff, A; Sangerman, MA; Sekeres, MA; Selleslag, D; Tzvetkov, N; Watts, J; Zeidner, JF; Zhao, D | 1 |
| Bowen, S; Dai, Y; Faller, DV; Friedlander, S; Haikawa, K; Hua, Z; Kupperman, E; Kuroda, S; Nakai, K; Sedarati, F; Venkatakrishnan, K; Yamamoto, Y; Yuan, Y; Zhou, X | 1 |
| Du, X; Hu, N; Pan, L; Qin, T; Qu, S; Wang, B; Wang, X; Xiao, Z; Xu, Z | 1 |
| Aisa, Y; Akimoto, M; Ito, C; Nakazato, T; Nishiyama-Fujita, Y; Sakurai, A | 1 |
| Adamopoulos, I; Bouronikou, E; Diamantopoulos, PT; Dimou, M; Galanopoulos, AG; Harchalakis, N; Hatzimichael, E; Karakatsanis, S; Kontopidou, F; Kotsianidis, I; Kourakli, A; Liapis, K; Megalakaki, A; Panayiotidis, P; Papadopoulos, V; Papageorgiou, SG; Papaioannou, M; Papoutselis, M; Pappa, V; Pontikoglou, C; Symeonidis, A; Vardi, A; Vassilakopoulos, TP; Viniou, NA; Vrachiolias, G; Ximeri, M; Zikos, P; Τsokanas, D | 1 |
| Alexopoulos, A; Bravou, V; Georgiou, S; Grafanaki, K; Koumoundourou, D; Kourakli, A; Skeparnias, I; Spiliopoulos, T; Symeonidis, A | 1 |
| Ades, L; Attalah, H; Berthon, C; Bève, B; Carpentier, AF; Chermat, F; Chevret, S; Cluzeau, T; Cuzzubbo, S; Fenaux, P; Komrokji, R; Lehmann-Che, J; Loschi, M; Madelaine, I; Miekoutima, E; Peterlin, P; Quesnel, B; Raffoux, E; Rahmé, R; Rauzy, OB; Recher, C; Sallman, DA; Sebert, M; Stamatoullas, A; Walter-Petrich, A; Willems, L | 1 |
| Angelopoulou, MK; Chatzidimitriou, C; Konstantopoulos, K; Korkolopoulou, P; Lafioniatis, S; Lakiotaki, E; Pappa, V; Plata, E; Vassilakopoulos, TP | 1 |
| Diamantopoulos, PT; Viniou, NA | 1 |
| Ababou, M; Ahchouch, S; Doghmi, K; Hammani, A; Jennane, S; Maaroufi, HE; Mahtat, M; Messaoudi, N; Mikdmae, M | 1 |
| Abe, T; Kanehira, D; Kato, T; Koinuma, M; Sagara, A; Sato, F; Yumoto, T | 1 |
| Fenaux, P; Garcia, JS; Garcia-Manero, G; Hong, WJ; Jacoby, MA; Platzbecker, U; Roboz, GJ; Steensma, DP; Swords, RT; Wolff, JE; Yang, X; Zhou, Y | 1 |
| Chen, L; Liu, W; Wang, X; Zhou, Z | 1 |
| Abbadessa, A; Alesiani, F; Allione, B; Angelucci, E; Balleari, E; Bigazzi, C; Cametti, G; Capalbo, SF; Castelli, A; Catarini, M; Ceccarelli, M; Centurioni, R; Cilloni, D; Clavio, M; Crisà, E; Crugnola, M; Danise, P; Di Tucci, AA; Fanin, R; Ferrero, D; Finelli, C; Freilone, R; Guolo, F; Miglino, M; Musto, P; Oliva, EN; Poloni, A; Salvi, F; Santini, V; Selleri, C; Zambello, R | 1 |
| Byun, SY; Cho, JY; Cho, R; Hong, J; Hur, K; Kim, M; Kim, Y; Koh, Y; Ku, Y; Lee, Y; Lee, YS; Liu, J; Park, HM; Park, JH; Shin, DY; Shum, D; Yoon, SS | 1 |
| Basak, GW; Biecek, P; Bołkun, Ł; Czyż, A; Drozd-Sokołowska, J; Dutka, M; Dwilewicz-Trojaczek, J; Giebel, S; Góra-Tybor, J; Gołos, A; Karakulska-Prystupiuk, E; Kobylińska, K; Kopińska, A; Mądry, K; Piekarska, A; Szwedyk, P; Waszczuk-Gajda, A | 1 |
| H Wei, A; Kipp, D | 1 |
| Cardamone, L; Paul, E; Rogers, B; Shaw, B; Shepherd, S; Shortt, J; Tey, A | 1 |
| Atallah, E; Badar, T | 1 |
| Liu, L; Luo, J; Mu, J; Zhang, M; Zhao, B | 1 |
| Alvarado, Y; Andreeff, M; Borthakur, G; Cortes, JE; Daver, N; DiNardo, CD; Estrov, Z; Ferrajoli, A; Garcia-Manero, G; Guerra, V; Jabbour, EJ; Jain, N; Kadia, T; Kantarjian, HM; Konopleva, M; Levis, M; Ohanian, M; Pemmaraju, N; Pierce, S; Pinsoy, MR; Ravandi, F; Swaminathan, M; Wierda, WG; Xiao, L | 1 |
| Bewersdorf, JP; Johnson, A; Lee, J; Schiffer, M; Zeidan, AM; Zhao, J | 1 |
| Bin, Z; Guoliang, H; Hongmei, N; Jiangwei, H; Jianlin, C; Liangding, H; Yao, S; Yuhang, L; Zhuoqing, Q | 1 |
| Cahill, K; Odenike, O; Patel, AA; Saygin, C | 1 |
| Abbas, HA; Chen, K; Futreal, A; Garcia-Manero, G; Im, JS; Jiang, X; Little, L; Reuben, A; Reville, PK; Sinson, JC; Yang, H | 1 |
| Munakata, S; Nohara, S; Tomimatsu, H; Uji, R; Yasumura, Y; Yuzawa, H | 1 |
| Al Ali, N; DeZern, A; Garcia-Manero, G; Komrokji, R; Lancet, J; Nazha, A; Padron, E; Roboz, G; Sallman, D; Sekeres, MA; Steensma, D | 1 |
| Avilia, S; Cappuccio, I; Cerciello, G; Giordano, C; Grimaldi, F; Pane, F; Picardi, M; Pugliese, N; Rascato, MG; Salemme, A; Severino, A | 1 |
| Cassinat, B; Diawara, Y; Fenaux, P; Giraudier, S; Maslah, N; Sebert, M | 1 |
| Kamitsuji, Y; Kobayashi, T; Komori, Y; Kuroda, J; Miyashita, A; Mizutani, S; Okamoto, H; Sasaki, N; Shimura, Y; Tsukamoto, T; Tsutsumi, Y; Uoshima, N | 1 |
| Bowen, D; Cargo, C; Culligan, D; Enright, H; Green, S; Ingram, W; Jones, GL; Kell, J; Killick, SB; Krishnamurthy, P; Kulasekararaj, A; Mills, J; Mufti, G; Payne, EM; Quek, L; Raghavan, M; Stanworth, SJ; Sternberg, A; Wiseman, DH | 1 |
| Kidoguchi, K; Shibusawa, M; Tanimoto, T | 1 |
| Andersen, MK; Breinholt, MF; Dufva, IH; El Fassi, D; Gang, AO; Grønbæk, K; Hadrup, SR; Holmberg-Thydén, S; Kadivar, M; Schejbel, L; Svane, IM | 1 |
| Bourgeois, AL; Bris, YL; Ceballos, P; Chevallier, P; François, S; Fronteau, C; Garnier, A; Giltat, A; Guillaume, T; Orvain, C; Peterlin, P; Planche, L; Thépot, S | 1 |
| Beelen, D; Bethge, W; Bleckert, G; Buchner, H; Bug, G; Giagounidis, A; Haase, D; Heinzelmann, M; Kobbe, G; Kröger, N; Krönke, J; Nolte, F; Platzbecker, U; Schäfer-Eckart, K; Scheid, C; Schlenk, RF; Sockel, K; Stadler, M; Stelljes, M; Wolf, D; Wolschke, C; Wulf, G | 1 |
| Dezern, AE; Gojo, I; Jones, RJ; Morrow, J; Prince, GT; Showel, M; Smith, BD; Symons, H; Webster, JA; Yogarajah, M; Zahurak, M | 1 |
| Apostolopoulou, C; Bouchla, A; Loucari, C; Mpazani, E; Papageorgiou, SG; Pappa, V; Thomopoulos, TP | 1 |
| Alvarado, Y; Andreeff, M; Borthakur, G; Bose, P; Chien, KS; Cortes, JE; Daver, NG; DiNardo, CD; Dong, XQ; Garcia-Manero, G; Huang, X; Jabbour, E; Jain, N; Kadia, TM; Kantarjian, HM; Kim, K; Klingner-Winton, C; Montalban-Bravo, G; Naqvi, K; Nogueras-Gonzalez, GM; Pierce, SA; Sheppard, KB; Soltysiak, KA | 1 |
| Basak, G; Centkowski, P; Czemerska, M; Czerw, T; Drozd-Sokołowska, J; Dwilewicz-Trojaczek, J; Gołos, A; Hałka, J; Hołojda, J; Kapelko-Słowik, K; Kopińska, A; Lis, K; Machowicz, R; Mądry, K; Makowska, W; Masternak, A; Pogłódek, B; Rusicka, P; Subocz, E; Szwedyk, P; Tukiendorf, A; Waszczuk-Gajda, A; Wiater, E; Zawadzka-Leska, S | 1 |
| Götze, KS; Hecker, JS; Pachzelt, L | 1 |
| Kajikawa, S; Kondo, Y; Nakagawa, N; Okumura, H; Yamada, S | 1 |
| Bae, SB; Jang, GH; Ji, YS; Kim, CK; Kim, SH; Lim, SH; Park, SK; Won, JH; Yun, J | 1 |
| Ashida, T; Inoue, H; Kakutani, H; Matsumura, I; Morita, Y; Ohyama, Y; Rai, S; Shimada, T; Tanaka, H; Taniguchi, Y; Tatsumi, Y | 1 |
| Hofmann, WK; Nolte, F; Platzbecker, U; Radsak, M; Schmidt, CS | 1 |
| Balleari, E; Bernal, T; Beyne-Rauzy, O; Bordessoule, D; Calabuig, M; Cametti, G; Campelo, MD; Cheze, S; Cony-Makhoul, P; Dreyfus, F; Fenaux, P; Fensterl, J; Ferrero, D; Gaidano, G; Germing, U; Gioia, D; Götze, K; Guerci-Bresler, A; Hamel, JF; Kaivers, J; Kelaidi, C; Komrokji, R; Kotsianidis, I; Müller-Thomas, C; Pane, F; Park, S; Ramos, F; Roboz, GJ; Rose, C; Sanna, A; Santini, V; Sanz, GF; Sapena, R; Sekeres, MA; Stamatoullas, A; Steensma, DP; Thépot, S; Toma, A; Vey, N; Wattel, E | 1 |
| Bazarbachi, A; Charafeddine, M; El-Cheikh, J; Fares, E; Kharfan-Dabaja, MA; Kreidieh, N; Mahfouz, R; Massoud, R | 1 |
| Alessandrino, EP; Candoni, A; Carella, AM; Cerqui, E; Cortelezzi, A; Criscuolo, M; Fianchi, L; Finelli, C; Leone, G; Masciulli, A; Molteni, A; Parma, M; Piciocchi, A; Poloni, A; Rambaldi, A; Salvi, F; Santarone, S; Sica, S; Spina, F; Voso, MT | 1 |
| Fukuhara, S; Kobayashi, Y; Maeshima, AM; Makita, S; Maruyama, D; Munakata, W; Taniguchi, H; Tobinai, K; Toyoda, K; Watabe, D; Yamauchi, N | 1 |
| Abdulkadir, H; Ben Azenkoud, A; Corddedu, L; De Paepe, A; Einarsdottir, E; Ekwall, K; Grövdal, M; Hellström-Lindberg, E; Jansson, M; Karimi, M; Katayama, S; Kere, J; Krjutskov, K; Lehmann, S; Lennartsson, A; Marabita, F; Tobiasson, M; Ungerstedt, J | 1 |
| Guo, H; Li, XX; Lin, J; Ma, JC; Qian, J; Wen, XM; Yan, Y; Yang, L; Zhang, TJ; Zhang, W; Zhou, JD | 1 |
| Gattermann, N; Germing, U; Goette, MC; Haas, R; Kobbe, G; Kuendgen, A; Neukirchen, J; Schroeder, T; Schuck, A | 1 |
| Hata, T | 1 |
| Appelbaum, FR; Atallah, E; Attar, EC; Bloomfield, CD; Buckstein, R; Cook, EK; Cull, AH; Erba, HP; Fang, M; Gaur, R; Gore, SD; List, AF; Litzow, MR; Moseley, A; Nazha, A; Odenike, O; Othus, M; Rauh, MJ; Roulston, D; Sekeres, MA; Stone, RM; Velasco, MR; Zhang, Y | 1 |
| Beyne-Rauzy, O; Braun, T; Chait, Y; Chretien, ML; Duchmann, M; Dumas, PY; Fenaux, P; Gruson, B; Guieze, R; Hirsch, P; Itzykson, R; Laribi, K; Legros, L; Micol, JB; Park, S; Pilorge, S; Platzbecker, U; Sahnes, L; Salanoubat, C; Sébert, M; Solary, E; Vey, N | 1 |
| Matsuguma, M; Nakamura, Y; Tanaka, M; Tanaka, Y; Tanizawa, Y; Tokunaga, Y; Yamamoto, K; Yujiri, T | 1 |
| Ades, L; Auberger, P; Braun, T; Chomienne, C; Cluzeau, T; Dombret, H; Durand, L; Fenaux, P; Garnier, G; Gastaud, L; Ginet, C; Goursaud, L; Hirsch, P; Karsenti, JM; Luciano, F; Nloga, AM; Padua, RA; Raffoux, E; Robert, G; Rohrlich, P; Vidal, V | 1 |
| Egle, A; Grabmer, C; Greil, R; Jungbauer, C; Leisch, M; Lindlbauer, N; Pleyer, L; Rohde, E; Weiss, L | 1 |
| Acharyya, S; Borbenyi, Z; Breccia, M; Cavenagh, JD; DeAngelo, DJ; Egyed, M; Fenaux, P; Garcia-Manero, G; Gazi, L; Graux, C; Ide, S; Illes, A; Lee, JH; MacWhannell, A; Marker, M; Ottmann, OG; Salman, H; Sekeres, MA; Stauder, R; Valcarcel, D; Yee, K; Zhu, N | 1 |
| Craddock, C | 1 |
| Eslin, D; Glade Bender, JL; Glasser, CL; Lee, A; Marks, L; Modak, S | 1 |
| Baker, K; Deeg, HJ; Festuccia, M; Gooley, TA; Sandmaier, BM; Scott, BL | 1 |
| Delgado, E; López, B; Sampol, A | 1 |
| Goswami, M; Hourigan, CS; Lindblad, KE; Oetjen, KA | 1 |
| Hiraga, J; Kagami, Y; Kato, H; Narita, M; Suzuki, N; Takagi, Y; Ujihira, N | 1 |
| Miyazaki, Y | 2 |
| Ito, S; Kudo, D; Kuroda, A; Shimizu, M; Shinagawa, A; Suyama, T | 1 |
| Aiba, K; Dobashi, N; Fukushima, R; Ishii, H; Ito, Y; Machishima, T; Ohba, R; Shiota, Y; Usui, N; Yahagi, Y; Yamauchi, H; Yano, S; Yokoyama, H | 1 |
| Ali, Z; Arthur, C; Beck, D; Boultwood, J; Campbell, PJ; Chandrakanthan, V; Crispin, P; Curnow, J; Deshpande, NP; Galbraith, S; Hellstrom-Lindberg, E; Huang, Y; Jacobsen, SEW; Karimi, M; Knezevic, K; Kulasekararaj, AG; Kumari, A; Lindeman, R; Lynch, K; MacKenzie, KL; Mufti, GJ; Olivier, J; Papaemmanuil, E; Pellagatti, A; Pimanda, JE; Ramakrishna, R; Richards, LA; Roncolato, F; Stark, R; Thoms, JAI; Tobiasson, M; Tursky, ML; Unnikrishnan, A; Verma, A; Warburton, P; Wilkins, MR; Wilson, SR; Woll, PS; Wong, JWH; Young, B | 1 |
| Carraway, HE; Gore, SD; Keefer, J; Prebet, T; Press, KR; Sakoian, S; Uy, N | 1 |
| Gore, SD; Komrokji, RS; Sekeres, MA; Stahl, M; Steensma, DP; Zeidan, AM | 1 |
| Santini, V | 4 |
| Ragon, BK; Savona, MR | 1 |
| Ai, H; Chen, L; Mi, RH; Song, YP; Wang, P; Wei, XD; Yin, QS; Yuan, FF | 1 |
| Binder, G; Broder, MS; Chang, E; Cogle, CR; McGuire, M; Papoyan, E; Reddy, SR | 1 |
| Cheong, JW; Kim, H; Kim, HJ; Kim, MK; Kim, YJ; Lee, GW; Lee, HS; Lee, JH; Lee, WS; Lim, SN; Sohn, SK; Yoon, SS | 1 |
| Bailen, A; Calderon, C; Casaño, FJ; Falantes, J; Hermosin, L; Hernandez-Mohedo, F; Hernández-Rivas, JM; Hernandez-Sanchez, JM; Labrador, M; Lumbreras, E; Medina Perez, A; Sanchez-Garcia, J; Serrano, J; Solé Rodriguez, M; Torres-Sabariego, A; Vahí, M | 1 |
| Abaza, YM; Alfonso, A; Borthakur, G; Chang, JE; Chong, TH; Chuah, C; Dong, XQ; Durkes, DE; Estrov, Z; Ferrajoli, A; Foudray, MC; Garcia-Manero, G; Goh, BC; Jabbour, EJ; Kadia, TM; Kantarjian, HM; Koh, LP; Konopleva, MY; Wierda, WG | 1 |
| Aguilera, P; Badenas, C; Combalia, A; Costa, D; Gaya, A; Guijarro, F; Jorge, S; Podlipnik, S; Rozman, M; To-Figueras, J | 1 |
| Aoki, S; Fuse, K; Katagiri, T; Masuko, M; Miyakoshi, S; Shibasaki, Y; Sone, H; Takizawa, J; Tanaka, T; Ushiki, T | 1 |
| Bitsani, C; Dimitrakopoulou, A; Dimou, M; Kotsanti, S; Kyrtsonis, MC; Panayiotidis, P; Papaioannou, P; Petsa, P; Roumelioti, M | 1 |
| Kobayashi, T; Kobayashi, Y; Matsuoka, F; Minami, H; Munakata, W; Ogura, M; Shimada, F; Tajima, T; Taniwaki, M; Uchida, T; Yakushijin, K; Yonemura, M | 1 |
| March López, P; Martí, JM; Nicolás Picó, J; Pardo Pastor, J; Pineda, A; Redondo Capafons, S | 1 |
| Zeidan, AM | 1 |
| Dodillet, H; Kreuzer, KA; Monsef, I; Skoetz, N | 1 |
| Thakral, B; Wang, SA | 1 |
| Bug, G; Lang, F; Ottmann, OG; Pfeifer, H; Schnittger, S; Wunderle, L | 1 |
| Ferrari, M; Hu, Z; Nizzero, S; Ramirez, MR; Shen, H; Shi, C; Wu, X; Zhang, G; Zhou, J | 1 |
| Doghmi, K; El Haddad, M; Jennane, S; Mahtat, EM; Mikdame, M | 1 |
| Caccetta, T; Harvey, N; Kumarasinghe, SP; Tiwari, SM | 1 |
| Fujiwara, S; Katayama, Y; Kawano, H; Matsui, T; Nakano, H; Nishigori, C; Taketani, S; Yoshioka, A | 1 |
| Abboud, CN; Ali, AM; Cashen, AF; DiPersio, JF; Fehniger, TA; Gao, F; Ghobadi, A; Jacoby, MA; Oh, ST; Pusic, I; Romee, R; Schroeder, MA; Stockerl-Goldstein, KE; Uy, GL; Vij, R; Wartman, LD; Weisel, D; Welch, JS; Westervelt, P | 1 |
| Hao, JX; Li, J; Wu, D; Zhang, M | 1 |
| Guo, R; Han, HH; Jiang, ZX; Liu, YF; Sun, H; Wang, M | 1 |
| Adès, L; Ali, NH; Cluzeau, T; Eclache, V; Fenaux, P; Gyan, E; Hobson, S; Komrokji, RS; List, A; Prebet, T; Sanna, A; Santini, V; Sébert, M; Sekeres, MA | 1 |
| Fliss, A; Grinblatt, D; Komrokji, R; Lyons, RM; Sayar, H; Silverman, LR; Sugrue, MM; Swern, AS; Tobiasson, M; Tu, N; Vij, R | 1 |
| Cai, X; Dai, H; Ke, M; Liu, Z; Luo, H; Yan, M; Zeng, W | 1 |
| Flotho, C; Lübbert, M; Sommer, S | 1 |
| Elnair, R; Galal, A; Hassouna, T; Sethi, P | 1 |
| Germing, U; Haas, R; Kobbe, G; Rautenberg, C; Schroeder, T | 1 |
| Bornhäuser, M; Bug, G; Germing, U; Geyh, S; Haas, R; Hopfer, O; Klein, S; Kobbe, G; Kondakci, M; Krüger, W; Nachtkamp, K; Platzbecker, U; Rautenberg, C; Schroeder, T; Steinmann, J | 1 |
| Barulli, S; Ciabatti, E; Fabiani, E; Fazi, P; Finelli, C; Fuligni, F; Gabucci, E; Galimberti, S; Giacomini, E; Graziano, F; Isidori, A; Loscocco, F; Magnani, M; Magro, D; Piccaluga, P; Piciocchi, A; Rocchi, M; Ruzzo, A; Vignetti, M; Visani, G; Volpe, A; Voso, MT | 1 |
| Allen, BG; Mamarbachi, M; Mayer, G; Mnasri, N | 1 |
| Odenike, O | 1 |
| Ahn, JS; Bae, SH; Cho, YY; Chung, JS; Kim, H; Kim, HJ; Kim, SH; Kim, YS; Kwon, JH; Lee, HS; Lee, IH; Lee, JH; Lee, SM; Lee, WS; Lee, YJ; Moon, JH; Park, SW; Shin, HJ; Sohn, SK; Song, IC | 1 |
| Azarnia, N; Fenaux, P; Fruchtman, SM; Garcia-Manero, G; Kantarjian, H; Komrokji, R; Nazha, A; Platzbecker, U; Prebet, T; Roboz, G; Santini, V; Sekeres, MA; Silverman, LR; Steensma, DP; Zbyszewski, PS | 1 |
| Al-Ali, HK; Beach, CL; Butrym, A; Candoni, A; Cavenagh, J; Del Castillo, TB; Döhner, H; Dombret, H; Falantes, J; Jang, JH; Kumar, R; Minden, MD; Récher, C; Sandhu, I; Schuh, AC; Selleslag, D; Seymour, JF; Songer, S; Stone, RM; Weaver, J; Wierzbowska, A | 1 |
| Hesson, LB; Nunez, AC; Pickford, R; Pimanda, JE; Raftery, MJ; Unnikrishnan, A; Verma, A; Vo, ANQ | 1 |
| Enoki, E; Hagiwara, S; Inoue, H; Kamata, K; Komeda, Y; Kono, M; Kudo, M; Matsumura, I; Minaga, K; Okamoto, A; Sakurai, T; Watanabe, T | 1 |
| Davidoff, AJ; Gore, SD; Hu, X; Huntington, SF; Ma, X; Podoltsev, NA; Stahl, M; Wang, R; Zeidan, AM | 1 |
| Guo, XZ; Huang, YQ; Pan, JX; Wu, SX; Zhang, XY | 1 |
| Garcia-Manero, G; Jabbour, E; Montalban-Bravo, G | 1 |
| Beach, CL; Dong, Q; Du, X; Hu, Y; Jin, J; Lai, YY; Laille, E; Li, X; Liu, T; Shen, ZX; Songer, S; Sun, A; Xiao, Z; Yu, L | 1 |
| Fuchs, EJ | 1 |
| Deng, C; Du, X; Geng, S; Lai, P; Li, M; Lu, Z; Weng, J; Wu, P | 1 |
| Burgstaller, S; Egle, A; Faber, V; Geissler, K; Greil, R; Huemer, F; Lang, A; Machherndl-Spandl, S; Neureiter, D; Pfeilstöcker, M; Pichler, A; Pleyer, L; Sperr, W; Stampfl, M; Stauder, R; Voskova, D; Weiss, L; Zebisch, A | 1 |
| Abe, M; Arai, N; Ariizumi, H; Baba, Y; Fujiwara, S; Harada, H; Hattori, N; Kabasawa, N; Kawaguchi, Y; Murai, S; Nakamaki, T; Saito, B; Sasaki, Y; Shimada, S; Tsukamoto, H; Uto, Y; Yanagisawa, K | 1 |
| Almohareb, F; El Fakih, R; Hassanein, M; Komrokji, R; Rasheed, W; Shaheen, M | 1 |
| Allison, J; Boddu, P; Daver, N; Garcia-Manero, G; Kantarjian, H; Sharma, P; Yadav, SS | 1 |
| Chang, GS; DiPersio, JF; Duncavage, EJ; Elliott, K; Fronick, CC; Fulton, RS; Graubert, TA; Heath, SE; Jacoby, MA; Ley, TJ; Link, DC; Miller, CA; O'Laughlin, M; Pusic, I; Robinson, J; Shao, J; Walter, MJ; Welch, JS; Westervelt, P | 1 |
| Adès, L; Ali, A; Ben Abdelali, R; Clappier, E; Dal Bello, R; Dombret, H; Fenaux, P; Hernandez, L; Itzykson, R; Massé, A; Penneroux, J; Pimanda, J; Preudhomme, C; Puissant, A; Quentin, S; Raffoux, E; Renneville, A; Soulier, J; Unnikrishnan, A | 1 |
| Ame, S; Badiella, L; Bargay, J; Berthon, C; Beyne-Rauzy, O; Bordessoule, D; Cañizo, C; Cedena, T; de Botton, S; Delaunay, J; Díez-Campelo, M; Fenaux, P; Guieze, R; Gyan, E; Hernández-Rivas, JM; Isnard, F; Itzykson, R; López-Cadenas, F; Lorenzo, JI; Luño, E; Muñoz, JA; Park, S; Pérez Guallar, J; Perez-Oteyza, J; Rojas, SM; Salanoubat, C; Sanz, G; Stamatoullas, A; Such, E; Vey, N; Visanica, S | 1 |
| Hawks, KG; Maples, KT; McCarty, JM; Sabo, RT; Toor, AA | 1 |
| Belickova, M; Cermak, J; Dyr, JE; Hrustincova, A; Jonasova, A; Krejcik, Z; Merkerova, MD; Votavova, H | 1 |
| Imoto, S; Konuma, T; Miyano, S; Shimizu, E; Takahashi, S; Takei, T; Tojo, A; Yamaguchi, R; Yokoyama, K | 1 |
| Bouronikou, E; Diamantopoulos, P; Galanopoulos, AG; Hatzimichael, E; Kontos, CK; Kotsianidis, I; Megalakaki, A; Mparmparousi, D; Panayiotidis, P; Papadaki, H; Papageorgiou, SG; Pappa, V; Poulakidas, E; Symeonidis, A; Vasilatou, D; Vassilakopoulos, TP; Viniou, NA; Zikos, P | 1 |
| Cevreska, L; Dimovski, AJ; Ivanovski, M; Matevska-Geshovska, N; Noveski, P; Panovska-Stavridis, I; Pivkova-Veljanovska, A; Plaseska-Karanfilska, D; Popova-Labaceska, M; Trajkova, S | 1 |
| Ma, Y; Shen, J; Wang, LX | 1 |
| Diamantopoulos, P; Garefalakis, G; Giannakopoulou, N; Rougala, N; Skarlatou, V; Spetsieris, N; Viniou, NA; Zervakis, K | 1 |
| Armağan, B; Bilgin, E; Büyükaşık, Y; Erden, A; Kalyoncu, U; Kılıç, L; Sarı, A | 1 |
| Bandeira, SP; Borges, DP; Brilhante, RSN; Cordeiro, RA; Magalhaes, SMM; Pinheiro, RF; Rocha, MFG; Santos, AWA; Sidrim, JJ; Valença Junior, JT | 1 |
| Hiraga, J; Kagami, Y; Narita, M; Suzuki, N; Takagi, Y; Tomita, A | 1 |
| Buckstein, R; Cheung, MC; Fallahpour, S; Gill, T; Lau, O; Maloul, A; Mozessohn, L; Zhang, L | 1 |
| Aoyagi, T; Daitoku, S; Kuroiwa, M; Tada, S; Takao, S | 1 |
| Alani, M; Baugier de Materre, A; Besançon, A; Bolle, D; Denizon, N; Farhi, J; Ghnaya, H; Laribi, K; Le Bourdelles, S | 1 |
| Davidoff, AJ; DeVeaux, M; Giri, S; Gore, SD; Huntington, S; Ma, X; Podoltsev, N; Stahl, M; Wang, R; Zeidan, AM | 1 |
| Champlin, RE; Craddock, C; de Lima, M; Giralt, SA; Hetzer, J; Hubbell, B; Laille, E; Oran, B; Papadopoulos, EB; Scott, BL; Skikne, BS; William, BM | 1 |
| Goo, K; Roswarski, J; Uy, R | 1 |
| Han, Y; Pan, T; Qi, J; Wu, D; Yang, L; You, T; Zhu, L | 1 |
| Chen, W; Malli, A; Mumtaz, K; Sobotka, LA | 1 |
| Amraoui, K; Colombat, P; Delain, M; Ertault, M; Ferreira-Maldent, N; Gyan, E; Hérault, O; Jonville-Béra, AP; Ponard, A; Regina, S | 1 |
| Borthakur, G; Burger, J; Daver, N; DiNardo, CD; Garcia-Manero, G; Gasior, Y; Kantarjian, H; Konopleva, M; Kornblau, S; Ohanian, M; Pierce, S; Rezvani, K; Yalniz, FF | 1 |
| Bouronikou, E; Diamantopoulos, P; Galanopoulos, A; Hatzimichael, E; Kontos, CK; Kotsianidis, I; Panayiotidis, P; Papadaki, H; Papageorgiou, SG; Pappa, V; Poulakidas, E; Symeonidis, A; Vassilakopoulos, TP; Viniou, NA; Zikos, P | 1 |
| Becerra, C; Conkling, P; Dong, Q; Kellerman, A; Kingsley, EC; Kolibaba, K; Laille, E; Morris, JC; Rifkin, RM; Savona, MR; Skikne, BS; Ukrainskyj, SM | 1 |
| Kiselev, P; Ma, X; Scott, BL; Steensma, DP; Sugrue, MM; Swern, AS | 1 |
| Ahn, JS; Ahn, SY; Bae, SH; Baek, DW; Cho, YY; Choi, Y; Kim, H; Kim, HJ; Lee, HS; Lee, SM; Lee, WS; Lee, YJ; Moon, JH; Park, SW; Shin, HJ; Sohn, SK; Song, IC | 1 |
| Li, Y; Lv, N; Wang, H; Wang, L; Yu, L | 1 |
| Hannig, CV; Harde, J; Harich, HD; Klausmann, M; Losem, C; Müller, J; Niemeier, B; Potthoff, K; Schmitz, S; Tessen, HW; Wehmeyer, J; Zaiss, M | 1 |
| Bouchla, A; Bouronikou, E; Diamantopoulos, MA; Diamantopoulos, P; Galanopoulos, A; Hatzimichael, E; Kontos, CK; Kotsianidis, I; Mparmparousi, D; Panayiotidis, P; Papadaki, H; Papageorgiou, SG; Pappa, V; Poulakidas, E; Repousis, P; Symeonidis, A; Vasilatou, D; Vassilakopoulos, TP; Viniou, NA; Zikos, P | 1 |
| Doi, A; Fujii, T; Irie, S; Matsui, T; Ohno, N; Sahara, N; Sakamoto, N | 1 |
| Basak, G; Boguradzki, P; Chmarzyńska-Mróz, E; Drozd-Sokołowska, J; Dwilewicz-Trojaczek, J; Jędrzejczak, W; Karakulska-Prystupiuk, E; Kulikowska, A; Paluszewska, M; Stefaniak, A; Waszczuk-Gajda, A | 1 |
| Al-Kali, A; Alkhateeb, HB; Almasri, J; Damlaj, M; Firwana, B; Murad, MH; Sonbol, MB; Wang, Z | 1 |
| Candoni, A; Cerqui, E; Criscuolo, M; Fabiani, E; Falconi, G; Fianchi, L; Finelli, C; Leone, G; Lindfors Rossi, EL; Lo-Coco, F; Molteni, A; Ottone, T; Parma, M; Piciocchi, A; Santarone, S; Sica, S; Voso, MT | 1 |
| Appelbaum, FR; Erba, HP; Estey, E; Garcia-Manero, G; Nand, S; Othus, M; Sekeres, MA | 1 |
| Ali, A; Montoro, J; Raza, A; Yerlikaya, A | 1 |
| Ades, L; Braun, T; Chevret, S; Cony-Makhoul, P; Delaunay, J; Desseaux, K; Fenaux, P; Guerci-Bresler, A; Legros, L; Sebert, M | 1 |
| Ramos, F | 1 |
| Baldus, CD; Bochtler, T; Borkmann, C; Bornhäuser, M; Bug, G; Dührsen, U; Ehninger, G; Fransecky, L; Götze, KS; Groth, C; Hänel, M; Herbst, R; Krämer, A; Kramer, M; Kubasch, AS; Mende, M; Middeke, JM; Mütherig, A; Noppeney, R; Oelschlägel, U; Platzbecker, U; Röllig, C; Schetelig, J; Schubert, A; Serve, H; Sockel, K; Stelljes, M; Stölzel, F; Thiede, C; von Bonin, M; Wolf, D | 1 |
| Alvarez, MC; Cury, NM; Dos Santos, GP; Duarte, ADSS; Favaro, P; Ferro, KP; Giardini Rosa, R; Longhini, AL; Lopes, MR; Machado-Neto, JA; Pericole, FV; Roversi, FM; Saad, STO; Yunes, JA | 1 |
| Cairoli, R; Cassin, R; Cortelezzi, A; Fattizzo, B; Freyrie, A; Giannarelli, D; Molteni, A; Pennisi, M; Reda, G; Riva, M | 1 |
| Bassermann, F; Buschbeck, M; Garz, AK; Götze, KS; Grath, S; Hecker, J; Huberle, C; Kyncl, M; Leonhardt, H; Malinverni, R; Metzeler, KH; Mulholland, CB; Müller-Thomas, C; Niggemeyer, J; Oostendorp, RAJ; Pagel, C; Weickert, M; Wenk, C; Witham, D | 1 |
| Bari, S; Cheung, AMS; Dighe, N; Fan, X; Ghosh, S; Hota, M; Hwang, WYK; Poon, Z; Venkatesan, SS | 1 |
| Albano, F; Anelli, L; Brunetti, C; Carluccio, P; Casieri, P; Coccaro, N; Cumbo, C; Impera, L; Minervini, A; Minervini, CF; Orsini, P; Parciante, E; Ricco, A; Specchia, G; Tota, G; Zagaria, A | 1 |
| Armatys, A; Boral, K; Chromik, K; Dworaczek, M; Helbig, G; Koclęga, A; Kopińska, AJ; Markiewicz, M; Panz-Klapuch, M; Woźniczka, K | 1 |
| Kamiya, T; Nakazato, T | 1 |
| Boasman, K; Graham, C; Rinaldi, CR; Saunthararajah, Y; Simmonds, MJ | 1 |
| Armstrong, RN; Bochicchio, MT; Boultwood, J; Cavo, M; Cocco, L; De Fanti, S; Finelli, C; Follo, MY; Gobbi, M; Luiselli, D; Manzoli, L; Martinelli, G; McCubrey, JA; Miglino, M; Mongiorgi, S; Parisi, S; Pellagatti, A; Ratti, S; Russo, D; Suh, PG | 1 |
| Angelopoulou, M; Christopoulou, G; Diamantopoulos, PT; Dimou, M; Galanopoulos, A; Kontandreopoulou, CN; Kotsianidis, I; Kourakli, A; Kyrtsonis, MC; Panayiotidis, P; Papageorgiou, S; Pappa, V; Roumelioti, M; Siakantaris, M; Solomou, E; Symeonidis, A; Vassilakopoulos, T; Viniou, NA | 1 |
| Adamopoulos, I; Christoulas, D; Delimpasis, S; Diamantopoulos, P; Dimou, M; Galanopoulos, A; Hatzimichael, E; Konstantinos Papoutselis, M; Kontopidou, F; Kotsianidis, I; Kotsopoulou, M; Koumbi, D; Kourakli, A; Kyriakakis, G; Kyrtsonis, MC; Megalakaki, A; Mparmparousi, D; Panayiotidis, P; Papadaki, HA; Papageorgiou, S; Pappa, V; Repousis, P; Symeonidis, A; Tsokanas, D; Variami, E; Vassilopoulos, G; Viniou, NA; Zikos, P | 1 |
| de Witte, T | 1 |
| Ravandi, F; Short, NJ | 1 |
| Angelopoulou, M; Dagla, K; Gkirkas, K; Gkodopoulos, K; Grigoriou, E; Kapsimalli, V; Karagiannidou, A; Konsta, E; Lowdell, M; Pappa, V; Stamouli, M; Stavroulaki, G; Tsirigotis, P; Tsirogianni, M | 1 |
| Alani, M; Baugier de Materre, A; Besançon, A; Bolle, D; Denizon, N; Farhi, J; Ghnaya, H; Laribi, K; Mheidly, K | 1 |
| Chen, YY; Guo, SQ; Li, YH; Liu, S; Shi, R | 1 |
| Abbasi, T; Abbott, D; Cogle, CR; Drusbosky, L; Fullerton, A; Gutman, JA; Hammes, A; Hemenway, G; Jordan, CT; Miltgen, N; Pollyea, DA; Schatz, D; Singh, NK; Smith, C; Stevens, B; Vali, S; Wei, Q; Winters, A | 1 |
| Hale, G; Oshrine, BR; Petrovic, A; Shyr, D | 1 |
| Duchmann, M; Itzykson, R | 2 |
| Caughey, G; Chhetri, R; Edwards, S; Germing, U; Hiwase, D; Molga, A; Ross, D; Shakib, S; Singhal, D; Singhal, N; To, LB; To, T; Wall, M; Wee, LY | 1 |
| Aziz, M; Bandyopathyay, D; Chung, H; Claiborne, J; Clark, W; Hawks, K; McCarty, J; Roberts, C; Simmons, G; Toor, A; Wiedl, C | 1 |
| Adès, L; Fenaux, P; Sebert, M | 1 |
| Ahn, JS; Baek, DW; Cho, YY; Choi, Y; Chung, JS; Kim, HJ; Lee, GW; Lee, HS; Lee, SM; Lee, WS; Lee, YJ; Lim, SN; Moon, JH; Park, S; Shin, HJ; Sohn, SK | 1 |
| Borel, C; Chevallier, P; Garnier, A; Gaugler, B; Guillaume, T; Huynh, A; Labopin, M; Magro, L; Malard, F; Milpied, N; Mohty, M; Moreau, P; Peterlin, P; Rubio, MT; Tabrizi, R; Vigouroux, S; Yakoub-Agha, I | 1 |
| Abedin, SM; Platanias, LC | 1 |
| Alunni Fegatelli, D; Breccia, M; Colafigli, G; Efficace, F; Foà, R; Latagliata, R; Mancini, M; Molica, M; Rizzo, L; Scalzulli, E | 1 |
| Davidoff, AJ; Giri, S; Gore, SD; Huntington, SF; Ma, X; Podoltsev, NA; Stahl, M; Wang, R; Zeidan, AM; Zhu, W | 1 |
| Bernard, E; Bezirgiannidou, Z; Kordella, C; Kotsianidis, I; Lamprianidou, E; Papaemmanuil, E; Papoutselis, M; Vrachiolias, G; Zoulia, E | 1 |
| Cavelier, L; Pandzic, T; Sander, B; Tobiasson, M; Wahlin, BE | 1 |
| Blanco, ML; Brunet, S; Bussaglia, E; Carricondo, M; Esquirol, A; García-Cadenas, I; Garrido, A; Gich, I; Hoyos, M; Martino, R; Nomdedéu, JF; Pratcorona, M; Santaliestra, M; Sierra, J | 1 |
| Kunacheewa, C; Owattanapanich, W; Thongthang, P; Ungprasert, P; Utchariyaprasit, E | 1 |
| Bewersdorf, JP; Stahl, M; Zeidan, AM | 1 |
| Akahane, D; Asano, M; Azuma, K; Fujimoto, H; Imanishi, S; Ito, Y; Kobayashi-Kawana, C; Ohyashiki, JH; Ohyashiki, K; Umezu, T | 1 |
| Gattermann, N; Germing, U; Kaivers, J; Kobbe, G; Kündgen, A; Schroeder, T | 1 |
| Bouchla, A; Bouronikou, E; Diamantopoulos, P; Galanopoulos, A; Hatzimichael, E; Karousi, P; Kontos, CK; Kotsianidis, I; Mparmparousi, D; Panayiotidis, P; Papadaki, H; Papageorgiou, SG; Pappa, V; Poulakidas, E; Repousis, P; Symeonidis, A; Vassilakopoulos, TP; Viniou, NA; Zikos, P | 1 |
| Kubasch, AS; Platzbecker, U | 1 |
| Edel, Y; Hodak, E; Kaftory, R; Lapidoth, M; Levi, A; Sherman, S; Snast, I | 1 |
| Cerqui, E; Criscuolo, M; Fabiani, E; Falconi, G; Fianchi, L; Finelli, C; Gurnari, C; Laurenti, L; Lo-Coco, F; Pelosi, E; Piciocchi, A; Postorino, M; Screnci, M; Testa, U; Voso, MT; Zangrilli, I | 1 |
| Cho, SH; Choi, Y; Joo, YD; Kim, DY; Kim, SD; Lee, JH; Lee, KH; Lee, SM; Lee, WS | 1 |
| Bang, SM; Cheong, JW; Kim, BS; Kim, CS; Kim, HJ; Kim, I; Kim, SY; Kim, YK; Lee, HG; Lee, JH; Lee, JO; Lee, YG; Min, YH; Mun, YC; Park, J; Park, S; Park, Y; Seong, CM; Yi, HG; Yoon, SS | 1 |
| Seiter, K | 1 |
| Kami, M; Kobayashi, K; Nishikawa, Y; Okuda, S; Takebayashi, C; Tanimoto, T | 1 |
| Han, XP; Huang, WR; Jiang, MM; Jing, Y; Mei, JH; Wang, QS; Wang, SH; Yang, H; Yu, L; Zhang, SS; Zhu, HY | 1 |
| Adès, L; Bally, C; Dartigeas, C; de Botton, S; de Renzis, B; Dreyfus, F; Fadlallah, J; Fenaux, P; Itzykson, R; Quesnel, B; Thépot, S; Turlure, P; Vey, N | 1 |
| Matsumura, I; Morita, Y; Tanaka, H | 1 |
| Bug, G; Cadeddu, RP; Czibere, A; Dienst, A; Fenk, R; Fröbel, J; Germing, U; Haas, R; Kobbe, G; Kröger, N; Platzbecker, U; Schroeder, T; Uharek, L | 1 |
| Hashimoto, S; Kawajiri, C; Nakaseko, C; Ohwada, C; Sakai, S; Sakaida, E; Shimizu, N; Takagi, T; Takeda, Y; Takeuchi, M; Tanaka, H; Tougasaki, E | 1 |
| Brossart, P; Feldmann, G; von Lilienfeld-Toal, M | 1 |
| Beach, CL; Bennett, JM; Fenaux, P; Gore, SD; Hellström-Lindberg, E; List, AF; Santini, V; Seymour, JF; Silverman, LR; Swern, AS | 1 |
| Bocchia, M; Candoni, A; Cattina, F; Clissa, C; Cocco, L; Defina, M; Fanin, R; Filì, C; Finelli, C; Follo, MY; Gobbi, M; Iacobucci, I; Malagola, M; Manzoli, L; Martinelli, G; Russo, D; Skert, C; Spedini, P | 1 |
| Benet, B; Billot, K; d'Allard, D; Ettou, S; Fontenay, M; Goodhardt, M; Humbrecht, C; Kosmider, O; Mariot, V; Mayeux, P; Solary, E | 1 |
| Almeida, A; Esteves, S; Pierdomenico, F | 1 |
| Ali, NA; Corrales-Yepez, M; Epling-Burnette, PK; Kharfan-Dabaja, M; Komrokji, RS; Lancet, JE; List, AF; Mishra, A; Padron, E; Pinilla-Ibarz, J; Zhang, L | 1 |
| de Fabritiis, P; Giovannini, M; Niscola, P; Palombi, M; Perrotti, A; Scaramucci, L; Tendas, A; Trawinska, MM | 1 |
| Freeman, CL; Giles, FJ; Keane, N; Krawczyk, J; O'Dwyer, M; Swords, R | 1 |
| Blau, IW; Böhme, A; Braulke, F; Brümmendorf, TH; Bug, G; Detken, S; Ganster, C; Germing, U; Giagounidis, AA; Götze, K; Haase, D; Hofmann, WK; Jentsch-Ullrich, K; Jung, K; Lübbert, M; Metz, M; Müller-Thomas, C; Ottmann, O; Pfeiffer, S; Platzbecker, U; Schafhausen, P; Schanz, J; Schlenk, RF; Schmidt, B; Seraphin, J; Shirneshan, K; Stadler, M; Trümper, L | 1 |
| Germing, U; Platzbecker, U | 1 |
| Beijnen, JH; Derissen, EJ; Schellens, JH | 1 |
| Chang, CK; Li, X; Song, LX; Wu, LY; Zhang, Y | 1 |
| Al Ustwani, O; Ambrus, J; Barcos, M; Block, AM; Ford, LA; Griffiths, EA; Sait, SJ; Thompson, JE; Vigil, CE; Wang, ES; Wetzler, M | 1 |
| Douvali, E; Kotsianidis, I; Papadopoulos, V; Papoutselis, M; Spanoudakis, E; Tsatalas, C; Vassilakopoulos, TP | 1 |
| Ichikawa, M; Iizuka, H; Kurokawa, M; Masuda, A; Nannya, Y; Yamamoto, G; Yatomi, Y; Yoshimi, A | 1 |
| Berdeja, JG; Borthakur, G; Estrov, Z; Faderl, S; Gabrail, N; Garcia-Manero, G; Godley, LA; Jabbour, E; Kantarjian, H; Kassalow, L; Maddipoti, S; Nadeem, A; Yang, H | 1 |
| Abáigar, M; Aguilar, C; Alonso, JM; Benito, R; de las Heras, N; del Cañizo, MC; Díez-Campelo, M; Fuertes, M; Hermosín, L; Hernández-Rivas, JM; Megido, M; Ramos, F; Recio, I; Rodríguez, JN; Sánchez-del-Real, J | 1 |
| Estey, EH | 1 |
| Auberger, P; Cassuto, JP; Cluzeau, T; Gabriel Fuzibet, J; Garnier, G; Gastaud, L; Gutnecht, J; Karsenti, JM; Legros, L; Montagne, N; Mounier, N; Raynaud, S; Re, D; Richez, V | 1 |
| Alessandrino, EP; Bacigalupo, A; Della Porta, MG; Pascutto, C; Rambaldi, A | 1 |
| Gore, SD; Komrokji, RS; Zeidan, AM | 1 |
| Cortes, J; Garcia-Manero, G; Jabbour, E; Kadia, T; Kantarjian, H; Malik, A; O'Brien, S; Ravandi, F; Teng, A; Welch, MA | 1 |
| Dou, LP; Jing, Y; Mei, JH; Wang, QS; Yu, L | 1 |
| Chen, SN; Gao, S; Han, Y; He, GS; Hu, XH; Jin, ZM; Qiu, HY; Sun, AN; Tang, XW; Wu, DP; Xu, Y | 1 |
| Andreu, R; Arilla, MJ; Bailén, A; Bargay, J; Benlloch, LE; Bernal, T; Brunet, S; Calvo, JM; Casaño, FJ; Cedena, MT; Cervero, CJ; de Paz, R; Díez, M; Gallardo, D; García, O; Gómez, E; Gómez, M; González, B; Grau, J; Jiménez, MJ; Luño, E; Marco, V; Martínez-Robles, V; Muñoz, J; Palomera, L; Pedro, C; Pérez de Oteyza, J; Ribera, JM; Sanz, G; Simiele, A; Vicente, AI; Xicoy, B | 1 |
| Adès, L; Ame, S; Beyne-Rauzy, O; Braun, T; Charbonnier, A; Delaunay, J; Dreyfus, F; Fenaux, P; Prebet, T; Raffoux, E; Stammatoullas, A; Vey, N; Wattel, E | 1 |
| Borthakur, G; Brandt, M; Cornelison, AM; Cortes, J; Garcia-Manero, G; Ghanem, H; Jabbour, E; Kadia, T; Kantarjian, H; O'Brien, S; Ravandi, F | 1 |
| Moon, JH; Sohn, SK | 1 |
| Gao, L; Gao, X; Jiang, M; Li, J; Li, Y; Luo, X; Wang, L; Yao, Y; Yu, L; Zhou, J; Zhou, M | 1 |
| Ekwall, K; Greco, D; Grövdal, M; Hellström-Lindberg, E; Jansson, M; Karimi, M; Kere, J; Reinius, L; Tobiasson, M; Ungerstedt, J | 1 |
| Al Ali, NH; Duong, VH; Komrokji, RS; Kumar, A; Lancet, JE; Lin, K; List, AF; Reljic, T | 1 |
| Chang, C; He, Q; Li, X; Song, L; Su, J; Wu, D; Wu, L; Xu, F; Zhang, Q; Zhang, X; Zhang, Z; Zhou, L | 1 |
| Egle, A; Melchardt, T; Weiss, L | 1 |
| Diagileva, OA; Dvirnyk, VN; Gemdzhian, ÉG; Glasko, EN; Kokhno, AV; Parovichnikova, EN; Platonova, TL | 1 |
| Merkel, DG; Nagler, A | 1 |
| Bosi, A; Buchi, F; Canzian, F; Cilloni, D; Fontenay, M; Gaidano, V; Gozzini, A; Kosmider, O; Martino, A; Masala, E; Rossi, A; Sanna, A; Santini, V; Valencia, A; Voso, MT | 1 |
| Aguilar-Guisado, M; Calderón, C; Espigado, I; Falantes, JF; González, J; Márquez-Malaver, FJ; Martín-Peña, A; Martino, ML; Montero, I; Parody, R; Pérez-Simón, JA | 1 |
| Douvali, E; Kotsianidis, I; Margaritis, D; Papadopoulos, V; Papoutselis, M; Spanoudakis, E; Tsatalas, C | 1 |
| Cai, LL; Chi, XH; Li, SW; Lu, XC; Ran, HH; Wang, HT; Yang, B; Yang, Y; Yu, RL; Zhao, Y; Zhu, HL | 1 |
| Radivoyevitch, T; Saunthararajah, Y | 1 |
| Bueso-Ramos, C; Cortes, J; Davanlou, M; DiNardo, C; Estecio, MR; Fang, Z; Garcia-Manero, G; Geng, QR; Kantarjian, H; Nguyen, M; Parmar, S; Pierce, S; Wei, Y; Yang, H | 1 |
| Saunthararajah, Y | 1 |
| Kharfan-Dabaja, MA; Komrokji, RS; Zeidan, AM | 1 |
| Ishii, S; Itoh, T; Katayama, Y; Kawano, H; Kawano, Y; Minagawa, K; Sada, A; Suzuki, T; Ueno, D; Wakahashi, K; Yamasaki, T; Yokozaki, H | 1 |
| Ishikawa, T | 2 |
| Beach, CL; Estey, E; Fenaux, P; Gore, S; Hellstrom-Lindberg, E; List, A; Mufti, GJ; Santini, V; Sanz, G; Seymour, JF; Silverman, L; Swern, AS | 1 |
| Lübbert, M; Navada, SC; Silverman, LR; Steinmann, J | 1 |
| Almazmi, A; Benjamin, D; Enright, H; Evans, P; Frankova, H; Hameed, A; McHale, C; McHugh, J; Murphy, P; O'Connell, N; O'Gorman, P; O'Reilly, MA; Quinn, J; Sargent, J; Thornton, P; Verburgh, E | 1 |
| Fang, BZ; Fu, ZZ; Han, Y; He, GS; Jin, ZM; Liu, ZZ; Ma, X; Miao, M; Qiu, HY; Ruan, CG; Sun, AN; Tang, XW; Wang, XL; Wu, DP | 1 |
| Correard, F; Pisano, P; Pourroy, B; Savry, A; Villano, LG | 1 |
| Al Ali, NH; Bello, CM; Duong, VH; Fernandez, HF; Jaglal, MV; Komrokji, RS; Lancet, JE; List, AF; Padron, E | 1 |
| Klepfish, A; Lugassy, G; Mittelman, M; Shimoni, A; Silbershatz, I | 1 |
| Ahmann, G; Azorsa, DO; Bogenberger, JM; Braggio, E; Camoriano, J; Cardone, M; Choudhary, A; Chow, D; Coombes, KR; Fauble, V; Gonzales, IM; Kornblau, SM; Lena, R; Mantei, J; Mesa, RA; Pierceall, WE; Qiu, YH; Shi, CX; Stewart, AK; Tibes, R; Tiedemann, RE; Valdez, R; Yin, H | 1 |
| Chizuka, A; Kojima, R; Miyakoshi, S; Miyamoto, K; Ogasawara, T; Ueda, S | 1 |
| Alimena, G; Aloe Spiriti, MA; Breccia, M; Buccisano, F; Fenu, S; Fianchi, L; Latagliata, R; Maurillo, L; Niscola, P; Pelliccia, S; Tendas, A; Voso, MT | 1 |
| Beach, CL; Bennett, JM; Fenaux, P; Gore, SD; Hetzer, J; List, AF; Mufti, GJ; Santini, V; Seymour, JF; Skikne, BS; Songer, S | 1 |
| Alhan, C; Buchi, F; Eeltink, C; Huls, G; Ossenkoppele, GJ; Santini, V; van de Loosdrecht, AA; van der Helm, LH; Westers, TM; Witte, BI | 1 |
| Robak, T; Wierzbowska, A | 1 |
| Tohyama, K | 3 |
| Anasetti, C; Fernandez, H; Field, T; Kharfan-Dabaja, MA; Kim, J; Komrokji, R; Lancet, J; List, A; Mishra, A; Nishihori, T; Perez, L; Perkins, J | 1 |
| Cavazzini, F; Cibien, F; Cuneo, A; Daghia, G; Gafà, R; Leo, G; Lista, E; Martinelli, S; Rigolin, GM; Sofritti, O | 1 |
| Altmeyer, P; Hessam, S; Kreuter, A; Möllenhoff, K; Othlinghaus, N; Patsinakidis, N; Stücker, M; Susok, L | 1 |
| Chang, C; Guo, C; He, Q; Li, X; Song, L; Su, J; Wu, D; Wu, L; Xiao, C; Zhang, X; Zhang, Z; Zhou, L | 1 |
| Inoue, A; Kawakami, C; Takitani, K; Tamai, H | 1 |
| Dornaus, S; Frietsch, JJ; Hochhaus, A; Kunert, C; La Rosée, P; Neumann, T; Sayer, HG; Schmidt, V; Scholl, S | 1 |
| Ahn, JS; Cheong, CW; Cheong, JW; Jang, JH; Kim, DY; Kim, HJ; Kim, IH; Kim, SJ; Kim, Y; Kim, YK; Lee, JH; Lee, KH; Park, S; Park, SY; Yoon, SS | 1 |
| Brandwein, J; Del Bel, R; Gupta, V; Minden, MD; Schimmer, AD; Schuh, AC; Xu, W; Yee, KW | 1 |
| Czader, M; Erba, HP; Figueroa, ME; Gabrilove, J; Gore, SD; Greenberg, PL; Herman, J; Juckett, M; Ketterling, R; Litzow, M; Malick, L; Melnick, A; Paietta, E; Prebet, T; Smith, MR; Sun, Z; Tallman, MS | 1 |
| Xiao, Z | 1 |
| Erba, HP; Gabrilove, J; Gore, SD; Greenberg, P; Juckett, M; Lee, JW; Paietta, E; Prebet, T; Smith, MR; Sun, Z; Tallman, MS; Zeidan, AM | 1 |
| Chang, C; Chen, Y; Hou, M; Li, X; Song, L; Song, Q; Su, J; Wu, D; Wu, L; Xu, F; Zhang, X; Zhang, Z; Zhou, L | 1 |
| Daskalakis, M; Hackanson, B | 1 |
| Florek, M; Müller, AM | 1 |
| Fulp, WJ; Komrokji, RS; Lancet, JE; List, AF; Padron, E; Rodriguez, Y; Tinsley, S; Yu, D | 1 |
| Andreu, R; Badiella, L; Bailén, A; Bargay, J; Brunet, S; Casaño, J; de Miguel, D; Falantes, JF; Figueredo, A; García-Delgado, R; González, JR; Jurado, AF; Medina, A; Ramos, F; Sanz, G; Tormo, M | 1 |
| Huang, TC; Lai, SW; Wu, YY; Ye, RH | 1 |
| Cuneo, A; Rigolin, GM | 1 |
| Adès, L; Bally, C; de The, H; Eclache, V; Fenaux, P; Lehmann-Che, J; Mozziconacci, MJ; Preudhomme, C; Renneville, A; Sebert, M | 1 |
| Adès, L; Beguin, Y; Blaise, D; Bories, P; Chevallier, P; Clavert, A; Cornillon, J; Damaj, G; Duhamel, A; Fegueux, N; Fenaux, P; Hermine, O; Huynh, A; Maillard, N; Michallet, M; Mohty, M; Nguyen, S; Robin, M; Rubio, MT; Thiébaut-Bertrand, A; Vigouroux, S; Yakoub-Agha, I | 1 |
| Cornelison, AM; Cortes, JE; Daver, N; Garcia-Manero, G; Jabbour, E; Kadia, T; Kantarjian, H; Ravandi, F; Teng, A | 1 |
| Schleiffenbaum, BE | 1 |
| Cherif, H; Chowdhury, O; Garelius, H; Hellström-Lindberg, E; Jacobsen, SE; Lorenz, F; Saft, L; Svensson, T | 1 |
| Chinen, Y; Horiike, S; Kiyota, M; Kobayashi, T; Kuroda, J; Maegawa, S; Matsumoto, Y; Mizutani, S; Nagoshi, H; Shimura, Y; Taniwaki, M | 1 |
| Buckstein, R; Charbonneau, LF; Cheung, MC; Guirguis, HR; Tyono, I; Wells, RA | 1 |
| Grinblatt, DL; Komrokji, RS; Narang, M; Sekeres, MA; Sullivan, KA; Swern, AS | 1 |
| Auberger, P; Cluzeau, T; Dubois, A; Jacquel, A; Karsenti, JM; Luciano, F; Mari, B; Mounier, N; Preudhomme, C; Raynaud, S; Renneville, A; Robert, G; Rohrlich, P | 1 |
| Blaser, R; Germing, U; Götze, K; Haferlach, T; Huberle, C; Kremer, M; Müller-Thomas, C; Peschel, C; Platzbecker, U; Rondak, IC; Rudelius, M; Schanz, J; Schmidt, B | 1 |
| Cai, L; Chi, X; Li, S; Lu, X; Tuo, S; Wang, H; Wang, X; Wu, X; Yang, B; Yang, Y; Yu, R; Zhang, F; Zhu, H | 1 |
| Alimena, G; Breccia, M; Molica, M; Zacheo, I | 1 |
| Erba, HP; Gabrilove, J; Gore, SD; Greenberg, P; Juckett, M; Katterling, RP; Lee, JW; Paietta, E; Prebet, T; Smith, MR; Sun, Z; Tallman, MS; Zeidan, AM | 1 |
| Honda, H; Inaba, T; Nagamachi, A | 1 |
| Jabbour, E | 1 |
| Kizaki, M | 1 |
| Alessandrino, EP; Della Porta, MG | 1 |
| Bredeson, C; Eid, JE; Frankel, P; Gojo, I; Goldberg, SL; Issa, JP; Kirschbaum, M; Kujawski, LA; Lubiniecki, GM; Marks, P; Sun, X; Tosolini, A; Yang, A | 1 |
| Jiang, Q; Xie, M; Xie, Y | 1 |
| Dear, AE; Liu, HB; Spencer, A; Tan, P; Urbanavicius, D | 1 |
| Duong, VH; Komrokji, RS; List, AF | 1 |
| Imanishi, D; Itonaga, H; Jakt, LM; Micklem, CN; Miyazaki, Y; Nishikawa, S; Sawayama, Y; Taguchi, M; Wong, YF | 1 |
| Kanashima, H; Nakao, T; Sugiyama, H; Ueda, H; Yamane, T; Yoshida, M | 1 |
| Cupelli, L; de Fabritiis, P; Del Poeta, G; Dentamaro, T; Giovannini, M; Niscola, P; Piccioni, D; Scaramucci, L; Tendas, A | 1 |
| Meers, S | 1 |
| Bar-Natan, M; Bejar, R; Caughey, B; Chen, R; Ebert, BL; Garcia-Manero, G; Getz, G; Kantarjian, H; Lord, A; Neuberg, D; Pérez-Ladaga, A; Steensma, DP; Stevenson, K; Stojanov, P; Stone, RM; Wang, H; Zaneveld, J | 1 |
| Byon, J; Deeg, HJ; Holman, ZJ; Jiang, PY; Karoopongse, E; Marcondes, AM; Ramakrishnan, A; Yeung, C; Yu, Q | 1 |
| Baer, MR; Bhatnagar, B; Chen, Q; Duong, VH; Tidwell, ML; Vannorsdall, EJ; Zandberg, DP | 1 |
| Hangaishi, A; Ito, A; Kida, M; Morioka, T; Takaoka, K; Usuki, K | 1 |
| Maeda, Y | 1 |
| Choi, Y; Joo, YD; Kim, DY; Kim, SD; Lee, JH; Lee, KH; Lee, SM; Lee, WS | 1 |
| Glasmacher, A; Meers, S; Mineur, P; Potier, H; Selleslag, D; Voelter, V | 1 |
| Aritaka, N; Hirano, T; Ichikawa, K; Komatsu, N; Ogura, K | 1 |
| Kuendgen, A; Lübbert, M | 2 |
| Borthakur, G; Brandt, M; Cortes, J; Garcia-Manero, G; Huang, X; Issa, JP; Jabbour, E; Kantarjian, HM; Pierce, S; Ravandi, F | 1 |
| Cui, GX; Wu, WZ; Zhang, YP | 1 |
| de Fabritiis, P; Dentamaro, T; Giovannini, M; Lissia, MF; Niscola, P; Perrotti, A; Piccioni, D; Scaramucci, L; Tendas, A; Tirimbelli, L | 1 |
| Chen, S; Fu, Z; Gao, S; Han, Y; Jin, Z; Ma, X; Qiu, H; Sun, A; Tang, X; Wu, D | 1 |
| Beguin, Y; Bries, G; Deeren, D; Graux, C; Meers, S; Mineur, P; Noens, L; Potier, H; Ravoet, C; Selleslag, D; Theunissen, K; Trullemans, F; Voelter, V; Vrelust, I | 1 |
| Fenaux, P; Gattermann, N; List, AF; Nilsson, L; Pfeilstöcker, M; Prebet, T; Santini, V; Vyas, P | 1 |
| Adès, L; Beyne-Rauzy, O; Boehrer, S; Chermat, F; Delaunay, J; Fenaux, P; Hunault, M; Jourdan, E; Kroemer, G; Prebet, T; Raffoux, E; Sebert, M; Seegers, V; Thepot, S; Wattel, E | 1 |
| Platzbecker, U; Wetzko, K | 1 |
| Andreu, R; Bailén, A; Bargay, J; Bernal, T; Bonanad, S; Brunet, S; Calderón-Cabrera, C; de Miguel, D; Delgado, RG; Falantes, J; González-Porras, JR; Jurado, AF; Márquez-Malaver, FJ; Nomdedeu, B; Pérez-Simón, JA; Ramos, F; Sánchez, J; Sanz, G; Tormo, M; Valcarcel, D; Xicoy, B | 1 |
| Calderón, C; Espigado, I; Falantes, JF; Gómez, M; González, J; Márquez-Malaver, FJ; Martín-Antonio, B; Martino, ML; Millán, A; Montero, I; Parody, R; Pérez-Simón, JA; Piruat, JI; Trujillo, P; Urbano-Ispizua, A | 1 |
| Andreeff, M; Borthakur, G; Cortes, J; Daver, N; Durand, M; Estrov, Z; Garcia-Manero, G; Kadia, T; Kantarjian, H; Konopleva, M; Levis, M; Nazha, A; Rajkhowa, T; Ravandi, F; Strati, P | 1 |
| Deng, C; Du, X; Geng, S; Lu, Z; Luo, C; Weng, J; Wu, P | 1 |
| Beelen, DW; Bornhäuser, M; Bug, G; Czibere, A; Dienst, A; Fenk, R; Germing, U; Haas, R; Klein, S; Kobbe, G; Kondakci, M; Kröger, N; Luft, T; Nachtkamp, K; Platzbecker, U; Rachlis, E; Ringhoffer, M; Schroeder, T; Stadler, M; Steckel, NK; Stelljes, M; Uharek, L; Wolf, D | 1 |
| Buquicchio, C; Galise, I; Greco, G; Guarini, A; Loseto, G; Melpignano, A; Merchionne, F; Minoia, C; Pavone, V; Sgherza, N; Tarantini, G; Toldo, C | 1 |
| Greil, R; Pleyer, L | 1 |
| Advani, A; Cooper, K; Copelan, E; Dean, R; Durkin, L; Earl, M; Englehaupt, R; Hamilton, B; Hobson, S; Hsi, E; Husseinzadeh, H; Juersivich, J; Kalaycio, M; Lichtin, A; Maciejewski, J; Mahfouz, R; Przychodzen, B; Radivoyevitch, T; Reu, F; Rump, M; Saunthararajah, Y; Sekeres, M; Sobecks, R; Tiu, R | 1 |
| Fang, Q; Gao, R; Hu, XY; Li, Y; Ma, D; Sun, J; Wang, JS; Wang, P | 1 |
| Klimek, V | 1 |
| Mukherjee, S; Ornstein, MC; Sekeres, MA | 1 |
| Chao, X; Chengming, F; Chunkang, C; Juan, G; Shucheng, G; Xi, Z; Xiao, L; Youshan, Z | 1 |
| Carella, AM | 1 |
| Chen, RL; Huang, BT; Li, BS; Zeng, QC; Zhao, WH | 1 |
| Adès, L; Berthon, C; Braun, T; Brechignac, S; Cherait, A; Fenaux, P; Gardin, C; Harel, S; Park, S; Quesnel, B; Rigal, M; Thépot, S; Willekens, C | 1 |
| Hara, Y; Imajo, K; Makita, M; Mishima, M; Sando, Y; Shiote, Y; Yamamoto, K; Yamamoto, Y | 1 |
| Alhusayen, R; Buckstein, R; Prica, A; Sade, S; Tseng, E | 1 |
| Fu, C; Han, Y; Jin, Z; Ma, X; Qiu, H; Sun, A; Tang, X; Wang, J; Wang, P; Wu, D; Zheng, H; Zhou, J | 1 |
| Akria, L; Arad, A; Aviv, A; Braester, A; Dally, N; Filanovsky, K; Gafter-Gvili, A; Gatt, ME; Hellmann, I; Herishanu, Y; Herzog-Tzarfati, K; Leiba, R; Merkel, D; Mittelman, M; Nagler, A; Nemets, A; Ofran, Y; Ronson, A; Rouvio, O; Silbershatz, I; Tadmor, T; Vidal, L; Yeganeh, S | 2 |
| Friis, LS; Grønbæk, K; Hokland, M; Holm, MS; Skovbo, A; Treppendahl, MB; Ørskov, AD | 1 |
| Bohannan, Z; Cabrero, M; Garcia-Manero, G; Jabbour, E; Kantarjian, HM; Pierce, S; Ravandi, F | 1 |
| Doki, N; Ikegawa, S; Kakihana, K; Kobayashil, T; Ohashi, K; Oshikawa, G; Sakamaki, H; Shingai, N; Takahashi, Y; Yoshioka, K | 1 |
| Candás, A; Cseh, A; Dworzak, M; Flotho, C; Furlan, I; Groß-Wieltsch, U; Hasle, H; Kulozik, AE; Locatelli, F; Masetti, R; Niemeyer, CM; Olcay, L; Schmugge, M; Strahm, B; Suttorp, M; van den Heuvel-Eibrink, MM; Yoshimi, A | 1 |
| Berda, Y; Ciccolini, J; Costello, R; Fanciullino, R; Fina, F; Lacarelle, B; Mercier, C; Ouafik, L; Serdjebi, C | 1 |
| Buckstein, R; Callum, J; Kim, T; Mittmann, N; Prica, A; Seung, SJ; Tseng, E; Wells, RA; Zhang, L | 1 |
| Jang, JH; Jung, CW; Jung, HA; Kim, M; Kim, S; Maeng, CH | 1 |
| Amigo, ML; Ardanaz, MT; Bargay, J; Benlloch, L; Bernal, T; Brunet, S; de Paz, R; del Cañizo, C; Luño, E; Martínez-Camblor, P; Nomdedeu, B; Pedro, C; Sánchez-García, J; Sanz, G; Tormo, M; Valcárcel, D; Xicoy, B | 1 |
| Gao, L; Kang, HY; Li, MY; Wang, CB; Wang, LL; Wang, W; Wang, XR; Yu, L | 1 |
| Horio, K; Jo, T; Shigematsu, K | 1 |
| Hong, JY; Jang, JH; Jung, CW; Jung, HA; Kim, HJ; Kim, JS; Kim, K; Kim, SH; Park, JS; Park, S; Seo, JY | 1 |
| Billi, AM; Bosi, C; Clissa, C; Cocco, L; Finelli, C; Follo, MY; Malagola, M; Manzoli, L; Mariani, GA; Mongiorgi, S; Parisi, S; Quaranta, M; Ramazzotti, G; Russo, D; Stanzani, M | 1 |
| Aloe-Spiriti, MA; Breccia, M; Buccisano, F; Criscuolo, M; Fenu, S; Fianchi, L; Filardi, N; Fragasso, A; Latagliata, R; Mansueto, G; Maurillo, L; Musto, P; Niscola, P; Pagano, L; Piccioni, AL; Piciocchi, A; Tendas, A; Venditti, A; Voso, MT; Zini, G | 1 |
| Chang, C; Guo, J; Li, X; Shi, W; Wu, L; Xu, F | 1 |
| Abboud, CN; Cashen, AF; Choi, J; DiPersio, JF; Fiala, MA; Gao, F; Holt, M; Jacoby, MA; Pusic, I; Stockerl-Goldstein, KE; Uy, GL; Vij, R; Westervelt, P | 1 |
| William, BM | 1 |
| Ahn, JS; Cheong, JW; Chung, JS; Jang, JH; Jung, CW; Kim, H; Kim, HJ; Kim, IH; Kim, YJ; Kim, YK; Lee, HG; Lee, JH; Min, YH; Moon, JH; Mun, YC; Sohn, SK; Won, JH; Yoon, HJ | 1 |
| Fu, C; Han, Y; Jin, Z; Liu, H; Ma, L; Miao, M; Qiu, H; Tang, X; Wang, J; Wang, P; Wu, D; Yan, S; Zheng, H; Zhou, J | 1 |
| Jaksic, O; Kusec, R; Lasan-Trcic, R; Lucijanic, M; Pejsa, V; Stoos-Veic, T | 1 |
| Berthon, C; Delaunay, J; Dreyfus, F; Esterni, B; Fenaux, P; Itzykson, R; Kulasekararaj, A; Micol, JB; Mufti, G; Prebet, T; Recher, C; Roux, C; Sebert, M; Thepot, S; Vey, N; Wanquet, A | 1 |
| Ali, A; Itzykson, R; Loiseau, C | 1 |
| Angelucci, E; Barraqueddu, F; Contini, S; Corda, G; Dore, F; Fozza, C; Galleu, A; Isoni, A; Longinotti, M; Virdis, P | 1 |
| Bazani, E; Bouchla, A; Dimitriadis, G; Foukas, P; Ioannidou, ED; Kefala, M; Kontos, CK; Papageorgiou, SG; Pappa, V; Vasilatou, D | 1 |
| Lin, CH; Lin, TY; Yeh, SP | 1 |
| Frøsig, TM | 1 |
| Bakarakos, P; Diamantopoulos, P; Dimitrakopoulou, A; Galanopoulos, A; Giannakopoulou, N; Iliakis, T; Kalala, F; Papadopoulou, V; Rougala, N; Variami, E; Viniou, NA; Zervakis, K | 1 |
| Costa, S; Javier, KP; Linares, M; Orero, M; Ortiz, S; Pérez, PL; Roig, M; Villegas, C | 1 |
| Kobbe, G; Schroeder, T | 1 |
| Braulke, F; Ganster, C; Haase, D; Platzbecker, U; Salinas-Riester, G; Schanz, J; Shirneshan, K | 1 |
| Garcia-Manero, G; Goswami, M; Hasserjian, RP; Jabbour, EJ; Medeiros, LJ; Patel, KP; Peng, J; Tang, G; Wang, SA | 1 |
| Cogle, CR; Garcia-Manero, G; Gore, SD; Hetzer, J; Kumar, K; Laille, E; MacBeth, KJ; Shi, T; Skikne, B | 1 |
| Azab, M; Chung, W; Daver, N; Griffiths, EA; Hao, Y; Issa, JJ; Jabbour, E; Kantarjian, H; Lowder, JN; Naim, S; O'Connell, C; Oganesian, A; Rizzieri, D; Roboz, G; Stock, W; Taverna, P; Tibes, R; Walsh, K; Yee, K | 1 |
| Kharfan-Dabaja, MA | 1 |
| Cao, YB; DA, WM; Li, SW; Li, XH; Liu, B; Liu, ZY; Wu, XX; Wu, YM; Xu, LX; Yan, B; Yang, XL | 1 |
| Qin, Y; Tong, Y; Wan, L; Wang, C; Zhou, K; Zhou, Z; Zou, J | 1 |
| Adès, L; Amoura, Z; Braun, T; Buchdaul, AL; Cathebras, P; Costedoat-Chalumeau, N; De Wazieres, B; Decaux, O; Denis, G; Dion, J; Fain, O; Falgarone, G; Fenaux, P; Gardin, C; Georgin-Lavialle, S; Gombert, B; Grignano, E; Hamidou, M; Kahn, JE; Launay, D; Lioger, B; Liozon, E; Lortholary, O; Madaule, S; Mathian, A; Mekinian, A; Montestruc, F; Morel, N; Nimubona, S; Omouri, M; Park, S; Piette, JC; Puéchal, X; Raffray, L; Rose, C; Rossignol, J; Schoindre, Y; Toussirot, E; Trouiller, S; Ziza, JM | 1 |
| Borthakur, G; Cortes, J; Daver, N; Diaz-Pines-Mateo, M; Dinardo, C; Estey, E; Garcia-Manero, G; Huang, X; Jabbour, E; Kadia, T; Kantarjian, H; Konopleva, M; O'Brien, S; Pemmaraju, N; Pierce, S; Ravandi, F; Verstovsek, S; Wang, X | 1 |
| Dinmohamed, AG; Huijgens, PC; Jongen-Lavrencic, M; Posthuma, EF; Sonneveld, P; van de Loosdrecht, AA; van Norden, Y; Visser, O | 1 |
| Dou, MH; Hu, C; Huang, J; Jin, J; Li, Y; Lou, YJ; Luo, YW; Ma, LY; Mao, LP; Mei, C; Niu, LM; Ren, YL; Tong, HY; Wang, JH; Wei, JY; Xie, LL; Xu, GX; Ye, L; Ye, XN; Yu, WJ; Zhou, XP | 1 |
| Berube, C; Cardone, MH; Coutre, S; Doykan, C; Garcia, JS; Gotlib, J; Greenberg, P; Hewitt, R; Liedtke, M; McMillan, A; Medeiros, BC; Narayan, R; Percival, ME; Regan, K; Williamson, C | 1 |
| Chang, C; Chao, X; He, Q; Li, X; Song, L; Su, J; Wu, D; Wu, L; Xu, F; Zhang, Z; Zhao, Y; Zhou, L | 1 |
| Bastard, C; Cassuto, O; Contentin, N; Daliphard, S; David, M; Jardin, F; Lanic, H; Lemasle, E; Lenain, P; Lepretre, S; Mareschal, S; Ménard, AL; Penther, D; Rezine, I; Stamatoullas, A; Tilly, H | 1 |
| Chen, SN; Fu, JH; Gao, S; Han, Y; Hu, XH; Jin, ZM; Li, Z; Qiu, HY; Sun, AN; Tang, XW; Wu, DP; Xu, Y | 1 |
| Cogle, CR; Edenfield, WJ; Garcia-Manero, G; Gore, SD; Hetzer, J; Kambhampati, S; Kumar, K; Laille, E; MacBeth, KJ; Scott, B; Shi, T; Skikne, B; Tefferi, A | 1 |
| Boyd, T; Cogle, CR; Garcia-Manero, G; Scott, BL | 1 |
| Ali, NA; Barnard, J; DeZern, A; Garcia-Manero, G; Gore, SD; Jabbour, E; Kantarjian, H; Komrokji, R; List, A; Maciejewski, JP; Nazha, A; Roboz, G; Sekeres, MA; Steensma, DP; Zeidan, AM; Zell, K; Zimmerman, C | 1 |
| Al-Kali, A; Bhagavatula, K; Bogenberger, JM; Delman, DH; Foran, JM; Hansen, N; Mesa, RA; Mohan, J; Oliver, GR; Rakhshan, F; Tibes, R; Wood, T | 1 |
| Eom, KS; Han, S; Hong, T; Jeon, S; Kim, HJ; Kim, YJ; Lee, J; Lee, S; Lee, SE; Min, CK; Park, GJ; Shin, SH; Yahng, SA; Yim, DS; Yoon, JH | 1 |
| Andersson, S; Baumann, BC; Hellström-Lindberg, E; Malmberg, KJ; Pfefferle, A; Sohlberg, E | 1 |
| Choi, CW; Do, YR; Jang, JH; Jeong, SH; Joo, YD; Kim, HG; Kim, I; Kim, SJ; Kim, SR; Kim, YJ; Kim, YK; Lee, JH; Lee, WS; Mun, YC; Na, SM; Park, SK; Yi, HG | 1 |
| Issa, JP; Lowder, JN; Taverna, P | 1 |
| Becker, PS; Dean, C; Deeg, HJ; Estey, E; Hendrie, P; Mawad, R; Myint, H; Pagel, JM; Sandhu, V; Scott, B; Singer, JW; Walter, R; Wang, L; Wood, BL | 1 |
| Cai, Z; Chen, B; Du, X; He, G; Huang, X; Jin, J; Li, J; Li, X; Liang, H; Liu, T; Ruan, C; Shao, Z; Shen, Z; Wu, D; Xiao, Z; Yu, L | 1 |
| Itano, Y; Kondo, T; Okamoto, S; Ouchida, M; Suemori, S; Takahashi, K; Tohyama, K; Tohyama, Y; Tsujioka, T; Yokoi, A | 1 |
| Czader, M; Erba, HP; Figueroa, M; Gabrilove, J; Gore, SD; Greenberg, P; Herman, J; Juckett, M; Ketterling, RP; Litzow, M; Malick, L; Paietta, E; Prebet, T; Smith, MR; Sun, Z; Tallman, MS; Zeidan, A | 1 |
| Endo, M; Maruo, T; Osaki, Y; Sekikawa, A; Tsumura, T | 1 |
| Aul, C; Baron, F; Becker, H; Bogatyreva, L; de Witte, T; Ganser, A; Germing, U; Giagounidis, A; Hagemeijer, A; Huls, G; Labar, B; Lübbert, M; Marie, JP; Muus, P; Pflüger, KH; Platzbecker, U; Rüter, B; Salih, HR; Schaefer, HE; Selleslag, D; Suciu, S; van der Helm, L; Vellenga, E; Wijermans, PW | 1 |
| Inagaki, S; Kanbe, E; Sato, S; Tamai, Y; Tanaka, E; Yoshizawa, M | 1 |
| Fujimaki, K; Kawasaki, R; Miyashita, K; Tomita, N | 1 |
| DeZern, AE | 1 |
| Harada, Y; Ito, M; Iwasaki, T; Kurahashi, S; Nishiwaki, S; Okuno, S; Sugiura, I; Suzuki, K; Watarai, R; Yamamoto, S | 1 |
| Borthakur, G; Bueso-Ramos, C; Cortes, JE; Daver, N; DiNardo, CD; Garcia-Manero, G; Jabbour, E; Kadia, T; Kantarjian, HM; Konopleva, M; Patel, KP; Pemmaraju, N; Pierce, S; Ravandi, F; Wierda, W; Yang, H | 1 |
| Adamopoulos, PG; Galanopoulos, AG; Garypidou, V; Hatjiharissi, E; Kontos, CK; Kotsianidis, I; Lamprianidou, E; Miltiades, P; Nakou, E; Papadaki, HA; Papageorgiou, SG; Papaioannou, M; Pappa, V; Scorilas, A; Spanoudakis, E; Tsatalas, C; Vakalopoulou, S; Vassilakopoulos, TP | 1 |
| Lu, JH; Xu, M | 1 |
| Bernal, T; Martínez-Camblor, P; Sánchez-García, J; Sanz, G | 1 |
| Bernig, T; Catala, A; Cseh, AM; De Moerloose, B; Flotho, C; Frühwald, MC; Furlan, I; Gruhn, B; Hasle, H; Kulozik, AE; Lauten, M; Metzler, M; Niemeyer, CM; Olcay, L; Smith, OP; Strahm, B; Suttorp, M; van den Heuvel-Eibrink, MM; Yoshimi, A | 1 |
| Gangat, N; Patnaik, MM; Tefferi, A | 1 |
| Al Ali, NH; Barnard, J; DeZern, AE; Garcia-Manero, G; Jabbour, EJ; Kantarjian, HM; Komrokji, RS; List, AF; Maciejewski, JP; Nazha, A; Roboz, GJ; Sekeres, MA; Steensma, DP; Zell, K; Zimmerman, C | 1 |
| Al-Kali, A; Baidoun, F; Elliott, M; Hashmi, S; Hogan, W; Hreh, M; Litzow, M; Patnaik, M; Subari, S | 1 |
| Fang, Q; Gao, R; Ma, D; Sun, J; Wang, JS; Wang, P | 1 |
| Abuqayas, B; Alnimer, Y; Alrabi, K; Salah, S | 1 |
| Ito, S; Ohigashi, H; Shiratori, S; Teshima, T; Tsutsumi, Y | 1 |
| Bernardi, M; Borin, L; Cairoli, R; Caramazza, D; Della Porta, M; Freyrie, A; Gigli, F; Greco, R; Guarco, S; Mariotti, J; Molteni, A; Morra, E; Nichelatti, M; Pelizzari, AM; Quaresmini, G; Ravano, E; Riva, M; Ubezio, M | 1 |
| Bär, B; Blijlevens, NNM; Bremmers, MEJ; Cruijsen, M; Dolstra, H; Falkenburg, JHF; Hobo, W; Huls, G; Jansen, J; Kester, M; Schaap, NPM; van der Velden, WJFM; Woestenenk, R | 1 |
| Andreff, M; Bueso-Ramos, C; Cortes, J; Daver, N; DiNardo, C; Estrov, Z; Futreal, A; Garcia-Manero, G; Gumbs, C; Jabbour, E; Kadia, T; Kantarjian, H; Konopleva, M; Patel, K; Takahashi, K; Zhang, J | 1 |
| Al Ali, NH; Bart-Smith, E; Craig, BM; Epling-Burnette, PK; Komrokji, RS; Kordasti, S; Kulasekararaj, A; Lancet, JE; List, AF; Mufti, GJ; Padron, E; Pinilla-Ibarz, J; Zhang, L | 1 |
| Dreger, P; Ho, AD; Luft, T; Radujkovic, A; Schnitzler, P | 1 |
| Aouba, A; Arlet, JB; Berthier, S; Braun, T; Buchdahl, AL; Decaux, O; Denis, G; Fain, O; Fenaux, P; Fraison, JB; Gardin, C; Grignano, E; Kahn, JE; Leon, N; Liozon, E; Lortholary, O; Maigne, G; Mekinian, A; Omouri, M; Park, S; Rossignol, J | 1 |
| Gojo, I; Malla, M; Newman, M | 1 |
| Chang, C; He, Q; Li, X; Shi, W; Song, L; Su, J; Wu, D; Wu, L; Xiao, C; Xu, F; Zhang, Z; Zhou, L | 1 |
| Abdulkadir, H; Ben Azenkoud, A; Dimitriou, M; Ekwall, K; Hellström-Lindberg, E; Jädersten, M; Jansson, M; Karimi, M; Kulasekararaj, A; Lennartsson, A; Lindberg, G; McLornan, DP; Mufti, GJ; Tobiasson, M; Ungerstedt, J | 1 |
| Barraco, M; Clissa, C; Cocco, L; Finelli, C; Follo, MY; Mongiorgi, S; Parisi, S; Stanzani, M | 1 |
| Al-Kali, A; Atallah, E; Azarnia, N; Baer, MR; Collins, R; Fenaux, P; Gaidano, G; Garcia-Manero, G; Godley, LA; Greenberg, P; Jabbour, E; Kambhampati, S; Kantarjian, H; Kreuzer, KA; Platzbecker, U; Roboz, GJ; Scott, BL; Sekeres, MA; Silverman, LR; Steensma, DP; Wilhelm, FE | 1 |
| Leitch, HA; Tsang, E | 1 |
| Deng, C; Du, X; Geng, S; Huang, X; Li, M; Lu, Z; Tong, J; Weng, J; Wu, P; Yao, H | 1 |
| Ali, NA; Barnard, J; DeZern, AE; Garcia-Manero, G; Greenberg, MD; Jabbour, E; Kantarjian, HM; Komrokji, RS; List, AF; Maciejewski, JP; Nazha, A; Roboz, GJ; Sekeres, MA; Steensma, DP; Zell, K; Zimmerman, C | 1 |
| Blaise, D; Bourhis, JH; Chevallier, P; Craddock, C; Finke, J; Hallek, M; Kröger, N; Labopin, M; Luft, T; Mohty, M; Nagler, A; Robin, M; Sengelov, H; Yakoub-Agha, I | 1 |
| Andel, J; Autzinger, EM; Burgstaller, S; Geissler, D; Geissler, K; Girschikofsky, M; Greil, R; Halter, B; Hojas, S; Lang, A; Machherndl-Spandl, S; Pfeilstöcker, M; Pichler, A; Pleyer, L; Rogulj, IM; Schlick, K; Sill, H; Sperr, WR; Stauder, R; Thaler, J; Voskova, D; Zebisch, A | 1 |
| Ciarlantini, M; Leoni, P; Mancini, S; Mariani, M; Mattiucci, D; Maurizi, G; Olivieri, A; Poloni, A; Traini, S | 1 |
| Atagunduz, IK; Avsar, E; Deveci, B; Ferhanoglu, B; Geduk, A; Kara, O; Kurtoglu, E; Mehtap, O; Ozturk, E; Salim, O; Tiftik, EN; Tombak, A; Toptas, T; Tuglular, TF; Undar, L; Yucel, OK | 1 |
| Dong, W; Gu, W; Hua, X; Li, H; Lin, Y; Ling, Y; Wu, W; Xiang, L; Xie, X; Yan, F | 1 |
| Chen, YH; Ding, Y; Liang, AB; Luo, X; Wu, H | 1 |
| Scott, LJ | 1 |
| Dinmohamed, AG; Jongen-Lavrencic, M; van de Loosdrecht, AA; van Norden, Y | 1 |
| Bastié, JN; Ben Abdelali, R; Beyne-Rauzy, O; Chaury, MP; Chermat, F; Chevret, S; Cheze, S; Choufi, B; Delaunay, J; Dreyfus, F; Fenaux, P; Gardin, C; Guerci-Bresler, A; Legros, L; Park, S; Prébet, T; Preudhomme, C; Renneville, A; Sanhes, L; Stamatoullas, A; Tertian, G; Thépot, S; Vey, N; Wattel, E | 1 |
| Begaj, I; Boulet, S; Chevret, S; Jacob, L; Uvarova, M | 1 |
| Kimura, S; Kurogi, K; Miyahara, M; Tanabe, M; Ureshino, H | 1 |
| Abraham, I; Fernandez-Zapico, ME; Patnaik, MM; Robertson, KD; Vincelette, ND; Yun, S | 1 |
| Colizzi, F; Dolcetti, R; Fratta, E; Montico, B; Rizzo, A; Sigalotti, L | 1 |
| Navada, SC; Silverman, LR | 1 |
| Carbonell, F; Collado, R; Costa, S; Ivars, D; Javier, K; Linares, M; López, M; Luna, I; Orero, MT; Ortiz, S; Pérez, P; Roig, M; Villegas, C | 1 |
| Cermak, J; Hajkova, H; Jonasova, A; Klema, J; Merkerova, MD; Monika Belickova, M; Pejsova, B; Valka, J; Vesela, J; Votavova, H | 1 |
| Choi, YS; Chung, YJ; Goo, BK; Hur, EH; Jung, SH; Kim, HJ; Kim, YJ; Kwon, YR; Lee, JH; Lee, SH; Yim, SH | 1 |
| Alvarez, M; Duarte, AD; Lazarini, M; Machado-Neto, JA; Niemann, FS; Pericole, FV; Saad, ST; Traina, F; Vieira, KP | 1 |
| Dasanu, CA; Keating, M | 1 |
| Basak, GW; Drozd-Sokołowska, J; Dutka, M; Dwilewicz-Trojaczek, J; Gil, L; Karakulska-Prystupiuk, E; Mądry, K; Piekarska, A; Waszczuk-Gajda, A | 1 |
| Ahn, JS; Cho, YY; Chung, JS; Joo, YD; Kim, H; Kim, HJ; Kim, YS; Lee, HS; Lee, IH; Lee, SM; Lee, WS; Lee, YJ; Moon, JH; Park, SW; Shin, HJ; Sohn, SK | 1 |
| Abdelhaleem, M; Ali, SS; Cada, M; Dror, Y; Irwin, MS; Klaassen, RJ; Lieberman, L; Liebman, M; Schechter, T; Van Den Akker, M; Waespe, N; Zlateska, B | 1 |
| Braester, A; Ellis, M; Filanovsky, K; Goldschmidt, N; Herishanu, Y; Kirgner, I; Mittelman, M; Ofran, Y; Oster, HS; Perri, C; Raanani, P; Rosenbaum, H | 1 |
| Altman, J; Dinner, S; Frankfurt, O; Gao, J; Helenowski, I; McMahon, BJ; Stein, BL; Waisbren, J | 1 |
| Aoki, K; Muta, T; Ogawa, R; Shimamoto, S; Tamura, Y; Yoshihiro, T | 1 |
| Abel, GA; Davidoff, AJ; Gore, SD; Gross, CP; Hajime, U; Hu, X; Huntington, SF; Long, JB; Ma, X; Podoltsev, NA; Prebet, T; Wang, R; Zeidan, AM | 1 |
| Dimitriou, M; Doolittle, H; Douagi, I; Hellström-Lindberg, E; Jacobsen, SE; Karimi, M; Mortera-Blanco, T; Papaemmanuil, E; Wedge, DC; Woll, PS | 1 |
| Chang, CK; Guo, J; He, Q; Li, X; Song, LX; Su, JY; Tao, Y; Wu, D; Wu, LY; Xiao, C; Xu, F; Zhang, Z; Zhou, LY | 1 |
| Fenaux, P; Prebet, T; Vey, N | 1 |
| Eom, KS; Jeon, YW; Kim, DW; Kim, HJ; Kim, M; Kim, TM; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, WS; Shin, SH; Yahng, SA; Yoon, JH | 1 |
| Al Ali, N; Barnard, J; Brown, F; DeZern, AE; Garcia-Manero, G; Hand, W; Komrokji, RS; Roboz, GJ; Sekeres, MA; Steensma, DP; Zeidan, AM; Zimmerman, C | 1 |
| Lu, SY; Wang, C; Wang, Z; Zhao, XH; Zhou, ZH | 1 |
| Deeg, HJ; Fang, M; Mielcarek, M; Scott, BL; Storer, B; Woo, J; Yeung, C | 1 |
| Abedin, S; Platanias, LC | 1 |
| Anagnostopoulos, A; Bouronikou, E; Briasoulis, E; Galanopoulos, A; Karmas, P; Karvounis, K; Kioumi, A; Kotsianidis, I; Meletis, J; Pagoni, M; Papadaki, H; Pappa, V; Poulakidas, E; Symeonidis, A; Tsionos, K; Vervessou, EC; Viniou, N; Zikos, P | 1 |
| Marconi, G; Martinelli, G; Ottaviani, E; Paolini, S; Papayannidis, C; Parisi, S; Sartor, C; Simonetti, G; Tenti, E; Testoni, N | 1 |
| Aoyama, Y; Hino, M; Ichihara, H; Ido, K; Manabe, M; Mugitani, A; Nagasaki, J; Ohta, T | 1 |
| Adès, L; Auberger, P; Campos, L; Cornillon, J; Fenaux, P; Flandrin-Gresta, P; Guyotat, D; Koering, C; Kosmider, O; Maucort-Boulch, D; Mohamed, AM; Mortreux, F; Robert, G; Solly, F; Tavernier-Tardy, E; Wattel, E | 1 |
| Becker, H; Bissé, E; Bogatyreva, L; Claus, R; Ihorst, G; Lübbert, M; Sander, PN; Suciu, S; Wijermans, PW | 1 |
| Carraway, HE | 1 |
| Ando, T; Kimura, S; Kizuka, H; Kojima, K; Kubota, Y; Kusaba, K; Nishioka, A; Sano, H; Shindo, T; Ureshino, H | 1 |
| Abboud, CN; Baty, JD; Cashen, AF; DiPersio, JF; Duncavage, EJ; Fehniger, TA; Fronick, CC; Fulton, RS; Ghobadi, A; Graubert, TA; Hantel, A; Heath, SE; Jacoby, MA; Janke, MR; Khan, N; Knoebel, RW; Lee, YS; Ley, TJ; Link, DC; Luber, K; Miller, CA; O'Laughlin, M; Oh, ST; Petti, AA; Pusic, I; Romee, R; Schroeder, MA; Stock, W; Stockerl-Goldstein, KE; Sukhanova, MJ; Tandon, B; Tomasson, MH; Uy, GL; Vij, R; Walter, MJ; Wartman, LD; Welch, JS; Westervelt, P; Wilson, RK | 1 |
| Braun, T; Chermat, F; Chevret, S; Cony-Makhoul, P; Delaunay, J; Dimicoli, S; Fenaux, P; Lejeune, J; Prebet, T; Vey, N; Wattel, E; Wickenhauser, S | 1 |
| Chang, CK; Guo, J; He, Q; Li, X; Song, LX; Su, JY; Wu, D; Wu, LY; Xiao, C; Xu, F; Zhang, Z; Zhao, YS | 1 |
| Hagihara, M; Hua, J; Inoue, M; Uchida, T | 1 |
| Gao, S; Hua, FL; Li, Y; Meng, YS | 1 |
| Cashen, AF; DiPersio, JF; Duncavage, EJ; Fronick, CC; Fulton, RS; Gao, F; Jacoby, MA; Lee, YS; Ley, TJ; Link, DC; Miller, CA; O'Laughlin, M; Petti, AA; Tandon, B; Uy, GL; Walter, MJ; Wartman, LD; Welch, JS; Westervelt, P; Wilson, RK | 1 |
| Abaza, Y; Anz, B; Babu, S; Berdeja, JG; Boccia, R; DeZern, AE; Essell, J; Garcia-Manero, G; Ghalie, R; Heller, B; Jabbour, E; Kantarjian, HM; Komrokji, RS; Kuriakose, P; Lyons, RM; Maris, M; Montalban-Bravo, G; Ravandi, F; Reeves, J; Roboz, GJ; Sekeres, MA; Wright, D | 1 |
| Stahl, M; Zeidan, AM | 2 |
| Beach, CL; Chen, TY; Chen, YC; Chou, WC; Dong, Q; Galettis, A; Hsiao, LT; Laille, E; Lin, SF; Songer, S; Yeh, SP | 1 |
| Agarwal, R; Blombery, P; Dawson, MA; Dawson, SJ; Dickinson, M; Doig, K; Fong, CY; Ftouni, S; Hunter, T; Sinha, D; Vedururu, R; Westerman, D; Wong, SQ; Yeh, P | 1 |
| Aoe, M; Fujii, K; Fujii, N; Imada, M; Inomata, T; Ishikawa, T; Kondo, E; Maeda, Y; Matsuoka, KI; Meguri, Y; Nakashima, H; Nishimori, H; Tanimoto, M; Yoshida, S | 1 |
| Al Ali, N; Apuri, S; Komrokji, RS; Lancet, JE; List, AF; Padron, E | 1 |
| Deeg, HJ; Fang, M; Howard, NP; Scott, BL; Storer, BE; Woo, J; Yeung, CC | 1 |
| Dickinson, M; Seymour, JF; Slavin, MA; Spelman, T; Thursky, KA; Trubiano, JA; Worth, LJ | 1 |
| Chang, CK; Guo, J; Li, X; Song, LL; Wu, D; Wu, LY; Xiao, C; Xu, F; Zhao, YS | 1 |
| Garcia-Manero, G; Kantarjian, H; Sharma, S; Stoltz, ML; Ward, MR | 1 |
| Maslak, P; O'Dwyer, K | 1 |
| Götze, KS; Müller-Thomas, C; Peschel, C; Schuster, T | 1 |
| Ding, XS; Hang, HM; Jiang, SH; Liu, H; Song, GQ; Wang, XF; Xu, RR; Yang, L | 1 |
| Ali, F; Galili, N; Lascher, S; Mehdi, M; Mumtaz, M; Raza, A | 1 |
| Bokelmann, I; Lyko, F; Mahlknecht, U; Stresemann, C | 1 |
| Miyazawa, K | 1 |
| Cosler, LE; Ferro, SA; Greenberg, PL; Lyman, GH | 1 |
| Nomdedeu, B | 1 |
| Baer, MR; James, SR; Jones, DA; Karpf, AR; Link, PA | 1 |
| Alkan, S; Barton, K; Germano, E; Godwin, J; Michaelis, L; Nand, S; Rychlik, K; Smith, S; Stiff, P; Veerappan, R | 1 |
| Stone, RM | 2 |
| Estey, E; Scott, BL | 1 |
| Champlin, R; Davisson, J; de Lima, M; De Padua Silva, L; Faderl, S; Garcia-Manero, G; Giralt, S; Issa, JP; Kantarjian, H; Kebriaei, P; Ravandi, F | 1 |
| Chan, CH; Chen, CC; Gau, JP; Lee, KD; Lin, JT; Lu, CH; You, JY | 1 |
| Arora, S; Hogan, WJ; Litzow, MR; Porcher, JC; Steensma, DP; Van Laar, ES | 1 |
| Backstrom, J; Beach, C; Bennett, JM; Byrd, J; Fenaux, P; Finelli, C; Gattermann, N; Giagounidis, A; Gore, SD; Hellstrom-Lindberg, E; List, A; McKenzie, D; Mufti, GJ; Santini, V; Sanz, G; Schoch, R; Seymour, JF; Silverman, LR; Zimmerman, L | 1 |
| Backstrom, JT; Beach, CL; Cohn, AL; Cosgriff, TM; Fernando, IJ; Gersh, RH; Hainsworth, JD; Lyons, RM; McIntyre, HJ; Modi, SS | 1 |
| Bertz, H; Claus, R; Finke, J; Lübbert, M; Marks, R; Rüter, B; Wäsch, R | 1 |
| Garcia-Manero, G; Lyons, RM; Sekeres, M; Stone, R | 1 |
| Farzaneh, F; Gaymes, TJ; Lea, NC; MacPherson, LJ; Mufti, GJ; Shall, S; Twine, NA | 1 |
| Fenaux, P; Itzykson, R | 4 |
| Houldin, AD; Zhou, G | 1 |
| Issa, JP; Kantarjian, HM | 1 |
| Albitar, M; Arora, S; Baer, MR; Buckstein, R; Cullen, MT; Garcia-Manero, G; Godley, LA; Kantarjian, H; Larsen, JS; Slack, JL; Steensma, DP | 1 |
| Alsina, M; Anasetti, C; Ayala, E; Fernandez, HF; Field, T; Huang, Y; Janssen, W; Kharfan-Dabaja, MA; Lancet, J; List, A; Perez, L; Perkins, J; Sullivan, D | 1 |
| Ahn, JS; Bae, SH; Bang, SM; Kim, DY; Kim, HJ; Kim, I; Kim, YK; Lee, HG; Lee, JH; Lee, KH; Min, YH; Mun, YC; Oh, D; Park, S; Shin, HJ; Won, JH; Yoon, SS | 1 |
| Cataldo, VD; Cortes, J; Quintás-Cardama, A | 1 |
| Alimena, G; Amadori, S; Angelucci, E; Borin, L; Buccisano, F; Cortelezzi, A; Di Tucci, A; Fabiani, E; Fazi, P; Finelli, C; Fioritoni, G; Gobbi, M; Leone, G; Liso, V; Martinelli, G; Maurillo, L; Musto, P; Petti, MC; Piciocchi, A; Pogliani, E; Santini, V; Vignetti, M; Voso, MT; Zini, G | 1 |
| Abboud, CN; Augustin, K; Cashen, AF; Dipersio, JF; Kreisel, F; Martin, MG; Procknow, E; Stockerl-Goldstein, K; Uy, GL; Vij, R; Walgren, RA; Westervelt, P | 1 |
| Carraway, H; Fandy, TE; Fernandez, H; Figueroa, ME; Gore, SD; Greally, JM; Jiemjit, A; Li, Y; Licht, JD; Melnick, A; Paietta, E; Skrabanek, L; Tallman, MS | 1 |
| Becherer, K; Caldwell, C; Diaz-Arias, A; Feldman, M; Golda, N | 1 |
| Galili, N; Raza, A | 2 |
| Rose, MG | 1 |
| Silverman, LR | 4 |
| Aul, C; Ehninger, G; Giagounidis, A; Platzbecker, U | 1 |
| Abramowtiz, M; Alencar, C; Braunshweig, I; Jacobson, M; Parekh, S; Silverman, L; Verma, A | 1 |
| Lyons, RM | 2 |
| Scott, BL | 2 |
| Tuma, RS | 1 |
| Belnik, Y; Gafter-Gvili, A; Gurion, R; Raanani, P; Shpilberg, O; Vidal, L; Yeshurun, M | 1 |
| Gotlib, J; Greenberg, PL | 1 |
| Borthakur, G; Cortes, J; Faderl, S; Garcia-Manero, G; Issa, JP; Kantarjian, H; O'Brien, S; Pierce, S; Ravandi, F; Shan, J; Verstovsek, S | 1 |
| Baccarani, M; Bosi, C; Chiarini, F; Clissa, C; Cocco, L; Finelli, C; Follo, MY; Manzoli, L; Martelli, AM; Martinelli, G; Mongiorgi, S; Ramazzotti, G; Testoni, N | 1 |
| Bruns, I; Czibere, A; Fenk, R; Germing, U; Gräf, T; Haas, R; Kobbe, G; Kröger, N; Lind, J; Platzbecker, U; Schröder, T; Zohren, F | 1 |
| Djulbegovic, B; Hozo, I; Komrokji, R; Kumar, A; List, AF | 1 |
| Keating, GM | 2 |
| Ades, L; Fenaux, P | 1 |
| Garcia-Manero, G; Issa, JP; Kantarjian, H; Ravandi, F; Santos, FP | 1 |
| Berry, D; Borthakur, G; Faderl, S; Ferrajoli, A; Huang, X; Issa, JP; Kantarjian, H; Morris, G; Ravandi, F; Torma, R | 1 |
| Aw, DC; Chng, WJ; Koh, LP; Liu, TC; Ng, ES; Poon, ML; Tan, KB; Tan, LK; Yap, ES | 1 |
| Cho, BS; Cho, SG; Eom, KS; Kim, DW; Kim, HJ; Kim, MS; Kim, SY; Kim, YJ; Lee, JW; Lee, S; Min, CK; Min, WS | 1 |
| Cashen, AF; DiPersio, JF; O'Donnell, MR; Schiller, GJ | 1 |
| Becker, PS; Deeg, HJ; Estey, EH; Petersdorf, S; Ramakrishnan, A; Scott, BL; Storer, B | 1 |
| Blagitko-Dorfs, N; Daskalakis, M; Hackanson, B | 1 |
| Florek, M; Müller, A | 1 |
| Frame, D | 1 |
| Dunn, JD; Kogan, AJ | 1 |
| Backstrom, J; Beach, CL; Beyne-Rauzy, O; Duehrsen, U; Fenaux, P; Gattermann, N; Gore, SD; Hellström-Lindberg, E; List, A; McKenzie, D; Mufti, GJ; Ramos, F; Seymour, JF | 1 |
| Aloe-Spiriti, MA; Gozzini, A; Lunghi, M; Maurillo, L; Musto, P; Rivellini, F; Santini, V; Spagnoli, A; Venditti, A; Villani, O | 1 |
| Allegra, A; Alonci, A; Granata, A; Musolino, C; Penna, G; Russo, S; Sant'antonio, E | 1 |
| Anders, V; Bolaños-Meade, J; Villela, L | 1 |
| Braulke, F; Haase, D; Jung, K; Schanz, J; Schuetze, C; Schulte, K; Shirneshan, K; Steffens, R; Trümper, L | 1 |
| Malik, A; Misbah, S; Spaccavento, C; Yudelman, I | 1 |
| Baek, JH; Chae, YS; Chung, JS; Jo, DY; Joo, YD; Kang, BW; Kim, HJ; Kim, JG; Kim, SN; Kim, YK; Lee, SM; Moon, JH; Park, JH; Sohn, SK; Song, MK; Won, JH | 1 |
| Brown, R; Cogle, CR; Hsu, J; Imanirad, I; Scornik, JC; Wiggins, LE; Wingard, JR | 1 |
| Afable, M; Cuthbertson, D; Ganetsky, R; Ganetzky, R; Latham, D; List, AF; Loughran, TP; Maciejewski, JP; Paquette, R; Paulic, K; Saba, HI; Sekeres, MA | 1 |
| Ebert, BL | 1 |
| Issa, JP | 2 |
| Steensma, DP; Stone, RM | 1 |
| Backstrom, J; Beach, CL; Fenaux, P; Gore, SD; Hellström-Lindberg, E; List, A; Mufti, GJ; Santini, V; Seymour, JF; Silverman, LR | 1 |
| Gergis, U; Wissa, U | 1 |
| Koppel, A; Schiller, G | 1 |
| Lachs, MS; Ritchie, EK | 1 |
| Blagitko-Dorfs, N; Daskalakis, M; Hackanson, B; Lübbert, M | 1 |
| Backstrom, J; Beach, CL; Fenaux, P; Gore, SD; Hellström-Lindberg, E; List, AF; McKenzie, D; Mufti, GJ; Santini, V; Seymour, JF; Silverman, LR | 1 |
| Leary, C; Lowery-Nordberg, M; Stephens, J; Turturro, F; Veillon, D | 1 |
| Aggerholm, A; Antunovic, P; Astermark, J; Bernell, P; Engström, LM; Grövdal, M; Hellström-Lindberg, E; Hokland, P; Holm, MS; Jacobsen, SE; Karimi, M; Khan, R; Kjeldsen, L; Linder, O; Nilsson, L; Oberg, G; Olsson, A; Porwit, A; Tangen, JM; Wallvik, J | 1 |
| Connock, M; Edlin, R; Fry-Smith, A; Greenheld, W; Hyde, C; Round, J; Tubeuf, S | 1 |
| Batty, GN; Cortés, JE; Garcia-Manero, G; Issa, JP; Jabbour, E; Kantarjian, H; McCue, D; O'Brien, S; Pierce, S; Ravandi, F; Santos, FP | 1 |
| Agathanggelou, A; Cavenagh, J; Craddock, C; Goodyear, O; McSkeane, T; Moss, P; Novitzky-Basso, I; Ryan, G; Siddique, S; Stankovic, T; Vyas, P | 1 |
| Bauer, K; Brillant, C; Engert, A; Herbst, C; Kluge, S; Monsef, I; Skoetz, N | 1 |
| Garcia-Manero, G; Quintás-Cardama, A; Santos, FP | 1 |
| Batty, N; Cortes, J; Garcia-Manero, G; Issa, JP; Jabbour, E; Kantarjian, H; O'Brien, S; Ravandi, F; Shan, J | 1 |
| Aul, C; Ganser, A; Germing, U; Giagounidis, A; Götze, K; Haase, D; Hofmann, WK; Lübbert, M; Platzbecker, U | 1 |
| Buckstein, R; Wells, RA; Yee, K | 1 |
| Bowen, D; Fenaux, P; Gattermann, N; Hellström-Lindberg, E; Hofmann, WK; Pfeilstöcker, M; Santini, V; Sanz, G | 1 |
| Berger, DP; Franklin, JL; Gabrilove, JL; Garcia-Manero, G; Giles, FJ; Greenberg, PL; Hu, K; Kantarjian, HM; Paquette, RL; Wang, ES | 1 |
| Kalra, A; Kurmayagari, K; Palaniswamy, C; Sekhri, A; Selvaraj, DR | 1 |
| Adès, L; Chait, Y; Cluzeau, T; Dartigeas, C; Delaunay, J; Dreyfus, F; Eclache, V; Fenaux, P; Harel, S; Itzykson, R; Kiladjian, JJ; Quesnel, B; Raffoux, E; Salanoubat, C; Sanhes, L; Seegers, V; Sorin, L; Thepot, S; Turlure, P | 1 |
| Braun, TM; Champlin, R; de Lima, M; de Padua Silva, L; Garcia-Manero, G; Giralt, S; Jones, RB; Komanduri, K; Nguyen, HQ; Thall, PF | 1 |
| Choi, MY; Choi, Y; Joo, YD; Kim, DY; Kim, SD; Kim, SH; Lee, JH; Lee, KH; Lee, SM; Lee, WS; Lim, SN | 1 |
| Kondoh, T; Mori, N; Motoji, T; Ohwashi, M; Okada, M; Shimura, H; Shiseki, M; Tomita, K; Wang, YH; Yoshinaga, K | 1 |
| Hofmann, WK; Nolte, F | 1 |
| Han, H; Jones, PA; Lay, F; Yang, X | 1 |
| Tefferi, A | 1 |
| D'Alò, F; Di Ruscio, A; Fabiani, E; Giachelia, M; Guidi, F; Hohaus, S; Leone, G; Saulnier, N; Voso, MT | 1 |
| Arias-Bofill, D; Candelaria, M; Cervera, E; de la Cruz-Hernández, E; Dueñas-Gonzalez, A; González-Fierro, A; Herrera, A; Labardini, J; Pérez-Cárdenas, E; Taja-Chayeb, L; Trejo-Becerril, C; Vidal, S | 1 |
| Basquiera, A; Bernard, HI; Iastrebner, M; Jang, JH; Jung, CW; Kim, DH; Kim, K; Klein, G; Korin, J; Nucifora, E; Orlando, S; Sackmann, F; Santini, F; Taborda, G | 1 |
| Adès, L; Ame, S; Beach, CL; Beyne-Rauzy, O; Boehrer, S; Chelghoum, Y; Dartigeas, C; de Botton, S; Delaunay, J; Dreyfus, F; Fenaux, P; Gardin, C; Isnard, F; Itzykson, R; Legros, L; Marfaing-Koka, A; Plantier, I; Quesnel, B; Recher, C; Salanoubat, C; Stamatoullas, A; Taksin, AL; Thépot, S; Turlure, P; Vey, N; Visanica, S | 1 |
| Karaman, R | 1 |
| Garcia-Manero, G; Martin-Santos, T; Vigil, CE | 1 |
| Lim, SH; Mcmahan, J; Zhang, J; Zhang, Y | 1 |
| Galili, N; Gross, CP; Halene, S; Ma, X; Maggiore, RJ; Raza, A; Soulos, PR; Wang, R | 1 |
| Chiarini, F; Clissa, C; Cocco, L; Finelli, C; Follo, MY; Martelli, AM; Martinelli, G; Mongiorgi, S; Paolini, S; Ramazzotti, G | 1 |
| Jones, P | 1 |
| Fenaux, P; Garcia-Manero, G | 1 |
| Al Ustwani, O; Ambrus, J; Francis, J; Wallace, PK; Wetzler, M | 1 |
| Calin, GA; Fang, Z; Garcia-Manero, G; Hu, Y; Kantarjian, HM; Wei, Y; Yang, H | 1 |
| Doleris, LM; Dreyfus, F; Park, S; Pilorge, S | 1 |
| Ahn, JS; Kim, HJ; Kim, HN; Kim, YK; Lee, IK; Lee, JJ; Tran, HT; Yang, DH | 1 |
| Boëlle, PY; Chevret, S; Chomienne, C; Cras, A; Daniel, MT; de Labarthe, A; Degos, L; Dombret, H; Fenaux, P; Gardin, C; Maarek, O; Malfuson, JV; Marolleau, JP; Maury, S; Raffoux, E; Recher, C; Reman, O; Rousselot, P; Turlure, P; Victor, M | 1 |
| Alimena, G; Breccia, M; Cannella, L; Federico, V; Loglisci, G; Mancini, M; Nanni, M; Salaroli, A; Santopietro, M | 1 |
| Bozzoli, V; Calcagni, ML; D'Alò, F; Hohaus, S; Leone, G; Rufini, V; Teofili, L; Tisi, MC; Voso, MT | 1 |
| Fleurence, R; Kim, E; Knopf, K; Linnehan, JE; Pan, F; Peng, S | 1 |
| Ar, C; Atesoglu, EB; Bekoz, H; Cetiner, M; Ferhanoglu, B; Ozbalak, M; Salihoglu, A; Tuzuner, N | 1 |
| Chan, EM; Chan, RJ; Cripe, LD; Hood, D; Hui, CL; Kohlbacher, KJ; Nabinger, SC; Orschell, CM; Plett, A; Sampson, C; Sayar, H; Walter, A; West, ES; Wu, J; Yang, Z; Yu, Z | 1 |
| Sanchez, JF | 1 |
| Delgado, RG; Diez Campelo, M; Molias, AC; Sanchez, JF | 1 |
| Font, P | 1 |
| de Marcos, NS; Font, P; Molina, CA; Rodríguez, MJ | 1 |
| Adès, L; Beyne-Rauzy, O; Boehrer, S; Dreyfus, F; Eclache, V; Fenaux, P; Gardin, C; Itzykson, R; Quesnel, B; Recher, C; Thépot, S; Turlure, P; Vey, N | 1 |
| Ahn, SY; Choi, Y; Jeon, M; Jung, AR; Kang, YA; Kim, DY; Kim, SD; Lee, JH; Lee, KH; Lee, SB; Lee, YJ; Lee, YS; Park, YH; Seol, M | 1 |
| Aul, C; Baila, L; Beeldens, F; Coens, C; de Witte, T; Eckart Schaefer, H; Ganser, A; Germing, U; Giagounidis, A; Hagemeijer, A; Labar, B; Lübbert, M; Muus, P; Pflüger, KH; Platzbecker, U; Rüter, BH; Salih, HR; Selleslag, D; Suciu, S; Wijermans, PW | 1 |
| Adès, L; Beyne-Rauzy, O; Cluzeau, T; Dreyfus, F; Fenaux, P; Fontenay, M; Gelsi-Boyer, V; Itzykson, R; Kosmider, O; Mansat-De Mas, V; Preudhomme, C; Quesnel, B; Raynaud, S; Vey, N | 1 |
| Halasz, C; Patel, V; Ruskin, A; Tintle, S | 1 |
| Bryan, J; Garcia-Manero, G; Jabbour, E; Kantarjian, H | 1 |
| Buchner, D; Hatoum, HT; Kim, E; Lin, SJ | 1 |
| Cogle, C; Garcia-Manero, G; Giordano, H; Gore, SD; Jabbour, E; Kantarjian, H; Laille, E; Macbeth, KJ; Sakoian, S; Shi, T; Skikne, B; Ward, R | 1 |
| George, E; Holden, J; Miller, W; Stein, K | 1 |
| Campbell, LJ; Carney, DA; Gangatharan, SA; Kenealy, MK; Prince, HM; Seymour, JF | 1 |
| Akiyama, H; Ando, K; Hata, T; Hotta, T; Ishikawa, T; Kobayashi, Y; Nakao, S; Ogawa, Y; Ogura, M; Ohashi, H; Ohnishi, K; Ohyashiki, K; Okamoto, S; Ozawa, K; Taniwaki, M; Tobinai, K; Tomita, A; Uchida, T; Usui, N | 1 |
| Auberger, P; Cassuto, JP; Cluzeau, T; Jean-Michel, K; Puissant, A; Raynaud, S; Robert, G | 1 |
| Fenaux, P; Gattermann, N; Gore, SD; Hellström-Lindberg, E; List, AF; Mufti, GJ; Santini, V; Sanz, G; Seymour, JF; Silverman, LR | 1 |
| Choi, CW; Jang, JH; Joo, YD; Kim, HG; Kim, SH; Kim, YK; Lee, JH; Min, YH; Park, E; Park, J; Park, S; Park, SK | 1 |
| Alimena, G; Breccia, M; D'Elia, GM; Loglisci, G; Martelli, M; Mauro, FR; Nanni, M; Salaroli, A | 1 |
| Martínez-Francés, A | 1 |
| Franco Osorio, R; Martínez-Francés, A; Mercadal Vilchez, S; San Miguel Amigo, L | 1 |
| Li, Z; Wang, J; Wang, S; Yi, Z | 1 |
| Bechelli, J; Ifthikharuddin, JJ; Jordan, CT; Liesveld, JL; Lu, C; Messina, P; Mulford, D; Phillips Ii, GL; Rosell, KE | 1 |
| Angelucci, E; Brandimarte, L; Criscuolo, M; Fabiani, E; Fianchi, L; Finelli, C; Fioritoni, G; Greco, M; Hohaus, S; Leone, G; Matteucci, C; Mecucci, C; Musto, P; Piciocchi, A; Pogliani, E; Santini, V; Vignetti, M; Voso, MT | 1 |
| Adès, L; Beach, CL; Dreyfus, F; Esterni, B; Fenaux, P; Gardin, C; Gore, SD; Itzykson, R; Prébet, T; Quesnel, B; Rauzy, OB; Recher, C; Thepot, S; Vey, N | 1 |
| Abboud, CN; Cashen, AF; DiPersio, JF; Gao, F; Hassan, A; Klco, JM; Procknow, E; Stockerl-Goldstein, KE; Uy, GL; Vij, R; Welch, JS; Westervelt, P | 1 |
| Bordoni, RE; Buchner, D; Farrelly, E; Feinberg, BA; Gilmore, JW; Haislip, S; Jackson, JH; Kim, E | 1 |
| Maki, K; Mitani, K | 1 |
| Brissot, E; Clavert, A; Delaunay, J; Frikeche, J; Gaugler, B; Grégoire, M; Mohty, M | 1 |
| Castoro, R; Chung, W; El Ahdab, S; He, R; Issa, JP; Jelinek, J; Kantarjian, HM; Qin, T; Shu, J; Si, J; Wang, X; Zhang, N | 1 |
| Bornhäuser, M; Ehninger, G; Graehlert, X; Kiani, A; Klut, IM; Knoth, H; Mohr, B; Oelschlaegel, U; Platzbecker, U; Radke, J; Röllig, C; Schetelig, J; Seltmann, F; Thiede, C; Wermke, M | 1 |
| Horiike, S; Kuroda, J; Nagoshi, H; Taniwaki, M | 1 |
| Criscuolo, M; D'Alo, F; Fianchi, L; Greco, M; Hohaus, S; Leone, G; Pagano, L; Voso, MT | 1 |
| Cho, YH; Choi, HS; Kim, SY; Lee, HG; Lee, JH; Yoon, SY | 1 |
| Jabbour, E; Kadia, TM; Kantarjian, H | 1 |
| Alhan, C; Beeker, A; Biemond, BJ; Brouwer, RE; Croon-de Boer, F; de Weerdt, O; Eefting, M; Hoogendoorn, M; Huls, G; Jie, KS; Koedam, J; Libourel, WJ; Luykx-de Bakker, SA; Minnema, MC; Schaafsma, R; van de Loosdrecht, AA; van der Helm, LH; van Marwijk Kooy, M; van Rees, BP; Veeger, NJ; Vellenga, E; Wegman, J; Wijermans, PW | 1 |
| Beach, CL; Fenaux, P; Gidwani, R; Khan, ZM; Pashos, CL | 1 |
| Jones, PA; Pillai, AR; Sadik, W; Thachil, J | 1 |
| Gorin, NC; Isnard, F; Malak, S; Perot, C; Rubio, MT; Scherman, E | 1 |
| Charles, M; Nair, GB; Ogden, L; Spiegler, P | 1 |
| Clissa, C; Cocco, L; Colombi, C; Filì, C; Finelli, C; Follo, MY; Gobbi, M; Manzoli, L; Martelli, AM; Mongiorgi, S; Piazzi, M; Russo, D | 1 |
| Alimena, G; Breccia, M; Cannella, L; Finsinger, P; Loglisci, G; Mancini, M; Salaroli, A; Santopietro, M; Serrao, A | 1 |
| Gore, SD | 2 |
| Barozzi, P; Bigliardi, S; Bonacorsi, G; Colaci, E; Coluccio, V; Fantuzzi, V; Forghieri, F; Leonardi, G; Leonardi, L; Luppi, M; Maccaferri, M; Marasca, R; Morselli, M; Narni, F; Paolini, A; Potenza, L; Riva, G; Rossi, A; Zaldini, P | 1 |
| Ades, L; Ame, S; Berthon, C; Beyne-Rauzy, O; Boehrer, S; Chelgoum, Y; Dreyfus, F; Fenaux, P; Gardin, C; Isnard, F; Itzykson, R; Legros, L; Malfuson, JV; Salanoubat, C; Taksin, AL; Thépot, S; Turlure, P; Vey, N | 1 |
| Bazanis, E; Benopoulou, O; Diamantopoulos, PT; Meletis, J; Michael, M; Tzeletas, G; Vayopoulos, G; Viniou, NA | 1 |
| Kotsianidis, I; Margaritis, D; Miltiades, P; Nakou, E; Oikonomou, A; Spanoudakis, E; Tsatalas, C; Tzouvelekis, A | 1 |
| Appelbaum, FR; Deeg, HJ; Estey, EH; Gerds, AT; Gooley, TA; Scott, BL | 1 |
| Beijnen, JH; Derissen, EJ; Manson, ML; Schellens, JH; Wijermans, PW | 1 |
| Alimena, G; Breccia, M; Loglisci, G; Mancini, M; Petrucci, L; Salaroli, A; Serrao, A | 1 |
| Mittelman, M | 1 |
| Guan, XJ; Liang, H; Shao, XR | 1 |
| Belickova, M; Burda, P; Cermak, J; Curik, N; Hajkova, H; Haskovec, C; Jonasova, A; Krivjanska, M; Laslo, P; Necas, E; Pospisil, V; Savvulidi, F; Stopka, T; Trneny, M; Vargova, K; Vlckova, P | 1 |
| Gao, Y; Ping, B; Zhou, S | 1 |
| Beijnen, JH; Jansen, RS; Keizer, RJ; Rosing, H; Schellens, JH; Wijermans, PW | 1 |
| Beyne Rauzy, O; Dreyfus, F; Esterni, B; Fenaux, P; Gardin, C; Gore, SD; Prébet, T; Quesnel, B; Thépot, S; Vey, N | 1 |
| Ego, T; Homan, J; Kimura, S; Kuramoto, K; Naito, H; Naruoka, H; Nogawa, M; Sugahara, S | 1 |
| Alimena, G; Breccia, M; Loglisci, G; Petrucci, L; Salaroli, A; Serrao, A; Zacheo, I | 1 |
| Choi, MH; Jung, SE; Kim, IH; Kim, YJ; Kwon, JC; Lee, DG; Lee, SE; Park, KS; Shin, SH; Yahng, SA; Youn, JH | 1 |
| Kamae, I; Tomonaga, M | 1 |
| Alhan, C; Bontkes, HJ; Ossenkoppele, GJ; Ruben, JM; van de Loosdrecht, AA; Westers, TM | 1 |
| Chen, JW; Li, XF; Wang, LX; Wen, HY; Zhang, XY | 1 |
| Ham, JC; Hoogendijk-van den Akker, JM; Verdonck, LF | 1 |
| Stauder, R | 1 |
| Craig, M; Cumpston, A; Trickett, HB | 1 |
| Alimena, G; Breccia, M; Colafigli, G; Federico, V; Finsinger, P; Latagliata, R; Loglisci, G; Petrucci, L; Salaroli, A; Santopietro, M; Serrao, A | 1 |
| Auberger, P; Cassuto, JP; Cluzeau, T; Dufies, M; Jacquel, A; Karsenti, JM; Luciano, F; Mounier, N; Preudhomme, C; Puissant, A; Raynaud, S; Renneville, A; Robert, G | 1 |
| Adès, L; Beelen, D; Bornhäuser, M; Deeg, HJ; Ehninger, G; Fenaux, P; Finke, J; Germing, U; Itzykson, R; Kobbe, G; Platzbecker, U; Schaefer-Eckart, K; Schetelig, J; Scott, BL; Trenschel, R | 1 |
| Chang, C; He, Q; Li, X; Wu, L; Xu, F; Zhang, Y; Zhang, Z | 1 |
| Devlin, SM; Dolezal, EK; Klimek, VM; Nimer, SD; Romero, A; Stein, K; Tees, MT | 1 |
| Almeida, AM; Pierdomenico, F | 1 |
| Hu, C; Jin, J; Tong, H; Wang, L; Zhuang, Z | 1 |
| Fan, R; Han, T; Lin, GW; Wang, H; Wang, W; Wang, XQ; Yang, B; Zhang, LY; Zhao, XL | 1 |
| Adès, L; Dreyfus, F; Fenaux, P; Gardin, C; Itzykson, R; Quesnel, B; Recher, C; Thépot, S; Wattel, E | 1 |
| Chen, WF; Huang, F; Zha, J | 1 |
| Bosi, A; Buchi, F; Gozzini, A; Masala, E; Nosi, D; Sanna, A; Santini, V; Sassolini, F; Spinelli, E; Valencia, A; Zecchi, S | 1 |
| Audureau, E; Bardet, V; Benet, B; Clozel, T; Dreyfus, F; Ettou, S; Fontenay, M; Humbrecht, C; Jammes, H; Lacombe, C; Mayeux, P; Solary, E | 1 |
| Cutler, C | 1 |
| Barreyro, L; Ben-Neriah, S; Bhagat, TD; Bhattacharyya, S; Boultwood, J; Greally, JM; Heuck, C; List, AF; Maciejewski, J; McMahon, C; Mo, Y; Montagna, C; Parekh, S; Pellagatti, A; Schinke, C; Silverman, L; Steidl, C; Steidl, U; Tamari, R; Verma, A; Vogler, TO; Will, B; Ye, BH; Yu, Y; Zhou, L | 1 |
| Cluzeau, T; Fenaux, P | 1 |
| Ritchie, EK | 1 |
| Cornfield, DB | 1 |
| Hotta, T; Kasai, M; Kobayashi, Y; Kondo, Y; Miyazaki, Y; Mukai, HY; Ogura, M; Ohnishi, K; Ohyashiki, K; Okamoto, S; Oki, Y; Tohyama, K; Tomita, A; Tomonaga, M; Uike, N; Watanabe, T; Yamamoto, K | 1 |
| Aloe Spiriti, A; Breccia, M; Criscuolo, M; D'Alò, F; Fianchi, L; Finelli, C; Gaidano, G; Hohaus, S; Leone, G; Leoni, P; Levis, A; Lunghi, M; Musto, P; Oliva, EN; Pagano, L; Santini, V; Voso, MT | 1 |
| Brower, V | 1 |
| Damon, L; Franklin, J; Garcia-Manero, G; Greenberg, PL; Hu, K; Moore, M; Roboz, G; Yang, AS | 1 |
| Castro, CC; Germano, RT; Magalhaes, SM; Pinheiro, RF; Sousa, JC | 1 |
| Advani, AS; Afable, M; Cuthbertson, D; Englehaupt, R; Jerez, A; Juersivich, J; Komrokji, R; Lancet, J; List, AF; Maciejewski, JP; Makishima, H; Paleveda, J; Paquette, R; Sekeres, MA; Tabarroki, A; Tiu, RV; Visconte, V | 1 |
| Frick, K; Galili, N; Gross, CP; Guan, Y; Long, J; Ma, X; Raza, A; Wang, R; Xu, X; Zikria, J | 1 |
| List, AF | 3 |
| Cupelli, L; de Fabritiis, P; Fratoni, S; Giovannini, M; Morino, L; Neri, B; Niscola, P; Scaramucci, L; Tendas, A | 1 |
| Bao, L; Huang, XJ | 1 |
| Hayashi, M; Iwasaki, T; Kokubu, F; Mori, H; Tada, M; Takayasu, H; Takeda, N; Tateno, H; Tazawa, S; Tomita, S; Tsuchiya, Y; Wakabayashi, A; Yamashita, J; Yamazaki, Y | 1 |
| Dreyfus, F; Fenaux, P; Gore, SD; Prébet, T; Thepot, S; Vey, N | 1 |
| Atallah, E; Olasz, E; Randhawa, J; Wong, S | 1 |
| Chang, C; Li, X; Xu, F; Yang, Y; Zhang, Q | 1 |
| Alimena, G; Breccia, M; Loglisci, G; Salaroli, A | 1 |
| Adès, L; Fenaux, P; Itzykson, R | 1 |
| Joeckel, TE; Lübbert, M | 1 |
| Kishimoto, M; Suemori, S; Tochigi, A; Tohyama, K; Tohyama, Y; Tsujioka, T; Uesugi, M; Yokoi, A | 1 |
| Bouteloup, C; De Botton, S; Enot, D; Fenaux, P; Galluzzi, L; Kroemer, G; Lainey, E; Leroy, C; Marie, N; Micol, JB; Scoazec, M; Wolfromm, A | 1 |
| Fan, R; Li, WY; Lin, GW; Wang, H; Wang, XQ; Wu, DP; Xu, Y | 1 |
| Ades, L; Bay, JO; Beguin, Y; Bories, P; Bulabois, CE; Clement, L; Cornillon, J; Damaj, G; Dauriac, C; Deconinck, E; Duhamel, A; El Cheikh, J; Fegueux, N; Fenaux, I; Garnier, A; Garnier, F; Guillerm, G; Huynh, A; Legrand, F; Maillard, N; Marjanovic, Z; Marolleau, JP; Michallet, M; Mohty, M; Park, S; Robin, M; Rubio, MT; Schmidt-Tanguy, A; Vigouroux, S; Yakoub-Agha, I | 1 |
| Blaise, D; Charbonnier, A; Gelsi-Boyer, V; Mozziconacci, MJ; Prebet, T; Vey, N | 1 |
| Dai, D; Deng, YF; Hu, MQ; Xu, YL; Zhang, L; Zhang, XQ; Zhang, XZ | 1 |
| Kimura, S; Okano, M; Takahashi, Y | 1 |
| Alimena, G; Breccia, M; Fianchi, L; Finelli, C; Gaidano, G; Hohaus, S; Leone, G; Leoni, P; Levis, A; Lunghi, M; Mansueto, G; Musto, P; Oliva, EN; Santini, V; Spiriti, MA; Voso, MT | 1 |
| Eisenhofer, G; Hagelgans, A; Lehnert, R; Menschikowski, M; Platzbecker, U; Schönefeldt, C; Siegert, G; Thiede, C; Vogel, M | 1 |
| Arrazi, J; Aztberger, A; Brookes, C; Burnett, A; Cavenagh, J; Craddock, C; Davies, B; Freeman, S; Goardon, N; Griffiths, M; Grimwade, D; Hills, R; Ivey, A; Knapper, S; Majeti, R; McSkeane, T; Price, A; Quek, L; Raghavan, M; Schuh, A; Siddique, S; Virgo, P; Vyas, P; Wall, K; Weissman, I | 1 |
| Abellan, PP; Costantini, B; Farzaneh, F; Jiang, J; Kordasti, SY; Kulasekararaj, AG; Mohamedali, A; Mufti, GJ; Seidl, T; Thomas, NS | 1 |
| Rizzieri, DA | 1 |
| Adès, L; Dartigeas, C; Delaunay, J; Dreyfus, F; Fenaux, P; Itzykson, R; Lamarque, M; Legros, L; Quesnel, B; Rauzy, OB; Raynaud, S; Recher, C; Stamatoullas, A; Thepot, S; Turlure, P; Vey, N; Visanica, S | 1 |
| Cortes, JE; Faderl, S; Fullmer, A; Garcia-Manero, G; Jabbour, E; Kantarjian, H; O'Brien, S; Ravandi, F; Wierda, W | 1 |
| Do, YR; Huh, J; Kim, DD; Kim, H; Kim, HJ; Kim, KH; Kim, MK; Kim, SH; Kim, T; Mun, YC; Yi, JH | 1 |
| Chan, K; Covey, J; Ebrahem, Q; Engelke, KJ; Gu, X; Jankowska, A; Ling, Y; Maciejewski, J; Mahfouz, RZ; Radivoyevitch, T; Saunthararajah, Y; Sekeres, MA; Tabarroki, A; Terse, P; Tiu, R; Visconte, V | 1 |
| Bowen, DT; Durairaj, S; Groves, MJ; Hyslop, A; Keenan, N; Tauro, S | 1 |
| Czepulkowski, B; Gäken, J; Ireland, R; Krishnamurthy, P; Kulasekararaj, AG; Lea, NC; Marsh, JC; Mian, SA; Mohamedali, AM; Mufti, GJ; Pennaneach, C; Pomplun, S; Smith, AE | 1 |
| Bruns, I; Bug, G; Czibere, A; Fenk, R; Germing, U; Giagounidis, A; Haas, R; Kobbe, G; Kröger, N; Luft, T; Platzbecker, U; Rieger, K; Schroeder, T; Uharek, L; Wolschke, C; Zohren, F | 1 |
| Alimena, G; Bari, A; Breccia, M; Fianchi, L; Finelli, C; Leone, G; Lunghi, M; Musto, P; Niscola, P; Poloni, A; Voso, MT; Zambello, R | 1 |
| Champlin, R; Chen, J; Daver, N; de Lima, M; Garcia-Manero, G; Giralt, S; Jabbour, E; Kadia, T; Kantarjian, H; Khouri, I; Koca, E; Mathisen, MS; Oran, B; Parmar, S; Pierce, S; Popat, U; Rondon, G; Tanaka, M | 1 |
| Bornhäuser, M; Braulke, F; Bug, G; Ehninger, G; Germing, U; Giagounidis, A; Götze, K; Haase, D; Hofmann, WK; Kündgen, A; Naumann, R; Neesen, J; Platzbecker, U; Röllig, C; Schönefeldt, C; Shirneshan, K; Wermke, M | 1 |
| Hua-Yung, C; Kurtin, S; Murray, C; Nixon, S; von Riedemann, S; Wereley, A | 1 |
| Evans, C; Gryn, J; Lister, J; Meisner, D; Raymond, JM; Sbeitan, I; Shadduck, RK; Srodes, C; Zeigler, ZR | 1 |
| Daskalakis, M; Guldberg, P; Jones, PA; Köhler, G; Lübbert, M; Nguyen, C; Nguyen, TT; Wijermans, P | 1 |
| Leone, G; Lübbert, M; Teofili, L; Voso, MT | 1 |
| Sumida, KN; Suwanawiboon, B | 1 |
| Lübbert, M; van den Bosch, J; Verhoef, G; Wijermans, PW | 1 |
| Lin, MF; Tong, HY | 1 |
| Daskalakis, M; Engelhardt, M; Guo, Y; Kunzmann, R; Lübbert, M; Wijermans, P | 1 |
| Dörken, B; Lübbert, M; Sattler, N; Schmelz, K; Tamm, I; Wagner, M | 1 |
| Dörken, B; Schmelz, K; Tamm, I; Wagner, M | 1 |
| Farrell, AT; Kaminskas, E; Pazdur, R; Sridhara, R; Wang, YC | 1 |
| Beach, CL; Eller, M; Lintz, L; Marcucci, G; Silverman, L | 1 |
| Issa, JP; Kantarjian, HM; Kirkpatrick, P | 1 |
| Giles, FJ; Jabbour, EJ | 1 |
| Abraham, S; Baird, A; Farrell, A; Hsieh, LS; Kaminskas, E; Lee, SL; Leighton, JK; Patel, H; Pazdur, R; Rahman, A; Sridhara, R; Wang, YC | 1 |
| Adams, CD; Baroletti, SA; Lilly, CM; Szumita, PM | 1 |
| Emi, N; Iwai, M; Kinoshita, T; Kiyoi, H; Naoe, T; Ohno, R; Ozeki, K | 1 |
| Issa, JP; Kantarjian, H | 1 |
| Fukumoto, JS; Greenberg, PL | 1 |
| Saba, HI; Wijermans, PW | 1 |
| Galili, N; Mehdi, M; Mumtaz, M; Qawi, H; Raza, A | 1 |
| Hahn, K; Kolesar, JM; Sullivan, M | 1 |
| Hackanson, B; Lübbert, M; Lyko, F; Mund, C; Stresemann, C | 1 |
| Scott, LJ; Siddiqui, MA | 1 |
| Demakos, EP; Linebaugh, JA | 1 |
| Kuykendall, JR | 1 |
| Haas, PS; Lübbert, M; Verhoef, G; Wijermans, P | 1 |
| Breed, C; Latsko, JM; Shadduck, RK; Stone, R | 1 |
| Rosenfeld, CS | 1 |
| Bosly, A; Klimek, V; Lübbert, M; Verhoef, G; Wijermans, PW | 1 |
| de Vos, D; van Overveld, W | 1 |
| Giles, FJ; Jabbour, E; Kantarjian, HM; Yee, KW | 1 |
| Hackanson, B; Lübbert, M; Robbel, C; Wijermans, P | 1 |
| Germing, U; Haas, PS; Kündgen, A; Lübbert, M; Müller-Berndorff, H; Pitako, JA; Van den Bosch, J; Wijermans, PW | 1 |
| Lübbert, M; Schaefer, HE | 1 |
| Mufti, GJ; Silverman, LR | 1 |
| Camacho, LH; Chanel, S; Guernah, I; Maslak, P; Nimer, S; Pandolfi, PP; Soignet, S; Warrell, R | 1 |
| Bouabdallah, K; Daskalakis, M; Johansson, B; Kunzmann, R; Lübbert, M; Mauritzson, N; Müller-Berndorff, H; Onida, F; Schmitt-Gräff, A | 1 |
| Letendre, L; Tefferi, A | 1 |
| Albitar, M; Bennett, JM; de Castro, C; DiPersio, J; Helmer, R; Issa, JP; Kantarjian, H; Klimek, V; Leavitt, R; Nimer, SD; Ravandi, F; Raza, A; Rosenfeld, CS; Saba, H; Shen, L; Slack, J | 1 |
| Lübbert, M; Rüter, B; Wijermans, PW | 1 |
| Lübert, M; Wijermans, P | 1 |
| Fenk, R; Graef, T; Haas, R; Kobbe, G; Kuendgen, A; Zohren, F | 1 |
| Nimer, SD | 1 |
| Croom, KF; McKeage, K | 1 |
| Garcia-Manero, G; Saba, HI | 1 |
| Baylin, S; Carducci, M; Carraway, H; Dauses, T; Dover, G; Galm, O; Gore, SD; Grever, M; Herman, JG; Jiemjit, A; Karp, JE; Manning, J; Mays, A; Miller, CB; Murgo, A; Rudek, MA; Smith, BD; Sugar, E; Weng, LJ; Zhao, M; Zwiebel, J | 1 |
| Bueso-Ramos, C; Cortes, J; Davis, J; Estrov, Z; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, F; Huang, X; Issa, JP; Kantarjian, H; O'Brien, S; Oki, Y; Ravandi, F; Saba, HI; Shan, J; Wierda, W | 1 |
| Bueso-Ramos, C; Cortes, J; Estey, E; Estrov, Z; Faderl, S; Fiorentino, J; Garcia-Manero, G; Issa, JP; Jabbour, E; Kantarjian, HM; Koller, C; O'brien, S; Ravandi, F; Rosner, G; Rytting, M; Sanchez-Gonzalez, B; Verstovsek, S; Wierda, WG; Xiao, L; Yang, H | 1 |
| Backstrom, JT; Beach, CL; Holland, JF; Larson, RA; McKenzie, DR; Peterson, BL; Silverman, LR | 1 |
| Fortenbaugh, C | 1 |
| Thomas, ML | 1 |
| Cecconi, N; Galimberti, S; Orciuolo, E; Papineschi, F; Petrini, M | 1 |
| Gore, SD; Jones, C; Kirkpatrick, P | 1 |
| Aribi, A; Cortes, J; Davisson, J; Garcia-Manero, G; Issa, JP; Jabbour, E; Kantarjian, HM; O'Brien, S; Ravandi, F; Shan, J | 1 |
| Galili, N; Raza, A; Raza, FZ | 1 |
| Atallah, E; Garcia-Manero, G; Kantarjian, H | 1 |
| Cui, X; Liu, T; Meng, WT; Xi, YM; Ye, XS | 1 |
| Steensma, DP; Tefferi, A | 1 |
| Bueso-Ramos, CE; Cortes, J; Davisson, J; Garcia-Manero, G; Huang, X; Issa, JP; Kantarjian, HM; O'Brien, S; Ravandi, F; Shan, J | 1 |
| Deeg, HJ; Mhyre, AJ | 1 |
| Schiffer, CA | 1 |
| Kantarjian, HM | 2 |
| Bruserud, Ø; Ryningen, A; Stapnes, C | 1 |
| Dalal, J; Gonzalez, C; Kearns, GL; Peters, C; Tsao, CF | 1 |
| Cashen, AF; DiPersio, J; Fisher, N; Shah, AK; Todt, L | 1 |
| Cortes, J; Estey, EH; Estrov, Z; Faderl, S; Garcia-Manero, G; Giles, F; Issa, JP; Kantarjian, HM; Ouzounian, S; Pierce, S; Quezada, A; Ravandi, F; Soriano, AO; Wierda, WG; Yang, H | 1 |
| Chronis, C; Ho, A; John, A; Khan, S; Mufti, GJ; Pomplun, S; Raj, K; Samuel, J; Thomas, NS | 1 |
| Bai, S; Ghoshal, K | 1 |
| Egger, G; Jeong, S; Jones, PA; Liang, G; Phiasivongsa, P; Redkar, S; Tang, C; Yoo, CB | 1 |
| Baccarani, M; Blalock, WL; Bosi, C; Cocco, L; Finelli, C; Follo, MY; Manzoli, L; Martelli, AM; Martinelli, G; Mongiorgi, S | 1 |
| Claus, R; Kunzmann, R; Lübbert, M; Rüter, B; Wijermans, P | 1 |
| Giagounidis, AA | 1 |
| Atallah, E; Garcia-Manero, G | 1 |
| Hueser, CN; Patel, AJ | 1 |
| Abdulhaq, H; Rossetti, JM | 1 |
| Sloand, EM | 1 |
| Gore, SD; Griffiths, EA | 2 |
| Garcia-Manero, G; Jagasia, M; Yang, AS | 1 |
| Ekström, TJ; Gogvadze, V; Hassan, M; Hellström-Lindberg, E; Karimi, M; Khan, R; Schmidt-Mende, J; Zhivotovsky, B | 1 |
| Billi, AM; Cocco, L; Faenza, I; Follo, MY; Gaboardi, GC; Manzoli, L; Martelli, AM; Ramazzotti, G | 1 |
| Mitani, K | 1 |
| Ahdab, SE; Borthakur, G; Faderl, S; Ferrajoli, A; Issa, JP; Kantarjian, H; Newman, B; Ravandi, F | 1 |
| Garcia-Manero, G; Issa, JP; Jabbour, E; Kantarjian, H | 1 |
| Issa, JP; Oki, Y | 1 |
| Pinto, A; Zagonel, V | 1 |
| Huijgens, PC; Krulder, JW; Neve, P; Wijermans, PW | 2 |
| Ferrini, PR; Santini, V | 1 |
| Fenaux, P; Quesnel, B | 1 |
| Andre, M; Bosly, A; Ferrant, A; Lübbert, M; Ravoet, C; Verhoef, G; Wijermans, P | 1 |
| Lübbert, M | 1 |
| Andre, M; Bosly, A; Ferrant, A; Kunzmann, R; Lübbert, M; Ravoet, C; Verhoef, G; Wijermans, P | 1 |
| Ganser, A; Verbeek, W | 1 |
| Hofmann, WK; Koeffler, HP | 1 |
| DeCastro, CM; Demakos, EP; Ellerton, J; Holland, JC; Holland, JF; Kornblith, AB; Larson, RA; Nelson, D; Odchimar-Reissig, R; Peterson, BL; Powell, BL; Schiffer, CA; Silverman, LR; Stone, RM | 1 |
| DeCastro, C; Demakos, EP; Ellerton, J; Herndon, JE; Holland, JC; Holland, JF; Kornblith, AB; Larson, RA; Odchimar-Reissig, R; Powell, BL; Schiffer, CA; Silverman, LR | 1 |
| Kizaki, M; Koeffler, HP | 1 |
| Anderson, T; Ash, RC; Chitambar, CR; Libnoch, JA; Matthaeus, WG; Ritch, PS | 1 |
| Attadia, V; Bullian, PL; Carbone, A; Colombatti, A; Gattei, V; Monfardini, S; Pinto, A; Zagonel, V | 1 |
217 review(s) available for azacitidine and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Optimizing DNA hypomethylating therapy in acute myeloid leukemia and myelodysplastic syndromes.
Topics: Aged; Azacitidine; Decitabine; Genetic Therapy; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Treatment Outcome | 2021 |
Response of autoimmune and inflammatory disorders in myelodysplastic syndromes to 5-azacytidine: report of two cases and literature review.
Topics: Aged; Azacitidine; Humans; Male; Myelodysplastic Syndromes; Sweet Syndrome | 2021 |
[Treatment for myelodysplastic syndromes and future perspectives in the genomic era].
Topics: Azacitidine; Genomics; Humans; Myelodysplastic Syndromes; Quality of Life; Risk Factors | 2021 |
Novel agents for myelodysplastic syndromes.
Topics: Azacitidine; Decitabine; Drug Approval; Humans; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; United States; United States Food and Drug Administration | 2021 |
Oral Azacitidine (CC-486) for the Treatment of Myeloid Malignancies.
Topics: Adult; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials, Phase III as Topic; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Myeloproliferative Disorders; Randomized Controlled Trials as Topic | 2022 |
Different mechanisms of drug resistance to hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukemia.
Topics: Aged; Azacitidine; Decitabine; Drug Resistance; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2022 |
New Approaches to Myelodysplastic Syndrome Treatment.
Topics: Anemia; Antineoplastic Agents; Azacitidine; Humans; Lenalidomide; Myelodysplastic Syndromes; Quality of Life | 2022 |
Hypomethylating agents for the treatment of myelodysplastic syndromes and acute myeloid leukemia: Past discoveries and future directions.
Topics: Azacitidine; Decitabine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2022 |
Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Topics: Azacitidine; Humans; Immune Checkpoint Inhibitors; Immunologic Factors; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2022 |
SOHO State of the Art and Next Questions: Treatment of Higher-Risk Myelodysplastic Syndromes.
Topics: Azacitidine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Quality of Life | 2022 |
Diagnosis and Treatment of Myelodysplastic Syndromes: A Review.
Topics: Antineoplastic Agents; Azacitidine; Decitabine; Erythropoietin; Female; Hematinics; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Neutropenia; Prognosis; Thrombocytopenia | 2022 |
Current status of phase 3 clinical trials in high-risk myelodysplastic syndromes: pitfalls and recommendations.
Topics: Antineoplastic Agents; Azacitidine; Humans; Myelodysplastic Syndromes | 2023 |
Azacitidine Monotherapy in Patients With Treatment-Naïve Higher-risk Myelodysplastic Syndrome: A Systematic Literature Review and Meta-analysis.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Humans; Myelodysplastic Syndromes; Remission Induction; Treatment Outcome | 2023 |
Role of Bcl-2 inhibition in myelodysplastic syndromes.
Topics: Aged; Azacitidine; Hematologic Neoplasms; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Proto-Oncogene Proteins c-bcl-2 | 2023 |
Improving clinical trials in higher-risk myelodysplastic syndromes.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Patient Selection | 2022 |
Targeting DNA Methylation in Leukemia, Myelodysplastic Syndrome, and Lymphoma: A Potential Diagnostic, Prognostic, and Therapeutic Tool.
Topics: Azacitidine; Decitabine; DNA Methylation; Epigenesis, Genetic; Hematologic Neoplasms; Humans; Leukemia; Lymphoma; Myelodysplastic Syndromes; Prognosis | 2022 |
Advances in myelodysplastic syndromes: promising novel agents and combination strategies.
Topics: Azacitidine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Risk | 2023 |
MYELODYSPLASTIC SYNDROME: DIAGNOSIS, TREATMENT AND PROGNOSIS (LITERATURE REVIEW).
Topics: Azacitidine; Humans; Leukemia; Myelodysplastic Syndromes; Prognosis; Quality of Life | 2023 |
Efficacy of epigenetic agents for older patients with acute myeloid leukemia and myelodysplastic syndrome in randomized controlled trials: a systematic review and network meta-analysis.
Topics: Aged; Azacitidine; Epigenesis, Genetic; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Network Meta-Analysis; Randomized Controlled Trials as Topic; Systematic Reviews as Topic; Treatment Outcome | 2023 |
STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials, Phase III as Topic; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes | 2023 |
[Dysimmune manifestations associated with myelodysplastic neoplasms and chronic myelomonocytic leukaemias].
Topics: Azacitidine; Humans; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Skin Diseases | 2023 |
Guadecitabine (SGI-110): an investigational drug for the treatment of myelodysplastic syndrome and acute myeloid leukemia.
Topics: Aged; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Drugs, Investigational; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis; Survival Rate; Time Factors | 2019 |
[Treatment of higher risk myelodysplastic syndromes].
Topics: Azacitidine; Hematopoietic Stem Cell Transplantation; Humans; Myelodysplastic Syndromes; Transplantation, Homologous | 2019 |
Hypomethylating agents for patients with myelodysplastic syndromes prior to hematopoietic stem cell transplantation: a systematic review and meta-analysis.
Topics: Allografts; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Disease-Free Survival; DNA Methylation; Hematopoietic Stem Cell Transplantation; Humans; Myelodysplastic Syndromes; Premedication; Survival Analysis; Treatment Outcome | 2019 |
Does early diagnosis and treatment of myelodysplastic syndromes make a difference?
Topics: Allografts; Azacitidine; Decitabine; Early Diagnosis; Hematinics; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Myelodysplastic Syndromes; Risk Factors | 2019 |
In MDS, is higher risk higher reward?
Topics: Aged; Allografts; Azacitidine; Clinical Trials as Topic; Decitabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Myelodysplastic Syndromes; Translational Research, Biomedical | 2019 |
Hypomethylating agent based combinations in higher risk myelodysplastic syndrome.
Topics: Antimetabolites, Antineoplastic; Azacitidine; DNA Methylation; Humans; Myelodysplastic Syndromes | 2020 |
Cutaneous adverse events induced by azacitidine in myelodysplastic syndrome patients: Case reports and a lesson from published work review.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Erythema; Female; Humans; Injection Site Reaction; Injections, Subcutaneous; Male; Myelodysplastic Syndromes; Neutrophil Infiltration; Skin | 2020 |
Following in the footsteps of acute myeloid leukemia: are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes?
Topics: Antimetabolites, Antineoplastic; Azacitidine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2020 |
Combination treatment with CPX-351 and midostaurin in patients with secondary acute myeloid leukaemia that are FLT3 mutated: three cases and review of literature.
Topics: Aged; Allografts; Anemia, Refractory, with Excess of Blasts; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase III as Topic; Cytarabine; Daunorubicin; Fatal Outcome; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm, Residual; Neoplasms, Radiation-Induced; Oncogene Proteins, Fusion; Peripheral Blood Stem Cell Transplantation; Point Mutation; Protein Kinase Inhibitors; Pyrazines; Remission Induction; Salvage Therapy; Staurosporine; Sulfonamides | 2020 |
Myelodysplastic Syndromes.
Topics: Azacitidine; Decitabine; Enzyme Inhibitors; Erythrocyte Transfusion; Genetic Predisposition to Disease; Humans; Leukemia, Myeloid, Acute; Mutation; Myelodysplastic Syndromes; Stem Cell Transplantation; Transplantation, Homologous; Watchful Waiting | 2020 |
[Management of patients with higher-risk myelodysplastic syndromes].
Topics: Azacitidine; Hematopoietic Stem Cell Transplantation; Humans; Myelodysplastic Syndromes | 2020 |
Factors affecting response to 5-azacytidine and prognosis of myelodysplastic syndrome. Is long-term survival a realistic goal?
Topics: Age Factors; Azacitidine; Decitabine; Disease-Free Survival; Humans; Myelodysplastic Syndromes; Risk Factors; Survival Rate | 2021 |
A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Disease-Free Survival; Humans; Myelodysplastic Syndromes; Survival Rate | 2021 |
Comparison of Azacitidine and Decitabine in Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Network Meta-analysis.
Topics: Age Factors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Disease Management; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Odds Ratio; Prognosis; Treatment Outcome | 2021 |
Management of patients with higher-risk myelodysplastic syndromes after failure of hypomethylating agents: What is on the horizon?
Topics: Antineoplastic Agents; Azacitidine; DNA Methylation; Enzyme Inhibitors; Humans; Myelodysplastic Syndromes; Remission Induction; Treatment Outcome | 2021 |
Do histone deacytelase inhibitors and azacitidine combination hold potential as an effective treatment for high/very-high risk myelodysplastic syndromes?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Drug Synergism; Hematopoietic Stem Cell Transplantation; Histone Deacetylase Inhibitors; Humans; Myelodysplastic Syndromes; Patient Selection; Randomized Controlled Trials as Topic; Treatment Outcome | 2021 |
Cedazuridine/decitabine: from preclinical to clinical development in myeloid malignancies.
Topics: Azacitidine; Decitabine; Humans; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Uridine | 2021 |
Predicting outcome in higher-risk myelodysplastic syndrome patients treated with azacitidine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Biomarkers; Disease Management; Disease Susceptibility; Humans; Mutation; Myelodysplastic Syndromes; Prognosis; Treatment Outcome | 2021 |
Infectious complications in patients with myelodysplastic syndromes: A review of the literature with emphasis on patients treated with 5-azacitidine.
Topics: Antibiotic Prophylaxis; Antimetabolites, Antineoplastic; Azacitidine; Granulocyte Colony-Stimulating Factor; Humans; Infection Control; Infections; Morbidity; Mortality; Myelodysplastic Syndromes; Neutropenia | 2017 |
Immunological effects of hypomethylating agents.
Topics: Animals; Antineoplastic Agents; Azacitidine; Biomarkers; Decitabine; Dendritic Cells; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation; Humans; Immunomodulation; Killer Cells, Natural; Leukemia, Myeloid, Acute; Mutation; Myelodysplastic Syndromes; T-Lymphocytes | 2017 |
Myelodysplastic syndrome with neutrophilic dermatosis successfully treated with azacitidine.
Topics: Aged; Azacitidine; Humans; Male; Myelodysplastic Syndromes; Sweet Syndrome; Treatment Outcome | 2017 |
Myelodysplastic syndrome with myelofibrosis in which azacitidine therapy was effective and cord blood transplantation was carried out.
Topics: Azacitidine; Cord Blood Stem Cell Transplantation; Fetal Blood; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Primary Myelofibrosis; Transplantation, Homologous | 2017 |
A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Decitabine; Humans; Myelodysplastic Syndromes; Patient Selection; Reproducibility of Results; Survival Analysis; Treatment Failure | 2017 |
The Challenge of Treating Myelodysplastic Syndromes/Myeloproliferative Neoplasms.
Topics: Adult; Azacitidine; DNA (Cytosine-5-)-Methyltransferases; Enzyme Inhibitors; Humans; Myelodysplastic Syndromes; Myeloproliferative Disorders; Survival Analysis; World Health Organization | 2017 |
Successful 5-azacytidine treatment of myeloid sarcoma and leukemia cutis associated with myelodysplastic syndrome: A case report and literature review.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Diagnosis, Differential; Female; Humans; Leukemia; Myelodysplastic Syndromes; Sarcoma, Myeloid | 2017 |
Thrombopoietin mimetics for patients with myelodysplastic syndromes.
Topics: Adult; Azacitidine; Benzoates; Blood Transfusion; Decitabine; Female; Hemorrhage; Humans; Hydrazines; Lenalidomide; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Pyrazoles; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Fc; Recombinant Fusion Proteins; Thalidomide; Thrombocytopenia; Thrombopoietin | 2017 |
Dasatinib and Azacitidine Followed by Haploidentical Stem Cell Transplant for Chronic Myeloid Leukemia with Evolving Myelodysplasia: A Case Report and Review of Treatment Options.
Topics: Adult; Azacitidine; Dasatinib; Drug Therapy, Combination; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myelodysplastic Syndromes; Protein Kinase Inhibitors; Stem Cell Transplantation | 2017 |
Azacitidine in Lower-Risk Myelodysplastic Syndromes: A Meta-Analysis of Data from Prospective Studies.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Humans; Myelodysplastic Syndromes; Prognosis; Prospective Studies | 2018 |
DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Combined Modality Therapy; Decitabine; DNA Methylation; Epigenesis, Genetic; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelomonocytic, Juvenile; Myelodysplastic Syndromes | 2018 |
Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation.
Topics: Allografts; Azacitidine; Decitabine; Drug Administration Schedule; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Recurrence; Retrospective Studies; Salvage Therapy; Secondary Prevention; Stem Cell Transplantation | 2018 |
Incorporating novel approaches in the management of MDS beyond conventional hypomethylating agents.
Topics: Allografts; Azacitidine; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Humans; Myelodysplastic Syndromes; Stem Cell Transplantation | 2017 |
Therapeutic choices after hypomethylating agent resistance for myelodysplastic syndromes.
Topics: Antibodies, Monoclonal, Humanized; Azacitidine; Drug Resistance; Enzyme Inhibitors; Humans; Ipilimumab; Myelodysplastic Syndromes; Nivolumab | 2018 |
Azacitidine Use for Myeloid Neoplasms.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Humans; Myelodysplastic Syndromes; Myeloproliferative Disorders | 2018 |
Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Cycle Checkpoints; DNA Methylation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2018 |
Remission of relapsing polychondritis after successful treatment of myelodysplastic syndrome with azacitidine: a case and review of the literature.
Topics: Adult; Azacitidine; Humans; Immunosuppressive Agents; Male; Myelodysplastic Syndromes; Polychondritis, Relapsing; Remission Induction; Time Factors; Treatment Outcome | 2018 |
Addition of histone deacetylase inhibitors does not improve prognosis in patients with myelodysplastic syndrome and acute myeloid leukemia compared with hypomethylating agents alone: A systematic review and meta-analysis of seven prospective cohort studie
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cohort Studies; Decitabine; Histone Deacetylase Inhibitors; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis; Prospective Studies; Treatment Outcome | 2018 |
Predictors of clinical responses to hypomethylating agents in acute myeloid leukemia or myelodysplastic syndromes.
Topics: Azacitidine; DNA Methylation; DNA, Neoplasm; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; Mutation; Myelodysplastic Syndromes; Neoplasm Proteins; Predictive Value of Tests | 2018 |
A systematic review and network meta-analysis comparing azacitidine and decitabine for the treatment of myelodysplastic syndrome.
Topics: Azacitidine; Blood Transfusion; Decitabine; Humans; Mortality; Myelodysplastic Syndromes; Network Meta-Analysis; Quality of Life | 2018 |
Improving Treatment for Myelodysplastic Syndromes Patients.
Topics: Aging; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Enzyme Inhibitors; Humans; Lenalidomide; Myelodysplastic Syndromes; Stem Cell Transplantation; Transplantation, Homologous | 2018 |
Bone Marrow Fibrosis and Early Hematological Response as Predictors of Poor Outcome in Azacitidine Treated High Risk-Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Primary Myelofibrosis; Retrospective Studies; Treatment Outcome | 2018 |
Clinical update on hypomethylating agents.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Methylation; Drug Administration Schedule; Drug Combinations; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Uridine | 2019 |
A systematic review and meta
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cohort Studies; Female; Hematologic Diseases; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome | 2019 |
Novel therapies in low- and high-risk myelodysplastic syndrome.
Topics: Activin Receptors, Type II; Anemia; Antineoplastic Agents; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; Erythrocyte Transfusion; Hematinics; Humans; Immunoglobulin Fc Fragments; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Oligonucleotides; Prognosis; Recombinant Fusion Proteins; Risk Assessment; Stem Cell Transplantation; Sulfonamides; Thalidomide; Thrombopoietin; Transplantation, Homologous | 2019 |
Acquired erythropoietic protoporphyria: A systematic review of the literature.
Topics: Adult; Aged; Azacitidine; beta Carotene; Chromosomes, Human, Pair 18; Erythrocytes; Female; Ferrochelatase; Genetic Loci; Humans; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Photosensitivity Disorders; Protoporphyria, Erythropoietic; Protoporphyrins | 2020 |
5-Azacytidine for the treatment of myelodysplastic syndromes.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; DNA Methylation; Drug Approval; Humans; Myelodysplastic Syndromes; Prognosis; Quality of Life; Survival | 2013 |
Combination of azacitidine and lenalidomide in myelodysplastic syndromes or acute myeloid leukemia-a wise liaison?
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome | 2013 |
Myelodysplastic syndromes and autoimmune diseases--case series and review of literature.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Autoimmune Diseases; Azacitidine; Female; Humans; Middle Aged; Myelodysplastic Syndromes; Prognosis; Treatment Outcome; Young Adult | 2013 |
Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Epigenesis, Genetic; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis; Remission Induction; Treatment Outcome | 2013 |
When is the optimal timing for allogeneic transplantation in the case of MDS patients treated with hypomethylating agents?
Topics: Adult; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Hematopoietic Stem Cell Transplantation; Humans; Male; Myelodysplastic Syndromes; Prognosis; Survival Rate; Transplantation, Homologous; Treatment Outcome | 2013 |
The role of hypomethylating agents in myelodysplastic syndrome: changing the management paradigm.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Modification Methylases; Drug Therapy, Combination; Histone Deacetylase Inhibitors; Humans; Myelodysplastic Syndromes; Prognosis; Stem Cell Transplantation | 2013 |
The euphoria of hypomethylating agents in MDS and AML: is it justified?
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Decitabine; DNA Methylation; Endpoint Determination; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Patient Selection; Randomized Controlled Trials as Topic; Remission Induction; Survival Analysis; Treatment Outcome | 2013 |
Key clinical observations after 5-azacytidine and decitabine treatment of myelodysplastic syndromes suggest practical solutions for better outcomes.
Topics: Azacitidine; Cell Proliferation; Chromosome Aberrations; Decitabine; Disease-Free Survival; DNA-Cytosine Methylases; Enzyme Inhibitors; Gene Expression Regulation; Humans; Myelodysplastic Syndromes; S Phase; Survival Rate; Transcription Factors | 2013 |
Beyond hypomethylating agents failure in patients with myelodysplastic syndromes.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; DNA Methylation; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Molecular Targeted Therapy; Myelodysplastic Syndromes; Prognosis; Recurrence; Retreatment; Thalidomide; Transplantation, Homologous; Treatment Failure; Treatment Outcome | 2014 |
Novel therapeutic strategies using hypomethylating agents in the treatment of myelodysplastic syndrome.
Topics: Azacitidine; Benzamides; Decitabine; DNA Methylation; Humans; Imatinib Mesylate; Lenalidomide; Molecular Targeted Therapy; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Thalidomide | 2014 |
Clinical development of demethylating agents in hematology.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; Epigenesis, Genetic; Humans; Leukemia, Myeloid, Acute; Mutation, Missense; Myelodysplastic Syndromes | 2014 |
[Myelodysplastic syndromes: treatment strategy up-to-date].
Topics: Antilymphocyte Serum; Azacitidine; Benzoates; Cyclosporine; Cytarabine; Deferasirox; Disease Progression; Drug Discovery; Drug Therapy, Combination; Erythropoietin; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Iron Chelating Agents; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Quality of Life; Risk Assessment; Thalidomide; Triazoles | 2014 |
Paraneoplastic inflammation in myelodysplastic syndrome or bone marrow failure: case series with focus on 5-azacytidine and literature review.
Topics: Adult; Aged; Anemia, Aplastic; Antimetabolites, Antineoplastic; Autoimmunity; Azacitidine; Bone Marrow; Bone Marrow Diseases; Bone Marrow Failure Disorders; Diagnosis, Differential; Female; Hemoglobinuria, Paroxysmal; Humans; Inflammation; Male; Middle Aged; Myelodysplastic Syndromes; Paraneoplastic Syndromes; Treatment Outcome | 2014 |
Decitabine.
Topics: Animals; Antineoplastic Agents; Azacitidine; Decitabine; DNA Modification Methylases; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2014 |
5-Azacytidine/5-Azacitidine.
Topics: Animals; Antineoplastic Agents; Azacitidine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2014 |
Azacitidine for myelodysplastic patients aged > 65 years: a review of clinical efficacy.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Humans; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Treatment Outcome | 2014 |
-7/7q- syndrome in myeloid-lineage hematopoietic malignancies: attempts to understand this complex disease entity.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 7; Decitabine; Gene Expression Regulation, Neoplastic; Genetic Association Studies; Hematologic Neoplasms; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Myeloid Cells; Prognosis | 2015 |
Comparison between decitabine and azacitidine for the treatment of myelodysplastic syndrome: a meta-analysis with 1,392 participants.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Comparative Effectiveness Research; Decitabine; Humans; Myelodysplastic Syndromes; Publication Bias; Treatment Outcome | 2015 |
Update on the pharmacotherapy for myelodysplastic syndromes.
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Modification Methylases; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Prognosis; Remission Induction; Risk Assessment; Thalidomide | 2014 |
The myelodysplastic syndromes: the era of understanding.
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Azacitidine; Blood Transfusion; Erythropoietin; Gene Expression Regulation, Neoplastic; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Myelodysplastic Syndromes; Neoplasm Proteins; Prognosis; Spliceosomes; Thalidomide; Transplantation, Homologous | 2015 |
[Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk myelodysplastic syndrome].
Topics: Allografts; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Hematopoietic Stem Cell Transplantation; Humans; Immunomodulation; Myelodysplastic Syndromes; Prognosis; Risk | 2014 |
[Treatment of MDS].
Topics: Allografts; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Autografts; Azacitidine; Enzyme Inhibitors; Erythrocyte Transfusion; Erythropoietin; Hematopoietic Stem Cell Transplantation; Histocompatibility; HLA Antigens; Humans; Immunologic Factors; Immunosuppressive Agents; Induction Chemotherapy; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Recombinant Proteins; Thalidomide; Transplantation Conditioning | 2014 |
Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Biomarkers; Disease-Free Survival; Europe; Humans; Myelodysplastic Syndromes; Practice Guidelines as Topic; Risk Factors; Survival Rate | 2014 |
Transplants in myelodysplastic syndromes.
Topics: Azacitidine; DNA Methylation; Enzyme Inhibitors; Hematopoietic Stem Cell Transplantation; Humans; Myelodysplastic Syndromes; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2014 |
Digging deep into "dirty" drugs - modulation of the methylation machinery.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Methylation; Epigenesis, Genetic; Histone Code; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Transcription, Genetic | 2015 |
More is better: combination therapies for myelodysplastic syndromes.
Topics: Antineoplastic Agents; Azacitidine; Benzamides; Clinical Trials as Topic; Decitabine; Disease Progression; Drug Therapy, Combination; Gene Expression; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrimidines; Thalidomide; Valproic Acid; Vorinostat | 2015 |
Managing patients with higher-risk myelodysplastic syndrome with stable disease on hypomethylating agents.
Topics: Antineoplastic Agents; Azacitidine; Decitabine; Disease Management; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Humans; Molecular Targeted Therapy; Myelodysplastic Syndromes; Risk Assessment; Treatment Outcome | 2015 |
New therapeutic approaches in myelodysplastic syndromes: Hypomethylating agents and lenalidomide.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials, Phase III as Topic; Decitabine; Humans; Lenalidomide; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Thalidomide; Translational Research, Biomedical | 2015 |
Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Decitabine; Disease Management; Disease Progression; Hematopoietic Stem Cell Transplantation; Humans; Intercellular Signaling Peptides and Proteins; Karyotype; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Research Design; Thalidomide; Transplantation, Homologous | 2015 |
Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia.
Topics: Administration, Oral; Azacitidine; Clinical Trials as Topic; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2015 |
[Research Advances on Pathogenesis of Myelodysplastic Syndrome].
Topics: Azacitidine; Bone Marrow; Cytokines; Decitabine; Hematopoietic Stem Cells; Humans; Immunophenotyping; Myelodysplastic Syndromes; Stromal Cells | 2015 |
Myelodysplastic syndromes: Contemporary review and how we treat.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Disease-Free Survival; Humans; Myelodysplastic Syndromes; Stem Cell Transplantation | 2016 |
Azacitidine-induced cryptogenic organizing pneumonia: a case report and review of the literature.
Topics: Adrenal Cortex Hormones; Antimetabolites, Antineoplastic; Azacitidine; Bronchoscopy; Cough; Cryptogenic Organizing Pneumonia; Home Care Services; Humans; Lung; Male; Middle Aged; Myelodysplastic Syndromes; Oxygen Inhalation Therapy; Radiography; Treatment Outcome | 2016 |
Azacitidine: A Review in Myelodysplastic Syndromes and Acute Myeloid Leukaemia.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials, Phase III as Topic; DNA Methylation; Humans; Leukemia, Myeloid, Acute; Multicenter Studies as Topic; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic | 2016 |
Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Prognosis; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2016 |
Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies.
Topics: Acetylation; Antineoplastic Agents; Azacitidine; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Hematologic Neoplasms; Histones; Humans; Lymphoma, T-Cell, Cutaneous; Male; Myelodysplastic Syndromes; Protein Domains | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndromes; Prognosis; Sulfones; Survival Rate; Treatment Outcome | 2016 |
Efficacy and adverse events of azacitidine in the treatment of hemodialysis patients with high-risk myelodysplastic syndrome.
Topics: Aged; Azacitidine; Blood Transfusion; Febrile Neutropenia; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Renal Dialysis; Risk Factors | 2016 |
Efficacy of Azacitidine in the treatment of adult patients aged 65 years or older with AML.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; DNA Methylation; Epigenesis, Genetic; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Quality of Life; Treatment Outcome | 2016 |
Treatment options for patients with myelodysplastic syndromes after hypomethylating agent failure.
Topics: Azacitidine; Drug Resistance; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2016 |
5q- syndrome-like features as the first manifestation of myelodysplastic syndrome in a patient with an unbalanced whole-arm translocation der(5;19)(p10;q10).
Topics: Anemia, Macrocytic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carboplatin; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 19; Chromosomes, Human, Pair 5; Fatal Outcome; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Thalidomide; Translocation, Genetic | 2017 |
Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications.
Topics: Anemia; Antimetabolites, Antineoplastic; Azacitidine; Chromosomes, Human, Pair 5; Disease Progression; Humans; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome | 2017 |
Azacitidine and the beginnings of therapeutic epigenetic modulation.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Epigenesis, Genetic; Humans; Myelodysplastic Syndromes; Treatment Outcome | 2008 |
[Pathogenesis of and therapeutic progress for myelodysplastic syndromes].
Topics: Azacitidine; Clinical Trials as Topic; Decitabine; Deoxycytidine; DNA Methylation; Drug Design; Gene Targeting; Humans; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Tumor Necrosis Factor-alpha | 2008 |
Demethylating agents in myeloid malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Silencing; Humans; Leukemia; Myelodysplastic Syndromes; Risk; Treatment Outcome; Valproic Acid | 2008 |
Are new agents really making a difference in MDS?
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome | 2008 |
Management of myelodysplastic syndromes: 2008 update.
Topics: Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Decitabine; Disease-Free Survival; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematinics; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Survival Analysis; Thalidomide; Treatment Outcome | 2008 |
How I treat patients with myelodysplastic syndromes.
Topics: Acute Disease; Aged; Azacitidine; Chelation Therapy; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Decitabine; Disease Progression; DNA Methylation; Erythropoietin; Hematopoietic Cell Growth Factors; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Lenalidomide; Leukemia, Myeloid; Myelodysplastic Syndromes; Severity of Illness Index; Thalidomide; Transplantation, Homologous | 2009 |
Optimal sequencing of treatments for patients with myelodysplastic syndromes.
Topics: Azacitidine; Decitabine; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Transplantation, Homologous | 2009 |
Azacitidine for the treatment of myelodysplastic syndrome.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Humans; Myelodysplastic Syndromes; Prognosis; Randomized Controlled Trials as Topic; Survival Rate | 2009 |
5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome--a systematic review and meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Humans; Middle Aged; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2010 |
Novel biospecific agents for the treatment of myelodysplastic syndromes.
Topics: Arsenic Trioxide; Arsenicals; Azacitidine; Decitabine; Etanercept; Farnesyltranstransferase; Humans; Immunoglobulin G; Lenalidomide; Myelodysplastic Syndromes; Oxides; Receptors, Tumor Necrosis Factor; Thalidomide | 2003 |
Decitabine versus 5-azacitidine for the treatment of myelodysplastic syndrome: adjusted indirect meta-analysis.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Humans; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Treatment Outcome | 2010 |
Azacitidine: a review of its use in higher-risk myelodysplastic syndromes/acute myeloid leukaemia.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Bone Marrow Cells; Chromosome Inversion; Combined Modality Therapy; Erythrocyte Transfusion; Erythroid Precursor Cells; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis; Randomized Controlled Trials as Topic; Remission Induction; Risk Assessment; Stem Cell Transplantation; Transplantation Conditioning; Treatment Outcome | 2009 |
[Novel therapeutic agents for myelodysplastic syndrome].
Topics: Antineoplastic Agents; Azacitidine; Clinical Trials as Topic; Decitabine; Drug Discovery; Drug Therapy, Combination; Erythropoietin; Humans; Lenalidomide; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Remission Induction; Thalidomide | 2009 |
Review of azacitidine trials in Intermediate-2-and High-risk myelodysplastic syndromes.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Female; Humans; Male; Myelodysplastic Syndromes | 2009 |
Treatment of MDS: something old, something new, something borrowed...
Topics: Azacitidine; Benzoates; Blood Transfusion; Bone Marrow Diseases; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Combined Modality Therapy; Decitabine; DNA-Cytosine Methylases; Glutathione; Hematinics; Humans; Hydrazines; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Fc; Recombinant Fusion Proteins; Risk; Thalidomide; Thrombopoietin | 2009 |
Decitabine in the treatment of myelodysplastic syndromes.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Methylation; Gene Silencing; Genes, Tumor Suppressor; Humans; Myelodysplastic Syndromes; Treatment Outcome | 2010 |
Decitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Modification Methylases; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary Myelofibrosis; Stem Cell Transplantation; Transplantation, Homologous | 2010 |
5-Azacytidine/Azacitidine.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Drug Therapy, Combination; Epigenesis, Genetic; Humans; Myelodysplastic Syndromes | 2010 |
Epigenetic therapy in myelodysplastic syndromes.
Topics: Acid Anhydride Hydrolases; Apoptosis Regulatory Proteins; Azacitidine; Calcium-Calmodulin-Dependent Protein Kinases; Clinical Trials as Topic; Cyclin-Dependent Kinase Inhibitor p15; Death-Associated Protein Kinases; Decitabine; DNA Methylation; Epigenesis, Genetic; Humans; Meta-Analysis as Topic; Myelodysplastic Syndromes; Neoplasm Proteins | 2010 |
Epigenetic changes in the myelodysplastic syndrome.
Topics: Acetylation; Acute Disease; Azacitidine; Cell Transformation, Neoplastic; Decitabine; DNA Methylation; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Leukemia, Myeloid; Methylation; Myelodysplastic Syndromes; Neoplasms; Protein Processing, Post-Translational | 2010 |
Practical recommendations for hypomethylating agent therapy of patients with myelodysplastic syndromes.
Topics: Aged; Antibiotic Prophylaxis; Antifungal Agents; Azacitidine; Clinical Trials as Topic; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Drug Administration Schedule; Enzyme Inhibitors; Epigenesis, Genetic; Fatigue; Gastrointestinal Diseases; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Injections, Subcutaneous; Mucositis; Myelodysplastic Syndromes; Pancytopenia; Patient Selection | 2010 |
High-risk myelodysplastic syndromes: chemotherapy, transplantation, and beyond.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Blood Transfusion; Clinical Trials as Topic; Combined Modality Therapy; Decitabine; DNA Methylation; DNA-Cytosine Methylases; Forecasting; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Multicenter Studies as Topic; Myelodysplastic Syndromes; Prognosis; Retrospective Studies; Risk; Transplantation Conditioning | 2010 |
[Epigenetic therapy in myelodysplastic syndromes (MDS). Treatment with DNA methyltransferase inhibitors].
Topics: Azacitidine; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Epigenesis, Genetic; Humans; Myelodysplastic Syndromes | 2010 |
Pharmacotherapy of myelodysplastic syndromes.
Topics: Azacitidine; Decitabine; DNA Methylation; Drug Approval; Erythropoietin; Humans; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Recombinant Proteins; Thalidomide; United States; United States Food and Drug Administration | 2010 |
Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cost-Benefit Analysis; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Models, Economic; Myelodysplastic Syndromes; Quality of Life; Quality-Adjusted Life Years; Survival; United Kingdom | 2010 |
Therapy with azanucleosides for myelodysplastic syndromes.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Chromosomes, Human, Pair 7; Decitabine; Deoxycytidine; Disease Progression; DNA Methylation; Drug Therapy, Combination; Humans; Myelodysplastic Syndromes; Risk Assessment; Treatment Outcome | 2010 |
Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group.
Topics: Azacitidine; Germany; Hematologic Diseases; Humans; Myelodysplastic Syndromes; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Treatment Outcome | 2010 |
5-Azacytidine in myelodysplastic syndromes: a clinical practice guideline.
Topics: Age Factors; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Disease Progression; Humans; Myelodysplastic Syndromes; Practice Guidelines as Topic; Quality of Life | 2011 |
Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Expert Testimony; Humans; Myelodysplastic Syndromes; Risk | 2010 |
[Current treatment options for myelodysplastic syndromes].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Azacitidine; Blood Transfusion; Bone Marrow Transplantation; Chelation Therapy; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Iron Overload; Lenalidomide; Leukemia, Myeloid, Acute; Long-Term Care; Male; Middle Aged; Myelodysplastic Syndromes; Palliative Care; Thalidomide | 2010 |
Targeting DNA methylation for epigenetic therapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; DNA Methylation; DNA Modification Methylases; Epigenesis, Genetic; Female; Humans; Molecular Targeted Therapy; Myelodysplastic Syndromes; Neoplasms | 2010 |
Safety and efficacy of azacitidine in myelodysplastic syndromes.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Disease Progression; Drug Administration Schedule; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Survival | 2010 |
Azacitidine: activity and efficacy as an epigenetic treatment of myelodysplastic syndromes.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Humans; Myelodysplastic Syndromes; Prognosis | 2009 |
Hypomethylating agents and other novel strategies in myelodysplastic syndromes.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Epoetin Alfa; Erythropoietin; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lenalidomide; Myelodysplastic Syndromes; Prognosis; Recombinant Proteins; Thalidomide; Transplantation, Homologous | 2011 |
Treatment of myelodysplastic syndromes in elderly patients.
Topics: Aged; Anemia, Macrocytic; Antineoplastic Agents; Azacitidine; Blood Component Transfusion; Case Management; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Contraindications; Hematinics; Hematopoietic Stem Cell Transplantation; Histocompatibility; Humans; Immunomodulation; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Palliative Care; Quality of Life; Risk Assessment; Survival Rate; Thalidomide | 2011 |
Azacitidine for the treatment of patients with acute myeloid leukemia with 20%-30% blasts and multilineage dysplasia.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Clinical Trials, Phase III as Topic; Contraindications; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Lymphocyte Activation; Myelodysplastic Syndromes; Neutropenia; Practice Guidelines as Topic; Prognosis; Stem Cell Transplantation; Survival Analysis; Treatment Outcome | 2011 |
Therapeutic epigenetics: an emerging clinical approach to hematologic malignancies.
Topics: Azacitidine; Decitabine; DNA Methylation; Epigenesis, Genetic; Hematologic Neoplasms; Histone Deacetylase Inhibitors; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2005 |
Pharmacokinetic evaluation of decitabine for the treatment of leukemia.
Topics: Age Factors; Aged; Animals; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Drug Delivery Systems; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2011 |
Adverse effects of azacitidine: onset, duration, and treatment.
Topics: Age of Onset; Antimetabolites, Antineoplastic; Azacitidine; Disease Management; DNA Methylation; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Administration Schedule; Fatigue; Gastrointestinal Diseases; Humans; Maximum Tolerated Dose; Myelodysplastic Syndromes; Neutropenia; Prognosis; Survival Rate | 2011 |
Azacitidine adverse effects in patients with myelodysplastic syndromes.
Topics: Antimetabolites, Antineoplastic; Azacitidine; DNA Methylation; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Administration Schedule; Fatigue; Gastrointestinal Diseases; Humans; Maximum Tolerated Dose; Myelodysplastic Syndromes; Neutropenia; Prognosis; Quality-Adjusted Life Years; Survival Rate | 2011 |
[Hypomethylating agents for the treatment of myelodysplastic syndromes].
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Epigenesis, Genetic; Humans; Mutation; Myelodysplastic Syndromes | 2011 |
[Epigenetic therapy in myelodysplastic syndromes].
Topics: Azacitidine; Decitabine; Depsipeptides; DNA Methylation; DNA Modification Methylases; Drug Design; Drug Therapy, Combination; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Molecular Targeted Therapy; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Vorinostat | 2011 |
Cytogenetic and molecular abnormalities in myelodysplastic syndrome.
Topics: Animals; Antineoplastic Agents; Azacitidine; Chromosome Aberrations; Humans; Lenalidomide; Mutation; Myelodysplastic Syndromes; Thalidomide | 2011 |
Treatment of higher-risk myelodysplastic syndrome.
Topics: Algorithms; Antineoplastic Agents; Azacitidine; Combined Modality Therapy; Decitabine; DNA Methylation; Drug Therapy, Combination; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Lenalidomide; Myelodysplastic Syndromes; Patient Selection; Stem Cell Transplantation; Thalidomide | 2011 |
Failure of hypomethylating agent-based therapy in myelodysplastic syndromes.
Topics: Adenine Nucleotides; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Arabinonucleosides; Azacitidine; Clofarabine; Cytosine; Decitabine; Drug Resistance; Drug Substitution; Enzyme Inhibitors; Glutathione; Glycine; Humans; Myelodysplastic Syndromes; Stem Cell Transplantation; Sulfones; Treatment Failure | 2011 |
[Novel therapeutics for myelodysplastic syndromes].
Topics: Azacitidine; Decitabine; DNA Methylation; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2011 |
New ways to use DNA methyltransferase inhibitors for the treatment of myelodysplastic syndrome.
Topics: Azacitidine; Bone Marrow Neoplasms; DNA Modification Methylases; Enzyme Inhibitors; Humans; Maintenance Chemotherapy; Myelodysplastic Syndromes | 2011 |
Atraumatic splenic rupture in patients with myelodysplastic syndromes: report of a case occurred during treatment with 5-azacitidine and review of the literature.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Female; Humans; Middle Aged; Myelodysplastic Syndromes; Splenic Rupture; Treatment Outcome | 2012 |
Optimizing hypomethylating agents in myelodysplastic syndromes.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; DNA Methylation; Drug Administration Schedule; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Humans; Immunomodulation; Myelodysplastic Syndromes; Patient Compliance; Treatment Failure | 2012 |
[Demethylating medication in myelodysplastic syndrome].
Topics: Age Factors; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; DNA Modification Methylases; Humans; Myelodysplastic Syndromes; Treatment Outcome | 2012 |
[MDS].
Topics: Azacitidine; Benzoates; Clinical Trials as Topic; Cytokines; Deferasirox; Drug Therapy, Combination; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Thrombopoietin; Treatment Outcome; Triazoles | 2012 |
[Decitabine for treatment of myelodysplastic syndrome in an elderly patient and review of literature].
Topics: Azacitidine; Decitabine; DNA Modification Methylases; Female; Humans; Middle Aged; Myelodysplastic Syndromes | 2012 |
The challenge of individualised risk assessment and therapy planning in elderly high-risk myelodysplastic syndromes (MDS) patients.
Topics: Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Azacitidine; Case Management; Comorbidity; Decision Support Systems, Clinical; DNA Methylation; Female; Frail Elderly; Humans; Life Expectancy; Male; Myelodysplastic Syndromes; Palliative Care; Precision Medicine; Prognosis; Risk Assessment; Risk Factors; Severity of Illness Index | 2012 |
Azacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukaemia.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase III as Topic; Humans; Leukemia, Myeloid, Acute; Multicenter Studies as Topic; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic | 2012 |
Utility of DNA methyltransferase inhibitors for the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Decitabine; DNA Modification Methylases; Enzyme Inhibitors; Humans; Life Expectancy; Myelodysplastic Syndromes; Treatment Outcome | 2012 |
Myelodysplastic syndromes: therapy and outlook.
Topics: Algorithms; Azacitidine; Decitabine; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Myelodysplastic Syndromes | 2012 |
[New tools and treatments in myelodysplastic syndromes].
Topics: Antimetabolites, Antineoplastic; Azacitidine; Blood Transfusion; Cytogenetics; Decitabine; Flow Cytometry; Gene Expression Profiling; Humans; Immunologic Factors; Lenalidomide; Mutation; Myelodysplastic Syndromes; Prognosis; Thalidomide | 2013 |
Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome.
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Aberrations; Cytarabine; Disease Progression; Drug Evaluation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Outcome Assessment, Health Care; Quality of Life; Risk Assessment; Sickness Impact Profile | 2012 |
New therapeutics for myelodysplastic syndromes.
Topics: Antineoplastic Agents; Azacitidine; Bone Marrow; Chromosomes, Human, Pair 5; Glycine; Humans; Hydroxamic Acids; Lenalidomide; Myelodysplastic Syndromes; Neoplastic Stem Cells; p38 Mitogen-Activated Protein Kinases; Sequence Deletion; Sulfones; Thalidomide; Transforming Growth Factor beta; Tumor Microenvironment | 2012 |
Azacitidine-induced pneumonitis in a patient with myelodysplastic syndrome: first case report in Japan.
Topics: Adrenal Cortex Hormones; Aged; Antimetabolites, Antineoplastic; Azacitidine; Humans; Japan; Male; Myelodysplastic Syndromes; Pneumonia; Treatment Outcome | 2012 |
Treatment of advanced myelodysplastic syndrome with demethylating agents: azacitidine.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Humans; Myelodysplastic Syndromes; Treatment Outcome | 2012 |
Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Decitabine; DNA Methylation; Humans; Myelodysplastic Syndromes; Prognosis; Treatment Outcome | 2012 |
[Pharmacological profiles and clinical roles of 5-azacitidine (Vidaza(®) for injection 100 mg) for the treatment of myelodysplastic syndrome (MDS)].
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Cell Proliferation; DNA Methylation; Humans; In Vitro Techniques; Myelodysplastic Syndromes | 2012 |
Can hypomethylating agents provide a platform for curative therapy in myelodysplastic syndromes?
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Hematopoietic Stem Cell Transplantation; Humans; Myelodysplastic Syndromes; Risk Factors; Transplantation, Homologous | 2012 |
Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS.
Topics: Acetylation; Azacitidine; Cytidine; Decitabine; DNA Methylation; Hematologic Neoplasms; Histones; Humans; Leukemia, Myeloid; Myelodysplastic Syndromes | 2003 |
5-azacitidine: An alternative treatment of myelodysplastic syndromes in patient with refractory response to hematopoietic growth factor, a case report and review of literatures.
Topics: Aged; Anemia; Antimetabolites, Antineoplastic; Azacitidine; Blood Transfusion; Erythropoietin; Hematopoietic Cell Growth Factors; Humans; Male; Myelodysplastic Syndromes; Thrombocytopenia | 2004 |
DNA methyltransferase inhibitors in myelodysplastic syndrome.
Topics: Azacitidine; DNA Modification Methylases; Enzyme Inhibitors; Humans; Myelodysplastic Syndromes; Treatment Outcome | 2004 |
FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Blood Transfusion; Drug Approval; Female; Humans; Infusions, Intravenous; Injections, Subcutaneous; Male; Middle Aged; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Treatment Outcome; United States; United States Food and Drug Administration | 2005 |
New agents in myelodysplastic syndromes.
Topics: Alkyl and Aryl Transferases; Angiogenesis Inhibitors; Apoptosis; Arsenicals; Azacitidine; Benzamides; Chromosome Aberrations; Clinical Trials as Topic; Cytokines; DNA Methylation; Enzyme Inhibitors; Farnesyltranstransferase; Growth Substances; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Immunosuppressive Agents; Myelodysplastic Syndromes; Oligonucleotides, Antisense; Piperazines; Prognosis; Pyrimidines; Treatment Outcome | 2005 |
Management of patients with higher risk myelodysplastic syndromes.
Topics: Age Factors; Antimetabolites, Antineoplastic; Arsenic Trioxide; Arsenicals; Azacitidine; Combined Modality Therapy; Disease-Free Survival; Farnesyltranstransferase; Hematopoietic Stem Cell Transplantation; Humans; Myelodysplastic Syndromes; Oxides; Prognosis; Risk Factors; Treatment Outcome | 2005 |
Decitabine in myelodysplastic syndromes.
Topics: Azacitidine; Decitabine; DNA Methylation; DNA Modification Methylases; Drug Administration Schedule; Humans; Myelodysplastic Syndromes; Prognosis; Treatment Outcome | 2005 |
Translational research in myelodysplastic syndromes.
Topics: Angiogenesis Inhibitors; Apoptosis; Azacitidine; Bone Marrow; Cell Death; Enzyme Inhibitors; Humans; Myelodysplastic Syndromes; Neovascularization, Pathologic; Thalidomide | 2004 |
Azacitidine: a novel agent for myelodysplastic syndromes.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Humans; Myelodysplastic Syndromes | 2005 |
Azacitidine: in myelodysplastic syndromes.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials, Phase III as Topic; Humans; Myelodysplastic Syndromes; Quality of Life | 2005 |
Advances in myelodysplastic syndrome: nursing implications of azacitidine.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Humans; Myelodysplastic Syndromes; Quality of Life | 2005 |
5-azacytidine and decitabine monotherapies of myelodysplastic disorders.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Modification Methylases; Humans; MEDLINE; Myelodysplastic Syndromes; Treatment Outcome | 2005 |
Clinical development of decitabine as a prototype for an epigenetic drug program.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Adducts; Enzyme Inhibitors; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Gene Silencing; Histone Deacetylase Inhibitors; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neoplasms; Remission Induction; Time Factors; Treatment Outcome | 2005 |
An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2'-deoxycytidine (decitabine) in 177 patients.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Decitabine; DNA Modification Methylases; Epigenesis, Genetic; Europe; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction | 2005 |
In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies.
Topics: Acute Disease; Animals; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Aberrations; Clinical Trials as Topic; Cyclin-Dependent Kinase Inhibitor p15; Decitabine; DNA Methylation; Epigenesis, Genetic; Humans; Leukemia, Myeloid; Mice; Myelodysplastic Syndromes | 2005 |
The hematopathological basis for studying effects of the demethylating agent 5-aza-2'-deoxycytidine (decitabine) in myelodysplasia.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow Examination; Cell Differentiation; Decitabine; DNA Methylation; DNA Modification Methylases; Humans; Myelodysplastic Syndromes | 2005 |
Methylation inhibitor therapy in the treatment of myelodysplastic syndrome.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Modification Methylases; Drug Administration Schedule; Drug Monitoring; Humans; Myelodysplastic Syndromes; Patient Selection; Treatment Outcome | 2005 |
Optimizing therapy with methylation inhibitors in myelodysplastic syndromes: dose, duration, and patient selection.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Modification Methylases; Drug Administration Schedule; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Patient Selection; Treatment Outcome | 2005 |
Epigenetic therapy with decitabine for myelodysplasia and leukemia.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Methylation; Epigenesis, Genetic; Humans; Leukemia; Myelodysplastic Syndromes | 2005 |
Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
Topics: Anemia, Hypochromic; Azacitidine; Bone Marrow; Chromosome Aberrations; Chromosomes, Human, Pair 5; Erythrocyte Transfusion; Erythropoiesis; Erythropoietin; Gene Deletion; Hematinics; Hematopoietic Stem Cell Transplantation; Humans; Karyotyping; Lenalidomide; Myelodysplastic Syndromes; Predictive Value of Tests; Prognosis; Randomized Controlled Trials as Topic; Recombinant Proteins; Thalidomide | 2006 |
MDS: navigating the complex course.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow Transplantation; Combined Modality Therapy; Humans; Immunosuppressive Agents; Lenalidomide; Medical History Taking; Myelodysplastic Syndromes; Neoplasm Staging; Nurse's Role; Nursing Assessment; Oncology Nursing; Physical Examination; Thalidomide | 2006 |
Strategies for achieving transfusion independence in myelodysplastic syndromes.
Topics: Anemia; Antilymphocyte Serum; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Drug Costs; Erythrocyte Transfusion; Erythropoietin; Health Services Needs and Demand; Humans; Immunosuppressive Agents; Informed Consent; Myelodysplastic Syndromes; Nurse's Role; Oncology Nursing; Patient Education as Topic; Patient Selection; Quality of Life; Thalidomide; Treatment Outcome | 2007 |
The role of decitabine in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Clinical Trials, Phase III as Topic; Decitabine; DNA Methylation; Drug Therapy, Combination; Humans; Myelodysplastic Syndromes | 2007 |
Risk-based management of myelodysplastic syndrome.
Topics: Anemia, Sideroblastic; Antilymphocyte Serum; Azacitidine; Benzoates; Decitabine; Deferasirox; DNA Modification Methylases; Enzyme Inhibitors; Erythropoietin; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Histone Deacetylase Inhibitors; Humans; Immunosuppressive Agents; Interleukin-11; Iron Chelating Agents; Lenalidomide; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Prognosis; Risk; Stem Cell Transplantation; Thalidomide; Triazoles | 2007 |
Control of hematopoiesis and apoptosis in MDS: more than FLIPing the coin.
Topics: Antigens, Differentiation; Antineoplastic Agents; Apoptosis; Azacitidine; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 8; Cell Differentiation; Endothelial Cells; Enzyme Inhibitors; Gene Expression Regulation; Hematopoiesis; Hematopoietic Stem Cells; Humans; Lenalidomide; Monocytes; Myelodysplastic Syndromes; Signal Transduction; Stromal Cells; T-Lymphocytes; Thalidomide | 2007 |
Myelodysplasia: the good, the fair and the ugly.
Topics: Antilymphocyte Serum; Antineoplastic Agents; Azacitidine; Bone Marrow Transplantation; Clinical Trials as Topic; Decitabine; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2007 |
Recent experience with decitabine in MDS.
Topics: Azacitidine; Decitabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Myelodysplastic Syndromes; Treatment Outcome | 2007 |
DNA methyltransferases as targets for cancer therapy.
Topics: Antineoplastic Agents; Azacitidine; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Regulation; Gene Silencing; Hematologic Neoplasms; Humans; Leukemia, Myeloid; Male; Myelodysplastic Syndromes; Transcriptional Activation | 2007 |
Use of hypomethylating agents in myelodysplastic syndromes.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; DNA Methylation; DNA Modification Methylases; Histone Deacetylase Inhibitors; Humans; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic | 2007 |
The role of azacitidine in the treatment of myelodysplastic syndromes.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Humans; Myelodysplastic Syndromes; Treatment Outcome | 2007 |
DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Clinical Trials as Topic; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Modification Methylases; Drug Therapy, Combination; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes | 2008 |
Evaluating new treatment options for MDS.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Decitabine; Epigenesis, Genetic; Humans; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Survival Analysis; Thalidomide | 2007 |
Inositide signaling: Nuclear targets and involvement in myelodysplastic syndromes.
Topics: Animals; Azacitidine; Cell Differentiation; Humans; Myelodysplastic Syndromes; Phosphatidylinositol 3-Kinases; Phosphatidylinositols; Phospholipase C beta; Protein Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases | 2008 |
[Myelodysplastic syndrome].
Topics: alpha Catenin; Antineoplastic Agents; Azacitidine; Cholecalciferol; Cyclosporine; Decitabine; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Lenalidomide; Myelodysplastic Syndromes; Prognosis; Thalidomide; Vitamin K 2; World Health Organization | 2008 |
Current status of epigenetic treatment in myelodysplastic syndromes.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Methylation; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Humans; Myelodysplastic Syndromes; Valproic Acid | 2008 |
DNA methyltransferase inhibitors: class effect or unique agents?
Topics: Azacitidine; Decitabine; DNA Modification Methylases; Humans; Myelodysplastic Syndromes; Treatment Outcome | 2008 |
Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Decitabine; Drug Evaluation, Preclinical; History, 20th Century; History, 21st Century; Humans; Myelodysplastic Syndromes | 2008 |
Review: recent clinical trials in epigenetic therapy.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Cytidine; Decitabine; DNA Methylation; Epigenesis, Genetic; Genetic Therapy; Histone Deacetylases; Humans; Myelodysplastic Syndromes | 2006 |
5-Aza-2'-deoxycytidine (Decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present and future trends.
Topics: Acute Disease; Antineoplastic Agents; Azacitidine; Decitabine; Humans; Leukemia, Myeloid; Myelodysplastic Syndromes | 1993 |
Differentiation therapy of myelodysplastic syndromes: fact or fiction?
Topics: Acetamides; Amifostine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arginine; Azacitidine; Butyrates; Cholecalciferol; Cytarabine; Harringtonines; Hematopoietic Cell Growth Factors; Heme; Homoharringtonine; Humans; Interferons; Myelodysplastic Syndromes; Retinoids | 1998 |
P15INK4b gene methylation and myelodysplastic syndromes.
Topics: Acute Disease; Animals; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Carrier Proteins; Cell Cycle; Cell Cycle Proteins; Cell Differentiation; Cell Transformation, Neoplastic; Chromosomes, Human, Pair 9; Clinical Trials, Phase II as Topic; Cyclin-Dependent Kinase Inhibitor p15; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinases; Decitabine; Disease Progression; DNA Methylation; Genes, p16; Genes, Tumor Suppressor; Hematopoiesis; Humans; Leukemia, Myeloid; Mice; Myelodysplastic Syndromes; Neoplasm Proteins; Precancerous Conditions; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transforming Growth Factor beta; Tumor Suppressor Proteins | 1999 |
DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Methylation; DNA Modification Methylases; Hemoglobinopathies; Humans; Leukemia; Myelodysplastic Syndromes | 2000 |
Evolving treatment options of myelodysplastic syndromes.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Middle Aged; Myelodysplastic Syndromes; Prognosis; Risk Factors | 2001 |
Targeting hypomethylation of DNA to achieve cellular differentiation in myelodysplastic syndromes (MDS).
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cytokines; Decitabine; DNA Methylation; DNA Modification Methylases; DNA, Neoplasm; Humans; Myelodysplastic Syndromes; Myeloid Cells; Prognosis; Quality of Life | 2001 |
New approaches to the treatment of myelodysplasia.
Topics: Amifostine; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Azacitidine; Enzyme Inhibitors; Humans; Myelodysplastic Syndromes; Neovascularization, Pathologic; Oxides; Prognosis; Proto-Oncogene Mas; Risk Factors; Severity of Illness Index; Thalidomide; Topotecan; Treatment Outcome | 2002 |
Differentiation-inducing agents in the treatment of myelodysplastic syndromes.
Topics: Acetamides; Azacitidine; Calcitriol; Drug Therapy, Combination; Humans; Interferons; Myelodysplastic Syndromes; Retinoids | 1992 |
177 trial(s) available for azacitidine and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Clinical Trials Assessing Hypomethylating Agents Combined with Other Therapies: Causes for Failure and Potential Solutions.
Topics: Antineoplastic Agents; Azacitidine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Treatment Outcome | 2021 |
Combination of dociparstat sodium (DSTAT), a CXCL12/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Chemokine CXCL12; DNA Methylation; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Heparin; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Pilot Projects; Prognosis; Receptors, CXCR4; Survival Rate | 2021 |
Phase 1/2 study evaluating the safety and efficacy of DSP-7888 dosing emulsion in myelodysplastic syndromes.
Topics: Azacitidine; Cancer Vaccines; Emulsions; Humans; Myelodysplastic Syndromes; Treatment Outcome; Vaccines, Subunit; WT1 Proteins | 2022 |
Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome.
Topics: Antibodies, Monoclonal, Humanized; Azacitidine; Cohort Studies; Drug Therapy, Combination; Humans; Myelodysplastic Syndromes | 2022 |
A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Humans; Myelodysplastic Syndromes | 2022 |
A phase II randomized study evaluating azacitidine versus conventional care regimens in newly diagnosed elderly Japanese patients with unfavorable acute myeloid leukemia.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Humans; Japan; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Treatment Outcome | 2022 |
A Phase 1/2 Study of the Oral Janus Kinase 1 Inhibitors INCB052793 and Itacitinib Alone or in Combination With Standard Therapies for Advanced Hematologic Malignancies.
Topics: Acetonitriles; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Hematologic Neoplasms; Humans; Janus Kinase 1; Janus Kinase Inhibitors; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrazoles; Pyrimidines; Pyrroles | 2022 |
"Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)".
Topics: Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Karyotype; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2022 |
FDA Approval Summary: Decitabine and Cedazuridine Tablets for Myelodysplastic Syndromes.
Topics: Adult; Azacitidine; Decitabine; Humans; Myelodysplastic Syndromes; Tablets; Treatment Outcome; Uridine | 2022 |
Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma.
Topics: Azacitidine; Decitabine; Genomics; Humans; Lymphoma, T-Cell, Peripheral; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Neutropenia; Treatment Outcome | 2022 |
A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes.
Topics: Adult; Azacitidine; Benzimidazoles; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Phenylurea Compounds; Risk Assessment; Treatment Outcome | 2022 |
Prospective comparison of 5- and 7-day administration of azacitidine for myelodysplastic syndromes: a JALSG MDS212 trial.
Topics: Anemia, Refractory, with Excess of Blasts; Antimetabolites, Antineoplastic; Azacitidine; Humans; Myelodysplastic Syndromes | 2022 |
G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Granulocyte Colony-Stimulating Factor; Humans; Myelodysplastic Syndromes | 2022 |
Phase Ib study of eltrombopag and azacitidine in patients with high-risk myelodysplastic syndromes and related disorders (the ELASTIC study).
Topics: Azacitidine; Benzoates; Drug Combinations; Humans; Hydrazines; Myelodysplastic Syndromes; Pyrazoles; Treatment Outcome | 2022 |
Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Myelodysplastic Syndromes; Proto-Oncogene Proteins c-bcl-2; Sulfonamides | 2022 |
A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML.
Topics: Azacitidine; Humans; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Prospective Studies; Steroids | 2022 |
Five-day versus 7-day treatment regimen with azacitidine in lower risk myelodysplastic syndrome: A phase 2, multicenter, randomized trial.
Topics: Adult; Antimetabolites, Antineoplastic; Azacitidine; Blood Transfusion; Humans; Middle Aged; Myelodysplastic Syndromes; Thrombocytopenia; Treatment Outcome | 2022 |
High efficacy of Azacitidine plus HAG in acute myeloid leukemia: an open-label, single-arm, multi-center, phase 2 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Treatment Outcome | 2022 |
A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Neutropenia; Sulfonamides; Treatment Outcome | 2023 |
Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Febrile Neutropenia; Female; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Thrombocytopenia | 2023 |
A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the
Topics: Azacitidine; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Middle Aged; Myelodysplastic Syndromes; Nivolumab | 2023 |
Phase 1/1b study of azacitidine and hedgehog pathway inhibitor sonidegib in patients with myeloid neoplasms.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Hedgehog Proteins; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Myeloproliferative Disorders; Treatment Outcome | 2023 |
Azacitidine (Vidaza
Topics: Adult; Azacitidine; Child; Hematologic Neoplasms; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Juvenile; Myelodysplastic Syndromes; Remission Induction | 2023 |
Oral vitamin C supplementation to patients with myeloid cancer on azacitidine treatment: Normalization of plasma vitamin C induces epigenetic changes.
Topics: Administration, Oral; Aged; Aged, 80 and over; Ascorbic Acid; Azacitidine; CpG Islands; Denmark; DNA Methylation; Double-Blind Method; Epigenesis, Genetic; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Pilot Projects | 2019 |
Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibody-Dependent Cell Cytotoxicity; Antimetabolites, Antineoplastic; Azacitidine; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Interleukin-3 Receptor alpha Subunit; Male; Myelodysplastic Syndromes; Prognosis; Survival Rate | 2020 |
Impact of clinical features, cytogenetics, genetic mutations, and methylation dynamics of CDKN2B and DLC-1 promoters on treatment response to azacitidine.
Topics: Aged; Aged, 80 and over; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 7; Cyclin-Dependent Kinase Inhibitor p15; Disease-Free Survival; DNA Methylation; DNA, Neoplasm; Female; GTPase-Activating Proteins; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Nucleophosmin; Promoter Regions, Genetic; Survival Rate; Tumor Suppressor Proteins | 2020 |
A sequential two-stage dose escalation study of eltrombopag in patients with myelodysplastic syndrome and thrombocytopenia after hypomethylating agent failure.
Topics: Azacitidine; Benzoates; Humans; Hydrazines; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrazoles; Thrombocytopenia; Treatment Outcome | 2020 |
Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Female; Glycine; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Sulfones | 2020 |
Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Infant; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Prognosis; Retrospective Studies; Sulfonamides; Young Adult | 2020 |
Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Hydrazines; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Patient Safety; Prognosis; Survival Rate; Triazoles | 2020 |
Phase II study of the clinical efficacy and safety of tosedostat in patients with myelodysplastic syndromes (MDS) after failure of hypomethylating agent-based therapy.
Topics: Azacitidine; DNA Methylation; Glycine; Humans; Hydroxamic Acids; Myelodysplastic Syndromes; Treatment Outcome | 2021 |
A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients.
Topics: Adolescent; Adult; Aged; Azacitidine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Remission Induction; Young Adult | 2020 |
[Comparison of the Curative Efficacy of Elderly Patients with High-Risk MDS and MDS-Transformed AML between Decitabine Combined with Low-Dose CEG Regimen and Decitabine Combined with Low-Dose CAG Regimen].
Topics: Aclarubicin; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prospective Studies; Treatment Outcome | 2020 |
A phase I trial evaluating the effects of plerixafor, G-CSF, and azacitidine for the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Benzylamines; Cyclams; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Myelodysplastic Syndromes | 2021 |
Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cyclopentanes; Enzyme Inhibitors; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Pyrimidines | 2021 |
Asia-inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asia; Azacitidine; Cyclopentanes; Drugs, Investigational; Global Burden of Disease; Humans; Incidence; International Cooperation; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Maximum Tolerated Dose; Myelodysplastic Syndromes; Pharmacology, Clinical; Pyrimidines; Translational Research, Biomedical; Ubiquitin-Activating Enzymes; United States | 2021 |
Eprenetapopt Plus Azacitidine in
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mutation; Myelodysplastic Syndromes; Quinuclidines; Tumor Suppressor Protein p53 | 2021 |
A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome.
Topics: Azacitidine; Benzothiazoles; Cytarabine; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mutation; Myelodysplastic Syndromes; Phenylurea Compounds | 2021 |
Epigenetic therapy in combination with a multi-epitope cancer vaccine targeting shared tumor antigens for high-risk myelodysplastic syndrome - a phase I clinical trial.
Topics: Aged; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; Cancer Vaccines; Drug Therapy, Combination; Epigenesis, Genetic; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Myelodysplastic Syndromes; Prognosis; Tissue Distribution | 2022 |
Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study).
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Disease Progression; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Progression-Free Survival; Prospective Studies; Recurrence; Stem Cell Transplantation; Survival Rate; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous | 2021 |
A phase II study of azacitidine in combination with granulocyte-macrophage colony-stimulating factor as maintenance treatment, after allogeneic blood or marrow transplantation in patients with poor-risk acute myeloid leukemia (AML) or myelodysplastic synd
Topics: Azacitidine; Bone Marrow; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Recurrence | 2021 |
Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antimetabolites; Arthralgia; Azacitidine; Constipation; DNA Methylation; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myelodysplastic Syndromes; Pneumonia; Programmed Cell Death 1 Receptor; Progression-Free Survival; Risk | 2021 |
Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Feasibility Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Italy; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Risk Factors; Survival Analysis; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Young Adult | 2017 |
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Humans; Hydroxamic Acids; Lenalidomide; Leukemia, Myelomonocytic, Chronic; Middle Aged; Myelodysplastic Syndromes; Thalidomide; Vorinostat | 2017 |
A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow; Female; Humans; Hydroxamic Acids; Indoles; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Panobinostat; Treatment Outcome | 2017 |
Prospective randomized trial of 5 days azacitidine versus supportive care in patients with lower-risk myelodysplastic syndromes without 5q deletion and transfusion-dependent anemia.
Topics: Aged; Aged, 80 and over; Anemia; Antimetabolites, Antineoplastic; Azacitidine; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Palliative Care; Prognosis; Prospective Studies; Survival Rate | 2018 |
Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Azacitidine; Benzimidazoles; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hematologic Neoplasms; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Neoplasm Invasiveness; Neoplasm Staging; Patient Safety; Risk Assessment; Sex Factors; Survival Analysis; Treatment Outcome | 2017 |
Phase I study of panobinostat and 5-azacitidine in Japanese patients with myelodysplastic syndrome or chronic myelomonocytic leukemia.
Topics: Aged; Asian People; Azacitidine; Drug Administration Schedule; Drug Therapy, Combination; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Panobinostat; Treatment Outcome | 2018 |
Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care.
Topics: Antineoplastic Agents; Azacitidine; Decitabine; Drug Resistance, Neoplasm; Glycine; Humans; Kaplan-Meier Estimate; Myelodysplastic Syndromes; Prognosis; Sulfones; Treatment Outcome | 2017 |
Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.
Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Prognosis; Treatment Outcome | 2017 |
Efficacy, safety and pharmacokinetics of subcutaneous azacitidine in Chinese patients with higher risk myelodysplastic syndromes: Results from a multicenter, single-arm, open-label phase 2 study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Asian People; Azacitidine; Female; Humans; Infusions, Subcutaneous; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome; Young Adult | 2018 |
Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries.
Topics: Aged; Azacitidine; Chromosome Aberrations; Chromosomes, Human, Pair 7; Disease-Free Survival; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Registries; Retrospective Studies; Risk Factors; Survival Rate | 2018 |
CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes.
Topics: Adult; Aged; Allografts; Azacitidine; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Middle Aged; Myelodysplastic Syndromes; Survival Rate | 2018 |
A Pilot Trial of Lirilumab With or Without Azacitidine for Patients With Myelodysplastic Syndrome.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Azacitidine; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Pilot Projects; Prognosis; Receptors, KIR; Survival Rate | 2018 |
Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; DNA Methylation; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Fatigue; Female; Food; Food-Drug Interactions; Gastric Acidity Determination; Gastrointestinal Diseases; Hematologic Diseases; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Proton Pump Inhibitors | 2018 |
Response to hypomethylating agents improves long-term outcomes for lower-risk patients with myelodysplastic syndrome in case-matched cohorts.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Decitabine; Disease-Free Survival; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Risk Factors; Survival Rate | 2018 |
A phase II study of the efficacy and safety of an intensified schedule of azacytidine in intermediate-2 and high-risk patients with myelodysplastic syndromes: a study by the Groupe Francophone des Myelodysplasies (GFM).
Topics: Adolescent; Adult; Aged; Azacitidine; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Risk Factors | 2019 |
Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Drug Administration Schedule; Female; Germany; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm, Residual; Nucleophosmin; Progression-Free Survival; Prospective Studies; Recurrence; Risk Assessment; Risk Factors; Time Factors | 2018 |
Sequential azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia: Clinical results and predictive modeling using computational analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Computational Biology; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Predictive Value of Tests; Retrospective Studies; Salvage Therapy; Survival Rate; Young Adult | 2019 |
Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome.
Topics: Adolescent; Adult; Aged; Allografts; Azacitidine; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Leukemia, Myeloid, Acute; Lymphocyte Transfusion; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Risk Factors; Survival Rate; Unrelated Donors | 2019 |
Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites; Azacitidine; Bone Marrow Examination; Decitabine; Disease-Free Survival; Female; Humans; Infection Control; Kaplan-Meier Estimate; Karyotyping; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Research Design; Retrospective Studies; Risk Assessment; Treatment Outcome; Young Adult | 2013 |
Azacitidine in the treatment of therapy related myelodysplastic syndrome and acute myeloid leukemia (tMDS/AML): a report on 54 patients by the Groupe Francophone Des Myelodysplasies (GFM).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Protocols; Azacitidine; Cohort Studies; Female; France; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Radiation Injuries; Societies, Medical; Young Adult | 2013 |
A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Follow-Up Studies; Humans; Multivariate Analysis; Myelodysplastic Syndromes; Survival Rate; Treatment Outcome | 2013 |
Prospective phase II Study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Azacitidine; Drug Administration Schedule; Erythropoietin; Female; Gene Expression Regulation, Neoplastic; Hematologic Tests; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Phospholipase C beta; Polymorphism, Single Nucleotide; Prospective Studies; Treatment Outcome; Wnt1 Protein | 2013 |
Molecular cytogenetic monitoring from CD34+ peripheral blood cells in myelodysplastic syndromes: first results from a prospective multicenter German diagnostic study.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromosome Aberrations; Chromosome Banding; Female; Follow-Up Studies; Germany; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Thalidomide; Time Factors; Treatment Outcome | 2013 |
Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Injections, Subcutaneous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Prognosis; Proportional Hazards Models; Risk Assessment; Severity of Illness Index; Survival Analysis; Treatment Outcome | 2013 |
Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Hydroxamic Acids; In Vitro Techniques; Middle Aged; Myelodysplastic Syndromes; Nausea; Neutropenia; Recurrence; Risk Factors; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vomiting; Vorinostat | 2014 |
Decitabine can be safely reduced after achievement of best objective response in patients with myelodysplastic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Survival Rate; Treatment Outcome | 2013 |
[Morphological evaluation of dysmyelopoiesis in decitabine-treated patients with myelodysplastic syndromes].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Myelodysplastic Syndromes; Myelopoiesis; Prospective Studies; Treatment Outcome; Young Adult | 2013 |
Real-life experience with azacitidine in myelodysplastic syndromes according to IPSS cytogenetic profile.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Humans; Myelodysplastic Syndromes | 2014 |
Pretransplantation 5-azacitidine in high-risk myelodysplastic syndrome.
Topics: Adult; Aged; Azacitidine; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Pilot Projects; Prospective Studies; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors | 2014 |
Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzamides; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Pyridines; Survival Analysis; Treatment Outcome | 2014 |
Phase II clinical study of erlotinib for treatment of myelodysplastic syndromes.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Azacitidine; Erlotinib Hydrochloride; Female; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Failure | 2014 |
A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Azacitidine; Benzoates; Blood Platelets; Cell Cycle; Drug Synergism; Drug Therapy, Combination; Female; Hematopoietic Stem Cells; Humans; Hydrazines; Ischemic Attack, Transient; Male; Middle Aged; Myelodysplastic Syndromes; Pilot Projects; Platelet Count; Pyrazoles; Receptors, Thrombopoietin; Remission Induction; Thrombocytopenia; Treatment Outcome; Venous Thrombosis | 2014 |
A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome; Vorinostat; Young Adult | 2014 |
Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bayes Theorem; Decitabine; Drug Administration Schedule; Female; Histone Deacetylase Inhibitors; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome; Valproic Acid | 2015 |
A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Protein Kinase Inhibitors; Quinazolines; Remission Induction | 2014 |
Multivariable time-dependent analysis of the impact of azacitidine in patients with lower-risk myelodysplastic syndrome and unfavorable specific lower-risk score.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Disease-Free Survival; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Risk Factors; Survival Rate; Time Factors | 2015 |
Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Staurosporine; Young Adult | 2015 |
Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions--a retrospective multicenter analysis from the German Cooperative Transplant Study Group.
Topics: Adult; Aged; Allografts; Antimetabolites, Antineoplastic; Azacitidine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Lymphocyte Transfusion; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Recurrence; Retrospective Studies; Survival Rate | 2015 |
Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Survival Analysis; Treatment Outcome | 2015 |
Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: retrospective analysis of survival after long-term follow-up.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Retrospective Studies; Survival Analysis; Treatment Outcome; Withholding Treatment | 2015 |
Mutations in the Spliceosomal Machinery Genes SRSF2, U2AF1, and ZRSR2 and Response to Decitabine in Myelodysplastic Syndrome.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Decitabine; Female; Humans; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Nuclear Proteins; Prognosis; Ribonucleoproteins; RNA Splicing; Serine-Arginine Splicing Factors; Spliceosomes; Splicing Factor U2AF; Treatment Outcome | 2015 |
Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome.
Topics: Adult; Aged; Allografts; Antimetabolites, Antineoplastic; Azacitidine; Combined Modality Therapy; Decitabine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gastrointestinal Diseases; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Young Adult | 2015 |
Azacitidine Pre-Treatment Followed by Reduced-Intensity Stem Cell Transplantation in Patients with Higher-Risk Myelodysplastic Syndrome.
Topics: Adolescent; Adult; Allografts; Antimetabolites, Antineoplastic; Azacitidine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Stem Cell Transplantation; Survival Rate | 2015 |
Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Area Under Curve; Azacitidine; DNA Methylation; Dose-Response Relationship, Drug; Drug Administration Schedule; Epigenesis, Genetic; Half-Life; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Survival Analysis | 2015 |
Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Neoplasm Staging; Prognosis | 2015 |
A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Female; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Sialic Acid Binding Ig-like Lectin 3 | 2016 |
Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; BH3 Interacting Domain Death Agonist Protein; Biomarkers; Bone Marrow; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retreatment; Thalidomide; Treatment Outcome | 2016 |
Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Staging; Prognosis; Risk Factors; Safety; Tissue Distribution | 2016 |
Model-based adaptive phase I trial design of post-transplant decitabine maintenance in myelodysplastic syndrome.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Combined Modality Therapy; Decitabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Maintenance Chemotherapy; Male; Middle Aged; Models, Biological; Myelodysplastic Syndromes; Research Design; Transplantation, Homologous; Treatment Outcome; Young Adult | 2015 |
Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Female; Glycine; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Survival Analysis; Treatment Outcome | 2016 |
Decitabine for Treatment of Myelodysplastic Syndromes in Chinese Patients: An Open-Label, Phase-3b Study.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Asian People; Azacitidine; China; Decitabine; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Myelodysplastic Syndromes; Research Design; Survival Rate; Treatment Outcome; Young Adult | 2015 |
Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzamides; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Pyridines; Treatment Outcome | 2016 |
Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Disease Progression; Disease-Free Survival; Female; Germany; Humans; Leukemia; Male; Middle Aged; Monosomy; Myelodysplastic Syndromes; Risk Factors | 2016 |
Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Survival Analysis; Thalidomide; Treatment Outcome | 2015 |
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial.
Topics: Aged; Azacitidine; Decitabine; Disease-Free Survival; DNA Methylation; Drug Administration Schedule; Europe; Female; Glycine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myelodysplastic Syndromes; Risk; Sulfones; Treatment Outcome | 2016 |
The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure.
Topics: Adult; Azacitidine; Decitabine; Disease-Free Survival; Female; Humans; Male; Models, Biological; Myelodysplastic Syndromes; Predictive Value of Tests; Retrospective Studies; Survival Rate | 2016 |
A randomized phase II trial of azacitidine +/- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Biomarkers; Cytogenetic Analysis; DNA Mutational Analysis; Drug Resistance; Erythropoietin; Female; Hematinics; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Polymorphism, Single Nucleotide; Recombinant Proteins; Survival Analysis; Treatment Outcome | 2016 |
Evaluation of a multi-arm multi-stage Bayesian design for phase II drug selection trials - an example in hemato-oncology.
Topics: Adult; Azacitidine; Bayes Theorem; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Myelodysplastic Syndromes; Research Design; Sample Size; Valproic Acid; Young Adult | 2016 |
Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocol.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antimetabolites; Azacitidine; Bone Marrow; Disease-Free Survival; DNA Methylation; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Quality of Life; Risk; Thalidomide; Treatment Outcome | 2016 |
Factors Determining Responses to Azacitidine in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia with Early Post-Transplantation Relapse: A Prospective Trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Remission Induction; Survival Rate | 2017 |
Elevated fetal haemoglobin is a predictor of better outcome in MDS/AML patients receiving 5-aza-2'-deoxycytidine (Decitabine).
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers; Decitabine; Disease-Free Survival; DNA Methylation; Female; Fetal Hemoglobin; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Survival Analysis | 2017 |
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Topics: 5-Methylcytosine; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Bone Marrow; Decitabine; Exome; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Prospective Studies; Risk Factors; Survival Rate; Tumor Suppressor Protein p53 | 2016 |
Addition of suberoylanilide hydroxamic acid (Vorinostat) to azacitidine for patients with higher risk myelodysplastic syndromes and azacitidine failure: a phase II add-on study from the Groupe Francophone des Myelodysplasies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Disease-Free Survival; Humans; Kaplan-Meier Estimate; Myelodysplastic Syndromes; Risk Factors; Treatment Outcome; Vorinostat | 2018 |
Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy.
Topics: Azacitidine; Blood Cells; Decitabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Mutation; Myelodysplastic Syndromes; Neoplasm Proteins | 2017 |
Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzimidazoles; Biomarkers; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Treatment Outcome | 2017 |
A pilot pharmacokinetic study of oral azacitidine.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Biological Availability; Drug-Related Side Effects and Adverse Reactions; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Pharmacokinetics; Pilot Projects | 2008 |
Azacytidine causes complex DNA methylation responses in myeloid leukemia.
Topics: Antineoplastic Agents; Azacitidine; Cell Line, Tumor; Cytosine; Decitabine; DNA Methylation; Genome, Human; Humans; Leukemia, Myeloid; Myelodysplastic Syndromes; Oligonucleotide Array Sequence Analysis | 2008 |
Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial.
Topics: Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Drug-Related Side Effects and Adverse Reactions; Gemtuzumab; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Pilot Projects; Remission Induction; Risk Assessment; Survival Analysis | 2008 |
Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome.
Topics: Adult; Aged; Azacitidine; Decitabine; Disease Progression; Female; Graft vs Host Disease; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2009 |
Assessment of ATRX expression in patients with myelodysplastic syndromes treated with decitabine.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Core Binding Factor Alpha 3 Subunit; Cytogenetic Analysis; Decitabine; DNA Helicases; Humans; Myelodysplastic Syndromes; Nuclear Proteins; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; X-linked Nuclear Protein | 2009 |
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Proportional Hazards Models | 2009 |
Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Blood Transfusion; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome | 2009 |
Non-intensive treatment with low-dose 5-aza-2'-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Combined Modality Therapy; Decitabine; Disease Progression; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Risk Factors; Survival Rate; Transplantation Conditioning | 2009 |
Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Myelodysplastic Syndromes; Outpatients; Treatment Outcome | 2009 |
Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Aryl Hydrocarbon Hydroxylases; Azacitidine; Cytochrome P-450 CYP2C19; DNA Methylation; Drug Therapy, Combination; Enzyme Inhibitors; Epigenesis, Genetic; Female; Histone Deacetylase Inhibitors; Humans; Male; Methyltransferases; Middle Aged; Myelodysplastic Syndromes; Polymorphism, Single Nucleotide; Prognosis; Valproic Acid | 2009 |
A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic syndromes.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Humans; Injections; Methylation; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Risk Assessment; Survival Analysis | 2009 |
MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation.
Topics: Antigens, CD34; Azacitidine; Bone Marrow Cells; DNA Methylation; DNA, Neoplasm; Enzyme Inhibitors; Female; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Leukemia, Myeloid, Acute; Male; MAP Kinase Signaling System; Myelodysplastic Syndromes; Neoplasms, Second Primary; Promoter Regions, Genetic; Time Factors; Wnt Proteins | 2009 |
Reduction of 5-azacitidine induced skin reactions in MDS patients with evening primrose oil.
Topics: Azacitidine; Dermatitis; gamma-Linolenic Acid; Humans; Linoleic Acids; Myelodysplastic Syndromes; Oenothera biennis; Plant Oils | 2010 |
Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Treatment Outcome | 2010 |
Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Survival Rate; Treatment Outcome | 2010 |
Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Disease Progression; Etanercept; Female; Humans; Immunoglobulin G; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Receptors, Tumor Necrosis Factor; Remission Induction; Treatment Outcome | 2010 |
Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Drug Administration Schedule; Erythrocyte Transfusion; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Survival Analysis; Treatment Outcome | 2010 |
Predictive value of pretreatment risk group and baseline LDH levels in MDS patients receiving azacitidine treatment.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Disease-Free Survival; Female; Humans; L-Lactate Dehydrogenase; Male; Middle Aged; Myelodysplastic Syndromes; Risk Factors; Survival Rate | 2010 |
Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes.
Topics: Aged; Azacitidine; Chromosome Aberrations; DNA Methylation; DNA Modification Methylases; DNA Mutational Analysis; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Karyotyping; Lenalidomide; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Precancerous Conditions; Risk Assessment; Thalidomide; Time Factors; Treatment Outcome; United States | 2010 |
Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Antimetabolites, Antineoplastic; Azacitidine; Disease Management; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome | 2010 |
Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Female; Humans; Male; Myelodysplastic Syndromes | 2010 |
Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; DNA Methylation; DNA, Neoplasm; Drug Administration Schedule; Epidemiologic Methods; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Polymerase Chain Reaction; Promoter Regions, Genetic; Remission Induction; Thrombocytopenia; Treatment Outcome | 2010 |
Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Female; Humans; Incidence; Male; Middle Aged; Myelodysplastic Syndromes; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin | 2010 |
Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Disease Progression; Female; France; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Philadelphia Chromosome; Prognosis; Treatment Outcome | 2010 |
Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study.
Topics: Adult; Aged; Azacitidine; Disease-Free Survival; DNA Methylation; Drug Administration Schedule; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Transplantation, Homologous | 2010 |
Decreased incidence of febrile episodes with antibiotic prophylaxis in the treatment of decitabine for myelodysplastic syndrome.
Topics: Adult; Aged; Antibiotic Prophylaxis; Antimetabolites, Antineoplastic; Appendicitis; Azacitidine; Decitabine; Drug Administration Schedule; Female; Fever; Fluoroquinolones; Hemorrhage; Hospitalization; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Time Factors; Treatment Outcome | 2011 |
Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial.
Topics: Adult; Aged; Azacitidine; Cytogenetic Analysis; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Modification Methylases; Epigenomics; Female; Histone Deacetylase Inhibitors; Humans; Hydralazine; Kaplan-Meier Estimate; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome; Valproic Acid; Young Adult | 2011 |
Decitabine in myelodysplastic syndromes and chronic myelomonocytic leukemia: Argentinian/South Korean multi-institutional clinical experience.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Argentina; Azacitidine; Decitabine; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Republic of Korea; Survival Analysis; Treatment Outcome; Young Adult | 2010 |
Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Young Adult | 2011 |
A phase II study of low dose intravenous clofarabine for elderly patients with myelodysplastic syndrome who have failed 5-azacytidine.
Topics: Adenine Nucleotides; Aged; Antineoplastic Agents; Arabinonucleosides; Azacitidine; Clofarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Injections, Intravenous; Male; Myelodysplastic Syndromes; Salvage Therapy; Treatment Failure | 2010 |
Synergistic induction of PI-PLCβ1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Case-Control Studies; Cells, Cultured; DNA Methylation; Drug Synergism; Enzyme Inhibitors; Epigenesis, Genetic; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Phosphoinositide Phospholipase C; Promoter Regions, Genetic; Signal Transduction; Valproic Acid | 2011 |
Levels of miR-29b do not predict for response in patients with acute myelogenous leukemia treated with the combination of 5-azacytidine, valproic acid, and ATRA.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cohort Studies; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; MicroRNAs; Myelodysplastic Syndromes; Treatment Outcome; Tretinoin; Valproic Acid | 2011 |
Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome.
Topics: Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; DNA Methylation; DNA, Neoplasm; Epigenomics; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Polymerase Chain Reaction; Survival Rate; Treatment Outcome; Tretinoin; Valproic Acid | 2010 |
Thrice weekly azacitidine does not improve hematological responses in lower-risk myelodysplastic syndromes: a study of the Hoosier Oncology Group.
Topics: Aged; Aged, 80 and over; Anemia; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; bcl-X Protein; Erythroid Precursor Cells; Erythropoiesis; Erythropoietin; Female; Flow Cytometry; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis | 2011 |
Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Rese
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Disease-Free Survival; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Palliative Care; Quality of Life; Treatment Outcome | 2011 |
Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites; Antimetabolites, Antineoplastic; Azacitidine; Biological Availability; DNA Methylation; Fatigue; Female; Gastrointestinal Diseases; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myelomonocytic, Chronic; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Neutropenia | 2011 |
Phase I and II study of azacitidine in Japanese patients with myelodysplastic syndromes.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Enzyme Inhibitors; Female; Humans; Japan; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome | 2011 |
Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Risk; Time Factors | 2011 |
A prospective multicenter observational study of decitabine treatment in Korean patients with myelodysplastic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Prospective Studies; Republic of Korea; Transplantation, Homologous; Treatment Outcome; Young Adult | 2011 |
Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Azacitidine; Benzenesulfonates; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cytarabine; Cytokines; Farnesyltranstransferase; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Niacinamide; Oxides; Phenylurea Compounds; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyridines; Sorafenib | 2011 |
Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Azacitidine; Bone Marrow; Bone Marrow Cells; Cohort Studies; Decitabine; Dose-Response Relationship, Drug; Female; Gene Expression Profiling; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neovascularization, Pathologic; Oxides; Young Adult | 2011 |
Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Chimerism; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm, Residual; Recurrence; Time Factors; Transplantation, Homologous; Treatment Outcome; Young Adult | 2012 |
Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named p
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Blood Platelets; Cohort Studies; Compassionate Use Trials; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Netherlands; Retrospective Studies; Survival Analysis; Treatment Outcome | 2011 |
Azacitidine differentially affects CD4(pos) T-cell polarization in vitro and in vivo in high risk myelodysplastic syndromes.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; CD3 Complex; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cell Differentiation; Cell Polarity; Cell Proliferation; Cells, Cultured; Cytokines; Humans; Myelodysplastic Syndromes; Neoplasm Staging; Risk | 2012 |
Phase I/II study of decitabine in patients with myelodysplastic syndrome: a multi-center study in Japan.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Dose-Response Relationship, Drug; Female; Humans; Japan; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome | 2012 |
A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine.
Topics: Aged; Aged, 80 and over; Azacitidine; Decitabine; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Platelet Count; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin; Treatment Outcome | 2013 |
Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cohort Studies; DNA Mutational Analysis; Female; Humans; Karyotyping; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome | 2012 |
Azacitidine-eligibility in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukaemia: a registry-based study.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myelodysplastic Syndromes; Registries; Retrospective Studies | 2013 |
Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Cell Transplantation; Combined Modality Therapy; Female; Humans; Leukemia, Myeloid, Acute; Lymphocytes; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Salvage Therapy; Stem Cell Transplantation; Transplantation, Homologous | 2013 |
Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Thalidomide | 2013 |
Nonclonal neutrophil responses after successful treatment of myelodysplasia with low-dose 5-aza-2'-deoxycytidine (decitabine).
Topics: Aged; Azacitidine; Cell Proliferation; Clone Cells; Decitabine; Female; Granulocytes; Humans; In Situ Hybridization, Fluorescence; Leukocyte Count; Leukopoiesis; Male; Myelodysplastic Syndromes; Neutropenia; Neutrophils | 2004 |
Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Area Under Curve; Azacitidine; Biological Availability; Cross-Over Studies; Female; Half-Life; Humans; Infusions, Intravenous; Injections, Subcutaneous; Male; Middle Aged; Myelodysplastic Syndromes | 2005 |
Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Drug Approval; Humans; Injections, Subcutaneous; Myelodysplastic Syndromes; Treatment Outcome; United States; United States Food and Drug Administration | 2005 |
Treatment of myelodysplastic syndrome with a DNA methyltransferase inhibitor: lack of evidence for induction of chromosomal instability.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Chromosomal Instability; Chromosome Deletion; Cytogenetic Analysis; Decitabine; Female; Follow-Up Studies; Humans; Male; Metaphase; Middle Aged; Monosomy; Myelodysplastic Syndromes | 2006 |
Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome.
Topics: Acetylation; Acute Disease; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; DNA Methylation; Drug Administration Schedule; Drug Therapy, Combination; Female; Histones; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Phenylbutyrates; Pilot Projects; Transcription, Genetic; Treatment Outcome | 2006 |
Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.
Topics: Acute Disease; Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Disease Progression; Disease-Free Survival; DNA Methylation; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Palliative Care; Quality of Life; Survival Rate | 2006 |
Superiority of prolonged low-dose azanucleoside administration? Results of 5-aza-2'-deoxycytidine retreatment in high-risk myelodysplasia patients.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Disease Progression; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Retreatment; Risk Factors; Survival Rate | 2006 |
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Bayes Theorem; Bone Marrow Diseases; Chemical and Drug Induced Liver Injury; Cyclin-Dependent Kinase Inhibitor p15; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gene Expression Regulation; Gene Expression Regulation, Leukemic; Humans; Infusions, Intravenous; Injections, Subcutaneous; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Proteins; Remission Induction; Risk; Treatment Outcome | 2007 |
Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.
Topics: Acetylation; Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; Child; Child, Preschool; Decitabine; DNA Methylation; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Histones; Humans; Leukemia; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Survival Analysis; Valproic Acid | 2006 |
Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Aberrations; Chromosomes, Human, Pair 5; Chromosomes, Human, Pair 7; Decitabine; Drug Administration Schedule; Fatigue; Humans; Infusions, Intravenous; Injections, Subcutaneous; Male; Middle Aged; Multivariate Analysis; Myelodysplastic Syndromes; Prognosis; Risk Factors; Survival Analysis; Survival Rate; Treatment Outcome; Vomiting | 2007 |
Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cohort Studies; Decitabine; DNA Modification Methylases; Enzyme Inhibitors; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Risk; Treatment Outcome | 2007 |
Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Area Under Curve; Azacitidine; Bone Marrow; Chromatography, High Pressure Liquid; Decitabine; Drug Administration Schedule; Female; Half-Life; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Mass Spectrometry; Middle Aged; Myelodysplastic Syndromes; Sepsis; Tissue Distribution | 2008 |
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.
Topics: Acetylation; Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; Child; Child, Preschool; DNA Methylation; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Gene Expression Regulation; Histones; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; RNA, Messenger; Tretinoin; Valproic Acid | 2007 |
CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Bone Marrow Cells; Chromosome Aberrations; Chromosomes, Human, Pair 7; Cyclin-Dependent Kinase Inhibitor p15; DNA Methylation; Female; Genetic Markers; Humans; Injections, Subcutaneous; Male; Middle Aged; Myelodysplastic Syndromes; Predictive Value of Tests; Promoter Regions, Genetic; Survival Rate; Treatment Outcome | 2007 |
Preferential cytogenetic response to continuous intravenous low-dose decitabine (DAC) administration in myelodysplastic syndrome with monosomy 7.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Chromosomes, Human, Pair 7; Decitabine; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Injections, Subcutaneous; Leukocyte Count; Monosomy; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Remission Induction; Time Factors; Treatment Outcome | 2007 |
Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine.
Topics: Aged; Aged, 80 and over; Azacitidine; Decitabine; DNA Methylation; Humans; Middle Aged; Myelodysplastic Syndromes; Salvage Therapy; Treatment Failure; Treatment Outcome | 2008 |
Continuous infusion of low-dose 5-Aza-2'-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Decitabine; Erythrocyte Count; Female; Humans; Infusions, Intravenous; Leukocyte Count; Male; Middle Aged; Morbidity; Myelodysplastic Syndromes; Platelet Count; Prognosis; Risk Assessment; Survival Rate | 1997 |
Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Patient Selection; Survival Rate; Treatment Outcome | 2000 |
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Blood Cell Count; Bone Marrow; Cross-Over Studies; Female; Humans; Injections, Subcutaneous; Leukemia, B-Cell; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Risk Factors; Treatment Outcome | 2002 |
Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Female; Humans; Injections, Subcutaneous; Leukemia, B-Cell; Male; Middle Aged; Myelodysplastic Syndromes; Quality of Life; Remission Induction; Surveys and Questionnaires; Treatment Outcome | 2002 |
675 other study(ies) available for azacitidine and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
In Vitro and in Vivo Evaluation of Fully Substituted (5-(3-Ethoxy-3-oxopropynyl)-4-(ethoxycarbonyl)-1,2,3-triazolyl-glycosides as Original Nucleoside Analogues to Circumvent Resistance in Myeloid Malignancies.
Topics: Animals; Antineoplastic Agents; Autophagy; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Glycosides; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Mice, Nude; Myelodysplastic Syndromes; Triazoles; Tumor Cells, Cultured | 2017 |
Risk factors for thrombocytopenia and analysis of time to platelet transfusion after azacitidine treatment.
Topics: Azacitidine; Humans; Myelodysplastic Syndromes; Platelet Transfusion; Risk Factors; Thrombocytopenia | 2021 |
Sequential administration of low dose 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in relapse after allogeneic stem cell transplantation (SCT): a prospective study
Topics: Azacitidine; Belgium; Hematology; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphocyte Transfusion; Lymphocytes; Myelodysplastic Syndromes; Prospective Studies; Recurrence; Retrospective Studies | 2022 |
Recurrent arthritis as an unexpected side effect associated with azacitidine in a patient with myelodysplastic syndrome.
Topics: Antimetabolites, Antineoplastic; Arthritis; Azacitidine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Treatment Outcome | 2022 |
Azacitidine for patients with Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Female; France; Genes, X-Linked; Genetic Diseases, X-Linked; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Registries; Skin Diseases, Genetic | 2022 |
Real-world assessment of myelodysplastic syndrome: Japanese claims data analysis.
Topics: Aged; Aged, 80 and over; Azacitidine; Blood Transfusion; Cost of Illness; Data Analysis; Female; Health Care Costs; Hematinics; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies | 2022 |
Injectable Hypomethylating Agents for Management of Myelodysplastic Syndromes: Patients' Perspectives on Treatment.
Topics: Adult; Antimetabolites, Antineoplastic; Azacitidine; Cross-Sectional Studies; Female; Humans; Middle Aged; Myelodysplastic Syndromes; Risk Factors; Treatment Outcome | 2022 |
Secondary basophilic leukemia in Ph-negative myeloid neoplasms: A distinct subset with poor prognosis.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Basophils; Female; Humans; Leukemia; Male; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasms, Second Primary; Prognosis | 2021 |
Bone marrow ribonucleotide reductase mRNA levels and methylation status as prognostic factors in patients with myelodysplastic syndrome treated with 5-Azacytidine.
Topics: Azacitidine; Bone Marrow; Humans; Methylation; Myelodysplastic Syndromes; Prognosis; Ribonucleoside Diphosphate Reductase; Ribonucleotide Reductases; RNA, Messenger | 2022 |
A cat with myelodysplastic syndrome by administration of the methylation inhibitor Azacytidine.
Topics: Anemia; Animals; Azacitidine; Cat Diseases; Cats; Female; Leukopenia; Methylation; Myelodysplastic Syndromes | 2022 |
Oral hypomethylating agents: beyond convenience in MDS.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Female; Humans; Myelodysplastic Syndromes; Quality of Life; Uridine | 2021 |
Successful treatment with azacitidine in VEXAS syndrome with prominent myofasciitis.
Topics: Azacitidine; Humans; Myelodysplastic Syndromes; Myositis; Ubiquitin-Activating Enzymes | 2022 |
Hemoglobin is a key determinant of quality of life before and during azacitidine-based therapy for myelodysplasia and low blast count acute myeloid leukemia.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Dyspnea; Fatigue; Hemoglobins; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Quality of Life | 2022 |
RAEB II type of myelodysplastic syndrome associated with axillary abscesses - Case Report.
Topics: Abscess; Anemia, Refractory, with Excess of Blasts; Azacitidine; Humans; Myelodysplastic Syndromes | 2021 |
Azacitidine-induced massive pericardial effusion in a child with myelodysplastic syndrome.
Topics: Adult; Azacitidine; Cardiac Tamponade; Child; Humans; Male; Myelodysplastic Syndromes; Pericardial Effusion; Pericardiocentesis | 2022 |
Novel inhibitor of hematopoietic cell kinase as a potential therapeutic agent for acute myeloid leukemia.
Topics: Animals; Azacitidine; Cytarabine; Leukemia, Myeloid, Acute; Mice; Myelodysplastic Syndromes; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-hck | 2022 |
Safety Concerns Prompt Pause of Magrolimab Trials.
Topics: Antibodies, Monoclonal, Humanized; Azacitidine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2022 |
Historical expectations with DNA methyltransferase inhibitor monotherapy in MDS: when is combination therapy truly "promising"?
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA; Enzyme Inhibitors; Humans; Methyltransferases; Motivation; Myelodysplastic Syndromes; Treatment Outcome | 2022 |
Dynamic change in peripheral blood WT1 mRNA levels within three cycles of azacitidine predict treatment response in patients with high-risk myelodysplastic syndromes.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Humans; Myelodysplastic Syndromes; Retrospective Studies; RNA, Messenger; Treatment Outcome; WT1 Proteins | 2022 |
Erythroblast predominance without CD41/cyCD41-positive blasts predicts favorable prognosis in patients with myelodysplastic syndromes and acute myeloid leukemias treated with azacitidine.
Topics: Abnormal Karyotype; Aged; Antimetabolites, Antineoplastic; Azacitidine; Erythroblasts; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis | 2022 |
Hard-wired biases in trials: maintenance azacitidine in patients with acute myeloid leukemia and framework for future trials.
Topics: Azacitidine; Bias; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2022 |
Real-world experience with venetoclax and hypomethylating agents in myelodysplastic syndromes with excess blasts.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Myelodysplastic Syndromes; Sulfonamides | 2022 |
Response to azacitidine in patients with chronic myelomonocytic leukemia according to overlap myelodysplastic/myeloproliferative neoplasms criteria.
Topics: Azacitidine; Humans; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Myelodysplastic-Myeloproliferative Diseases; Retrospective Studies | 2022 |
The Cell Type-Specific 5hmC Landscape and Dynamics of Healthy Human Hematopoiesis and TET2-Mutant Preleukemia.
Topics: Azacitidine; Chromatin; Dioxygenases; DNA-Binding Proteins; Hematopoiesis; Humans; Myelodysplastic Syndromes; Preleukemia; Proto-Oncogene Proteins | 2022 |
Enhancing our chances of picking a winner in higher-risk myelodysplastic syndromes.
Topics: Azacitidine; Clinical Trials, Phase II as Topic; Humans; Idarubicin; Lenalidomide; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Valproic Acid | 2022 |
Selinexor synergizes with azacitidine to eliminate myelodysplastic syndrome cells through p53 nuclear accumulation.
Topics: Azacitidine; Humans; Hydrazines; Myelodysplastic Syndromes; Neoplasms; Triazoles; Tumor Suppressor Protein p53 | 2022 |
Impact of Hypomethylating Agent Use on Hospital and Emergency Room Visits, and Predictors of Early Discontinuation in Patients With Higher-Risk Myelodysplastic Syndromes.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Emergency Service, Hospital; Hospitals; Humans; Medicare; Myelodysplastic Syndromes; Treatment Outcome; United States | 2022 |
Bone marrow fibrosis impact on response to azacitidine in myelodysplastic syndromes.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Fibrosis; Humans; Myelodysplastic Syndromes; Primary Myelofibrosis; Prospective Studies; Retrospective Studies; Treatment Outcome | 2022 |
Epigenetic Silencing of
Topics: Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Silencing; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neoplasms, Second Primary; Proto-Oncogene Proteins c-mdm2; PTEN Phosphohydrolase | 2022 |
Real-world data on efficacy and safety of azacitidine therapy in chronic myelomonocytic leukemia in China: results from a multicenter, retrospective study.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Humans; Leukemia, Myelomonocytic, Chronic; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Treatment Outcome | 2022 |
Oncogene Up-Regulation after Hypomethylating Therapy.
Topics: Azacitidine; Demethylation; Humans; Myelodysplastic Syndromes; Oncogenes; Up-Regulation | 2022 |
Oncogene Up-Regulation after Hypomethylating Therapy. Reply.
Topics: Azacitidine; Demethylation; Humans; Myelodysplastic Syndromes; Oncogenes; Up-Regulation | 2022 |
Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome.
Topics: Aged; Azacitidine; Humans; Isocitrate Dehydrogenase; Mutation; Myelodysplastic Syndromes | 2023 |
Megakaryopoiesis impairment through acute innate immune signaling activation by azacitidine.
Topics: Azacitidine; Humans; Immunity, Innate; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Thrombocytopenia | 2022 |
MDM2 antagonist improves therapeutic activity of azacitidine in myelodysplastic syndromes and chronic myelomonocytic leukemia.
Topics: Animals; Azacitidine; Imidazoles; Leukemia, Myelomonocytic, Chronic; Mice; Myelodysplastic Syndromes | 2022 |
An early glimpse at azacitidine plus venetoclax for myelodysplastic syndromes.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Sulfonamides | 2022 |
Transcriptomic Signatures of Hypomethylating Agent Failure in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia.
Topics: Animals; Azacitidine; Humans; Leukemia, Myelomonocytic, Chronic; Leukemia, Myelomonocytic, Juvenile; Mice; Myelodysplastic Syndromes; Transcriptome | 2022 |
[Updated treatment strategies for myelodysplastic syndromes].
Topics: Antineoplastic Agents; Azacitidine; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2022 |
[New treatment for myelodysplastic syndromes: luspatercept and oral hypomethylating agents].
Topics: Activin Receptors, Type II; Activins; Azacitidine; Cytidine Deaminase; Decitabine; Humans; Immunoglobulin Fc Fragments; Ligands; Myelodysplastic Syndromes; Recombinant Fusion Proteins; Treatment Outcome | 2022 |
Research Progress of B-Cell Lymphoma/Leukemia-2 Inhibitor Combined with Azacytidine in the Targeted Therapy of Acute Myeloid Leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Humans; Leukemia, Myeloid, Acute; Lymphoma, B-Cell; Myelodysplastic Syndromes | 2022 |
Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings.
Topics: Azacitidine; Decitabine; Humans; Ipilimumab; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2023 |
Ascertaining QUAZARs: slow-motion and light-speed development of oral azacitidine and decitabine.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2023 |
Venetoclax and hypomethylating agent therapy in myelodysplastic syndromes: Big picture perspective.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Myelodysplastic Syndromes; Sulfonamides | 2023 |
Prognostic implications of mono-hit and multi-hit TP53 alterations in patients with acute myeloid leukemia and higher risk myelodysplastic syndromes treated with azacitidine-based therapy.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis; Tumor Suppressor Protein p53 | 2023 |
Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML.
Topics: Azacitidine; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Myelodysplastic Syndromes; Retinoic Acid Receptor alpha | 2023 |
All-trans retinoic acid enhances the cytotoxic effect of decitabine on myelodysplastic syndromes and acute myeloid leukaemia by activating the RARα-Nrf2 complex.
Topics: Aged; Animals; Antineoplastic Agents; Azacitidine; Decitabine; Humans; Leukemia, Myeloid, Acute; Mice; Myelodysplastic Syndromes; NF-E2-Related Factor 2; Reactive Oxygen Species; Tretinoin | 2023 |
New investigational combinations for higher-risk MDS.
Topics: Aged; Azacitidine; Bone Marrow; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Stem Cell Transplantation | 2022 |
15-days duration of venetoclax combined with azacitidine in the treatment of relapsed/refractory high-risk myelodysplastic syndromes: A retrospective single-center study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Retrospective Studies | 2023 |
CCRL2 affects the sensitivity of myelodysplastic syndrome and secondary acute myeloid leukemia cells to azacitidine.
Topics: Azacitidine; Cell Line; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2023 |
Cytogenetic peripheral blood monitoring in azacitidine treated patients with high-risk MDS/sAML: A monocentric real-world experience.
Topics: Azacitidine; Bone Marrow; Humans; Karyotyping; Myelodysplastic Syndromes; Retrospective Studies; Treatment Outcome | 2023 |
Absence of early platelet increment in healthy mice during decitabine treatment.
Topics: Animals; Azacitidine; Blood Platelets; Decitabine; Megakaryocytes; Mice; Myelodysplastic Syndromes; Treatment Outcome | 2022 |
Fetal hemoglobin level predicts lower-risk myelodysplastic syndrome.
Topics: Azacitidine; Fetal Hemoglobin; Humans; Myelodysplastic Syndromes; Prognosis; Retrospective Studies | 2023 |
Clinical impact of transformation to acute myeloid leukemia in patients with higher-risk myelodysplastic syndromes.
Topics: Azacitidine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Retrospective Studies | 2022 |
Azacitidine Maintenance Therapy Post-Allogeneic Stem Cell Transplantation in Poor-Risk Acute Myeloid Leukemia.
Topics: Adult; Azacitidine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prospective Studies; Recurrence; Retrospective Studies | 2023 |
Successful azacitidine therapy for myelodysplastic syndrome associated with VEXAS syndrome.
Topics: Aged; Azacitidine; Enzyme Inhibitors; Exanthema; Fever; Humans; Inflammation; Male; Mutation; Myelodysplastic Syndromes | 2023 |
Myelodysplastic Syndrome associated TET2 mutations affect NK cell function and genome methylation.
Topics: Azacitidine; Dioxygenases; DNA-Binding Proteins; Humans; Killer Cells, Natural; Methylation; Mutation; Myelodysplastic Syndromes; Receptors, KIR | 2023 |
From cell surface to nucleus: CCRL2 regulates response to hypomethylating agents in myelodysplastic syndromes.
Topics: Azacitidine; Cell Nucleus; DNA Methylation; Humans; Myelodysplastic Syndromes | 2023 |
Incidence and predisposing factors of infection in patients treated with hypomethylating agents.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Causality; Female; Humans; Incidence; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Myelodysplastic Syndromes; Retrospective Studies; Thrombocytopenia; Treatment Outcome | 2023 |
A miRNA screening identifies miR-192-5p as associated with response to azacitidine and lenalidomide therapy in myelodysplastic syndromes.
Topics: Azacitidine; DNA Methylation; Humans; Lenalidomide; Leukemia, Myeloid, Acute; MicroRNAs; Myelodysplastic Syndromes; Proto-Oncogene Proteins c-bcl-2 | 2023 |
Inhibition of lysyl oxidases synergizes with 5-azacytidine to restore erythropoiesis in myelodysplastic and myeloid malignancies.
Topics: Animals; Azacitidine; Erythropoiesis; Female; Hematopoietic Stem Cells; Humans; Mice; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasms; Protein-Lysine 6-Oxidase | 2023 |
10-year nationwide trends in incidence, treatment patterns, and mortality of patients with myelodysplastic syndromes in Denmark.
Topics: Azacitidine; Comorbidity; Denmark; Humans; Incidence; Myelodysplastic Syndromes; Registries | 2023 |
Peripheral Blood CD34 Donor Chimerism has Greater Clinical Utility Than CD3 for Detecting Relapse after Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome.
Topics: Antigens, CD34; Azacitidine; Chimerism; Chronic Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Nuclear Proteins; Recurrence | 2023 |
Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms.
Topics: Azacitidine; Humans; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasms; Prognosis; Treatment Outcome | 2023 |
Treatment in patients with acute myeloid leukemia/high-risk myelodysplastic syndrome with hypomethylating agents: Day-hospital management compared to home care setting.
Topics: Azacitidine; Hospitals; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Retrospective Studies; Treatment Outcome | 2023 |
Azacitidine, lenalidomide and donor lymphocyte infusions for relapse of myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia after allogeneic transplant: the Azalena-Trial.
Topics: Adult; Azacitidine; Chronic Disease; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Lymphocyte Transfusion; Myelodysplastic Syndromes; Recurrence; T-Lymphocytes; Transplantation, Homologous | 2023 |
Azacitidine as a rare cause of reactive arthritis in a patient with acute myeloid leukemia.
Topics: Aged; Arthritis, Reactive; Azacitidine; Drug-Related Side Effects and Adverse Reactions; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Retrospective Studies | 2023 |
Myelodysplastic Syndrome Treated by Integrated Chinese and Western Medicine: A Case Report.
Topics: Aged; Asian People; Azacitidine; China; Female; Humans; Leukemia; Male; Middle Aged; Myelodysplastic Syndromes; Programmed Cell Death 1 Receptor | 2023 |
Real-world practice-based prognostic model for higher-risk myelodysplastic syndromes treated with azacitidine monotherapy: The Kyoto prognostic scoring system.
Topics: Abnormal Karyotype; Azacitidine; Humans; Myelodysplastic Syndromes; Prognosis; Retrospective Studies | 2023 |
Population Pharmacokinetics of Oral Azacitidine, and Exposure-Response Analysis in Acute Myeloid Leukemia.
Topics: Adult; Antimetabolites; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials, Phase III as Topic; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes | 2023 |
Case report: Positive response to venetoclax and azacitidine in the treatment of acute myeloid leukemia with myelodysplasia-related changes and blasts of the mixed T/myeloid phenotype.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Phenotype | 2023 |
Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Cycle Proteins; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Nuclear Proteins; Proto-Oncogene Proteins c-bcl-2; Recurrence; RNA-Binding Proteins; Transcription Factors | 2023 |
Treatment strategy at the decision for allogeneic transplantation in patients with myelodysplastic syndrome in the era of azacitidine: A KSGCT prospective study.
Topics: Azacitidine; Hematopoietic Stem Cell Transplantation; Humans; Myelodysplastic Syndromes; Prospective Studies; Retrospective Studies; Transplantation, Homologous | 2023 |
Cytidine deaminase status as a marker of response to azacytidine treatment in MDS and AML patients.
Topics: Adult; Antimetabolites, Antineoplastic; Azacitidine; Cytidine Deaminase; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Treatment Outcome | 2023 |
[Current state of treatment for myelodysplastic syndromes].
Topics: Azacitidine; Genome-Wide Association Study; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis | 2023 |
Evaluation of complete response to azacitidine according to the revised International Working Group 2023 response criteria for higher risk MDS. Does it make a difference in patients' outcome?
Topics: Antimetabolites, Antineoplastic; Azacitidine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Remission Induction; Treatment Outcome | 2023 |
[Recent findings in myelodysplastic syndrome].
Topics: Anemia; Azacitidine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis | 2023 |
Higher MDMX expression was associated with hypomethylating agent resistance and inferior survival in MDS patients, inferring it a potential therapeutic target.
Topics: Azacitidine; Humans; Myelodysplastic Syndromes; Prognosis | 2023 |
[Impact of time to hematological response on survival in patients treated with azacytidine: a single-center retrospective study].
Topics: Antimetabolites, Antineoplastic; Azacitidine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Retrospective Studies; Treatment Outcome | 2019 |
5-Azacytidine modulates CpG methylation levels of EZH2 and NOTCH1 in myelodysplastic syndromes.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Case-Control Studies; CpG Islands; DNA Methylation; Enhancer of Zeste Homolog 2 Protein; Female; Follow-Up Studies; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Receptor, Notch1; Tumor Cells, Cultured | 2019 |
Synergistic Antioncogenic Activity of Azacitidine and Curcumin in Myeloid Leukemia Cell Lines and Patient Samples.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Azacitidine; Cell Cycle; Cell Differentiation; Cell Line, Tumor; Curcumin; Drug Synergism; Female; Humans; Leukemia, Myeloid; Male; Myelodysplastic Syndromes | 2019 |
Long-term maintenance of the mucosal healing induced by azacitidine therapy in a patient with intestinal Behçet's-like disease accompanied with myelodysplastic syndrome involving trisomy 8.
Topics: Azacitidine; Behcet Syndrome; Chromosomes, Human, Pair 8; Female; Humans; Intestinal Diseases; Maintenance Chemotherapy; Middle Aged; Myelodysplastic Syndromes; Time Factors; Treatment Outcome; Trisomy | 2019 |
Azacitidine-induced hyperglycaemia.
Topics: Aged; Azacitidine; Female; Humans; Hyperglycemia; Myelodysplastic Syndromes | 2019 |
WT1 evaluation in higher-risk myelodysplastic syndrome patients treated with azacitidine.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Humans; Myelodysplastic Syndromes; WT1 Proteins | 2020 |
A case of polycyclic Sweet's syndrome arising from azacitidine injection sites in myelodysplasia.
Topics: Aged; Azacitidine; Humans; Male; Myelodysplastic Syndromes; Sweet Syndrome | 2020 |
Epigenetic therapy of myelodysplastic syndromes connects to cellular differentiation independently of endogenous retroelement derepression.
Topics: Aged; Alternative Splicing; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow Cells; Carrier Proteins; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Differentiation; GTPase-Activating Proteins; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Mannosyltransferases; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Retroelements; Transcriptome; Treatment Failure; Tumor Suppressor Proteins | 2019 |
Secondary Pulmonary Alveolar Proteinosis Following Treatment with Azacitidine for Myelodysplastic Syndrome.
Topics: Azacitidine; Female; Humans; Middle Aged; Myelodysplastic Syndromes; Pulmonary Alveolar Proteinosis; Tomography, X-Ray Computed | 2020 |
Knowledge of Secondary Pulmonary Alveolar Proteinosis Complicated with Myelodysplastic Syndrome.
Topics: Azacitidine; Humans; Myelodysplastic Syndromes; Pulmonary Alveolar Proteinosis | 2020 |
Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Azacitidine; Humans; Medicare; Myelodysplastic Syndromes; Propensity Score; Retrospective Studies; United States | 2020 |
Characteristics of Long-Term Survival in Patients With Myelodysplastic Syndrome Treated With 5-Azacyditine: Results From the Hellenic 5-Azacytidine Registry.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Registries | 2020 |
Pulmonary infections in patients with myelodysplastic syndromes receiving frontline azacytidine treatment.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Female; Follow-Up Studies; Humans; Lung; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Respiratory Tract Infections; Retrospective Studies; Survival Rate | 2020 |
[Successful treatment of myelodysplastic syndrome-associated autoinflammatory lymphedema with azacytidine].
Topics: Aged, 80 and over; Autoimmune Diseases; Azacitidine; Female; Humans; Lymphedema; Myelodysplastic Syndromes; Pancytopenia | 2019 |
Comparison between 5-day decitabine and 7-day azacitidine for lower-risk myelodysplastic syndromes with poor prognostic features: a retrospective multicentre cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Longitudinal Studies; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Retrospective Studies; Survival Rate; Young Adult | 2020 |
Clinical effects of the CD13/CD33 ratio on the prognosis of myelodysplastic syndrome treated with azacitidine.
Topics: Azacitidine; CD13 Antigens; Humans; Myelodysplastic Syndromes; Prognosis; Sialic Acid Binding Ig-like Lectin 3 | 2020 |
Clonal selection in therapy-related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Clonal Evolution; Female; High-Throughput Nucleotide Sequencing; Humans; Leukemia, Myeloid, Acute; Male; Mutation; Myelodysplastic Syndromes; Treatment Outcome | 2020 |
Usefulness of azacitidine therapy in a sickle cell disease patient with myelodysplastic syndrome.
Topics: Anemia, Sickle Cell; Azacitidine; Humans; Male; Middle Aged; Myelodysplastic Syndromes | 2020 |
[Therapeatic Efficacy of Decitabine on Low and Moderate-Risk MDS Patients and the Prognostic Factors].
Topics: Azacitidine; Decitabine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis; Retrospective Studies; Treatment Outcome | 2020 |
Healthcare utilization in patients with higher-risk MDS/low-blast count AML treated with azacitidine in the 'real-world'.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Delivery of Health Care; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Ontario | 2020 |
Clinical significance of CD41-positive blasts in association with a monosomal karyotype in patients with myelodysplastic syndrome treated with azacitidine.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Female; Humans; Karyotype; Male; Middle Aged; Myelodysplastic Syndromes; Platelet Membrane Glycoprotein IIb; Young Adult | 2020 |
Reduction of Extramedullary Complications in Patients With Acute Myeloid Leukemia/Myelodysplastic Syndrome Treated With Azacitidine.
Topics: Adolescent; Antimetabolites, Antineoplastic; Azacitidine; Child, Preschool; Chromosome Deletion; Chromosomes, Human, Pair 7; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Shwachman-Diamond Syndrome | 2020 |
Circulating Small Noncoding RNAs Have Specific Expression Patterns in Plasma and Extracellular Vesicles in Myelodysplastic Syndromes and Are Predictive of Patient Outcome.
Topics: Azacitidine; Biomarkers; Extracellular Vesicles; Gene Expression Regulation; High-Throughput Nucleotide Sequencing; Humans; Kaplan-Meier Estimate; MicroRNAs; Models, Biological; Multivariate Analysis; Mutation; Myelodysplastic Syndromes; Prognosis; Proportional Hazards Models; Reproducibility of Results; RNA Editing; RNA, Small Untranslated; Signal Transduction; Treatment Outcome | 2020 |
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzoates; Humans; Hydrazines; Middle Aged; Myelodysplastic Syndromes; Pyrazoles; Thrombopoiesis | 2021 |
Topics: Azacitidine; beta-Globins; beta-Thalassemia; DNA Mutational Analysis; Female; Heterozygote; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Phenotype; Pregnancy; Retrospective Studies; Risk Factors; Silent Mutation; Treatment Outcome | 2020 |
Prognostic value of indoleamine 2,3 dioxygenase in patients with higher-risk myelodysplastic syndromes treated with azacytidine.
Topics: Aged; Aged, 80 and over; Azacitidine; Biomarkers; Bone Marrow; CD8-Positive T-Lymphocytes; Cells, Cultured; Combined Modality Therapy; DNA Methylation; Drug Therapy, Combination; Enzyme Induction; Female; Hematopoietic Stem Cell Transplantation; Humans; Immune Checkpoint Inhibitors; Indoleamine-Pyrrole 2,3,-Dioxygenase; Macrophages; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Risk; Tryptophan | 2020 |
Azacitidine in patients older than 80 years with acute myeloid leukaemia or myelodysplastic syndromes: a report on 115 patients.
Topics: Abnormal Karyotype; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow Diseases; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Febrile Neutropenia; Female; France; Hospitalization; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Multicenter Studies as Topic; Myelodysplastic Syndromes; Renal Insufficiency, Chronic; Retrospective Studies; Treatment Outcome | 2020 |
IDO in MDS/AML disease progression and its role in resistance to azacitidine: a potential new drug target?
Topics: Azacitidine; Disease Progression; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pharmaceutical Preparations; Prognosis | 2020 |
Azacitidine-associated haemorrhagic enteritis in a case of myelodysplastic syndrome: A case report.
Topics: Aged, 80 and over; Azacitidine; Colonoscopy; Enteritis; Female; Gastrointestinal Hemorrhage; Humans; Myelodysplastic Syndromes | 2020 |
Strain-resolved microbiome sequencing reveals mobile elements that drive bacterial competition on a clinical timescale.
Topics: Anti-Infective Agents; Azacitidine; Azithromycin; Bacteria; Ciprofloxacin; Diet; DNA, Bacterial; Feces; Gastrointestinal Microbiome; Genome, Bacterial; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Metagenome; Middle Aged; Myelodysplastic Syndromes; Primary Myelofibrosis; RNA-Seq; Sequence Analysis, DNA | 2020 |
To target the untargetable: elucidation of synergy of APR-246 and azacitidine in
Topics: Azacitidine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Quinuclidines; Tumor Suppressor Protein p53 | 2020 |
The geriatric nutritional risk index predicts the early death and survival in patients with myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes treated with azacitidine.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Azacitidine; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Nutritional Status; Survival Rate | 2020 |
Myelodysplastic syndromes in a pediatric patient with Cri du Chat syndrome with a ring chromosome 5.
Topics: Adolescent; Age Factors; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Cri-du-Chat Syndrome; Cytogenetic Analysis; Female; Humans; Myelodysplastic Syndromes; Quality of Life; Ring Chromosomes; Treatment Outcome | 2020 |
Use of azacitidine and its safety and efficacy in daily clinical practice in The Netherlands: the OCEAN study.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Humans; Myelodysplastic Syndromes; Netherlands; Treatment Outcome | 2020 |
Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; Humans; Myelodysplastic Syndromes; Retrospective Studies; Sulfonamides; Treatment Outcome | 2020 |
The prognostic value of the controlling nutritional status score in patients with myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia related changes treated with azacitidine.
Topics: Azacitidine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Nutritional Status; Prognosis | 2020 |
Aberrantly elevated suprabasin in the bone marrow as a candidate biomarker of advanced disease state in myelodysplastic syndromes.
Topics: Antigens, Differentiation; Azacitidine; Biomarkers; Bone Marrow; Cell Compartmentation; Cell Line, Tumor; Chemokine CCL2; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Interferon-gamma; Leukocytes, Mononuclear; Lymphocyte Count; Myelodysplastic Syndromes; Myeloid Cells; Neoplasm Proteins; Prognosis; Proto-Oncogene Mas; RNA, Messenger | 2020 |
Eat and be healthy: nutritional status in myelodysplastic syndromes.
Topics: Azacitidine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Nutritional Status; Prognosis | 2020 |
The effect of 5-azacytidine treatment delays and dose reductions on the prognosis of patients with myelodysplastic syndrome: how to optimize treatment results and outcomes.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Disease-Free Survival; Drug Tapering; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Registries; Retrospective Studies; Survival Rate; Time-to-Treatment | 2021 |
Severe thrombocytopenia as a predictor of survival and response to hypomethylating agents in myelodysplastic syndromes: A Latin-American cohort of 212 patients.
Topics: Aged; Azacitidine; Databases, Factual; Disease-Free Survival; Female; Follow-Up Studies; Humans; Latin America; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Severity of Illness Index; Survival Rate; Thrombocytopenia | 2020 |
No clear survival benefit of azacitidine for lower-risk myelodysplastic syndromes: A retrospective study of Nagasaki.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cause of Death; Erythrocyte Transfusion; Female; Hematinics; Humans; Immunosuppressive Agents; Induction Chemotherapy; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myelodysplastic Syndromes; Platelet Transfusion; Prognosis; Regression Analysis; Retrospective Studies; Sex Factors; Treatment Outcome; Young Adult | 2020 |
Real-World Costs of Azacitidine Treatment in Patients With Higher-Risk Myelodysplastic Syndromes/Low Blast-Count Acute Myeloid Leukemia.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Ontario | 2021 |
Elevated TWIST1 expression in myelodysplastic syndromes/acute myeloid leukemia reduces efficacy of hypomethylating therapy with decitabine.
Topics: Azacitidine; Decitabine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Nuclear Proteins; Twist-Related Protein 1 | 2020 |
Azacitidine regulates DNA methylation of GADD45γ in myelodysplastic syndromes.
Topics: Apoptosis; Azacitidine; Bone Marrow Cells; Cell Cycle Proteins; Cell Line; Cell Proliferation; DNA Methylation; Gene Expression; Genetic Therapy; Humans; Myelodysplastic Syndromes | 2021 |
Azacitidine is removed effectively by hemodialysis.
Topics: Azacitidine; Humans; Myelodysplastic Syndromes; Renal Dialysis | 2021 |
Cancer testis antigens in myelodysplastic syndromes revisited: a targeted RNA-seq approach.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Humans; Male; Myelodysplastic Syndromes; Neoplasms; Sequence Analysis, RNA; Testis; Transcription Factor DP1 | 2020 |
[Behçet's-like syndrome and other dysimmunitary manifestations related to myelodysplastic syndromes with trisomy 8].
Topics: Azacitidine; Behcet Syndrome; Chromosomes, Human, Pair 8; Humans; Myelodysplastic Syndromes; Trisomy | 2021 |
Gene expression signatures associated with sensitivity to azacitidine in myelodysplastic syndromes.
Topics: Aged; Azacitidine; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Reproducibility of Results; Transcriptome; Treatment Outcome | 2020 |
Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
Topics: Allografts; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Combined Modality Therapy; Decitabine; DNA Methylation; Drug Evaluation; Febrile Neutropenia; Germany; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Leukocyte Count; Myelodysplastic Syndromes; Recurrence; Retrospective Studies; Salvage Therapy; Sulfonamides; Thrombocytopenia; Transplantation Conditioning; Tumor Lysis Syndrome | 2021 |
Upregulated hypoxia inducible factor 1α signaling pathway in high risk myelodysplastic syndrome and acute myeloid leukemia patients is associated with better response to 5-azacytidine-data from the Hellenic myelodysplastic syndrome study group.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Disease Progression; Female; Humans; Hypoxia-Inducible Factor 1; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Risk Factors; Up-Regulation | 2021 |
Multiple keratoacanthomas in a patient with myelodysplastic syndrome.
Topics: Aclarubicin; Administration, Topical; Antineoplastic Agents; Azacitidine; Carcinoma; Female; Humans; Imiquimod; Keratoacanthoma; Middle Aged; Myelodysplastic Syndromes | 2021 |
Azacytidine induced localized Sweets syndrome in Myelodysplastic syndrome.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Humans; Myelodysplastic Syndromes; Sweet Syndrome | 2021 |
Monitoring treatment with 5-Azacitidine by flow cytometry predicts duration of hematological response in patients with myelodysplastic syndrome.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Blood Cells; Bone Marrow; Drug Monitoring; Female; Flow Cytometry; Humans; Immunophenotyping; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Treatment Outcome | 2021 |
Treatment patterns and outcomes in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Humans; Medicare; Myelodysplastic Syndromes; Treatment Outcome; United States | 2021 |
Autoimmune hemolytic anemia in a patient with myelodysplastic syndrome: Responding to 5-azacitidine therapy.
Topics: Aged; Anemia, Hemolytic, Autoimmune; Autoimmune Diseases; Azacitidine; Female; Humans; Myelodysplastic Syndromes; Pancytopenia | 2021 |
Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; DNA Methylation; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Risk Assessment; Spain | 2021 |
Evaluation of Reduced-Dose Decitabine and Azacitidine for Treating Myelodysplastic Syndromes: A Retrospective Study.
Topics: Aged; Azacitidine; China; Decitabine; Dose-Response Relationship, Drug; Drug Tapering; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Retrospective Studies; Treatment Outcome | 2021 |
The prognostic value of the Fibrinogen-Albumin Ratio Index in patients with myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes treated with azacitidine.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Female; Fibrinogen; Follow-Up Studies; Humans; Inflammation; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Proportional Hazards Models; Retrospective Studies; ROC Curve; Serum Albumin, Human | 2021 |
Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Risk Factors; Survival Analysis | 2021 |
Rare lobular capillary hemangioma associated with azacitidine in high-risk myelodysplastic syndrome patient.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Granuloma, Pyogenic; Humans; Myelodysplastic Syndromes | 2021 |
Pancytopenia, eosinophilia and coagulation disorders in a patient with T-acute lymphoblastic leukemia in prolonged remission.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Biomarkers, Tumor; Blood Cell Count; Bone Marrow; Cancer Survivors; Chromosome Deletion; Chromosome Disorders; Chromosomes, Human, Pair 7; Diagnosis, Differential; Eosinophilia; Hemorrhagic Disorders; Humans; Interferon-alpha; Leukemia, Myeloid, Acute; Male; Mastocytosis, Systemic; Myelodysplastic Syndromes; Neoplasms, Second Primary; Pancytopenia; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Staurosporine; Tryptases | 2021 |
[A monocentric study on the management of patients with myelodysplastic syndromes in Morocco].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Azacitidine; Blood Transfusion; Bone Marrow Transplantation; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Morocco; Myelodysplastic Syndromes; Retrospective Studies; Time Factors; Treatment Outcome | 2020 |
Relationship between Low Pretreatment Geriatric Nutritional Risk Index and Poor Tolerability of Azacitidine in Patients with Myelodysplastic Syndromes.
Topics: Aged; Aged, 80 and over; Azacitidine; Diet, Healthy; Drug Monitoring; Female; Geriatric Assessment; Humans; Male; Malnutrition; Myelodysplastic Syndromes; Nutrition Assessment; Nutritional Status; Retrospective Studies; Treatment Outcome | 2020 |
Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practice.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Hematopoietic Stem Cell Transplantation; Humans; Myelodysplastic Syndromes; North America; Treatment Outcome | 2021 |
Noncanonical immune response to the inhibition of DNA methylation by Staufen1 via stabilization of endogenous retrovirus RNAs.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cohort Studies; Cytoskeletal Proteins; Decitabine; DNA Methylation; Drug Resistance, Neoplasm; Endogenous Retroviruses; Female; Gene Expression Regulation, Leukemic; Gene Knockout Techniques; HCT116 Cells; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Progression-Free Survival; RNA Stability; RNA-Binding Proteins; RNA-Seq; RNA, Double-Stranded; RNA, Long Noncoding; RNA, Viral | 2021 |
Azacitidine for relapse of acute myeloid leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation, multicenter PALG analysis.
Topics: Adolescent; Adult; Aged; Azacitidine; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Time Factors; Transplantation, Homologous; Treatment Outcome; Young Adult | 2021 |
The path to approval for oral hypomethylating agents in acute myeloid leukemia and myelodysplastic syndromes.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Biological Availability; Clinical Trials, Phase III as Topic; Decitabine; DNA Methylation; Drug Approval; Drug Combinations; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Remission Induction; Uridine | 2021 |
Risk factors for invasive fungal infection in 5-azacytidine treated patients with acute myeloid leukemia and myelodysplastic syndrome.
Topics: Aged; Aged, 80 and over; Antifungal Agents; Azacitidine; Disease Susceptibility; Female; Humans; Incidence; Invasive Fungal Infections; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Neutropenia; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Risk Factors; Treatment Outcome | 2021 |
SPAG6-silencing enhances decitabine-induced apoptosis and demethylation of PTEN in SKM-1 cells and in a xenograft mouse model.
Topics: Animals; Apoptosis; Azacitidine; Decitabine; Demethylation; DNA Methylation; Gene Silencing; Heterografts; Mice; Microtubule Proteins; Myelodysplastic Syndromes; PTEN Phosphohydrolase | 2021 |
The development and clinical use of oral hypomethylating agents in acute myeloid leukemia and myelodysplastic syndromes: dawn of the total oral therapy era.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes | 2021 |
Case Report: Combination Therapy With PD-1 Blockade for Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation Resulted in Fatal GVHD.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Combined Modality Therapy; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphoma, Follicular; Male; Middle Aged; Myelodysplastic Syndromes; Transplantation, Homologous | 2021 |
Response to Hypomethylating Agents in Myelodysplastic Syndrome Is Associated With Emergence of Novel TCR Clonotypes.
Topics: Aged; Aged, 80 and over; Azacitidine; Clone Cells; Cohort Studies; Complementarity Determining Regions; Decitabine; DNA Methylation; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Polymerase Chain Reaction; Receptors, Antigen, T-Cell, alpha-beta; Sequence Analysis, DNA; T-Lymphocytes; Treatment Outcome | 2021 |
[Successful Endoscopic Submucosal Dissection of Early Gastric Cancer in a Patient after Azacitidine Therapy for the Treatment of Myelodysplastic Syndrome].
Topics: Aged; Azacitidine; Endoscopic Mucosal Resection; Gastric Mucosa; Humans; Male; Myelodysplastic Syndromes; Retrospective Studies; Stomach Neoplasms | 2021 |
What is the optimal time to initiate hypomethylating agents (HMAs) in higher risk myelodysplastic syndromes (MDSs)?
Topics: Antimetabolites, Antineoplastic; Azacitidine; Humans; Myelodysplastic Syndromes; Remission Induction | 2021 |
Long-term Cryopreserved Autologous Hematopoietic Stem Cells Following Azacytidine to Successfully Treat Severe Invasive Pulmonary Aspergillosis After Therapy-Related Myelodysplastic Syndrome and CD8
Topics: Azacitidine; CD8-Positive T-Lymphocytes; Cryopreservation; Female; Humans; Invasive Pulmonary Aspergillosis; Middle Aged; Myelodysplastic Syndromes | 2021 |
In vitro assessment of the sensitivity to APR-246 + azacitidine combination predicts response to this combination in myelodysplastic/acute myeloid leukaemia patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Quinuclidines; Treatment Outcome; Tumor Cells, Cultured | 2021 |
Durable Remission of Chemotherapy-Refractory Myeloid Sarcoma by Azacitidine.
Topics: Aged, 80 and over; Azacitidine; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Sarcoma, Myeloid | 2021 |
British Society for Haematology guidelines for the management of adult myelodysplastic syndromes.
Topics: Adult; Anemia; Antineoplastic Agents; Azacitidine; Blood Transfusion; Decitabine; Disease Management; Hematinics; Hematopoietic Stem Cell Transplantation; Hemorrhage; Humans; Iron Chelating Agents; Myelodysplastic Syndromes; Neutropenia; Thrombocytopenia | 2021 |
Oral Azacitidine in Patients With Myelodysplastic Syndrome.
Topics: Antimetabolites; Azacitidine; Humans; Myelodysplastic Syndromes | 2021 |
Prophylactic or Preemptive Low-Dose Azacitidine and Donor Lymphocyte Infusion to Prevent Disease Relapse following Allogeneic Transplantation in Patients with High-Risk Acute Myelogenous Leukemia or Myelodysplastic Syndrome.
Topics: Azacitidine; Clinical Trials, Phase II as Topic; Humans; Leukemia, Myeloid, Acute; Lymphocyte Transfusion; Lymphocytes; Myelodysplastic Syndromes; Recurrence; Retrospective Studies; Transplantation, Homologous | 2021 |
Low serum albumin level deteriorates prognosis in azacitidine-treated myelodysplastic syndromes patients - results of the PALG study 'PolAZA'.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Retrospective Studies; Serum Albumin, Human; Treatment Outcome | 2021 |
Are myelodysplastic syndromes ready for venetoclax? Exploring future potential and considerations.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Sulfonamides | 2021 |
Coombs' test positive autoimmune hemolytic anemia accompanied by myelodysplastic syndrome that became Coombs' test negative after azacitidine administration.
Topics: Anemia, Hemolytic; Anemia, Hemolytic, Autoimmune; Azacitidine; Coombs Test; Humans; Myelodysplastic Syndromes | 2022 |
TET2 Mutation and High miR-22 Expression as Biomarkers to Predict Clinical Outcome in Myelodysplastic Syndrome Patients Treated with Hypomethylating Therapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers; Decitabine; Dioxygenases; DNA Methylation; DNA-Binding Proteins; Female; Humans; Male; MicroRNAs; Middle Aged; Mutation; Myelodysplastic Syndromes; Proto-Oncogene Proteins; Survival Rate; Treatment Outcome; Young Adult | 2021 |
Azacitidine therapy for low-risk myelodysplastic syndrome developing after solid organ transplantation.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Organ Transplantation; Risk; Treatment Outcome | 2017 |
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
Topics: Aged; Aged, 80 and over; Anemia; Antilymphocyte Serum; Antineoplastic Agents; Arsenic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Cyclosporine; Cytarabine; Decitabine; Disease Progression; Enzyme Inhibitors; Erythrocyte Transfusion; Female; Hematinics; Humans; Hydroxyurea; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Retreatment; Retrospective Studies; Risk Factors; Survival Rate; Thalidomide; Treatment Failure; Tretinoin; Valproic Acid | 2017 |
Low-dose 5-azacytidine as preventive therapy for relapse of AML and MDS following allogeneic HCT.
Topics: Adolescent; Adult; Aged; Allografts; Azacitidine; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence | 2017 |
Azacitidine-induced acute lung injury in a patient with therapy-related myelodysplastic syndrome.
Topics: Acute Lung Injury; Adrenal Cortex Hormones; Aged; Antimetabolites, Antineoplastic; Azacitidine; Humans; Lymphoma, Follicular; Male; Myelodysplastic Syndromes; Prednisolone; Tomography, X-Ray Computed | 2017 |
Comprehensive mapping of the effects of azacitidine on DNA methylation, repressive/permissive histone marks and gene expression in primary cells from patients with MDS and MDS-related disease.
Topics: Antigens, CD34; Antineoplastic Agents; Azacitidine; Bone Marrow Cells; Cells, Cultured; Chromatin Immunoprecipitation; Computational Biology; DNA Methylation; Endogenous Retroviruses; Epigenesis, Genetic; Gene Expression Regulation; Histones; Humans; Myelodysplastic Syndromes; Sequence Analysis, RNA; Transcriptome; Treatment Outcome | 2017 |
Epigenetic dysregulation of ID4 predicts disease progression and treatment outcome in myeloid malignancies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Azacitidine; Case-Control Studies; Cell Proliferation; Decitabine; Disease Progression; DNA Methylation; Epigenesis, Genetic; Female; HL-60 Cells; Humans; Inhibitor of Differentiation Proteins; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Remission Induction; Signal Transduction; Survival Analysis | 2017 |
A retrospective study evaluating the impact of infectious complications during azacitidine treatment.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Antimetabolites, Antineoplastic; Azacitidine; Bacterial Infections; Female; Humans; Kaplan-Meier Estimate; Length of Stay; Male; Middle Aged; Myelodysplastic Syndromes; Outcome Assessment, Health Care; Retrospective Studies; Risk Factors | 2017 |
Current diagnosis and treatment for myelodysplastc syndromes.
Topics: Azacitidine; Drug Discovery; Humans; Mutation; Myelodysplastic Syndromes; Prognosis; Risk Factors | 2017 |
Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Female; Humans; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Myelodysplastic-Myeloproliferative Diseases; Survival Analysis; Treatment Outcome | 2017 |
Successful Treatment of Behçet's Disease Associated with Acute Myeloid Leukemia with Myelodysplasia-related Changes Using Azacitidine and Tacrolimus before Allogeneic Hematopoietic Stem Cell Transplantation.
Topics: Adult; Antimetabolites, Antineoplastic; Asian People; Azacitidine; Behcet Syndrome; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Remission Induction; Tacrolimus; Transplantation, Homologous; Treatment Outcome | 2017 |
BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers; Bone Marrow Cells; Female; Gene Expression; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Staging; Prognosis; Proto-Oncogene Proteins c-bcl-2; Treatment Outcome | 2017 |
Red blood cell alloimmunization in 184 patients with myeloid neoplasms treated with azacitidine - A retrospective single center experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Erythrocyte Transfusion; Erythrocytes; Female; Humans; Isoantibodies; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Survival Rate; Transfusion Reaction | 2017 |
Improving Outcomes in High-Risk Myelodysplasia: Festina Lente.
Topics: Azacitidine; Humans; Lenalidomide; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; United States; Vorinostat | 2017 |
Epigenetic Combination Therapy for Children With Secondary Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML) and Concurrent Solid Tumor Relapse.
Topics: Adolescent; Antineoplastic Agents; Azacitidine; Decitabine; Drug Therapy, Combination; Epigenesis, Genetic; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neoplasms, Second Primary; Palliative Care; Quality of Life; Vorinostat | 2017 |
Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Disease Progression; DNA Methylation; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Recurrence; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2017 |
Feasibility and cost-effectiveness of at home azacitidine administration.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cost-Benefit Analysis; Feasibility Studies; Health Care Costs; Home Care Services, Hospital-Based; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Retrospective Studies; Spain; Treatment Outcome | 2017 |
EBV-positive Diffuse Large B-cell Lymphoma as a Secondary Malignancy Arising in a Myelodysplastic Syndrome Patient who Was Treated with Azacitidine.
Topics: Azacitidine; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary | 2017 |
JSH Guideline for Tumors of Hematopoietic and Lymphoid Tissues: Leukemia: 6. Myelodysplastic syndromes (MDS).
Topics: Algorithms; Allografts; Azacitidine; Blood Transfusion; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Japan; Lenalidomide; Myelodysplastic Syndromes; Practice Guidelines as Topic; Prognosis; Risk; Thalidomide | 2017 |
Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic Syndromes.
Topics: Aged; Aged, 80 and over; Azacitidine; Drug Resistance; Female; Genomics; Humans; Integrin alpha Chains; Middle Aged; Myelodysplastic Syndromes | 2017 |
Clinical evaluation of combined azacitidine and entinostat on the induction of fetal hemoglobin in patients with acute myeloid leukemias and myelodysplastic syndromes.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzamides; Clinical Trials, Phase I as Topic; Female; Fetal Hemoglobin; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Prognosis; Pyridines | 2018 |
First-line Therapeutic Strategies for Myelodysplastic Syndromes.
Topics: Algorithms; Azacitidine; Decitabine; Enzyme Inhibitors; Erythrocyte Transfusion; Erythropoietin; Hematopoietic Stem Cell Transplantation; Humans; Myelodysplastic Syndromes; Risk Factors; Transplantation, Homologous | 2017 |
[The clinical safety and efficacy of low dose subcutaneous decitabine in treating acute myeloid leukemia and intermediate- or higer-risk myelodysplastic syndromes in the elderly patients].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Patients; Remission Induction; Retrospective Studies; Treatment Outcome | 2017 |
Early treatment initiation in lower-risk myelodysplastic syndromes produces an earlier and higher rate of transfusion independence.
Topics: Aged; Aged, 80 and over; Azacitidine; Blood Transfusion; Decitabine; Female; Hematinics; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Secondary Prevention; Thalidomide; Time Factors | 2017 |
Benefits of hypomethylating therapy in IPSS lower-risk myelodysplastic syndrome patients: A retrospective multicenter case series study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Retrospective Studies; Risk Assessment; Survival Rate; Young Adult | 2017 |
Acquired erythropoietic uroporphyria secondary to myelodysplastic syndrome with chromosome 3 alterations: a case report.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Blood Transfusion; Bone Marrow; Bone Marrow Transplantation; Chromosome Inversion; Chromosomes, Human, Pair 3; Humans; Late Onset Disorders; Male; Myelodysplastic Syndromes; Porphyria, Erythropoietic; Porphyrins; Skin; Treatment Outcome | 2018 |
High-grade B-cell lymphoma of the peritoneum as a result of transformation of a CD5-negative monoclonal B lymphocytosis population in a patient with myelodysplastic syndrome treated with 5-azacytidine.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; CD5 Antigens; Humans; Lymphocytosis; Lymphoma, B-Cell; Male; Myelodysplastic Syndromes; Peritoneum; Prognosis | 2018 |
Image Gallery: Pyoderma gangrenosum in a patient with myelodysplastic syndrome treated with azacitidine.
Topics: Aged; Azacitidine; Dermatologic Agents; Humans; Male; Myelodysplastic Syndromes; Pyoderma Gangrenosum; Treatment Outcome | 2017 |
Hypomethylating agents in myelodysplastic syndromes and population-level outcomes: a changing landscape or a small dent?
Topics: Antimetabolites, Antineoplastic; Azacitidine; DNA Methylation; Humans; Myelodysplastic Syndromes | 2018 |
"Hof" in pronormoblasts: pure erythroid leukemia mimicking plasma cell myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cyclophosphamide; Cytoplasm; Dexamethasone; Diagnostic Errors; Erythroblasts; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Erythroblastic, Acute; Male; Multiple Myeloma; Myelodysplastic Syndromes; Thalidomide | 2017 |
Bone-targeting nanoparticle to co-deliver decitabine and arsenic trioxide for effective therapy of myelodysplastic syndrome with low systemic toxicity.
Topics: Alendronate; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Azacitidine; Bone and Bones; Bone Marrow Cells; Cell Survival; Cells, Cultured; Decitabine; Mice, Transgenic; Myelodysplastic Syndromes; Nanoparticles; Oxides; Phosphatidylethanolamines; Polyethylene Glycols; Tissue Distribution | 2017 |
Successful treatment of donor cell derived myelodysplastic syndrome with 5-azacytidine.
Topics: Adult; Antimetabolites, Antineoplastic; Azacitidine; Hematopoietic Stem Cell Transplantation; Humans; Male; Myelodysplastic Syndromes; Tissue Donors; Treatment Outcome | 2017 |
Azacitidine-induced Sweet syndrome: Two unusual clinical presentations.
Topics: Abdominal Wall; Antimetabolites, Antineoplastic; Azacitidine; Biopsy, Needle; Female; Follow-Up Studies; Humans; Immunohistochemistry; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prednisolone; Risk Assessment; Sampling Studies; Severity of Illness Index; Sweet Syndrome; Treatment Outcome | 2018 |
Late-onset Erythropoietic Protoporphyria Associated with Myelodysplastic Syndrome Treated with Azacitidine.
Topics: Aged; Azacitidine; Disease Progression; Enzyme Inhibitors; Humans; Male; Myelodysplastic Syndromes; Protoporphyria, Erythropoietic; Skin; Treatment Outcome | 2018 |
Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Drug Administration Schedule; Female; Fever; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Incidence; Leukemia, Myeloid, Acute; Male; Middle Aged; Missouri; Mycoses; Myelodysplastic Syndromes; Neutropenia; Opportunistic Infections; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Virus Diseases | 2017 |
[Clinical Observation of Therapeutic Regimen Consisted of Decitabine Combined with Low-Dose IA Regimen for Myelodysplastic Syndrome-EB].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Quality of Life; Retrospective Studies; Treatment Outcome | 2017 |
[Clinical Efficacy of Low-dose Decitabine Combined with CAG Regimen in Patients with Myelodysplastic Syndrome-refractory Anemia with Excess Blasts(MDS-RAEB)].
Topics: Aclarubicin; Anemia, Refractory, with Excess of Blasts; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Myelodysplastic Syndromes; Retrospective Studies; Treatment Outcome | 2017 |
Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Aberrations; Female; Follow-Up Studies; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Remission Induction; Risk Factors; Survival Rate | 2017 |
Decitabine-Induced Changes in Human Myelodysplastic Syndrome Cell Line SKM-1 Are Mediated by FOXO3A Activation.
Topics: Antimetabolites, Antineoplastic; Autophagy; Azacitidine; Cell Cycle Checkpoints; Cell Differentiation; Cell Line, Tumor; Decitabine; Epigenetic Repression; Forkhead Box Protein O3; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Monocytes; Myelodysplastic Syndromes; Phosphorylation | 2017 |
Sclerosing mesenteritis as a presentation of myelodysplastic syndrome (MDS) with improvement following treatment targeted at MDS.
Topics: Azacitidine; Bone Marrow; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Erythrocyte Transfusion; Female; Humans; Hyperplasia; Middle Aged; Myelodysplastic Syndromes; Panniculitis, Peritoneal; Tomography, X-Ray Computed | 2018 |
Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphocyte Transfusion; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Transplantation, Homologous; Treatment Outcome | 2018 |
MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; Genetic Association Studies; Genotype; Humans; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Myelodysplastic Syndromes; Palliative Care; Polymorphism, Single Nucleotide; Thymidylate Synthase; X-ray Repair Cross Complementing Protein 1 | 2018 |
5-Azacytidine engages an IRE1α-EGFR-ERK1/2 signaling pathway that stabilizes the LDL receptor mRNA.
Topics: 3' Untranslated Regions; AU Rich Elements; Azacitidine; Cell Line, Tumor; Cholesterol, LDL; Endoribonucleases; ErbB Receptors; Gene Expression Regulation; Hepatocytes; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Signaling System; Myelodysplastic Syndromes; Protein Serine-Threonine Kinases; Receptors, LDL; RNA Stability; RNA, Messenger | 2018 |
No benefit of hypomethylating agents compared to supportive care for higher risk myelodysplastic syndrome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; Databases, Factual; Decitabine; Disease Progression; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Palliative Care; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Transplantation, Homologous; Treatment Outcome; Young Adult | 2018 |
AZA-MS: a novel multiparameter mass spectrometry method to determine the intracellular dynamics of azacitidine therapy in vivo.
Topics: Azacitidine; Bone Marrow; Cell Line, Tumor; Cytoplasm; DNA Methylation; Drug Resistance, Neoplasm; Humans; Mass Spectrometry; Myelodysplastic Syndromes; RNA | 2018 |
Induction of Complete Remission by Azacitidine in a Patient with Myelodysplastic Syndrome-Associated Inflammatory Bowel Disease.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Cytokines; Down-Regulation; Humans; Inflammatory Bowel Diseases; Male; Myelodysplastic Syndromes; Remission Induction | 2018 |
Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; DNA Methylation; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Survivors | 2018 |
[Curative Effect of Decitabine Combined with IAG Regimen for Senile Patients with Myelodysplastic Syndrome (MDS) Transformed Acute Myeloid Leukemia].
Topics: Alzheimer Disease; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Treatment Outcome | 2017 |
Immunotherapy of Myelodysplastic Syndrome: You Can Run, but You Can't Hide.
Topics: Antigens, Neoplasm; Azacitidine; Cell Line, Tumor; Decitabine; Humans; Immunotherapy; Male; Membrane Proteins; Myelodysplastic Syndromes; T-Lymphocytes; Vaccination | 2018 |
WT1 mRNA level reflects disease changes and progression of myelodysplastic syndromes patients with 'stable disease'.
Topics: Adult; Aged; Azacitidine; Decitabine; Disease Progression; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; RNA, Messenger; WT1 Proteins | 2019 |
Establishment and validation of a novel risk model for estimating time to first treatment in 120 patients with chronic myelomonocytic leukaemia.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Female; Humans; Hydroxyurea; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Retrospective Studies; Time Factors | 2018 |
Association of red cell distribution width with clinical outcomes in myelodysplastic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Erythroblasts; Erythrocyte Indices; Erythropoiesis; Erythropoietin; Female; Hematopoietic Stem Cell Transplantation; Hemoglobins; Humans; Immunosuppressive Agents; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Retrospective Studies; Survival Analysis; Young Adult | 2018 |
Subclones dominate at MDS progression following allogeneic hematopoietic cell transplant.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow Cells; Clonal Evolution; Clone Cells; Disease Progression; DNA Mutational Analysis; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Mutation; Myeloablative Agonists; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2018 |
Granulomonocytic progenitors are key target cells of azacytidine in higher risk myelodysplastic syndromes and acute myeloid leukemia.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Gene Expression Regulation, Neoplastic; Granulocytes; Hematopoietic Stem Cells; High-Throughput Nucleotide Sequencing; Humans; Leukemia, Myeloid, Acute; Multipotent Stem Cells; Myelodysplastic Syndromes; Pilot Projects; Prognosis; Prospective Studies | 2018 |
Maintenance azacitidine after myeloablative allogeneic hematopoietic cell transplantation for myeloid malignancies.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Case-Control Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Retrospective Studies; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Young Adult | 2018 |
MicroRNA profiles as predictive markers of response to azacitidine therapy in myelodysplastic syndromes and acute myeloid leukemia.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Female; Humans; Leukemia, Myeloid, Acute; Male; MicroRNAs; Myelodysplastic Syndromes | 2018 |
Azacitidine effectively reduces
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Cord Blood Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Mutation; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Prognosis; Salvage Therapy; Tumor Suppressor Protein p53 | 2018 |
The prognostic value of monosomal karyotype (MK) in higher-risk patients with myelodysplastic syndromes treated with 5-Azacitidine: A retrospective analysis of the Hellenic (Greek) Myelodysplastic syndromes Study Group.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Cell Transformation, Neoplastic; Female; Greece; Humans; Karyotype; Leukemia, Myeloid, Acute; Male; Middle Aged; Monosomy; Myelodysplastic Syndromes; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome | 2018 |
Moleculary Confirmed, Cytogenetic Remission in a Case with Myelodysplastic Syndrome Treated with Azacitidne.
Topics: Anemia, Refractory, with Excess of Blasts; Azacitidine; Bone Marrow Examination; Chromosomes, Human, Y; Cytogenetic Analysis; DNA Modification Methylases; Drug Administration Schedule; Enzyme Inhibitors; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Predictive Value of Tests; Remission Induction; Treatment Outcome | 2017 |
Successful treatment of high-risk myelodysplastic syndrome with decitabine-based chemotherapy followed by haploidentical lymphocyte infusion: A case report and literature review.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Female; HLA Antigens; Humans; Lymphocyte Transfusion; Myelodysplastic Syndromes; Treatment Outcome | 2018 |
A case report of a very late response to 5-azacytidine in a patient with lower risk myelodysplastic syndrome: Time to update treatment guidelines for lower risk patients.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Humans; Male; Myelodysplastic Syndromes; Practice Guidelines as Topic; Risk Factors; Time Factors | 2018 |
Topics: Azacitidine; Biopsy; Diagnosis, Differential; Female; Fusariosis; Fusarium; Humans; Immunocompromised Host; Leukemia, Myeloid, Acute; Middle Aged; Mycelium; Myelodysplastic Syndromes; Sarcoma, Myeloid; Sequence Analysis, DNA; Skin | 2018 |
Partial restoration of CD20 protein expression and rituximab sensitivity after treatment with azacitidine in CD20-negative transformed diffuse large B cell lymphoma after using rituximab.
Topics: Antigens, CD20; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bendamustine Hydrochloride; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Fatal Outcome; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Molecular Targeted Therapy; Myelodysplastic Syndromes; Neoplasms, Second Primary; Prednisone; Rituximab; Vincristine | 2018 |
Azacitidine in the 'real-world': an evaluation of 1101 higher-risk myelodysplastic syndrome/low blast count acute myeloid leukaemia patients in Ontario, Canada.
Topics: Aged; Aged, 80 and over; Azacitidine; Disease-Free Survival; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Ontario; Risk Factors; Survival Rate | 2018 |
Successful Treatment of Hemophagocytic Lymphohistiocytosis Associated with Low-risk Myelodysplastic Syndrome by Azacitidine.
Topics: Aged; Antimetabolites, Antineoplastic; Asian People; Azacitidine; Hematologic Neoplasms; Humans; Lymphohistiocytosis, Hemophagocytic; Lymphoma; Male; Myelodysplastic Syndromes; Treatment Outcome | 2018 |
Prognostic impact of elevated pretreatment serum ferritin in patients with high-risk MDS treated with azacitidine.
Topics: Aged; Aged, 80 and over; Azacitidine; Enzyme Inhibitors; Female; Ferritins; Humans; Male; Myelodysplastic Syndromes; Prognosis; Risk Factors; Treatment Outcome | 2018 |
Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Clinical Trials as Topic; Counseling; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Treatment Outcome | 2018 |
The effect of azacitidine therapy on the M protein of MDS patients with concomitant MGUS.
Topics: Azacitidine; Bone Marrow Examination; Disease Progression; Female; Humans; Interleukin-6; Japan; Male; Monoclonal Gammopathy of Undetermined Significance; Myelodysplastic Syndromes; Myeloma Proteins; Retrospective Studies; Tumor Suppressor Protein p53 | 2018 |
Azacitidine-associated pleuropericardial effusion in myelodysplastic syndrome: A case report.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Humans; Male; Myelodysplastic Syndromes; Pericardial Effusion; Pleural Effusion | 2019 |
Acute liver failure due to liver parenchymal infiltration with acute myelogenous leukaemia in a patient with myelodysplastic syndrome.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Fatal Outcome; Female; Humans; Leukemia, Myeloid, Acute; Liver; Liver Failure, Acute; Myelodysplastic Syndromes | 2018 |
Glycemic dysregulation in a patient with type 2 diabetes treated with 5-azacitidine: a case report.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Diabetes Mellitus, Type 2; Epigenesis, Genetic; Glucose; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes | 2018 |
Body mass index and relative dose intensity does not affect the response and outcome of high-risk MDS patients treated with azacytidine. Results from the Hellenic (Greek) MDS study group.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Body Mass Index; Dose-Response Relationship, Drug; Female; Greece; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Treatment Outcome | 2018 |
Selection of patients with myelodysplastic syndromes from a large electronic medical records database and a study of the use of disease-modifying therapy in the United States.
Topics: Aged; Aged, 80 and over; Anemia; Azacitidine; Databases, Factual; Decitabine; Electronic Health Records; Enzyme Inhibitors; Female; Hematinics; Humans; Immunologic Factors; Iron Chelating Agents; Lenalidomide; Male; Middle Aged; Multivariate Analysis; Myelodysplastic Syndromes; Proportional Hazards Models; Recurrence; Retrospective Studies; Thalidomide; Treatment Outcome; United States | 2018 |
Impact of performance status and transfusion dependency on outcome of patients with myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia treated with azacitidine (PIAZA study).
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Blood Transfusion; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome | 2018 |
The outcome of patients with high-risk MDS achieving stable disease after treatment with 5-azacytidine: A retrospective analysis of the Hellenic (Greek) MDS Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Retrospective Studies; Risk Factors; Survival Rate; Treatment Outcome | 2018 |
[Azacitidine for Therapy-Related Myelodysplastic Syndrome Following Oxaliplatin (L-OHP)Therapy for Metastatic Rectal Cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Combined Modality Therapy; Fatal Outcome; Humans; Leucovorin; Male; Myelodysplastic Syndromes; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms | 2018 |
Azacitidine for Relapse After Allogeneic Stem Cell Transplantation-Single-Center Study.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow Neoplasms; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasm Recurrence, Local; Neoplasm, Residual; Primary Myelofibrosis; Retrospective Studies; Transplantation, Homologous; Young Adult | 2018 |
Somatic mutations as markers of outcome after azacitidine and allogeneic stem cell transplantation in higher-risk myelodysplastic syndromes.
Topics: Adult; Aged; Azacitidine; Biomarkers, Tumor; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Young Adult | 2019 |
Relative survival following response to 7 + 3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Cytarabine; Female; Follow-Up Studies; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Risk Factors; Survival Rate; Treatment Outcome; Young Adult | 2019 |
Pre-emptive azacitidine for relapse prevention in acute myeloid leukaemia.
Topics: Azacitidine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Secondary Prevention | 2018 |
Up-regulation of SPINT2/HAI-2 by Azacytidine in bone marrow mesenchymal stromal cells affects leukemic stem cell survival and adhesion.
Topics: Azacitidine; Cell Adhesion; Cell Line, Tumor; Cell Survival; Female; Humans; Integrin alpha2; Leukemia, Myeloid, Acute; Male; Membrane Glycoproteins; Mesenchymal Stem Cells; Middle Aged; Myelodysplastic Syndromes; Neoplastic Stem Cells; Tumor Microenvironment | 2019 |
Direct modulation of the bone marrow mesenchymal stromal cell compartment by azacitidine enhances healthy hematopoiesis.
Topics: Adipogenesis; Adult; Aged; Aged, 80 and over; Azacitidine; Bone Marrow Cells; Cell Differentiation; Cell Survival; Female; Gene Regulatory Networks; Hematopoiesis; Humans; Immunophenotyping; Male; Mesenchymal Stem Cells; Middle Aged; Myelodysplastic Syndromes; Osteogenesis; Transforming Growth Factor beta1; Young Adult | 2018 |
Bone marrow MSCs in MDS: contribution towards dysfunctional hematopoiesis and potential targets for disease response to hypomethylating therapy.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Biomarkers, Tumor; Case-Control Studies; Cell Proliferation; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Hematopoiesis; High-Throughput Nucleotide Sequencing; Humans; Male; Mesenchymal Stem Cells; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Myelodysplastic Syndromes; Prognosis; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Droplet digital PCR for the quantification of Alu methylation status in hematological malignancies.
Topics: Adult; Aged; Aged, 80 and over; Alu Elements; Azacitidine; Biomarkers, Tumor; Cell Line, Tumor; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Feasibility Studies; Female; Genetic Predisposition to Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Phenotype; Polymerase Chain Reaction; Predictive Value of Tests; Reproducibility of Results; Retrospective Studies | 2018 |
Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Safety; Survival Rate; Treatment Outcome | 2019 |
The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes treated with azacitidine.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Female; Granulocyte Precursor Cells; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Treatment Outcome | 2019 |
Using PU.1 and Jun dimerization protein 2 transcription factor expression in myelodysplastic syndromes to predict treatment response and leukaemia transformation.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Biomarkers; Biomarkers, Tumor; Bone Marrow; Cell Transformation, Neoplastic; Disease Progression; DNA Methylation; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis; Proto-Oncogene Proteins; Repressor Proteins; Trans-Activators; Up-Regulation | 2019 |
Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes.
Topics: Aged; Aged, 80 and over; Azacitidine; Cell Differentiation; Cell Proliferation; Disease-Free Survival; Female; Humans; Inositol; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Mutation; Myelodysplastic Syndromes | 2019 |
Bone marrow PARP1 mRNA levels predict response to treatment with 5-azacytidine in patients with myelodysplastic syndrome.
Topics: Aged; Aged, 80 and over; Antimetabolites; Azacitidine; Biomarkers; Bone Marrow; DNA Damage; DNA Methylation; DNA Repair; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myelodysplastic Syndromes; Poly (ADP-Ribose) Polymerase-1; Prognosis; Promoter Regions, Genetic; Proportional Hazards Models; RNA, Messenger; Up-Regulation | 2019 |
The prognostic significance of chromosome 17 abnormalities in patients with myelodysplastic syndrome treated with 5-azacytidine: Results from the Hellenic 5-azacytidine registry.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Chromosomes, Human, Pair 17; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis | 2019 |
Effective oral hypomethylating drugs in intermediate-risk or high-risk myelodysplasia: a breakthrough?
Topics: Administration, Oral; Azacitidine; Decitabine; DNA Methylation; Humans; Myelodysplastic Syndromes; Risk | 2019 |
10-day vs 5-day decitabine: equivalence cannot be concluded - Authors' reply.
Topics: Azacitidine; Decitabine; Humans; Myelodysplastic Syndromes | 2019 |
Natural killer cell cytotoxicity is a predictor of outcome for patients with high risk myelodysplastic syndrome and oligoblastic acute myeloid leukemia treated with azacytidine.
Topics: Aged; Aged, 80 and over; Azacitidine; Biomarkers; Cell Line, Tumor; Cytotoxicity, Immunologic; Female; Humans; Killer Cells, Natural; Leukemia, Myeloid, Acute; Lymphocyte Subsets; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; ROC Curve | 2019 |
Impact of the relative dose intensity on survival of patients with high-risk myelodysplastic syndromes treated with Azacitidine.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Survival Analysis; Treatment Outcome | 2019 |
[Effects of Low-Dose Decitabine on Soluble CD44, GDF11 Levels and Hematopoietic Function in Elderly Patients with MDS].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Morphogenetic Proteins; Decitabine; Growth Differentiation Factors; Hematopoietic Stem Cell Transplantation; Humans; Hyaluronan Receptors; Myelodysplastic Syndromes; Treatment Outcome | 2019 |
Low-dose azacitidine for relapse prevention after allogeneic hematopoietic cell transplantation in children with myeloid malignancies.
Topics: Adolescent; Antimetabolites, Antineoplastic; Azacitidine; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prognosis; Remission Induction; Retrospective Studies; Secondary Prevention; Tacrolimus; Transplantation, Homologous; Treatment Outcome; Young Adult | 2019 |
Comprehensive geriatric assessment predicts azacitidine treatment duration and survival in older patients with myelodysplastic syndromes.
Topics: Aged; Azacitidine; Duration of Therapy; Geriatric Assessment; Humans; Myelodysplastic Syndromes; Prospective Studies | 2020 |
Managing post allograft relapse of myeloid neoplasms: azacitidine and donor lymphocyte infusions as salvage therapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Disease Management; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphocyte Transfusion; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prognosis; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate; Transplantation, Homologous | 2019 |
Guadecitabine in myelodysplastic syndromes: promising but there is still progress to be made.
Topics: Azacitidine; Humans; Myelodysplastic Syndromes | 2019 |
Favorable Outcomes With Tumor Burden Reduction Following Administration of Hypomethylating Agents Before Allogeneic Hematopoietic Cell Transplantation in Patients With Higher Risk Myelodysplastic Syndrome.
Topics: Adolescent; Adult; Antineoplastic Agents; Azacitidine; Bone Marrow; DNA Methylation; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Transplantation, Homologous; Treatment Outcome; Young Adult | 2019 |
Natural killer cell activity and survival after azacitidine treatment in high-risk MDS.
Topics: Azacitidine; Hematologic Tests; Humans; Killer Cells, Natural; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2019 |
Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Opportunistic Infections; Prognosis; Retrospective Studies; Risk Factors; Survival Analysis; Treatment Outcome | 2019 |
RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Erythrocyte Transfusion; Female; Humans; Kaplan-Meier Estimate; Male; Medicare; Myelodysplastic Syndromes; Retrospective Studies; SEER Program; Severity of Illness Index; Treatment Outcome; United States | 2019 |
Multifaceted modes of action of azacytidine: a riddle wrapped up in an enigma.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Biopsy; Bone Marrow; Disease Progression; DNA Methylation; DNA Mutational Analysis; Drug Resistance, Neoplasm; Epigenesis, Genetic; Fatal Outcome; Gene Expression Regulation, Neoplastic; Humans; Karyotyping; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Treatment Outcome | 2019 |
Angioimmunoblastic T-cell lymphoma and myelodysplastic syndrome with mutations in
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow; Cyclophosphamide; Dioxygenases; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; DNA-Binding Proteins; Doxorubicin; Drug Resistance, Neoplasm; Female; Homeodomain Proteins; Humans; Immunoblastic Lymphadenopathy; Lymph Nodes; Lymphoma, T-Cell; Mutation; Myelodysplastic Syndromes; Prednisone; Proto-Oncogene Proteins; Repressor Proteins; Transcription Factors; Treatment Outcome; Vincristine | 2019 |
Bone marrow WT1 levels in patients with myeloid neoplasms treated with 5-azacytidine: Identification of responding patients.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow Cells; Combined Modality Therapy; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Transplantation, Homologous; Treatment Outcome; WT1 Proteins | 2019 |
One plus one does not always equal two, especially with regard to hypomethylating agents: the question of synergy of azacitidine and lenalidomide for treatment of relapsed acute myeloid leukemia and myelodysplastic syndromes post allogeneic hematopoietic
Topics: Antigens, CD; Azacitidine; CD8-Positive T-Lymphocytes; Clinical Trials as Topic; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Lymphocyte Activation Gene 3 Protein; Male; Middle Aged; Myelodysplastic Syndromes; Programmed Cell Death 1 Receptor; Recurrence; Transplantation, Homologous | 2019 |
A novel non-invasive monitoring assay of 5-azacitidine efficacy using global DNA methylation of peripheral blood in myelodysplastic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; DNA Methylation; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Spectrometry, Fluorescence; Young Adult | 2019 |
Effectiveness of 5-Azacytidine in older patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia: A retrospective analysis of the Hellenic (Greek) MDS Study Group.
Topics: Aged; Azacitidine; Greece; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Retrospective Studies | 2020 |
The wolf of hypomethylating agent failure: what comes next?
Topics: Animals; Azacitidine; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Vorinostat; Wolves | 2019 |
Transcription factors implicated in late megakaryopoiesis as markers of outcome after azacitidine and allogeneic stem cell transplantation in myelodysplastic syndrome.
Topics: Adult; Aged; Azacitidine; Cell Differentiation; Combined Modality Therapy; Female; GATA1 Transcription Factor; GATA2 Transcription Factor; Gene Expression; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Thrombopoiesis; Transcription Factors; Transplantation, Homologous; Treatment Outcome | 2019 |
Comparison of 7-day azacitidine and 5-day decitabine for treating myelodysplastic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Blood Transfusion; Combined Modality Therapy; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Drug Evaluation; Enzyme Inhibitors; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2013 |
Myelodysplasia: new approaches.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Decitabine; Disease Progression; Female; Granulocyte Colony-Stimulating Factor; Humans; Immunologic Factors; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Stem Cell Transplantation | 2013 |
A case of late onset erythropoietic protoporphyria associated with myelodysplastic syndrome treated by the combination of beta carotene and azacitidine.
Topics: Aged; Azacitidine; Benzoates; beta Carotene; Deferasirox; Humans; Male; Myelodysplastic Syndromes; Protoporphyria, Erythropoietic; Triazoles | 2013 |
[Clinical observation of decitabine-treating patients with myelodysplastic syndrome and acute myeloid leukemia].
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Decitabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2013 |
[Molecular target therapy for myelodysplastic syndrome].
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cytokines; Decitabine; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Humans; Lenalidomide; Molecular Targeted Therapy; Myelodysplastic Syndromes; Thalidomide; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2012 |
Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphocyte Count; Myelodysplastic Syndromes; Recurrence; Salvage Therapy; T-Lymphocytes, Regulatory; Transplantation, Homologous | 2013 |
Successful treatment by azacitidine therapy of intestinal Behçet's disease associated with myelodysplastic syndrome.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Behcet Syndrome; Bone Marrow; Colonoscopy; Humans; Intestinal Diseases; Intestines; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome | 2013 |
Transient and fully reversible leukocytosis in a myelodysplastic syndrome patient upon initiation of azacitidine treatment.
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Humans; Leukocytosis; Male; Myelodysplastic Syndromes; Treatment Outcome | 2013 |
Epigenetic control of NF-κB-dependent FAS gene transcription during progression of myelodysplastic syndromes.
Topics: Azacitidine; Base Sequence; Bone Marrow Cells; Cell Line, Tumor; Disease Progression; DNA Methylation; Epigenesis, Genetic; fas Receptor; Humans; Leukocytes, Mononuclear; Molecular Sequence Data; Myelodysplastic Syndromes; NF-kappa B; Nitriles; Promoter Regions, Genetic; Protein Binding; Sulfones; Transcription, Genetic | 2013 |
Efficacy and tolerability of 5-day azacytidine dose-intensified regimen in higher-risk MDS.
Topics: Adult; Aged; Azacitidine; Cohort Studies; Drug Administration Schedule; Exanthema; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Risk Factors; Survival Rate; Treatment Outcome | 2013 |
Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Practice Guidelines as Topic; Research Design; Retrospective Studies; Risk Factors; Survival Analysis; Transplantation, Homologous | 2013 |
Managing myelodysplastic syndromes in very old patients: a teaching case report.
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Blood Transfusion; Combined Modality Therapy; Female; Home Care Services; Humans; Myelodysplastic Syndromes | 2013 |
Concise drug review: azacitidine and decitabine.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials, Phase III as Topic; Decitabine; Drug Approval; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes | 2013 |
[p15(INK4B) methylation on prognosis and response to decitabine in patients with MDS].
Topics: Adult; Aged; Azacitidine; Cyclin-Dependent Kinase Inhibitor p15; Decitabine; DNA Methylation; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Survival Rate; Treatment Outcome | 2013 |
Safety and efficacy of 5-azacytidine treatment in myelodysplastic syndrome patients with moderate and mild renal impairment.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Disease-Free Survival; Drug Administration Schedule; Female; Glomerular Filtration Rate; Humans; Infections; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Remission Induction; Renal Insufficiency; Retrospective Studies; Thrombocytopenia; Treatment Outcome | 2013 |
Effective azacitidine treatment for myelodysplastic syndrome transformed from essential thrombocythemia.
Topics: Aged; Anemia, Macrocytic; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Drug Administration Schedule; Fatal Outcome; Female; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Thrombocythemia, Essential; Treatment Outcome | 2013 |
Prognostic impact of the number of methylated genes in myelodysplastic syndromes and acute myeloid leukemias treated with azacytidine.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cytogenetic Analysis; DNA Methylation; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Survival Rate; Treatment Outcome | 2013 |
Monosomal karyotype improves IPSS-R stratification in MDS and AML patients treated with Azacitidine.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Female; Humans; Karyotype; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Monosomy; Myelodysplastic Syndromes; Survival Analysis; Treatment Outcome | 2013 |
Should cytoreductive treatment be performed before transplantation in patients with high-risk myelodysplastic syndrome?
Topics: Antimetabolites, Antineoplastic; Azacitidine; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Myelodysplastic Syndromes | 2013 |
Higher-risk myelodysplastic syndromes with del(5q): is sequential azacitidine-lenalidomide combination the way to go?
Topics: Antimetabolites, Antineoplastic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Thalidomide | 2013 |
Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabine.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Decitabine; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Retrospective Studies; Treatment Outcome | 2013 |
[Clinical efficacy of decitabine plus improved CAG chemotherapy and haplo-identical donor peripheral lymphocyte infusion regimen on elderly patients with high risk myelodysplastic syndrome and acute myeloid leukemia].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Female; Haploidy; Humans; Leukemia, Myeloid, Acute; Lymphocyte Transfusion; Lymphocytes; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome | 2013 |
[5-day decitabine for treatment of myelodysplastic syndromes with complex karyotype abnormalities and acute myeloid leukemia].
Topics: Adult; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Female; Humans; Karyotype; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome | 2013 |
Results of treatment with azacitidine in patients aged ≥ 75 years included in the Spanish Registry of Myelodysplastic Syndromes.
Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Female; Humans; Male; Myelodysplastic Syndromes; Registries; Treatment Outcome | 2014 |
The cancer‑testis antigen NXF2 is activated by the hypomethylating agent decitabine in acute leukemia cells in vitro and in vivo.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Blotting, Western; Case-Control Studies; CpG Islands; Decitabine; DNA Methylation; Female; Humans; In Vitro Techniques; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Nucleocytoplasmic Transport Proteins; Promoter Regions, Genetic; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA-Binding Proteins; RNA, Messenger; Tumor Cells, Cultured | 2013 |
Azacitidine induces profound genome-wide hypomethylation in primary myelodysplastic bone marrow cultures but may also reduce histone acetylation.
Topics: Acetylation; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow Cells; Cells, Cultured; DNA Methylation; Epigenesis, Genetic; Epigenomics; Histones; Humans; Myelodysplastic Syndromes | 2014 |
Poor outcome of patients with myelodysplastic syndrome after azacitidine treatment failure.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Disease Progression; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Retrospective Studies; Risk; Treatment Failure; Treatment Outcome | 2013 |
Cytogenetic response based on revised IPSS cytogenetic risk stratification and minimal residual disease monitoring by FISH in MDS patients treated with low-dose decitabine.
Topics: Abnormal Karyotype; Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Aberrations; Cytogenetic Analysis; Decitabine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; In Situ Hybridization, Fluorescence; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm, Residual; Prognosis; Risk Assessment; Survival Rate | 2013 |
[Autoimmune hemolysis accompanied by thrombopenia: consumption or myelodysplasia?].
Topics: Aged; Anemia, Hemolytic, Autoimmune; Antimetabolites, Antineoplastic; Azacitidine; Biopsy, Needle; Bone Marrow; Diagnosis, Differential; Disease Progression; Follow-Up Studies; Humans; Leukopenia; Male; Myelodysplastic Syndromes; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Thrombocytopenia | 2013 |
Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Azacitidine; Enzyme Inhibitors; Enzymes; Female; Gene Silencing; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Nucleosides; Polymerase Chain Reaction; Prognosis | 2014 |
Patterns of infection in patients with myelodysplastic syndromes and acute myeloid leukemia receiving azacitidine as salvage therapy. Implications for primary antifungal prophylaxis.
Topics: Adult; Aged; Aged, 80 and over; Antifungal Agents; Antimetabolites, Antineoplastic; Azacitidine; Humans; Incidence; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Salvage Therapy | 2014 |
Has introduction of azacytidine in everyday clinical practice improved survival in late-stage Myelodysplastic syndrome? A single center experience.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Disease Progression; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Professional Practice; Retrospective Studies; Survival Analysis | 2014 |
Successful management of acute myeloid leukemia transformed from myelodysplastic syndromes in an elderly patient aged over 80 years old by ultralow dose decitabine combined with amifostine and autologous CIK cells.
Topics: Aged, 80 and over; Amifostine; Azacitidine; Cells, Cultured; Combined Modality Therapy; Cytokine-Induced Killer Cells; Decitabine; Disease Management; Disease Progression; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Transplantation, Autologous | 2014 |
Reply to T. Radivoyevitch et al.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Female; Humans; Male; Myelodysplastic Syndromes | 2014 |
Sex difference in myelodysplastic syndrome survival and balance in randomized clinical trials.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Female; Humans; Male; Myelodysplastic Syndromes | 2014 |
Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; B7-H1 Antigen; Biomarkers, Tumor; Cohort Studies; CTLA-4 Antigen; Decitabine; DNA Methylation; Female; Flow Cytometry; Humans; Immunoenzyme Techniques; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Leukocytes, Mononuclear; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Programmed Cell Death 1 Ligand 2 Protein; Programmed Cell Death 1 Receptor; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tumor Cells, Cultured | 2014 |
Recurrence of abdominal large-vessel vasculitis and development of severe Sweet syndrome after a single cycle of 5-azacytidine in a patient with myelodysplastic syndrome.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Fatal Outcome; Humans; Male; Myelodysplastic Syndromes; Sweet Syndrome; Vasculitis | 2014 |
Challenges of phase III trial design for novel treatments in diseases with no standard treatment: the AZA-001 myelodysplasia study model.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials, Phase III as Topic; Drugs, Investigational; Humans; Multicenter Studies as Topic; Myelodysplastic Syndromes; Patient Selection; Randomized Controlled Trials as Topic; Research Design; Standard of Care | 2014 |
A 5-day: the favourable way?
Topics: Azacitidine; Female; Humans; Male; Myelodysplastic Syndromes | 2014 |
[Lower risk myelodysplastic syndrome patients with transfusion dependent treated by dose-reduced decitabine].
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Blood Transfusion; Decitabine; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Treatment Outcome; Young Adult | 2013 |
Keeping sterile water for injection cold enough for reconstitution of azacitidine in isolators.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cold Temperature; Drug Compounding; Drug Labeling; Drug Stability; Drug Storage; Environment, Controlled; Freeze Drying; Humans; Injections; Myelodysplastic Syndromes; Time Factors; United States; Water | 2014 |
Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Case-Control Studies; Chemotherapy, Adjuvant; Cladribine; Cytarabine; Disease Progression; Drug Resistance, Neoplasm; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Recombinant Proteins; Treatment Failure; Young Adult | 2014 |
[Decitabine treatment in myelodysplastic syndromes--results of a compassionate patient program in Israel].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Compassionate Use Trials; Decitabine; Disease-Free Survival; Female; Humans; Israel; Male; Middle Aged; Myelodysplastic Syndromes; Survival Rate; Treatment Outcome | 2013 |
BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies.
Topics: Antimetabolites, Antineoplastic; Azacitidine; bcl-X Protein; Biphenyl Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Myeloid Cell Leukemia Sequence 1 Protein; Myeloproliferative Disorders; Nitrophenols; Piperazines; Proto-Oncogene Proteins c-bcl-2; RNA Interference; Sulfonamides | 2014 |
[Successful treatment with azacitidine for a patient with relapsed myelodysplastic syndrome after cord blood transplantation].
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Cord Blood Stem Cell Transplantation; Humans; Male; Myelodysplastic Syndromes; Recurrence; Treatment Outcome | 2013 |
Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Biopsy; Bone Marrow; Drug Tolerance; Humans; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome | 2014 |
Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Pharmacological; Bone Marrow Cells; Female; Flow Cytometry; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Myeloid Progenitor Cells; Prognosis; Research Design; Retrospective Studies; Risk Factors | 2014 |
Cladribine in the treatment of acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cladribine; Cytarabine; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Myelodysplastic Syndromes; Recombinant Proteins | 2014 |
Complete remission of Sweet's syndrome after azacytidine treatment for concomitant myelodysplastic syndrome.
Topics: Aged; Azacitidine; Biopsy; Bone Marrow; Humans; Male; Myelodysplastic Syndromes; Skin; Sweet Syndrome; Treatment Outcome | 2014 |
Interstitial granulomatous dermatitis associated with myelodysplastic syndrome - complete clearance under therapy with 5-azacytidine.
Topics: Aged; Azacitidine; Biopsy; Dermatitis; Granuloma; Humans; Male; Myelodysplastic Syndromes; Remission Induction; Treatment Outcome | 2014 |
[Clinical analysis of neutrophil suppression caused by decitabine for the treatment of myelodysplastic syndromes].
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Azacitidine; Decitabine; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Neutrophils; Young Adult | 2014 |
Azacitidine in the treatment of pediatric therapy-related myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Child; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Neoplasm, Residual; Prognosis; Transplantation, Homologous | 2014 |
Multicenter study evaluating the impact of hypomethylating agents as bridging therapy to hematopoietic stem cell transplantation in myelodysplastic syndromes.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; DNA (Cytosine-5-)-Methyltransferases; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Preoperative Care; Retrospective Studies; Transplantation, Homologous; Treatment Outcome; Young Adult | 2014 |
Salvage induction chemotherapy after azacitdine treatment failure in patients who received azacitidine as a bridge to allogeneic stem cell transplantation.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Drug Evaluation; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Leukemia; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Salvage Therapy; Treatment Failure; Young Adult | 2014 |
[Decitabine in myelodysplastic syndromes: the current status and future].
Topics: Azacitidine; Decitabine; Humans; Myelodysplastic Syndromes | 2014 |
[Identification of myelodysplastic syndromes patients].
Topics: Antimetabolites, Antineoplastic; Azacitidine; Disease Progression; Hematopoiesis; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis; Quality of Life; Risk Factors; Survival | 2014 |
Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Histone Deacetylase Inhibitors; Humans; Myelodysplastic Syndromes; Prognosis; Treatment Outcome | 2014 |
Decitabine of reduced dosage in Chinese patients with myelodysplastic syndrome: a retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Asian People; Azacitidine; China; Cyclin-Dependent Kinase Inhibitor p15; Decitabine; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Treatment Outcome | 2014 |
Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Proportional Hazards Models; Retrospective Studies | 2014 |
Necrotizing fasciitis in two patients with myelodysplastic syndrome treated with azacitidine.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Antimetabolites, Antineoplastic; Azacitidine; Fasciitis, Necrotizing; Humans; Immunoglobulins, Intravenous; Klebsiella Infections; Klebsiella pneumoniae; Leg; Male; Middle Aged; Myelodysplastic Syndromes | 2015 |
TP53 mutations and azacitidine treatment: to be or not to be related?
Topics: Antimetabolites, Antineoplastic; Azacitidine; Female; Genes, p53; Humans; Leukemia, Myeloid, Acute; Male; Mutation; Myelodysplastic Syndromes | 2014 |
Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Female; Genes, p53; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Prognosis | 2014 |
Upfront allogeneic stem cell transplantation after reduced-intensity/nonmyeloablative conditioning for patients with myelodysplastic syndrome: a study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Transplantation Conditioning; Transplantation, Homologous; Young Adult | 2014 |
The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes.
Topics: Acute Disease; Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Outcome Assessment, Health Care; Proportional Hazards Models; Retrospective Studies | 2015 |
[CME myelodysplasia - a frequent hematologic neoplasia in the elderly].
Topics: Aged, 80 and over; Anemia, Aplastic; Azacitidine; Bone Marrow; Bone Marrow Examination; Cell Proliferation; Cell Transformation, Neoplastic; Decitabine; Diagnosis, Differential; Disease Progression; Hematopoiesis; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Prognosis; Thalidomide | 2014 |
Azacitidine-associated acute interstitial pneumonitis.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Fatal Outcome; Humans; Lung; Lung Diseases, Interstitial; Male; Myelodysplastic Syndromes; Radiography | 2014 |
Shelf-life extension of azacitidine: waste and cost reduction in the treatment of myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cost Savings; Cost-Benefit Analysis; Drug Compounding; Drug Costs; Drug Stability; Drug Storage; Female; Freezing; Humans; Male; Medical Waste Disposal; Middle Aged; Myelodysplastic Syndromes; Outcome Assessment, Health Care | 2015 |
Patients with myelodysplastic syndromes treated with azacitidine in clinical practice: the AVIDA registry.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Outcome Assessment, Health Care; Prospective Studies; Quality of Life; Registries; Risk Factors; United States | 2015 |
Phenotypic and genotypic characterization of azacitidine-sensitive and resistant SKM1 myeloid cell lines.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Down-Regulation; Genotype; Humans; Myelodysplastic Syndromes; Myeloid Cells; Phenotype | 2014 |
Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Gene Expression; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Treatment Outcome; Tumor Suppressor Protein p53 | 2014 |
Ultra-low-dose decitabine combined with autologous cytokine-induced killer cells for elderly patients with acute myeloid leukemia transformed from myelodysplastic syndrome.
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Combined Modality Therapy; Cytokine-Induced Killer Cells; Decitabine; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Transplantation, Autologous; Treatment Outcome | 2014 |
Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Platelet Count; Prognosis; Retrospective Studies; Treatment Outcome | 2014 |
Treating myelodysplastic syndrome when hypomethylating agents stop working.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Humans; Myelodysplastic Syndromes | 2014 |
[Myelodysplastic syndromes (MDS)].
Topics: Azacitidine; Humans; Lenalidomide; Molecular Targeted Therapy; Myelodysplastic Syndromes; Thalidomide | 2014 |
Pretransplantation therapy with hypomethylating agents in patients with myelodysplastic syndromes receiving reduced-intensity conditioning regimens.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Myelodysplastic Syndromes; Transplantation Conditioning; Transplantation, Homologous | 2014 |
Mechanisms and potential molecular markers of early response to combination epigenetic therapy in patients with myeloid malignancies.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Epigenesis, Genetic; Female; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; Hydroxamic Acids; Indoles; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Panobinostat; Treatment Outcome | 2014 |
Longitudinal Analysis of DNA Methylation in CD34+ Hematopoietic Progenitors in Myelodysplastic Syndrome.
Topics: Antigens, CD34; Azacitidine; DNA Methylation; Enzyme Inhibitors; Hematopoietic Stem Cells; Humans; Longitudinal Studies; Myelodysplastic Syndromes; Polymerase Chain Reaction; Transcriptome | 2014 |
[Myelodysplastic syndrome with rapid disease progression after withdrawal of treatment with azacitidine].
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Disease Progression; Fatal Outcome; Female; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2014 |
Dismal outcome of acute myeloid leukemia secondary to myelodysplastic syndrome and chronic myelomonocytic leukemia after azacitidine failure in a daily-life setting.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Disease Progression; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Transplantation, Homologous; Treatment Failure | 2015 |
TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.
Topics: Aged; Animals; Azacitidine; Biomarkers, Tumor; Bone Marrow Transplantation; Decitabine; Dioxygenases; DNA Methylation; DNA Modification Methylases; DNA-Binding Proteins; Enzyme Inhibitors; Female; Gene Frequency; Genotype; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Mice, Knockout; Mutation; Myelodysplastic Syndromes; Proto-Oncogene Proteins; Repressor Proteins; Transplantation Chimera; Treatment Outcome; Tumor Suppressor Protein p53 | 2014 |
The KDM2B- let-7b -EZH2 axis in myelodysplastic syndromes as a target for combined epigenetic therapy.
Topics: Azacitidine; Bone Marrow Cells; Cell Line, Tumor; Cluster Analysis; Enhancer of Zeste Homolog 2 Protein; Epigenesis, Genetic; F-Box Proteins; Gene Expression; Gene Expression Profiling; Gene Knockdown Techniques; Histones; Humans; Jumonji Domain-Containing Histone Demethylases; Methylation; MicroRNAs; Molecular Targeted Therapy; Myelodysplastic Syndromes; Polycomb Repressive Complex 2 | 2014 |
Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Survival Rate; Treatment Failure | 2015 |
Late hematological improvement of myelodysplastic syndrome following treatment with 5-azacitidine therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Biopsy, Needle; Bone Marrow Cells; Follow-Up Studies; Hemoglobins; Humans; Male; Myelodysplastic Syndromes; Neutrophils; Platelet Count | 2014 |
Clinical outcome after failure of hypomethylating therapy for myelodysplastic syndrome.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Modification Methylases; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Patient Outcome Assessment; Salvage Therapy; Treatment Failure; Young Adult | 2015 |
Azacitidine access program for Belgian patients with myelodysplastic syndromes, acute myeloid leukemia or chronic myelomonocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Belgium; Female; Health Services Accessibility; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Reimbursement Mechanisms | 2015 |
Strongly suspicious hemolysis caused by azacitidine in a myelodysplastic syndrome patient.
Topics: Aged; Anemia, Hemolytic; Antimetabolites, Antineoplastic; Azacitidine; Haptoglobins; Hemolysis; Humans; Leukocyte Count; Male; Myelodysplastic Syndromes; Reticulocytes | 2014 |
Combining DNA methyltransferase and histone deacetylase inhibition to treat acute myeloid leukemia/myelodysplastic syndrome: achievements and challenges.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Modification Methylases; Drug Administration Schedule; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Research Design; Treatment Failure; Valproic Acid | 2015 |
[Comparison of clinical efficacy between decitabine combined with CAG regimen and CAG regimen alone in patients with intermediate to high-risk myelodysplastic syndromes].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Disease-Free Survival; Granulocyte Colony-Stimulating Factor; Humans; Myelodysplastic Syndromes; Remission Induction; Treatment Outcome | 2014 |
Obstacles to adherence to azacitidine administration schedule in outpatient myelodysplastic syndrome and related disorders.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Drug Administration Schedule; Female; Humans; Male; Medication Adherence; Middle Aged; Myelodysplastic Syndromes; Outpatients | 2015 |
[The clinical efficacy of the patients of acute myeloid leukemia and myelodysplastic syndromes treated with decitabine alone, combined with half or one couse of CAG regimen].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2014 |
Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing survey.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Belgium; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Product Surveillance, Postmarketing; Treatment Outcome | 2015 |
Overexpression of GYS1, MIF, and MYC is associated with adverse outcome and poor response to azacitidine in myelodysplastic syndromes and acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Gene Expression; Gene Expression Profiling; Genes, myc; Glycogen Synthase; Humans; Hypoxia; Intramolecular Oxidoreductases; Leukemia, Myeloid, Acute; Macrophage Migration-Inhibitory Factors; Middle Aged; Myelodysplastic Syndromes; Prognosis; Survival Analysis; Treatment Outcome | 2015 |
The hENT1 and DCK genes underlie the decitabine response in patients with myelodysplastic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Azacitidine; Decitabine; Deoxycytidine Kinase; Down-Regulation; Drug Resistance; Enzyme Inhibitors; Equilibrative Nucleoside Transporter 1; Humans; Male; Middle Aged; Myelodysplastic Syndromes; RNA, Messenger | 2015 |
Azacitidine in the front-line treatment of therapy-related myeloid neoplasms: a multicenter case series.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Retrospective Studies; Treatment Outcome | 2015 |
Downregulation of HO-1 promoted apoptosis induced by decitabine via increasing p15INK4B promoter demethylation in myelodysplastic syndrome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Apoptosis; Azacitidine; Cell Line, Tumor; Child; Cyclin-Dependent Kinase Inhibitor p15; Decitabine; DNA Methylation; Down-Regulation; Enzyme Inhibitors; Female; Heme Oxygenase-1; Humans; Male; Middle Aged; Mitochondria; Myelodysplastic Syndromes; Promoter Regions, Genetic; S Phase Cell Cycle Checkpoints; Young Adult | 2015 |
Myelodysplastic syndromes (MDS).
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Humans; Immunologic Factors; Karyotyping; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2015 |
Decitabine treatment could ameliorate primary iron-overload in myelodysplastic syndrome patients.
Topics: Aged; Aged, 80 and over; Azacitidine; Bone Morphogenetic Protein 2; Decitabine; DNA Methylation; DNA Modification Methylases; Female; Ferritins; GPI-Linked Proteins; Hemochromatosis Protein; Hemoglobins; Humans; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes | 2015 |
Clinical outcome after failure of hypomethylating therapy for myelodysplastic syndromes.
Topics: Antimetabolites, Antineoplastic; Azacitidine; DNA Modification Methylases; Female; Humans; Male; Myelodysplastic Syndromes | 2015 |
Decitabine plus thalidomide yields more sustained survival rates than decitabine monotherapy for risk-tailored elderly patients with myelodysplastic syndrome.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Staging; Prognosis; Prospective Studies; Risk Factors; Survival Rate; Thalidomide | 2015 |
Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Disease Progression; Female; Humans; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Retrospective Studies; Risk Factors; Treatment Failure; Treatment Outcome | 2015 |
[Successful treatment with azacitidine for myelodysplastic syndrome with large vessel vasculitis].
Topics: Aged; Azacitidine; Bone Marrow; Enzyme Inhibitors; Humans; Male; Myelodysplastic Syndromes; Treatment Outcome; Vasculitis | 2015 |
Pyoderma gangrenosum secondary to azacitidine in myelodysplastic syndrome.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Female; Humans; Myelodysplastic Syndromes; Pyoderma Gangrenosum | 2015 |
[Retrospective efficacy analysis of decitabine bridging allogeneic hematopoietic stem cell transplantation on the treatment of myelodysplastic syndrome].
Topics: Azacitidine; Decitabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Myelodysplastic Syndromes; Retrospective Studies; Transplantation, Homologous | 2015 |
Higher infection rate after 7- compared with 5-day cycle of azacitidine in patients with higher-risk myelodysplastic syndrome.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Bacterial Infections; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Mycoses; Myelodysplastic Syndromes; Platelet Count; Risk Factors; Virus Diseases | 2015 |
Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation.
Topics: Aged; Aged, 80 and over; Antimetabolites; Azacitidine; Blood Cells; DNA Methylation; Drug Resistance; Female; Gene Expression Regulation; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Lymphocyte Activation; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Proteins; Programmed Cell Death 1 Receptor; Promoter Regions, Genetic; RNA, Messenger; RNA, Neoplasm; T-Lymphocyte Subsets | 2015 |
Impact of prior azacitidine on the outcome of allogeneic hematopoietic transplantation for myelodysplastic syndrome.
Topics: Adolescent; Adult; Aged; Azacitidine; Disease-Free Survival; Enzyme Inhibitors; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Young Adult | 2015 |
Bridging to transplant with azacitidine in juvenile myelomonocytic leukemia: a retrospective analysis of the EWOG-MDS study group.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Child; Child, Preschool; Cytogenetic Analysis; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myelomonocytic, Juvenile; Male; Myelodysplastic Syndromes; Prognosis; Remission Induction; Retrospective Studies | 2015 |
Lethal toxicity after administration of azacytidine: implication of the cytidine deaminase-deficiency syndrome.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Cytidine Deaminase; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Inactivation, Metabolic; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Polymorphism, Single Nucleotide | 2015 |
Monthly blood transfusions decrease after four months of azacitidine.
Topics: Adult; Azacitidine; Blood Transfusion; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies | 2015 |
Platelet response during the second cycle of decitabine treatment predicts response and survival for myelodysplastic syndrome patients.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Blood Platelets; Decitabine; Disease-Free Survival; DNA Modification Methylases; Female; Humans; Male; Myelodysplastic Syndromes; Platelet Count; Retrospective Studies; Treatment Outcome | 2015 |
Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Disease Progression; Female; Follow-Up Studies; Humans; Incidence; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Prognosis; Registries; Spain; Treatment Outcome | 2015 |
[Clinical Significance of ID4 Gene Mehtylation in Demethylation-Treated MDS Cell Line and 2 MDS Patients].
Topics: Anemia, Aplastic; Azacitidine; Bone Marrow; Cell Line; Decitabine; DNA Methylation; Gene Expression; Genes, Tumor Suppressor; Humans; Inhibitor of Differentiation Proteins; Myelodysplastic Syndromes; Polymerase Chain Reaction; Promoter Regions, Genetic | 2015 |
Impact of Nagasaki atomic bomb exposure on myelodysplastic syndrome patients who are treated with azacitidine.
Topics: Aged; Aged, 80 and over; Azacitidine; Female; Humans; Japan; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Radiation-Induced; Nuclear Weapons; Retrospective Studies; Risk Factors | 2015 |
An increased expression of PI-PLCβ1 is associated with myeloid differentiation and a longer response to azacitidine in myelodysplastic syndromes.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Cell Differentiation; Female; Follow-Up Studies; Gene Expression Regulation, Enzymologic; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Myeloid Cells; Phospholipase C beta; Signal Transduction | 2015 |
Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cell Count; Disease Management; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Multivariate Analysis; Myelodysplastic Syndromes; Retrospective Studies; Survival Analysis; Treatment Outcome | 2016 |
[Functional study of hENT1 on SKM-1 cell resistance to decitabine].
Topics: Apoptosis; Azacitidine; Caspase 3; Cell Line; Decitabine; DNA Methylation; Drug Resistance; Equilibrative Nucleoside Transporter 1; Humans; Lentivirus; Myelodysplastic Syndromes | 2015 |
Azacitidine and Allogeneic Stem Cell Transplantation: When and Why?
Topics: Antimetabolites, Antineoplastic; Azacitidine; Female; Humans; Male; Myelodysplastic Syndromes; Stem Cell Transplantation | 2015 |
[Therapeutic efficacies of decitabine application prior to hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia].
Topics: Azacitidine; Decitabine; Disease-Free Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Transplantation, Homologous | 2015 |
Loss of response to azacitidine is associated with deletion 12p13 in a patient with myelodysplastic syndrome with unique translocation t(13;17)(q12;q25) after prior breast cancer and acute promyelocytic leukemia.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Breast Neoplasms; Chromosome Deletion; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 13; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Translocation, Genetic | 2015 |
Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalities.
Topics: Adult; Aged; Aged, 80 and over; Allografts; Antimetabolites, Antineoplastic; Azacitidine; Blast Crisis; Chromosome Aberrations; Chromosomes, Human, Pair 3; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Stem Cell Transplantation; Survival Rate | 2015 |
Azacitidine improves the T-cell repertoire in patients with myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Lineage; Female; Flow Cytometry; Gene Expression; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Receptors, Antigen, T-Cell; Treatment Outcome | 2015 |
Treatment with 5-Azacytidine improves clinical outcome in high-risk MDS patients in the 'real life' setting: A single center observational study.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Drug Administration Schedule; Female; Gene Expression; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Remission Induction; Retrospective Studies; Risk Assessment; Survival Analysis; Treatment Outcome; Tumor Suppressor Protein p53 | 2016 |
Azacitidine is effective for the treatment of myelodysplastic syndrome and accompanied Sweet syndrome.
Topics: Azacitidine; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Sweet Syndrome; Treatment Outcome | 2015 |
Elucidating the immunological effects of 5-azacytidine treatment in patients with myelodysplastic syndrome and identifying new conditional ligands and T-cell epitopes of relevance in melanoma.
Topics: Adult; Antimetabolites, Antineoplastic; Azacitidine; Epitopes, T-Lymphocyte; HLA-A Antigens; Humans; Immunologic Factors; Leukocytes, Mononuclear; Ligands; Melanoma; Myelodysplastic Syndromes; Nodal Protein; T-Lymphocytes; White People | 2015 |
5-Azacytidine in the Treatment of Intermediate-2 and High-risk Myelodysplastic Syndromes and Acute Myeloid Leukemia. A Five-year Experience with 44 Consecutive Patients.
Topics: Aged; Aged, 80 and over; Azacitidine; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Risk Factors; Treatment Outcome | 2015 |
Infection Rate and Risk Factors in Patients Treated With Azacitidine.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Bacterial Infections; Female; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Virus Diseases | 2015 |
First Steps Towards Successful Post-Transplantation Therapy for Myeloid Malignancies after Allogeneic Blood Stem Cell Transplantation.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Myelodysplastic Syndromes | 2015 |
Influence of total genomic alteration and chromosomal fragmentation on response to a combination of azacitidine and lenalidomide in a cohort of patients with very high risk MDS.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromosome Aberrations; Female; Humans; Kaplan-Meier Estimate; Karyotyping; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Oligonucleotide Array Sequence Analysis; Proportional Hazards Models; Thalidomide; Tumor Suppressor Protein p53 | 2015 |
Myelodysplastic syndromes following therapy with hypomethylating agents (HMAs): development of acute erythroleukemia may not influence assessment of treatment response.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Biopsy; Bone Marrow; Chromosome Aberrations; Decitabine; DNA Methylation; Female; Humans; In Situ Hybridization, Fluorescence; Leukemia, Erythroblastic, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Survival Analysis; Treatment Outcome; Young Adult | 2016 |
Guadecitabine for AML and MDS: hype or hope?
Topics: Azacitidine; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes | 2015 |
[Clinical Efficacy of Decitabine Combined with CAG Regimen for Myelodysplastic Syndrome-RAEB and Refractory Acute Myeloid Leukemia].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Karyotype; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pancytopenia; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome | 2015 |
Targeting the Sonic Hedgehog-Gli1 Pathway as a Potential New Therapeutic Strategy for Myelodysplastic Syndromes.
Topics: Adolescent; Adult; Aged; Animals; Azacitidine; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase Inhibitor p15; Decitabine; DNA Methylation; DNA Modification Methylases; Female; Gene Expression Regulation, Neoplastic; Hedgehog Proteins; Humans; Male; Mice; Middle Aged; Myelodysplastic Syndromes; Neoplasm Transplantation; Prognosis; Promoter Regions, Genetic; Signal Transduction; Transcription Factors; Young Adult; Zinc Finger Protein GLI1 | 2015 |
Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study.
Topics: Aged; Antimetabolites, Antineoplastic; Autoimmunity; Azacitidine; Drug Therapy, Combination; Female; Follow-Up Studies; France; Glucocorticoids; Humans; Inflammation; Leukemia, Myelomonocytic, Chronic; Male; Myelodysplastic Syndromes; Prognosis; Retrospective Studies | 2016 |
Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Female; Humans; Male; Myelodysplastic Syndromes | 2015 |
Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromosome Aberrations; Cytarabine; Decitabine; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Recurrence; Remission Induction; Treatment Outcome | 2016 |
Efficacy and toxicity of decitabine versus CHG regimen (low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor) in patients with higher risk myelodysplastic syndrome: a retrospective study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Female; Granulocyte Colony-Stimulating Factor; Harringtonines; Homoharringtonine; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Retrospective Studies; Treatment Outcome; Young Adult | 2016 |
Hypoalbuminemia and hypergammaglobulinemia are associated with an increased infection risk in patients with myeloid malignancies treated with azacitidine. A 3-year monocentric retrospective study.
Topics: Antibiotic Prophylaxis; Antimetabolites, Antineoplastic; Azacitidine; Humans; Hypergammaglobulinemia; Hypoalbuminemia; Infections; Myelodysplastic Syndromes; Retrospective Studies; Risk | 2016 |
Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively.
Topics: Abnormal Karyotype; Aclarubicin; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Child, Preschool; Cytarabine; Decitabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hematuria; Humans; Induction Chemotherapy; Infections; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2015 |
Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides.
Topics: Aged; Antineoplastic Agents; Azacitidine; Databases, Factual; Decitabine; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Research Design; Risk Factors; Survival Analysis | 2016 |
The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia.
Topics: Acute Disease; Aged; Aged, 80 and over; Anilides; Antimetabolites, Antineoplastic; Azacitidine; Biphenyl Compounds; Cell Line, Tumor; Cell Survival; Chromosomes, Human, Pair 5; Chromosomes, Human, Pair 7; Drug Synergism; Female; Hedgehog Proteins; High-Throughput Nucleotide Sequencing; HL-60 Cells; Humans; Leukemia, Myeloid; Male; Myelodysplastic Syndromes; Pyridines; RNA Interference; Signal Transduction | 2015 |
Imprint of 5-azacytidine on the natural killer cell repertoire during systemic treatment for high-risk myelodysplastic syndrome.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Female; Flow Cytometry; Humans; Killer Cells, Natural; Male; Middle Aged; Myelodysplastic Syndromes; Receptors, KIR | 2015 |
A prospective, multicenter, observational study of long-term decitabine treatment in patients with myelodysplastic syndrome.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antibiotic Prophylaxis; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Febrile Neutropenia; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Remission Induction; Republic of Korea; Risk Factors; Time Factors; Treatment Outcome; Young Adult | 2015 |
Will next-generation agents deliver on the promise of epigenetic hypomethylation therapy?
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cytidine Deaminase; Decitabine; DNA Methylation; DNA Modification Methylases; Drug Design; Drug Resistance, Neoplasm; Drug Stability; Enzyme Inhibitors; Epigenesis, Genetic; Half-Life; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic | 2015 |
Five-aza-2'-deoxycytidine-induced hypomethylation of cholesterol 25-hydroxylase gene is responsible for cell death of myelodysplasia/leukemia cells.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow Cells; Cell Death; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Gene Knockout Techniques; HL-60 Cells; Humans; Leukemia; Myelodysplastic Syndromes; Promoter Regions, Genetic; RNA, Small Interfering; Signal Transduction; Steroid Hydroxylases; Transcriptome | 2015 |
A Case of Myelodysplastic Syndrome with Intestinal Behçet's Disease-Like Symptoms Treated by Prednisolone and Azacitidine.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Behcet Syndrome; Bone Marrow Cells; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Female; Follow-Up Studies; Glucocorticoids; Humans; Ileal Diseases; Myelodysplastic Syndromes; Prednisolone | 2015 |
[Unidentified Inflammatory Disease Induced by Azacitidine Therapy for Myelodysplastic Syndrome].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Fatal Outcome; Female; Humans; Inflammation; Interleukin-6; Myelodysplastic Syndromes | 2015 |
Efficacy and safety of a 5-day regimen of azacitidine for patients with high-risk myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Disease Progression; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Retrospective Studies; Treatment Outcome | 2016 |
Nine years without a new FDA-approved therapy for MDS: how can we break through the impasse?
Topics: Algorithms; Azacitidine; Clinical Trials as Topic; Decitabine; Drug Approval; Drug Industry; Humans; Karyotyping; Lenalidomide; Methylation; Mutation; Myelodysplastic Syndromes; Prognosis; Risk Assessment; Thalidomide; United States; United States Food and Drug Administration | 2015 |
A new prognostic index to make short-term prognoses in MDS patients treated with azacitidine: A combination of p53 expression and cytogenetics.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Chromosome Aberrations; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Treatment Outcome; Tumor Suppressor Protein p53 | 2016 |
The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with Azacitidine.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers; Cluster Analysis; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplastic Stem Cells; Phenotype; Prognosis; Proteome; Signal Transduction; STAT3 Transcription Factor; STAT5 Transcription Factor; Survival Analysis; Treatment Outcome | 2016 |
Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: the authors' reply.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Female; Humans; Male; Myelodysplastic Syndromes | 2016 |
Therapy with low-dose azacitidine for MDS in children and young adults: a retrospective analysis of the EWOG-MDS study group.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Azacitidine; Child; Child, Preschool; Drug Administration Schedule; Drug Evaluation; Female; Humans; Male; Myelodysplastic Syndromes; Neutropenia; Palliative Care; Retrospective Studies; Treatment Outcome; Young Adult | 2016 |
Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Treatment Outcome | 2016 |
Prior hypomethylating agent use lacks impact on clinical outcome in patients with secondary acute myeloid leukemia arising from myelodysplastic syndromes treated with standard induction chemotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Survival Analysis; Treatment Outcome; Young Adult | 2016 |
Role of heme oxygenase-1 in demethylating effects on SKM-1 cells induced by decitabine.
Topics: Apoptosis; Azacitidine; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p15; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Gene Expression Regulation, Neoplastic; Heme Oxygenase-1; Humans; Myelodysplastic Syndromes; Neoplasm Proteins; RNA, Small Interfering | 2015 |
5-Azacytidine partially restores CD20 expression in follicular lymphoma that lost CD20 expression after rituximab treatment: a case report.
Topics: Aged; Antigens, CD20; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, Follicular; Myelodysplastic Syndromes; Rituximab; Up-Regulation | 2016 |
The influence of disease and comorbidity risk assessments on the survival of MDS and oligoblastic AML patients treated with 5-azacitidine: A retrospective analysis in ten centers of the "Rete Ematologica Lombarda".
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Comorbidity; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Risk Factors; ROC Curve; Young Adult | 2016 |
Addition of 10-Day Decitabine to Fludarabine/Total Body Irradiation Conditioning is Feasible and Induces Tumor-Associated Antigen-Specific T Cell Responses.
Topics: Adult; Aged; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; CD8-Positive T-Lymphocytes; Decitabine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2016 |
Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; DNA Methylation; Female; Follow-Up Studies; Humans; Longitudinal Studies; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Neoplasm Staging; Prognosis; Survival Rate; Tumor Suppressor Protein p53; Young Adult | 2016 |
Autoimmune diseases and myelodysplastic syndromes.
Topics: Adult; Aged; Aged, 80 and over; Autoimmune Diseases; Azacitidine; Comorbidity; Disease Progression; Disease Susceptibility; Female; Follow-Up Studies; Hashimoto Disease; Humans; Immunocompromised Host; Immunosuppressive Agents; Kaplan-Meier Estimate; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prevalence; Proportional Hazards Models; Retrospective Studies; Thalidomide; Thyroiditis, Autoimmune; Young Adult | 2016 |
Low serum vitamin D levels are associated with shorter survival after first-line azacitidine treatment in patients with myelodysplastic syndrome and secondary oligoblastic acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Calcitriol; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Treatment Outcome; Vitamin D | 2017 |
Efficacy of Azacitidine in autoimmune and inflammatory disorders associated with myelodysplastic syndromes and chronic myelomonocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Autoimmune Diseases; Azacitidine; Female; Humans; Inflammation; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies | 2016 |
Azacitidine-Induced Pericarditis: A Case Series.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Chest Pain; Combined Modality Therapy; Diagnosis, Differential; DNA Modification Methylases; Drug Monitoring; Enzyme Inhibitors; Female; Glucocorticoids; Humans; Leukemia, Myeloid, Acute; Male; Methylprednisolone; Middle Aged; Myelodysplastic Syndromes; Pericarditis; Prednisone; Treatment Outcome | 2016 |
High expression of the human equilibrative nucleoside transporter 1 gene predicts a good response to decitabine in patients with myelodysplastic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Cell Line; Decitabine; DNA Methylation; Equilibrative Nucleoside Transporter 1; Female; Gene Expression Regulation; Humans; Long Interspersed Nucleotide Elements; Male; Middle Aged; Multivariate Analysis; Myelodysplastic Syndromes; Remission Induction; Risk Factors; Survival Analysis; Treatment Outcome; Young Adult | 2016 |
Mutations in histone modulators are associated with prolonged survival during azacitidine therapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers; DNA Mutational Analysis; Female; Histones; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Prognosis; Proportional Hazards Models; Treatment Outcome | 2016 |
Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Humans; Myelodysplastic Syndromes | 2016 |
Pre- and post-treatment serum ferritin levels in patients with higher risk myelodysplastic syndromes receiving azacitidine.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Ferritins; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Treatment Outcome | 2016 |
Effects of the combination of decitabine and homoharringtonine in SKM-1 and Kg-1a cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Cell Proliferation; Decitabine; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2016 |
Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Prognosis; Recurrence; Salvage Therapy; Survival Analysis; Transplantation, Homologous; Treatment Outcome | 2016 |
Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Austria; Azacitidine; Female; France; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Outcome Assessment, Health Care; Prognosis; Proportional Hazards Models; Registries; United Kingdom; United States; World Health Organization | 2016 |
DNA demethylating therapy reverts mesenchymal stromal cells derived from high risk myelodysplastic patients to a normal phenotype.
Topics: Antineoplastic Agents; Azacitidine; Biomarkers; Bone Marrow; Cellular Microenvironment; DNA Methylation; Humans; Immunophenotyping; Mesenchymal Stem Cells; Myelodysplastic Syndromes; Phenotype | 2017 |
Azacitidine versus decitabine in patients with refractory anemia with excess blast-Results of multicenter study.
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Antimetabolites, Antineoplastic; Azacitidine; Blood Component Transfusion; Cell Transformation, Neoplastic; Decitabine; Drug Evaluation; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Patient Selection; Propensity Score; Remission Induction; Retrospective Studies; Survival Rate | 2016 |
Low-dose decitabine plus all-trans retinoic acid in patients with myeloid neoplasms ineligible for intensive chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Tretinoin | 2016 |
[Clinical Efficacy Comparison of Ultralow Dose of Decitabine and Cyclosporine on Low-risk and Intermediate-risk Type 1 of Myelodysplastic Syndrome].
Topics: Azacitidine; Cyclosporine; Decitabine; Humans; Myelodysplastic Syndromes; Pancytopenia; Retrospective Studies; Survival Rate; Treatment Outcome | 2016 |
Effectiveness of azacitidine in higher-risk myelodysplastic syndromes.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Ethnicity; Humans; Myelodysplastic Syndromes; Registries | 2016 |
Acute Megakaryoblastic Leukemia with Myelodysplasia-related Changes Associated with ATM Gene Deletion.
Topics: Aged, 80 and over; Ataxia Telangiectasia Mutated Proteins; Azacitidine; Female; Gene Deletion; Humans; Japan; Leukemia, Megakaryoblastic, Acute; Myelodysplastic Syndromes; Tumor Suppressor Proteins | 2016 |
Impact of azacitidine on red blood cell alloimmunisation in myelodysplastic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Autoantibodies; Azacitidine; Erythrocyte Transfusion; Erythrocytes; Female; Humans; Immunization; Male; Middle Aged; Myelodysplastic Syndromes; Transfusion Reaction | 2017 |
Up-regulation of ribosomal genes is associated with a poor response to azacitidine in myelodysplasia and related neoplasms.
Topics: Azacitidine; Bone Marrow Cells; Cell Proliferation; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Ribosomal Proteins; Transcriptome; Treatment Failure; Up-Regulation | 2016 |
Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome.
Topics: Adult; Aged; Azacitidine; Dioxygenases; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; DNA-Binding Proteins; Female; Genes, p53; Genes, ras; Humans; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Prognosis; Proto-Oncogene Proteins; Splicing Factor U2AF | 2016 |
BNIP3L in myelodysplastic syndromes and acute myeloid leukemia: impact on disease outcome and cellular response to decitabine.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Case-Control Studies; Cell Line; Decitabine; DNA Methylation; Humans; Leukemia, Myeloid, Acute; Membrane Proteins; Myelodysplastic Syndromes; Proto-Oncogene Proteins; Survival Analysis; Treatment Outcome; Tumor Suppressor Proteins | 2016 |
Severe phototoxic reaction secondary to subcutaneous 5-azacitidine.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Dermatitis, Phototoxic; Female; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2017 |
Azacitidine Use After Allogeneic Stem Cell Transplantation-Results From the Polish Adult Leukemia Group.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Poland; Retrospective Studies; Transplantation, Homologous; Young Adult | 2016 |
Report on outcomes of hypomethylating therapy for analyzing prognostic value of Revised International Prognostic Scoring System for patients with lower-risk myelodysplastic syndromes.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Databases, Factual; Decitabine; DNA Methylation; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Retrospective Studies; Risk; Severity of Illness Index; Survival Analysis; Treatment Outcome | 2016 |
Response to treatment with azacitidine in children with advanced myelodysplastic syndrome prior to hematopoietic stem cell transplantation.
Topics: Adolescent; Antimetabolites, Antineoplastic; Azacitidine; Blood Cell Count; Bone Marrow; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Myelodysplastic Syndromes; Preoperative Care; Severity of Illness Index; Survival Analysis; Treatment Outcome | 2016 |
Disease characteristics and prognosis of myelodysplastic syndrome presenting with isolated thrombocytopenia.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Benzoates; Decitabine; Female; Humans; Hydrazines; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Risk; Thrombocytopenia; Thrombopoietin | 2017 |
Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Female; Humans; Kaplan-Meier Estimate; Male; Myelodysplastic Syndromes; Survival Rate; Treatment Outcome | 2016 |
Perturbed hematopoietic stem and progenitor cell hierarchy in myelodysplastic syndromes patients with monosomy 7 as the sole cytogenetic abnormality.
Topics: Antigens, CD; Azacitidine; Biomarkers; Cell Differentiation; Cell Lineage; Chromosome Deletion; Chromosomes, Human, Pair 7; Female; Flow Cytometry; Hematopoietic Stem Cells; High-Throughput Nucleotide Sequencing; Humans; Immunophenotyping; In Situ Hybridization, Fluorescence; Male; Mutation; Myelodysplastic Syndromes | 2016 |
Increased PD-1/STAT1 ratio may account for the survival benefit in decitabine therapy for lower risk myelodysplastic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; B7-H1 Antigen; Biomarkers; CD4-CD8 Ratio; Decitabine; Female; Gene Expression; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Programmed Cell Death 1 Receptor; Proportional Hazards Models; STAT1 Transcription Factor; T-Lymphocytes; Treatment Outcome; Young Adult | 2017 |
Predicting outcome of patients with myelodysplastic syndromes after failure of azacitidine: validation of the North American MDS consortium scoring system.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Cohort Studies; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myelodysplastic Syndromes; North America; Predictive Value of Tests; Reproducibility of Results; Severity of Illness Index; Treatment Failure; Treatment Outcome | 2016 |
Better transplant outcome with pre-transplant marrow response after hypomethylating treatment in higher-risk MDS with excess blasts.
Topics: Azacitidine; Bone Marrow; Bone Marrow Transplantation; Combined Modality Therapy; Decitabine; DNA Methylation; Enzyme Inhibitors; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myelodysplastic Syndromes; Retrospective Studies; Risk Factors; Transplantation, Homologous; Treatment Outcome | 2017 |
Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Disease Progression; DNA Methylation; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Sex Factors; Treatment Outcome | 2017 |
[Clinical Comparation of Two Kinds of Chemotherapy Regimen in the Treatment of Elderly MDS Patients with AML Transformed by Abnormal Proliferation of Bone Marrow].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow; Cell Proliferation; Decitabine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neutropenia; Quality of Life; Treatment Outcome | 2016 |
PD1 and PDL1 upregulation and survival after decitabine treatment in lower risk MDS.
Topics: Azacitidine; B7-H1 Antigen; Decitabine; Humans; Myelodysplastic Syndromes; Up-Regulation | 2017 |
A retrospective study of azacitidine treatment in patients with intermediate-2 or high risk myelodysplastic syndromes in a real-world clinical setting in Greece.
Topics: Aged; Azacitidine; Blood Transfusion; Female; Greece; Humans; Male; Myelodysplastic Syndromes; Retrospective Studies; Risk; Treatment Outcome | 2017 |
Wilms Tumor 1 (WT1) mRNA Expression Level at Diagnosis Is a Significant Prognostic Marker in Elderly Patients with Myelodysplastic Syndrome.
Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers; Bone Marrow Cells; Chromosome Aberrations; Female; Gene Expression; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Research Design; Retrospective Studies; Risk Factors; RNA, Messenger; Survival Analysis; WT1 Proteins | 2017 |
An miRNA-DNMT1 Axis Is Involved in Azacitidine Resistance and Predicts Survival in Higher-Risk Myelodysplastic Syndrome and Low Blast Count Acute Myeloid Leukemia.
Topics: Aged; Aged, 80 and over; Azacitidine; Disease-Free Survival; DNA (Cytosine-5-)-Methyltransferase 1; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Male; MicroRNAs; Middle Aged; Myelodysplastic Syndromes; Prognosis; Signal Transduction | 2017 |
TP53 mutations predict decitabine-induced complete responses in patients with myelodysplastic syndromes.
Topics: Azacitidine; Cell Transformation, Neoplastic; Chromosome Aberrations; Decitabine; Humans; Leukemia, Myeloid, Acute; Mutation; Myelodysplastic Syndromes; Predictive Value of Tests; Recurrence; Remission Induction; Survival Analysis; Treatment Outcome; Tumor Suppressor Protein p53 | 2017 |
The effects of azacitidine on the response and prognosis of myelodysplastic syndrome and acute myeloid leukemia involving a bone marrow erythroblast frequency of >50.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Case-Control Studies; Erythroblasts; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Remission Induction; Retrospective Studies; Young Adult | 2017 |
[Reactivated Expression of MicroRNA-124 in Patients with Myelodysplastic Syndromes after Demethylating Therapy].
Topics: Aged; Azacitidine; Bone Marrow Cells; Cell Count; Decitabine; DNA Methylation; Humans; MicroRNAs; Myelodysplastic Syndromes; Real-Time Polymerase Chain Reaction | 2016 |
Hypomethylating agents in combination with histone deacetylase inhibitors in higher risk myelodysplastic syndromes: Is there a light at the end of the tunnel?
Topics: Azacitidine; DNA Methylation; Histone Deacetylase Inhibitors; Humans; Myelodysplastic Syndromes | 2017 |
Efficacy, safety, and pharmacokinetics of subcutaneous azacitidine in Taiwanese patients with higher-risk myelodysplastic syndromes.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Female; Humans; Infusions, Subcutaneous; Male; Middle Aged; Myelodysplastic Syndromes; Taiwan; Treatment Outcome | 2017 |
Molecular disease monitoring using circulating tumor DNA in myelodysplastic syndromes.
Topics: Azacitidine; Bone Marrow Examination; Clone Cells; DNA, Neoplasm; Drug Monitoring; Humans; Karyotyping; Mutation; Myelodysplastic Syndromes; Polymerase Chain Reaction | 2017 |
Graft-versus-leukemia effect with a WT1-specific T-cell response induced by azacitidine and donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation.
Topics: Azacitidine; Fatal Outcome; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy, Adoptive; Male; Middle Aged; Myelodysplastic Syndromes; Salvage Therapy; T-Cell Antigen Receptor Specificity; T-Lymphocytes; Tissue Donors; Transplantation, Homologous; WT1 Proteins | 2017 |
Choosing a hypomethylating agent in MDS: does gender matter?
Topics: Antimetabolites, Antineoplastic; Azacitidine; Humans; Myelodysplastic Syndromes | 2017 |
Evidence for Selective Benefit of Sequential Treatment With Hypomethylating Agents in Patients With Myelodysplastic Syndrome.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Female; Humans; Male; Myelodysplastic Syndromes; Risk; Treatment Failure; Treatment Outcome | 2017 |
Mutational analysis in serial marrow samples during azacitidine treatment in patients with post-transplant relapse of acute myeloid leukemia or myelodysplastic syndromes.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Bone Marrow; Bone Marrow Cells; DNA Mutational Analysis; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Mutation; Myelodysplastic Syndromes; Postoperative Care; Prognosis | 2017 |
Incidence, etiology and timing of infections following azacitidine therapy for myelodysplastic syndromes.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Bacterial Infections; Humans; Incidence; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Retrospective Studies; Risk Factors; Time Factors | 2017 |
[Predict response to decitabine in patients with myelodysplastic syndrome and related neoplasms].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; Chromosome Aberrations; Chromosomes, Human, Pair 7; Decitabine; Female; Humans; Karyotype; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Neoplasms; Remission Induction; Retrospective Studies; Young Adult | 2017 |
A limited number of 5-azacitidine cycles can be effective treatment in MDS.
Topics: Aged; Aged, 80 and over; Azacitidine; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Survival Rate; Treatment Outcome | 2009 |
[Effect of decitabine combined with Trichostatin A on MDS cell line SKM-1 in vitro].
Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Decitabine; Drug Synergism; fas Receptor; Humans; Hydroxamic Acids; Inhibitor of Apoptosis Proteins; Microtubule-Associated Proteins; Myelodysplastic Syndromes; Survivin | 2008 |
Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow Cells; Drug Administration Schedule; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Oligonucleotide Array Sequence Analysis; Pilot Projects; Survival Analysis; Thalidomide; Treatment Outcome | 2008 |
The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines.
Topics: Anemia; Antineoplastic Agents; Azacitidine; Cost of Illness; Costs and Cost Analysis; Darbepoetin alfa; Decision Support Techniques; Deferoxamine; Drug Costs; Drug Therapy; Epoetin Alfa; Erythropoietin; Hematinics; Humans; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Practice Guidelines as Topic; Recombinant Proteins; Siderophores; Thalidomide; United States | 2008 |
[Myelodysplastic syndromes: therapeutic advances and promising future].
Topics: Antineoplastic Agents; Azacitidine; Decitabine; Forecasting; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2008 |
p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Cycle Proteins; Cell Line, Tumor; CpG Islands; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; G1 Phase; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Ribonucleotide Reductases; Tumor Suppressor Protein p53 | 2008 |
Decitabine-induced effusions.
Topics: Azacitidine; Decitabine; Female; Humans; Middle Aged; Myelodysplastic Syndromes; Pleural Effusion | 2009 |
Improving survival in myelodysplastic syndromes.
Topics: Azacitidine; Humans; Myelodysplastic Syndromes | 2009 |
Recent advances in low- and intermediate-1-risk myelodysplastic syndrome: developing a consensus for optimal therapy.
Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Blood Transfusion; Clinical Trials as Topic; Consensus; Decitabine; Humans; Lenalidomide; Middle Aged; Myelodysplastic Syndromes; Prognosis; Risk Factors; Thalidomide | 2008 |
Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes.
Topics: Apoptosis; Azacitidine; Benzamides; Butyrates; Cell Cycle; Cell Line; Cell Line, Tumor; Cell Survival; Decitabine; DNA Modification Methylases; DNA Repair; Drug Synergism; Flow Cytometry; Fluorescent Antibody Technique; Fluorobenzenes; Histone Acetyltransferases; HL-60 Cells; Humans; Hydroxamic Acids; Immunohistochemistry; K562 Cells; Leukemia, Myeloid; Myelodysplastic Syndromes; Phenanthrenes; Phthalazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Pyridines; U937 Cells | 2009 |
Disseminated varicella-zoster virus infection following azacitidine in a patient with myelodysplastic syndrome.
Topics: Aged; Antiviral Agents; Azacitidine; Herpes Zoster; Humans; Incidence; Male; Myelodysplastic Syndromes; Risk Factors; Virus Activation | 2009 |
Targeting DNA methylation.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Methylation; DNA Modification Methylases; Epigenesis, Genetic; Humans; Myelodysplastic Syndromes; Neoplasms | 2009 |
5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation.
Topics: Adult; Aged; Azacitidine; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Secondary Prevention; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2010 |
Comparison of various criteria in predicting treatment response and prognosis of patients with myelodysplastic syndrome treated with azacitidine.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Predictive Value of Tests; Prognosis; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Neutrophilic panniculitis associated with myelodysplastic syndrome with abnormal nuclear forms.
Topics: Aged; Anemia; Antimetabolites, Antineoplastic; Azacitidine; Cell Nucleus Shape; Chelation Therapy; Erythropoietin; Granulocyte Colony-Stimulating Factor; Humans; Male; Myelodysplastic Syndromes; Neutrophils; Panniculitis | 2009 |
Clinical implications of gene expression profiling in myelodysplastic syndromes: recognition of ribosomal and translational gene dysregulation and development of predictive assays.
Topics: Antigens, CD34; Azacitidine; Cell Proliferation; Decitabine; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lenalidomide; Myelodysplastic Syndromes; Protein Biosynthesis; Ribosomes; Thalidomide | 2009 |
Hematology: Azacitidine improves survival in myelodysplastic syndromes.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials, Phase III as Topic; Hematology; Humans; Multicenter Studies as Topic; Myelodysplastic Syndromes; Practice Guidelines as Topic; Quality of Life; Survival Analysis; Time Factors | 2009 |
Clinical roundtable monograph. Overall survival and maintenance of MDS patients.
Topics: Azacitidine; Clinical Trials, Phase III as Topic; Decitabine; Disease-Free Survival; DNA Modification Methylases; Humans; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic | 2009 |
Atypical presentations of Sweet's syndrome in patients with MDS/AML receiving combinations of hypomethylating agents with histone deacetylase inhibitors.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Diagnosis, Differential; Fatal Outcome; Female; Histone Deacetylase Inhibitors; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Sweet Syndrome; Treatment Outcome | 2009 |
Clinical roundtable monograph. Choosing an appropriate therapy for lower-risk MDS in the community setting.
Topics: Azacitidine; Decitabine; DNA Modification Methylases; Drug Administration Schedule; Humans; Myelodysplastic Syndromes | 2009 |
Clinical roundtable monograph. Combination therapies for MDS.
Topics: Azacitidine; Carrier Proteins; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colony-Stimulating Factors; Enzyme Inhibitors; Etanercept; Humans; Hydroxamic Acids; Immunoglobulin G; Lenalidomide; Myelodysplastic Syndromes; Platelet Transfusion; Receptors, Fc; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Thalidomide; Thrombopoietin; Valproic Acid; Vorinostat | 2009 |
Epigenetic therapies move into new territory, but how exactly do they work?
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; DNA Methylation; DNA Modification Methylases; DNA-Binding Proteins; Drug Synergism; Enhancer of Zeste Homolog 2 Protein; Enzyme Inhibitors; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Humans; Myelodysplastic Syndromes; Polycomb Repressive Complex 2; Randomized Controlled Trials as Topic; Survival Analysis; Transcription Factors; Transplantation, Heterologous | 2009 |
Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromosome Aberrations; Chromosomes, Human, Pair 5; Decitabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome | 2009 |
Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS.
Topics: Aged; Aged, 80 and over; Azacitidine; Enzyme Inhibitors; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Phosphoinositide Phospholipase C; Phospholipase C beta; Promoter Regions, Genetic; RNA, Messenger | 2009 |
5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis.
Topics: Adult; Aged; Azacitidine; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Retrospective Studies; Risk Factors; Salvage Therapy; Stem Cell Transplantation; Survival Analysis; Transplantation, Homologous | 2010 |
Decitabine treatment of patients with higher-risk myelodysplastic syndromes.
Topics: Antineoplastic Agents; Azacitidine; Clinical Trials as Topic; Decitabine; Humans; Myelodysplastic Syndromes | 2009 |
Hypomethylating agents in myelodysplastic syndromes changing the inevitable: the value of azacitidine as maintenance therapy, effects on transfusion and combination with other agents.
Topics: Antineoplastic Agents; Azacitidine; Blood Transfusion; Epigenesis, Genetic; Gene Silencing; Humans; Myelodysplastic Syndromes | 2009 |
Azacitidine in lower-risk myelodysplastic syndromes.
Topics: Antineoplastic Agents; Azacitidine; Humans; Myelodysplastic Syndromes | 2009 |
Neutrophilic eccrine hidradenitis associated with decitabine.
Topics: Adult; Anti-Infective Agents; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Azacitidine; Dapsone; Decitabine; Female; Hidradenitis; Humans; Myelodysplastic Syndromes; Prednisolone | 2010 |
Azacytidine treatment after discontinuation of immunosuppressants in patients with myelodysplastic syndrome and relapse after allo-SCT at a single center.
Topics: Adult; Azacitidine; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Myelodysplastic Syndromes; Pilot Projects; Recurrence; Salvage Therapy; Transplantation, Homologous; Treatment Outcome | 2010 |
Myelodysplastic syndromes: emerging therapies, survival, and alternative outcomes.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Early Diagnosis; Humans; Myelodysplastic Syndromes; Outcome Assessment, Health Care; Survival | 2009 |
Alternative dosing schedules for methylation inhibitors in MDS treatment.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Drug Administration Schedule; Humans; Methylation; Myelodysplastic Syndromes | 2009 |
Myelodysplastic syndromes: health care management considerations.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cooperative Behavior; Cost Control; Decitabine; Drug Costs; Humans; Managed Care Programs; Myelodysplastic Syndromes; Quality of Health Care; Survival | 2009 |
Azacitidine for the treatment of lower risk myelodysplastic syndromes : a retrospective study of 74 patients enrolled in an Italian named patient program.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Drug Evaluation; Female; Humans; Italy; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Risk; Treatment Outcome | 2010 |
Predonor lymphocyte infusion treatment with 5-azacytidine as salvage treatment in relapsed acute myeloid leukaemia secondary to myelodysplastic syndrome.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Chemotherapy, Adjuvant; Female; Humans; Leukemia, Myeloid, Acute; Lymphocyte Transfusion; Middle Aged; Myelodysplastic Syndromes; Recurrence; Salvage Therapy | 2010 |
FISH analysis of circulating CD34+ cells as a new tool for genetic monitoring in MDS: verification of the method and application to 27 MDS patients.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Azacitidine; Bone Marrow Cells; Chromosome Aberrations; Chromosomes, Human, Pair 7; Female; Humans; In Situ Hybridization, Fluorescence; Male; Middle Aged; Monosomy; Myelodysplastic Syndromes | 2010 |
Is there an association between 5-azacitidine and ototoxicity?
Topics: Antimetabolites, Antineoplastic; Azacitidine; Female; Hearing Loss; Humans; Middle Aged; Myelodysplastic Syndromes | 2010 |
Hypomethylating agent induction therapy followed by hematopoietic cell transplantation is feasible in patients with myelodysplastic syndromes.
Topics: Azacitidine; Decitabine; Enzyme Inhibitors; Female; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; HLA Antigens; Humans; Male; Myelodysplastic Syndromes; Neoadjuvant Therapy; Recurrence; Retrospective Studies; Survival Rate; Transplantation Chimera | 2010 |
Preface. The biology and treatment of myelodysplastic syndrome.
Topics: Azacitidine; Bone Marrow Transplantation; Chromosome Aberrations; Drugs, Investigational; Epigenesis, Genetic; Humans; Mutation; Myelodysplastic Syndromes | 2010 |
Myelodysplastic syndrome: An update on diagnosis and therapy.
Topics: Antineoplastic Agents; Azacitidine; Cytogenetic Analysis; Decitabine; Flow Cytometry; Histone Deacetylase Inhibitors; Humans; Immunohistochemistry; Lenalidomide; Myelodysplastic Syndromes; Prognosis; Severity of Illness Index; Thalidomide | 2009 |
Management of myelodysplastic syndromes in the geriatric patient.
Topics: Aged; Anemia; Antineoplastic Agents; Azacitidine; Decitabine; Erythrocyte Transfusion; Erythropoietin; Humans; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Neutropenia; Thalidomide; Thrombocytopenia | 2009 |
Caution using hypomethylating agents in myelodysplasia or myeloid leukemia with complex cytogenetics.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Blast Crisis; Chromosome Deletion; Female; Humans; Leukemia, Myeloid; Middle Aged; Myelodysplastic Syndromes | 2010 |
Feasibility of therapy with hypomethylating agents in patients with renal insufficiency.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Humans; Kaplan-Meier Estimate; Kidney; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Middle Aged; Myelodysplastic Syndromes; Renal Insufficiency | 2010 |
Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia.
Topics: Acute Disease; Aged; Aged, 80 and over; Amino Acid Sequence; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cluster Analysis; Female; Flow Cytometry; Gene Expression Profiling; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; K562 Cells; Leukemia, Myeloid; Male; Melanoma-Specific Antigens; Middle Aged; Myelodysplastic Syndromes; Neoplasm Proteins; Reverse Transcriptase Polymerase Chain Reaction; T-Lymphocytes, Cytotoxic; U937 Cells; Valproic Acid | 2010 |
Eleventh biannual report of the Cochrane Haematological Malignancies Group: Focus on Hodgkin lymphoma.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bendamustine Hydrochloride; Bleomycin; Chlorambucil; Controlled Clinical Trials as Topic; Cyclophosphamide; Dacarbazine; Doxorubicin; Etoposide; Exercise; Hematinics; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Multicenter Studies as Topic; Myelodysplastic Syndromes; Nitrogen Mustard Compounds; Prednisone; Procarbazine; Quality of Life; Randomized Controlled Trials as Topic; Vinblastine; Vincristine | 2010 |
Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Humans; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Prognosis; Treatment Failure; Treatment Outcome | 2010 |
Interstitial lung disease associated with azacitidine use: a case report.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Myelodysplastic Syndromes; Steroids | 2012 |
Aberrant methylation of the RIZ1 gene in myelodysplastic syndrome and acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Base Sequence; Decitabine; DNA Methylation; DNA-Binding Proteins; Female; Gene Expression; Histone-Lysine N-Methyltransferase; HL-60 Cells; Humans; Leukemia, Myeloid; Male; Middle Aged; Molecular Sequence Data; Myelodysplastic Syndromes; Nuclear Proteins; Polymerase Chain Reaction; Promoter Regions, Genetic; Sequence Analysis, DNA; Transcription Factors; U937 Cells; Young Adult | 2011 |
Myelodysplastic syndromes--many new drugs, little therapeutic progress.
Topics: Age Distribution; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Benzoates; Deferasirox; Humans; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Survival Analysis; Thalidomide; Triazoles | 2010 |
Gene expression profiling of myelodysplastic CD34+ hematopoietic stem cells treated in vitro with decitabine.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antigens, CD34; Antimetabolites, Antineoplastic; Azacitidine; Cluster Analysis; Decitabine; DNA Methylation; Female; Gene Expression; Gene Expression Profiling; Hematopoietic Stem Cells; Humans; Integrin beta1; Male; Middle Aged; Myelodysplastic Syndromes; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Young Adult | 2011 |
Prodrugs of aza nucleosides based on proton transfer reaction.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Decitabine; Drug Design; Hydrogen Bonding; Kinetics; Myelodysplastic Syndromes; Nucleosides; Prodrugs; Protons; Thermodynamics | 2010 |
Pattern of hypomethylating agents use among elderly patients with myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; DNA Modification Methylases; Female; Humans; Male; Myelodysplastic Syndromes; Survival Rate; Treatment Outcome | 2011 |
Out of Africa and into epigenetics: discovering reprogramming drugs.
Topics: Africa; Antimetabolites, Antineoplastic; Azacitidine; Epigenesis, Genetic; Epigenomics; Humans; Myelodysplastic Syndromes; United States | 2011 |
Treating myelodysplastic syndrome improves an accompanying autoimmune disease along with a reduction in regulatory T-cells.
Topics: Adult; Antimetabolites, Antineoplastic; Autoimmune Diseases; Azacitidine; Blood Cell Count; Down-Regulation; Humans; Huntington Disease; Lupus Erythematosus, Systemic; Male; Myelodysplastic Syndromes; T-Lymphocytes, Regulatory | 2011 |
The autoimmune manifestations associated with myelodysplastic syndrome respond to 5-azacytidine: a report on three cases.
Topics: Aged; Autoimmune Diseases; Azacitidine; Humans; Immunologic Factors; Male; Middle Aged; Myelodysplastic Syndromes | 2011 |
DNA methylation changes following 5-azacitidine treatment in patients with myelodysplastic syndrome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Female; Genes, Tumor Suppressor; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Young Adult | 2011 |
5'-azacitidine in myelodysplastic syndromes with inversion of chromosome 3.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Chromosome Inversion; Chromosomes, Human, Pair 3; Humans; In Situ Hybridization, Fluorescence; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome | 2011 |
Response to 5-azacytidine in a patient with relapsed Hodgkin Lymphoma and a therapy-related myelodysplastic syndrome.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Hodgkin Disease; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome | 2011 |
Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes from a US payer perspective.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Decitabine; Disease-Free Survival; Drug Administration Schedule; Drug Costs; Humans; Leukemia, Myeloid, Acute; Markov Chains; Models, Economic; Myelodysplastic Syndromes; Patient Care; Randomized Controlled Trials as Topic; Risk; United States | 2010 |
Azacitidine has limited activity in 'real life' patients with MDS and AML: a single centre experience.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies | 2012 |
Azacytidine for the treatment of myelodysplastic syndromes in the elderly.
Topics: Age Factors; Aged; Anemia, Refractory, with Excess of Blasts; Antimetabolites, Antineoplastic; Azacitidine; Blood Component Transfusion; Bone Marrow; Bone Marrow Examination; Humans; Life Expectancy; Male; Monitoring, Physiologic; Myelodysplastic Syndromes; Pancytopenia; Treatment Outcome | 2011 |
Acute myeloblastic leukemia.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Dose-Response Relationship, Drug; Drug Hypersensitivity; Erythema Nodosum; Female; Hematopoiesis; Humans; Leukemia, Myeloid, Acute; Lung Diseases, Fungal; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction | 2011 |
Prognostic significance of monosomal karyotype in higher risk myelodysplastic syndrome treated with azacitidine.
Topics: Antimetabolites; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Chromosomes, Human, Pair 7; Compassionate Use Trials; Follow-Up Studies; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Karyotyping; Monosomy; Myelodysplastic Syndromes; Prognosis; Proportional Hazards Models; Treatment Outcome | 2011 |
Feasibility of hypomethylating agents followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome.
Topics: Adult; Aged; Azacitidine; Decitabine; Disease-Free Survival; DNA Methylation; Feasibility Studies; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Male; Middle Aged; Myelodysplastic Syndromes; Neutrophils; Risk; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2012 |
Azacitidine. Poor-prognosis myelodysplasia: promising, but more data needed.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Humans; Myelodysplastic Syndromes; Prognosis; Remission Induction | 2011 |
Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Dioxygenases; Disease-Free Survival; DNA Methylation; DNA-Binding Proteins; DNA, Neoplasm; Female; Hemoglobins; Humans; Kaplan-Meier Estimate; Karyotyping; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Neoplasm Proteins; Proto-Oncogene Proteins; Sequence Analysis, DNA; Treatment Outcome | 2011 |
Azacitidine: a new medication associated with Sweet syndrome.
Topics: Aged; Azacitidine; Drug Eruptions; Enzyme Inhibitors; Humans; Infusions, Intravenous; Injections, Subcutaneous; Male; Myelodysplastic Syndromes; Recurrence; Sweet Syndrome | 2011 |
Use of hypomethylating agents and associated care in patients with myelodysplastic syndromes: a claims database study.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Female; Humans; Insurance Claim Review; Male; Myelodysplastic Syndromes | 2011 |
NICE guidance on azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia, and acute myeloid leukaemia.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cost-Benefit Analysis; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Practice Guidelines as Topic; Quality-Adjusted Life Years | 2011 |
Cytogenetic response is not a prerequisite for clinical response in patients with myelodysplastic syndromes treated with azacitidine.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Cytogenetic Analysis; Humans; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome | 2011 |
Azacitidine-resistant SKM1 myeloid cells are defective for AZA-induced mitochondrial apoptosis and autophagy.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Autophagy; Azacitidine; Cell Line, Tumor; Humans; Microtubule-Associated Proteins; Mitochondria; Myelodysplastic Syndromes; RNA Interference; RNA, Small Interfering | 2011 |
5'-Azacitidine for therapy-related myelodysplastic syndromes after non-Hodgkin lymphoma treatment.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myelodysplastic Syndromes | 2011 |
The effect of decitabine on megakaryocyte maturation and platelet release.
Topics: Animals; Azacitidine; Blood Platelets; Bone Marrow Cells; Cell Differentiation; Cell Line; Decitabine; DNA Methylation; Fetal Blood; Humans; In Vitro Techniques; Megakaryocytes; Mice; Myelodysplastic Syndromes; Platelet Count; Polyploidy; Thrombocytopenia; Thrombopoiesis; Up-Regulation | 2011 |
Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidine.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Dioxygenases; DNA Methylation; DNA-Binding Proteins; Female; Humans; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Retrospective Studies; Risk Factors; Survival Rate | 2011 |
Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Cohort Studies; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Treatment Failure | 2011 |
Hematologic outcomes of myelodysplastic syndromes treatment with hypomethylating agents in community practice.
Topics: Aged; Aged, 80 and over; Azacitidine; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Female; Hemoglobins; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Neutrophils; Odds Ratio; Platelet Count; Retrospective Studies; Treatment Outcome | 2011 |
Impact of the hypomethylating agent 5-azacytidine on dendritic cells function.
Topics: Aged; Aged, 80 and over; Azacitidine; Cells, Cultured; Dendritic Cells; DNA Methylation; Epigenomics; Female; Humans; Immunity; Immunotherapy; Interleukins; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Th17 Cells | 2011 |
Mechanisms of resistance to decitabine in the myelodysplastic syndrome.
Topics: Aged; Aged, 80 and over; Azacitidine; Chromosome Aberrations; CpG Islands; Cytidine Deaminase; Decitabine; Deoxycytidine Kinase; DNA Methylation; Drug Resistance; Female; Gene Expression Regulation; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Reverse Transcriptase Polymerase Chain Reaction; Sequence Analysis, DNA | 2011 |
Azacitidine in a patient with myelodysplastic syndrome: Impact of switching from a 5-day to the approved 7-day dosing schedule.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Approval; Humans; Male; Myelodysplastic Syndromes; Time Factors | 2012 |
Successful allogeneic stem-cell transplantation in a patient with myelodysplastic syndrome with hemodialysis-dependent end-stage renal disease.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Diabetic Nephropathies; Humans; Kidney Failure, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Renal Dialysis; Risk; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous | 2011 |
A cost-effectiveness analysis of using azacitidine vs. decitabine in treating patients with myelodysplastic syndromes.
Topics: Aged; Azacitidine; Cost-Benefit Analysis; Decitabine; Enzyme Inhibitors; Female; Humans; Male; Myelodysplastic Syndromes; Outcome Assessment, Health Care; United States | 2012 |
Interstitial pneumonitis--An important differential diagnosis for pulmonary sepsis in haematology patients.
Topics: Aged; Antineoplastic Agents; Azacitidine; Diagnosis, Differential; Female; Hematology; Humans; Lung Diseases, Interstitial; Myelodysplastic Syndromes; Pneumonia; Sepsis | 2012 |
Interest of the association azacitidine-lenalidomide as frontline therapy in high-risk myelodysplasia or acute myeloid leukemia with complex karyotype.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; Humans; Karyotyping; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Risk; Thalidomide | 2012 |
Eosinophilic pneumonia associated with azacitidine in a patient with myelodysplastic syndrome.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Humans; Lung; Male; Myelodysplastic Syndromes; Pulmonary Eosinophilia; Tomography, X-Ray Computed | 2012 |
Epigenetic regulation of nuclear PI-PLCbeta1 signaling pathway in low-risk MDS patients during azacitidine treatment.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Base Sequence; DNA Methylation; DNA Primers; Epigenesis, Genetic; Female; Humans; Male; Middle Aged; Molecular Sequence Data; Myelodysplastic Syndromes; Phosphatidylinositols; Phospholipase C beta; Promoter Regions, Genetic; Signal Transduction | 2012 |
Application of French prognostic score to patients with International Prognostic Scoring System intermediate-2 or high risk myelodysplastic syndromes treated with 5-azacitidine is able to predict overall survival and rate of response.
Topics: Azacitidine; Humans; Myelodysplastic Syndromes; Prognosis; Risk Assessment; Survival Rate | 2012 |
Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cohort Studies; Female; Hematinics; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Risk Factors; Treatment Outcome | 2012 |
Predicting the outcome of patients with higher-risk myelodysplastic syndrome treated with hypomethylating agents.
Topics: Azacitidine; Humans; Myelodysplastic Syndromes | 2012 |
Antiretroviral activity of 5-azacytidine during treatment of a HTLV-1 positive myelodysplastic syndrome with autoimmune manifestations.
Topics: Anti-Retroviral Agents; Antimetabolites, Antineoplastic; Autoimmune Diseases; Azacitidine; HTLV-I Infections; Human T-lymphotropic virus 1; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Polymerase Chain Reaction; Treatment Outcome | 2012 |
Hypomethylating therapy and autoimmunity in MDS: an enigmatic relationship.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Sarcoidosis, Pulmonary | 2012 |
Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Child, Preschool; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Retrospective Studies; Survival Rate; Transplantation Conditioning; Treatment Outcome; Young Adult | 2012 |
5-azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Azacitidine; Cohort Studies; Cytogenetics; Disease Progression; Female; Humans; Male; Myelodysplastic Syndromes; Remission Induction; Treatment Outcome | 2012 |
AZA-ESA combo: a new standard for higher risk MDS?
Topics: Antimetabolites, Antineoplastic; Azacitidine; Female; Hematinics; Humans; Male; Myelodysplastic Syndromes | 2012 |
[The clinical research of treatment by decitabine moderate or high-risk myelodysplastic syndrome patients].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes | 2011 |
5-azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cell Differentiation; Cell Line, Tumor; Chromatin; Colony-Stimulating Factors; DNA Methylation; Female; Gene Expression Regulation, Leukemic; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Neoplastic Stem Cells; Proto-Oncogene Proteins; Regulatory Sequences, Nucleic Acid; Trans-Activators; Transcriptional Activation | 2012 |
Decitabine triphosphate levels in peripheral blood mononuclear cells from patients receiving prolonged low-dose decitabine administration: a pilot study.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Chromatography, Liquid; Decitabine; Humans; Leukocytes, Mononuclear; Myelodysplastic Syndromes; Pilot Projects; Tandem Mass Spectrometry | 2012 |
Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Retrospective Studies; Survival Rate | 2012 |
Antiproliferative and antitumor effects of azacitidine against the human myelodysplastic syndrome cell line SKM-1.
Topics: Antineoplastic Agents; Azacitidine; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p15; DNA Methylation; Humans; Myelodysplastic Syndromes | 2012 |
Combination of azacitidine and ESA in myelodysplastic patients: the need for prospective studies.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Female; Hematinics; Humans; Male; Myelodysplastic Syndromes | 2012 |
Neutrophilic panniculitis following azacitidine treatment for myelodysplastic syndromes.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Neutrophil Infiltration; Panniculitis; Radiography | 2012 |
[Cost-effectiveness analysis of azacitidine for myelodysplastic syndromes in Japan].
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cost-Benefit Analysis; Humans; Japan; Myelodysplastic Syndromes | 2012 |
[A case report of undifferentiated connective tissue disease associated myelodysplastic].
Topics: Azacitidine; Connective Tissue Diseases; Decitabine; Humans; Immunosuppressive Agents; Male; Middle Aged; Myelodysplastic Syndromes; Thalidomide | 2012 |
A hemodialysis patient with higher-risk myelodysplastic syndrome treated with standard-dose azacitidine.
Topics: Aged; Azacitidine; Enzyme Inhibitors; Humans; Male; Methyltransferases; Myelodysplastic Syndromes; Polycystic Kidney Diseases; Renal Dialysis; Risk Factors; Treatment Outcome | 2012 |
Azacitidine-associated Sweet's syndrome.
Topics: Adrenal Cortex Hormones; Aged; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Azacitidine; Biopsy; Drug Eruptions; Humans; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Skin; Sweet Syndrome | 2012 |
Deferasirox treatment for myelodysplastic syndromes: "real-life" efficacy and safety in a single-institution patient population.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites; Azacitidine; Benzoates; Chelating Agents; Deferasirox; Drug Eruptions; Drug Evaluation; Drug Therapy, Combination; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematinics; Humans; Iron Overload; Kidney Diseases; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Thalidomide; Treatment Outcome; Triazoles | 2012 |
BCL2L10 is a predictive factor for resistance to azacitidine in MDS and AML patients.
Topics: Azacitidine; Biomarkers, Pharmacological; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Predictive Value of Tests; Prognosis; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; Survival Analysis; Transgenes | 2012 |
Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Multivariate Analysis; Myelodysplastic Syndromes; Retrospective Studies; Risk; Survival Analysis; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2012 |
Over-expression of RPL23 in myelodysplastic syndromes is associated with apoptosis resistance of CD34+ cells and predicts poor prognosis and distinct response to CHG chemotherapy or decitabine.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Cell Transformation, Neoplastic; Cytarabine; Decitabine; Female; Gene Expression Regulation, Neoplastic; Granulocyte Colony-Stimulating Factor; Harringtonines; Homoharringtonine; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Predictive Value of Tests; Prognosis; Ribosomal Proteins; Risk Factors; Treatment Outcome; Young Adult | 2012 |
Efficacy of hypomethylating agents in therapy-related myelodysplastic syndromes.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Retrospective Studies; Treatment Outcome | 2012 |
Tuning the rigging before sailing off into the stormy sea of stem cell transplants for patients with myelodysplastic syndromes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Myelodysplastic Syndromes | 2012 |
Generalized skin reactions in patients with MDS and CMML treated with azacitidine: Effective management with concomitant prednisolone.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Exanthema; Female; Humans; Leukemia, Myelomonocytic, Chronic; Male; Myelodysplastic Syndromes; Prednisolone; Treatment Outcome | 2012 |
Hypoxia-inducible factor-1α expression indicates poor prognosis in myelodysplastic syndromes.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers; Bone Marrow; Bone Marrow Cells; Decitabine; Disease Progression; Female; Hemoglobins; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myelodysplastic Syndromes; Prognosis; Treatment Outcome; Young Adult | 2012 |
Methylation of the CpG island near SOX7 gene promoter is correlated with the poor prognosis of patients with myelodysplastic syndrome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; Cell Line, Tumor; CpG Islands; DNA Methylation; Female; Gene Expression Regulation; Humans; Male; Middle Aged; Multivariate Analysis; Myelodysplastic Syndromes; Prognosis; Promoter Regions, Genetic; RNA, Messenger; SOXF Transcription Factors; Survival Analysis; Transcription, Genetic; Young Adult | 2012 |
Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cohort Studies; Compassionate Use Trials; Female; Follow-Up Studies; France; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Risk Factors; Survival Analysis; Time Factors; Treatment Outcome | 2012 |
[The comparison of short-term efficacies between decitabine and HA regimen for MDS/AML patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Treatment Outcome | 2012 |
Hypermethylation of Wnt antagonist gene promoters and activation of Wnt pathway in myelodysplastic marrow cells.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Ataxia Telangiectasia Mutated Proteins; Azacitidine; Bone Marrow Cells; Cell Cycle Proteins; Cell Line, Tumor; DNA Methylation; Female; Hepatocyte Nuclear Factor 1-alpha; Humans; Immunoenzyme Techniques; Intercellular Signaling Peptides and Proteins; Lymphoid Enhancer-Binding Factor 1; Male; Membrane Proteins; Middle Aged; Myelodysplastic Syndromes; Prognosis; Promoter Regions, Genetic; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Real-Time Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Wnt Proteins; Wnt Signaling Pathway | 2012 |
Fas expression at diagnosis as a biomarker of azacitidine activity in high-risk MDS and secondary AML.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Biomarkers; CpG Islands; DNA Methylation; fas Receptor; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neoplasms, Second Primary; Promoter Regions, Genetic; Proportional Hazards Models; Risk | 2012 |
Transplantation for MDS in the elderly: more evidence, or more bias?
Topics: Antimetabolites, Antineoplastic; Azacitidine; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Transplantation Conditioning | 2012 |
Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations.
Topics: Antigens, CD; Azacitidine; Case-Control Studies; Cell Lineage; Chromosome Aberrations; Chromosomes, Human, Pair 7; DNA Methylation; Epigenesis, Genetic; Flow Cytometry; Gene Expression; Hematopoietic Stem Cells; Humans; Karyotyping; Myelodysplastic Syndromes; Primary Cell Culture; Recurrence; STAT3 Transcription Factor | 2012 |
Erythroblastic sarcoma, an extremely rare variant of myeloid sarcoma.
Topics: Abnormal Karyotype; Adenocarcinoma; Aged; Azacitidine; Biopsy, Large-Core Needle; Bone Marrow; Bone Marrow Neoplasms; Bone Neoplasms; Combined Modality Therapy; Disease Progression; Drug Therapy, Combination; Erythroblasts; Erythropoietin; Fatal Outcome; Humans; Lymph Nodes; Male; Myelodysplastic Syndromes; Rare Diseases; Rectal Neoplasms; Sarcoma, Myeloid | 2012 |
Outcome of therapy-related myeloid neoplasms treated with azacitidine.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; DNA Methylation; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Prognosis; Remission Induction; Retrospective Studies; Survival Rate | 2012 |
Improving the outlook for myelodysplastic syndrome.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Decitabine; Disease Progression; DNA Methylation; Enzyme Inhibitors; Epigenesis, Genetic; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Methyltransferases; Molecular Targeted Therapy; Myelodysplastic Syndromes; Phosphoproteins; Point Mutation; Prognosis; Ribonucleoprotein, U2 Small Nuclear; Risk Assessment; RNA Splicing; RNA Splicing Factors; Spliceosomes; Thalidomide | 2012 |
Case report of isochromosome 17q in acute myeloid leukemia with myelodysplasia-related changes after treatment with a hypomethylating agent.
Topics: Azacitidine; Cell Transformation, Neoplastic; Chromosomes, Human, Pair 17; Decitabine; DNA Methylation; Fatal Outcome; Humans; Isochromosomes; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes | 2012 |
The impact of hypomethylating agents on the cost of care and survival of elderly patients with myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Azacitidine; Decitabine; Drug Costs; Enzyme Inhibitors; Female; Humans; Male; Myelodysplastic Syndromes; SEER Program | 2012 |
Necrotizing fasciitis in myelodysplastic syndrome: an exceptionally rare occurrence.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Chemoprevention; Fasciitis, Necrotizing; Fatal Outcome; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Risk Factors; Stem Cell Transplantation | 2013 |
[Effective treatment of myelodysplastic syndromes-refractory anemia with excess blasts type II by decitabine: a case report].
Topics: Anemia, Refractory, with Excess of Blasts; Azacitidine; Decitabine; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome | 2012 |
Outcome of patients with low-risk myelodysplasia after azacitidine treatment failure.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Humans; Myelodysplastic Syndromes; Treatment Failure | 2013 |
Clinical regression of squamous cell carcinoma and keratoacanthomas in a patient treated with a hypomethylating agent.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Carcinoma, Squamous Cell; Humans; Immunosuppressive Agents; Keratoacanthoma; Kidney Transplantation; Male; Myelodysplastic Syndromes; Skin Neoplasms; Treatment Outcome | 2014 |
Aberrant promoter methylation of Dab2 gene in myelodysplastic syndrome.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Apoptosis Regulatory Proteins; Azacitidine; Cell Line; Decitabine; DNA Methylation; Down-Regulation; Female; Humans; Karyotyping; Male; Middle Aged; Myelodysplastic Syndromes; Polymerase Chain Reaction; Promoter Regions, Genetic; Risk Factors; Sequence Analysis, DNA; Tumor Suppressor Proteins | 2012 |
Revised IPSS (IPSS-R) stratification and outcome of MDS patients treated with azacitidine.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Cohort Studies; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Severity of Illness Index; Treatment Outcome | 2013 |
Effects of DNA methyltransferase inhibitors (DNMTIs) on MDS-derived cell lines.
Topics: Azacitidine; Cell Cycle; Cell Division; Cell Line; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Damage; DNA Methylation; Dose-Response Relationship, Drug; Enzyme Inhibitors; Gene Expression Profiling; HL-60 Cells; Humans; In Vitro Techniques; Inhibitory Concentration 50; Myelodysplastic Syndromes | 2013 |
Azacytidine and erlotinib exert synergistic effects against acute myeloid leukemia.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Cell Cycle; Cell Differentiation; Cell Line, Tumor; DNA Damage; Drug Synergism; Erlotinib Hydrochloride; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Protein Kinase Inhibitors; Quinazolines | 2013 |
Methylation of Wnt antagonist genes: a useful prognostic marker for myelodysplastic syndrome.
Topics: Adaptor Proteins, Signal Transducing; Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; beta Catenin; Bone Marrow Cells; Cell Cycle; Cell Line; Cell Nucleus; Chemokines; Cytoplasm; Decitabine; DNA Methylation; Eye Proteins; Female; Humans; Intercellular Signaling Peptides and Proteins; Kaplan-Meier Estimate; Male; Membrane Proteins; Middle Aged; Myelodysplastic Syndromes; Prognosis; Promoter Regions, Genetic; Proto-Oncogene Proteins; Real-Time Polymerase Chain Reaction; Severity of Illness Index; Wnt Proteins; Wnt Signaling Pathway; Young Adult | 2013 |
Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Transplantation, Homologous; Treatment Outcome | 2012 |
Lenalidomide treatment for patients with myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure.
Topics: Azacitidine; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Thalidomide; Treatment Failure; Treatment Outcome | 2013 |
[Methylation of FHIT gene promoter region in DNA from plasma of patients with myelodysplastic syndromes and demethylating effect of decitabine].
Topics: Acid Anhydride Hydrolases; Adult; Aged; Azacitidine; Decitabine; DNA; DNA Methylation; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Proteins; Promoter Regions, Genetic | 2012 |
Newly proposed therapy-related myelodysplastic syndrome prognostic score predicts significant differences in overall survival and leukemia-free survival in patients treated with azacitidine.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Humans; Myelodysplastic Syndromes; Neoplasms, Second Primary; Treatment Outcome | 2013 |
Aberrant methylation of the M-type phospholipase A(2) receptor gene in leukemic cells.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Female; Genes, Tumor Suppressor; Genetic Predisposition to Disease; Humans; Jurkat Cells; Leukemia; Male; Middle Aged; Myelodysplastic Syndromes; Receptors, Phospholipase A2; U937 Cells; Young Adult | 2012 |
Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Female; Humans; Immunophenotyping; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplastic Stem Cells; Prognosis | 2013 |
The effects of 5-azacytidine on the function and number of regulatory T cells and T-effectors in myelodysplastic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Female; Follow-Up Studies; Humans; Lymphocyte Count; Male; Middle Aged; Myelodysplastic Syndromes; T-Lymphocytes, Regulatory; Th1 Cells; Th17 Cells; Th2 Cells; Treatment Outcome | 2013 |
MDS: unraveling the mystery.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; Humans; Lenalidomide; Male; Myelodysplastic Syndromes; Thalidomide | 2012 |
The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Blood Cell Count; Cytogenetic Analysis; Follow-Up Studies; Humans; Myelodysplastic Syndromes; Prognosis; Treatment Outcome | 2012 |
Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Disease Progression; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Odds Ratio; Prognosis; Retrospective Studies; Risk Factors; Treatment Outcome | 2013 |
Genome-wide single-nucleotide polymorphism array-based karyotyping in myelodysplastic syndrome and chronic myelomonocytic leukemia and its impact on treatment outcomes following decitabine treatment.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Mapping; Decitabine; Drug Resistance, Neoplasm; Female; Genome, Human; Humans; Karyotyping; Leukemia, Myelomonocytic, Chronic; Male; Microarray Analysis; Middle Aged; Myelodysplastic Syndromes; Polymorphism, Single Nucleotide; Prognosis; Treatment Outcome | 2013 |
Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy.
Topics: Animals; Azacitidine; Cytarabine; Cytidine; Cytidine Deaminase; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Female; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Male; Mice; Myelodysplastic Syndromes; Polymorphism, Single Nucleotide; Survival Analysis; Treatment Outcome | 2013 |
TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Macrocytic; Antimetabolites; Azacitidine; Bone Marrow Cells; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; Female; Follow-Up Studies; Genes, p53; Humans; Incidence; Kaplan-Meier Estimate; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Polymorphism, Single Nucleotide; Prognosis; Risk; Treatment Outcome; Young Adult | 2013 |
Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Recurrence; Retrospective Studies | 2013 |
Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Aberrations; Disease Susceptibility; Female; Humans; Incidence; Infections; Israel; Leukemia, Myeloid, Acute; Male; Methylation; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Retrospective Studies; Risk Factors; Severity of Illness Index; Thrombocytopenia | 2013 |
Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Modification Methylases; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Research Design; Retrospective Studies; Severity of Illness Index; Survival Rate; Time Factors; Transplantation, Homologous; Treatment Outcome | 2013 |
Counselling and adverse event management for patients with myelodysplastic syndromes undergoing azacitidine therapy: a practice standard for Canadian nurses.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Canada; Counseling; Myelodysplastic Syndromes; Oncology Nursing; Practice Guidelines as Topic; Workforce | 2012 |
Treatment of myelodysplastic syndromes with 5-azacytidine.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Azacitidine; Blood Transfusion; Female; Humans; Leukocytes; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Retrospective Studies; Thrombocytopenia; Treatment Outcome | 2002 |
Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment.
Topics: Adult; Aged; Azacitidine; Cell Cycle Proteins; Cell Survival; Cyclin-Dependent Kinase Inhibitor p15; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; Disease Progression; DNA Methylation; DNA Modification Methylases; Female; Genes, Tumor Suppressor; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome; Tumor Suppressor Proteins | 2002 |
Myelodysplasia, megakaryocytes, and methylation.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; DNA Modification Methylases; Humans; Megakaryocytes; Myelodysplastic Syndromes | 2004 |
The effects of 5-aza-2'-deoxycytidine (Decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Female; Humans; Male; Megakaryocytes; Middle Aged; Myelodysplastic Syndromes; Platelet Count; Risk Factors; Survival Rate; Thrombopoietin; Treatment Outcome | 2004 |
[Effect of 5-aza-2'-deoxycytidine on cell of high-risk patients with myelodysplastic syndrome in vitro].
Topics: Azacitidine; Cell Cycle Proteins; Cell Line; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p15; Decitabine; DNA Methylation; DNA Methyltransferase 3A; DNA Modification Methylases; Humans; Myelodysplastic Syndromes; RNA, Messenger; Tumor Suppressor Proteins | 2004 |
Induction of gene expression by 5-Aza-2'-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation-dependent and -independent mechanisms.
Topics: Acute Disease; Apoptosis; Azacitidine; Base Sequence; Cell Division; Decitabine; DNA Methylation; DNA Primers; Epithelial Cells; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid; Myelodysplastic Syndromes; Polymerase Chain Reaction | 2005 |
5-Aza-2'-deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemia.
Topics: Apoptosis; Azacitidine; Blotting, Western; Caspase 3; Caspases; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; CpG Islands; Cyclin-Dependent Kinase Inhibitor p21; Cytochromes c; Decitabine; DNA Methylation; DNA-Binding Proteins; Epithelial Cells; Flow Cytometry; G1 Phase; Genes, Tumor Suppressor; HeLa Cells; HL-60 Cells; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; Membrane Potentials; Microscopy, Fluorescence; Mitochondria; Myelodysplastic Syndromes; Nuclear Proteins; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA; RNA, Messenger; Sulfites; Time Factors; Transfection; Tumor Protein p73; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; U937 Cells; Up-Regulation | 2005 |
Azacitine (vidaza) for myelodysplastic syndrome.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Humans; Myelodysplastic Syndromes | 2005 |
Azacitidine.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; DNA Methylation; Drug Design; Humans; Myelodysplastic Syndromes | 2005 |
Azacitidine-induced interstitial and alveolar fibrosis in a patient with myelodysplastic syndrome.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Humans; Male; Myelodysplastic Syndromes; Pulmonary Fibrosis | 2005 |
Expression and methylation status of the FHIT gene in acute myeloid leukemia and myelodysplastic syndrome.
Topics: Acid Anhydride Hydrolases; Acute Disease; Azacitidine; Bone Marrow; Cell Cycle Proteins; Cyclin-Dependent Kinase Inhibitor p15; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Leukemia, Myeloid; Myelodysplastic Syndromes; Neoplasm Proteins; Recurrence; RNA, Messenger; Tumor Suppressor Proteins | 2005 |
Azacitidine.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; DNA Methylation; Humans; Myelodysplastic Syndromes; Treatment Outcome | 2005 |
Characterization of DNA demethylation effects induced by 5-Aza-2'-deoxycytidine in patients with myelodysplastic syndrome.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Enzyme Inhibitors; HCT116 Cells; Humans; Jurkat Cells; Myelodysplastic Syndromes | 2005 |
MDS: practical treatment approaches for physicians and nurses.
Topics: Azacitidine; Bone Marrow Transplantation; Decision Trees; DNA Methylation; Drug Administration Schedule; Hematopoietic Cell Growth Factors; Humans; Injections, Subcutaneous; Medical Oncology; Myelodysplastic Syndromes; Nausea; Oncology Nursing | 2005 |
Decitabine: a historical review of the development of an epigenetic drug.
Topics: Anemia, Sickle Cell; Azacitidine; Decitabine; DNA Modification Methylases; Drug Design; Epigenesis, Genetic; History, 20th Century; History, 21st Century; Humans; Myelodysplastic Syndromes; Transplantation Conditioning | 2005 |
Clinical experience with decitabine in North American patients with myelodysplastic syndrome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Modification Methylases; Dose-Response Relationship, Drug; Drug Administration Schedule; Histone Deacetylase Inhibitors; Humans; Myelodysplastic Syndromes; North America; Valproic Acid | 2005 |
Quantification of outpatient management and hospitalization of patients with high-risk myelodysplastic syndrome treated with low-dose decitabine.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Agents; Azacitidine; Case-Control Studies; Decitabine; DNA Modification Methylases; Female; Humans; Length of Stay; Male; Matched-Pair Analysis; Middle Aged; Myelodysplastic Syndromes; Quality of Life; Retrospective Studies; Survival Analysis | 2005 |
Trisomy 19 as the sole chromosomal abnormality in proliferative chronic myelomonocytic leukemia.
Topics: Aged; Azacitidine; Chromosome Aberrations; Chromosomes, Human, Pair 19; Cytarabine; Cytogenetic Analysis; Daunorubicin; Decitabine; Dose-Response Relationship, Drug; Fatal Outcome; Female; Humans; Hydroxyurea; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Phenotype; Steroids; Treatment Outcome | 2006 |
New agents in the treatment of MDS.
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials, Phase III as Topic; Decitabine; Enzyme Inhibitors; Humans; Indoles; Lenalidomide; Myelodysplastic Syndromes; Predictive Value of Tests; Thalidomide; Treatment Outcome | 2005 |
Drug therapy for myelodysplastic syndrome: building evidence for action.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; DNA Modification Methylases; Humans; Myelodysplastic Syndromes | 2006 |
Successful treatment of relapsed AML after allogeneic stem cell transplantation with azacitidine.
Topics: Acute Disease; Antineoplastic Agents; Azacitidine; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Middle Aged; Myelodysplastic Syndromes; Recurrence; Remission Induction; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2007 |
Decitabine: in myelodysplastic syndromes.
Topics: Antimetabolites, Antineoplastic; Area Under Curve; Azacitidine; Clinical Trials as Topic; Decitabine; Humans; Molecular Structure; Myelodysplastic Syndromes; Treatment Outcome | 2006 |
Decitabine in myelodysplastic syndromes: viewpoints.
Topics: Antimetabolites, Antineoplastic; Area Under Curve; Azacitidine; Clinical Trials as Topic; Decitabine; Humans; Molecular Structure; Myelodysplastic Syndromes; Treatment Outcome | 2006 |
Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms.
Topics: Acetylation; Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Dose-Response Relationship, Drug; Feasibility Studies; Female; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Phenylbutyrates; Promoter Regions, Genetic; Treatment Outcome | 2006 |
Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Blood Transfusion; Humans; Infusions, Intravenous; Injections, Subcutaneous; Multicenter Studies as Topic; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Analysis; Treatment Outcome | 2006 |
Decitabine (Dacogen) for myelodysplastic syndromes.
Topics: Azacitidine; Decitabine; Humans; Myelodysplastic Syndromes | 2006 |
Match unrelated bone marrow transplantation in a case of high risk myelodysplastic syndrome treated with azacitidine and concomitant 1alpha-25-dihydroxyvitamin D3, as differentiating agent.
Topics: Adult; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow Transplantation; Cell Differentiation; Female; Humans; Myelodysplastic Syndromes; Vitamin D | 2007 |
Decitabine.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Drug Approval; Humans; Myelodysplastic Syndromes; United States; United States Food and Drug Administration | 2006 |
Low-dose decitabine and high-risk MDS.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Methylation; Myelodysplastic Syndromes; Neoplasm Proteins; Protein Processing, Post-Translational; Randomized Controlled Trials as Topic; Remission Induction; Risk Factors | 2006 |
[Methylation of P15INK4B gene in patients with myelodysplastic syndromes and demethylating effects of drugs].
Topics: Arsenic Trioxide; Arsenicals; Azacitidine; Cyclin-Dependent Kinase Inhibitor p15; Decitabine; Disease Progression; DNA Methylation; Genetic Predisposition to Disease; Humans; Leukemia; Myelodysplastic Syndromes; Oxides | 2007 |
Clonogenic acute myelogenous leukemia cells are heterogeneous with regard to regulation of differentiation and effect of epigenetic pharmacological targeting.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Azacitidine; Cell Cycle; Cell Differentiation; Cell Proliferation; Decitabine; DNA, Mitochondrial; Enzyme Inhibitors; Epigenesis, Genetic; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Phenylbutyrates; Thymidine; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2007 |
Azacitidine pharmacokinetics in an adolescent patient with renal compromise.
Topics: Acute Disease; Adolescent; Azacitidine; Chimerism; Dose-Response Relationship, Drug; Drug Administration Schedule; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Injections, Subcutaneous; Leukemia, Myeloid; Male; Myelodysplastic Syndromes; Recurrence; Renal Insufficiency; Treatment Outcome | 2007 |
Intravenous azacitidine for MDS.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Differentiation; Humans; Injections, Intravenous; Myelodysplastic Syndromes | 2007 |
Delivery of 5-aza-2'-deoxycytidine to cells using oligodeoxynucleotides.
Topics: Antineoplastic Agents; Azacitidine; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Drug Delivery Systems; Epigenesis, Genetic; Genetic Therapy; Humans; Models, Chemical; Myelodysplastic Syndromes; Oligonucleotides; Triazines; Urinary Bladder Neoplasms | 2007 |
PI-PLCbeta-1 and activated Akt levels are linked to azacitidine responsiveness in high-risk myelodysplastic syndromes.
Topics: Azacitidine; Enzyme Inhibitors; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Phosphatidylinositols; Phospholipase C beta; Proto-Oncogene Proteins c-akt | 2008 |
Decitabine dosage in myelodysplastic syndromes.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Injections, Subcutaneous; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Remission Induction; Treatment Outcome | 2007 |
Azacitidine-associated hyperthermia and interstitial pneumonitis in a patient with myelodysplastic syndrome.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Female; Fever; Glucocorticoids; Humans; Lung Diseases, Interstitial; Methylprednisolone; Middle Aged; Myelodysplastic Syndromes; Probability; Respiratory Distress Syndrome | 2007 |
Myelodysplastic syndromes: introduction.
Topics: Azacitidine; Decitabine; Hematopoietic Stem Cell Transplantation; Humans; Intercellular Signaling Peptides and Proteins; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2008 |
Hypomethylation and apoptosis in 5-azacytidine-treated myeloid cells.
Topics: Apoptosis; Azacitidine; Caspases; Cytosol; DNA Methylation; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Ionophores; Jurkat Cells; Membrane Potential, Mitochondrial; Mitochondria; Monensin; Myelodysplastic Syndromes; Myeloid Cells; Organometallic Compounds; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2; Time Factors | 2008 |
5-Aza-2'-Deoxycytidine and DNA Methyltransferase Inhibitors in the Treatment of Myeloid Leukemias and Myelodysplastic Syndromes: Biological Aspects and Clinical Results. Proceedings of a workshop. Rome, Italy, November 3, 1991.
Topics: Animals; Antineoplastic Agents; Azacitidine; Decitabine; Humans; Leukemia, Myeloid; Myelodysplastic Syndromes | 1993 |
Continuous infusion of low-dose 5-Aza-2'-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome.
Topics: Acute Disease; Aged; Aged, 80 and over; Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents; Azacitidine; Decitabine; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Pancytopenia | 1997 |
Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Anemia, Sideroblastic; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Aberrations; Chromosome Disorders; Decitabine; Drug Administration Schedule; Female; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Risk; Survival Rate | 2001 |
Differentiation therapy for myelodysplastic syndrome.
Topics: Azacitidine; Cell Differentiation; Decitabine; DNA Modification Methylases; Enzyme Inhibitors; Histone Deacetylase Inhibitors; HL-60 Cells; Humans; Myelodysplastic Syndromes; Tretinoin | 2002 |
Treatment of myelodysplastic syndrome: questions raised by the azacitidine experience.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Humans; Myelodysplastic Syndromes; Remission Induction; Risk Factors; Treatment Outcome | 2002 |
Evaluation of continuous infusion low-dose 5-azacytidine in the treatment of myelodysplastic syndromes.
Topics: Adult; Aged; Azacitidine; Blood Transfusion; Bone Marrow; Erythrocyte Transfusion; Female; Humans; Infusions, Intravenous; Leukocyte Count; Male; Middle Aged; Myelodysplastic Syndromes; Neutrophils; Platelet Count | 1991 |
5-Aza-2'-deoxycytidine as a differentiation inducer in acute myeloid leukaemias and myelodysplastic syndromes of the elderly.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Azacitidine; Bone Marrow; Cell Differentiation; Decitabine; Drug Evaluation; Female; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Neoplastic Stem Cells | 1989 |